Profile Image

Laureate Professor Nick Talley

Pro Vice-Chancellor (Global Research) & Laureate Professor

Office - DVC (Research and Innovation)

Gut feeling

Professor Nick Talley

Could problems in the gut be the cause of disorders such as anxiety and chronic fatigue? World-leading neurogastroenterologist Professor Nicholas J. Talley believes so, with his research showing that the causes of many diseases may lie in the stomach.

With a number of world-firsts and achievements in gastroenterological research under his belt, the Pro Vice-Chancellor of the Faculty of Health and Medicine at the University of Newcastle believes each of his discoveries together paint a hypothesis for gut disorders and general health.

Professor Talley, who is also the President-Elect of the Royal Australasian College of Physicians, said this research provides a paradigm shift in the causes of a number of diseases.

"Millions of people suffer from unidentified gut diseases worldwide, with some of these disorders affecting 10 to 20 per cent of the population. It is awful for these people and, in many cases, heavily impacts on their professional and personal lives," Professor Talley said.

"Our discoveries which have ranged from being the first to discover a genetic mutation in a subset of Irritable Bowel Syndrome (IBS) to a pathological link between bacteria and functional dyspepsia are helping explain the unexplained.  What is most interesting is what this research is also showing us about other disorders," he said.

"There has long been a theory that the brain drives psychological disorders, but we are unearthing growing evidence that the gut is the cause in many cases," Professor Talley said.

"Data is indicating that a third of anxiety disorders are actually being activated from the gut. This could mean that if we treat the gut we could cure diseases like anxiety," he said.

People with gut disorders often suffer from complaints like fatigue, back-ache or generalised flu-like symptoms. Doctors have traditionally attributed these problems to being psychological issues rather than symptomatic. 

"When you have the flu, the heavy unwell feeling you are experiencing through your body is what we call a 'cytokine' storm. Cytokines are small proteins that are important in cell signalling. They are there to calm inflammation, but often actually upset the body," Professor Talley said.

Professor Talley and his team are investigating cytokine profiling through a National Health and Medical Research Council grant and said that answers to many diseases lies in this research.

"The gut is one of the body's first lines of defence. Germs and or foods are critically important in how effective the gut lining is in protecting the body," Professor Talley said.

"Research is supporting our theory that food allergies and infection drive holes in that lining which turns on the immune system, fires up the cytokines, turning on inflammatory white blood cells called eosinophils which then manifest into disease," he said.

"If we are right, we can turn down the immune system a little bit, turn off the cytokines, and cure many diseases."

Talley's theory provides a paradigm shift in thinking and is already influencing other disease models with research data indicating that the gut could also be the cause of skin disorders, like psoriasis and dermatitis.  

Burning ambition

Listing over 1,000 publications and receiving more than $10 million in grants, Professor Talley's expertise has seen him receive numerous awards and accolades, including the 2014 American Gastroenterological Association Distinguished Educator Award. Professor Talley is also the author of the highly regarded textbooks Clinical Examination and Examination Medicine with Dr Simon O'Connor.

An academic clinician, researcher and scientist, Professor Talley has built a growing reputation of excellence for gastroenterology research at the University of Newcastle and the Hunter Medical Research Institute.

Professor Talley's impressive record includes recently discovering the bowel disease, duodenal eosinophilia. The disease is found in 40 per cent of people suffering from functional dyspepsia, a previously unexplained and severe form of indigestion that displays burning symptoms.

"Eosinophils are inflammatory white blood cells that release all kinds of 'nasties'.  Their purpose is to kill off parasites or fight an infection or food allergy. However, like cytokines, they often also aggravate the body," Professor Talley said.

"We have been able to prove that inflammation in the gut is an important activator for disease, a fact that is now becoming well accepted but certainly was not when we started this work," he said.

Building on this discovery, Professor Talley has also found a link to duodenal eosinophilia in children suffering from Recurrent Abdominal Pain (RAP).

The discovery of duodenal eosinophilia was a critical breakthrough and Professor Talley and his team are now testing a novel therapeutic strategy that could provide a new treatment.

Gut central

During his time as Chair of the Department of Internal Medicine at the prestigious Mayo Clinic in America, Professor Talley also led a team that for the first time discovered a genetic mutation that causes a subset of IBS.

Located in the sodium genetic channel in the gastrointestinal muscle, Professor Talley said the genetic mutation affects three per cent of people with IBS

"Fifteen to 20 per cent of people in western society suffer from IBS. It affects the large intestine and many patients experience cramping, constipation, abdominal pain, diarrhoea and more," Professor Talley said.

Professor Talley has also identified a main cause of IBS, showing that a bacteria previously thought to be a 'nothing' bacteria with no pathological or symptom link, was in fact more than three times likely to be found in people with IBS.

The colonic spirochaete is a large bacterium that sits along the surface of the cells of the bowel and Professor Talley has also identified a link between the spirochaete and eosinophils.

"Discovering a mutation in the gene and a protein abnormality is exciting, because we can find a way to intervene and alleviate these symptoms. The next stage is looking at blood tests and biomarkers for these syndromes.

"With the discovery of a new pathology, a new association and a new disease, we are piecing together the mysteries of the gut that ultimately are leading to new treatments to ease and prevent suffering for millions."

Watch Dr Nick Talley's appearance on the SBS Insight television program which was aired on Tuesday 10th June 2014. The topic of discussion was "Are we in denial about alcohol?"

Gut feeling

Could problems in the gut be the cause of disorders such as anxiety and chronic fatigue? World-leading neurogastroenterologist Professor Nicholas J. Talley believes so, with his research showing that the causes of many diseases may lie in the stomach.With a…

Read more

Career Summary

Biography

Laureate Professor Nick Talley is Pro Vice Chancellor, Global Research, after 4 years as Pro Vice-Chancellor, Faculty of Health and Medicine at the University of Newcastle, in Australia, and Professor of Medicine. He was formerly Chair of the Department of Internal Medicine at Mayo Clinic in Jacksonville, Florida where he held the rank of Professor of Medicine at the Mayo Clinic College of Medicine; he also held the rank of Professor of Epidemiology.

Previously, Nick was the Director of the Motility Interest Group in the Division of Gastroenterology and Hepatology at Mayo Clinic, Rochester, Minnesota, and before that was the Foundation Professor of Medicine at the University of Sydney, Nepean Hospital. He currently holds adjunct research appointments as Professor at Mayo Clinic, University of North Carolina and the Karolinska Institute. He undertook his undergraduate medical degree at the University of New South Wales, and holds doctorates from his alma mater and the University of Sydney as well as a Masters degree from the University of Newcastle. Nick is currently co-editor-in-chief of Alimentary Pharmacology & Therapeutics.

Previously, he was co-editor-in-chief of the American Journal of Gastroenterology, and serves on a number of prominent editorial boards. He is a founding member and Director of the Rome Foundation, a past President of the Functional Brain-Gut Research Group, was a counselor in the American Gastroenterology Association Motility Section, and served as a member of the Board of the American College of Gastroenterology. He currently serves as a Director on the Board of the Hunter Medical Research Institute in Newcastle.

He is a Fellow of the Royal Australasian College of Physicians, Royal College of Physicians (both London and Edinburgh), and the American College of Physicians. Nick is a Visiting Medical Officer at the John Hunter Hospital in Newcastle. Nick has a deep interest in medical education and has authored a number of prominent textbooks. His popular student textbook, "Clinical Examination: A Systematic Guide to Physical Diagnosis", is in its 6th edition and is distributed worldwide.

Nick's research is primarily focused on functional gastrointestinal disorders, dyspepsia, Helicobacter pylori, gastroesophageal reflux disease, and eosinophilic disorders of the gut. He has recently described with his team a new disease entity in adults, eosinophilic duodenitis, linked to functional dyspepsia. His group has documented a genetic component in upper and lower functional bowel diseases. He has published over 700 original and review articles in the peer-reviewed literature, and he is considered one of the world's leading authorities in clinical research on the stomach. He currently has research support as a Chief Investigator from the National Health and Medical Research Council, and has been funded as a Principal Investigator (RO1) by the National Institutes of Health in the USA.

Research Expertise
Neurogastroenteology - particularly Functional Gastrointestinal disorders, Irritable bowel syndrome, Dyspepsia, Eosinophilic Gastrointestinal disorders, Eosinophilic Oesophagitis, Gastroparesis.

Collaborations
- Neurogastroenteology - Functional gastrointestinal disorders - Irritable bowel syndrome - Dyspepsia - Eosinophilic Gastrointestinal disorders - Eosinophilic Oesophagitis - Gastroparesis


Qualifications

  • Doctor of Medicine, University of New South Wales
  • Bachelor of Medicine, Bachelor of Surgery, University of New South Wales
  • PhD, University of Sydney
  • Master of Medical Science (Clinical Epidemiology), University of Newcastle

Keywords

  • Dyspepsia
  • Gastroparesis
  • Neurogastroenteology

Fields of Research

CodeDescriptionPercentage
111799Public Health and Health Services not elsewhere classified40
110399Clinical Sciences not elsewhere classified30
160599Policy and Administration not elsewhere classified30

Professional Experience

UON Appointment

DatesTitleOrganisation / Department
1/03/2015 - 29/02/2020Pro Vice-Chancellor (Global ResearcUniversity of Newcastle
Office - DVC (Research and Innovation)
Australia

Professional appointment

DatesTitleOrganisation / Department
1/03/2015 - 1/01/2020Pro Vice-Chancellor (Global Research) & Laureate ProfessorUniversity of Newcastle
Office - DVC (Research and Innovation)
Australia

Awards

Honours

YearAward
2014NSW Science and Engineering Awards - Excellence in Biological Sciences
Office of the NSW Chief Scientist and Engineer

Recognition

YearAward
2014Distinguished Educator Award
American Gastroenterological Association
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Book (14 outputs)

YearCitationAltmetricsLink
2010Talley NJ, Clinical Examination. A Systematic Guide to Physical Diagnosis, Elsevier, Amsterdam, Netherlands, 480 (2010) [A1]
2010Talley NJ, Examination Medicine. A Guide to Physician Training, Elsevier, Amsterdam, Netherlands, 396 (2010)
2010Talley NJ, Clinical Gastroenterology: a practical problem-based approach, Elsevier, Amsterdam, Netherlands, 405 (2010) [A4]
2010Talley NJ, Devault KR, Fleischer DE, Practical Gastroenterology and Hepatology: Esophagus and Stomach, John Wiley & Sons, New York, 442 (2010) [A3]
2010Talley NJ, Kane SV, Wallace MB, Practical Gastroenterology and Hepatology: Small and Large Intestine and Pancreas, Blackwell Publishing, Oxford, 508 (2010) [A3]
CitationsScopus - 2
2010Talley NJ, Practical Gastroenterology and Hepatology, Wiley-Blackwell, Hoboken, New Jersey, United States of America, 544 (2010) [A1]
CitationsScopus - 1
2010Talley NJ, Lindor KD, Vargas HE, Gastroenterology and Hepatology: Liver and Biliary Disease, Blackwell Publishing, Oxford, 393 (2010) [A3]
2009Talley NJ, O'Connor S, Pocket Clinical Examination 3rd Edition, Elsevier, Amsterdam, Netherlands, 238 (2009) [A1]
2007Talley NJ, Locke GR, Saito YA, GI Epidemology, Blackwell Publishing, Malden, Massachusetts, United States of America, 288 (2007) [A1]
CitationsScopus - 6
2005Talley NJ, O'Connor S, Pocket Clinical Examination 2nd Edition, Elsevier, Amsterdam, Netherlands, 260 (2005) [A1]
2005Talley NJ, O'Connor S, Clinical Examination. A Systematic Guide to Physical Diagnosis, Elsevier, Amsterdam, Netherlands, 520 (2005) [A1]
2005Talley NJ, O'Connor S, Examination Medicine. A Guide to Physician Training, Elsevier, Amsterdam, Netherlands, 369 (2005) [A1]
2005Talley NJ, Conquering Irritable Bowel Syndrome, BC Decker, Hamilton, Canada, 198 (2005) [A1]
1999Kalantar J, Eslick GD, Talley NJ, Chronic gastritis and nonulcer dyspepsia, SPRINGER-VERLAG BERLIN, 15 (1999)
Author URL
CitationsScopus - 2Web of Science - 1
Show 11 more books

Chapter (13 outputs)

YearCitationAltmetricsLink
2013Talley NJ, 'Foreword', Irritable Bowel Syndrome: Diagnosis and Clinical Management, John Wiley & Sons, Chichester, UK ix-x (2013)
DOI10.1002/9781118444689Author URL
2013Koloski NA, Talley NJ, 'Irritable Bowel Syndrome', Women and Health, Elsevier Inc. 1353-1365 (2013) [B2]
DOI10.1016/B978-0-12-384978-6.00092-3
2012Moshiree B, Bollipo S, Horowitz M, Talley NJ, 'Epidemiology of gastroparesis', Gastroparesis. Pathophysiology, Presentation and Treatment, Springer, New York 11-23 (2012) [B1]
2010Chang JY, Talley NJ, 'Eosinophilic gastroenteritis', Practical Gastroenterology and Hepatology: Esophagus and Stomach, John Wiley & Sons, Hoboken 292-396 (2010) [B1]
DOI10.1002/9781444327311.ch50
2010Devault KR, Bouras EP, Talley NJ, 'Esophageal and gastric motor function', Practical Gastroenterology and Hepatology: Esophagus and Stomach, John Wiley & Sons, Hoboken 9-15 (2010) [B1]
2008Saito YA, Talley NJ, Locke GR, 'Irritable Bowel Syndrome', GI Epidemiology, Blackwell Publishing Ltd 176-183 (2008) [B2]
DOI10.1002/9780470692189.ch24
CitationsScopus - 2
2008Vakil NB, Talley NJ, 'Dyspepsia', GI Epidemiology, Blackwell Publishing Ltd 143-148 (2008) [B2]
DOI10.1002/9780470692189.ch19
2008Talley NJ, Locke GR, Saito YA, 'Preface', , Blackwell Publishing Ltd (2008) [B2]
DOI10.1002/9780470692189
2008Locke GR, Talley NJ, 'The Importance of GI Epidemiology', GI Epidemiology, Blackwell Publishing Ltd 1-7 (2008) [B2]
DOI10.1002/9780470692189.ch1
2008Talley NJ, 'Gastroesophageal reflux disease in the context of irritable bowel syndrome', From Gastrin to GERD, Felsenstein CCCP, Hannover, Germany 1079-1086 (2008) [B1]
2006Talley NS, 'Normal and abnormal esophageal motility', Mayo Clinic Gastroenterology and Hepatology Board Review, Taylor & Francis, London, United Kingdom 35-42 (2006) [B1]
2004Walker M, Talley NJ, 'Duodenitis', Encyclopedia of Gastroenterology, Elsevier, San Diego, United States 653-654 (2004) [B1]
DOI10.1016/B0-12-386860-2/00199-4
Co-authorsMarjorie Walker
2003Talley NJ, 'Is irritable bowel syndrome a genetic disorder?', Gastrointestinal Inflammation and Disturbed Gut Function: The Challenge of New Concepts, Kluwer, Dordecht, The Netherlands 245-252 (2003) [B1]
Show 10 more chapters

Journal article (1298 outputs)

YearCitationAltmetricsLink
2015Keightley PC, Koloski NA, Talley NJ, 'Pathways in gut-brain communication: Evidence for distinct gut-to-brain and brain-to-gut syndromes', AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 49 207-214 (2015)
DOI10.1177/0004867415569801Author URL
CitationsScopus - 1Web of Science - 1
2015Keshteli AH, Feizi A, Esmaillzadeh A, Zaribaf F, Feinle-Bisset C, Talley NJ, Adibi P, 'Patterns of dietary behaviours identified by latent class analysis are associated with chronic uninvestigated dyspepsia', British Journal of Nutrition, 113 803-812 (2015)

To our knowledge, no study has assessed the relationships between patterns of dietary behaviours, identified by latent class analysis (LCA), and chronic uninvestigated dyspepsia (... [more]

To our knowledge, no study has assessed the relationships between patterns of dietary behaviours, identified by latent class analysis (LCA), and chronic uninvestigated dyspepsia (CUD). The present study was conducted to determine the association between the patterns of dietary behaviours, identified by LCA, and CUD in a large sample of adults. In a cross-sectional study conducted on 4763 Iranian adults, we assessed the patterns of dietary behaviours in four domains, including 'meal patterns', 'eating rate', 'intra-meal fluid intake' and 'meal-to-sleep interval', as identified by LCA, using a pre-tested comprehensive questionnaire. Patients with CUD were identified using the Rome III diagnostic criteria. CUD was prevalent in 15·2% (95% CI 14·4, 16·2%; n 723) of patients. Early satiation occurred in 6·3% (n 302) of patients, bothersome postprandial fullness in 8·0% (n 384) of patients and epigastric pain in 7·8% (n 371) of patients. We defined two distinct classes of meal patterns: 'regular' and 'irregular'. For eating rates, three classes were defined: 'moderate', 'moderate-to-slow' and 'moderate-to-fast'. Participants were identified as ingesting fluid with meals in two major classes: 'moderate intra-meal drinking' and 'high intra-meal drinking'. In terms of the interval between meals and sleeping, two distinct classes were identified: 'short meal-to-sleep interval' and 'long meal-to-sleep interval'. After controlling for potential confounders, the 'irregular meal pattern' was significantly associated with a greater odds of CUD (OR 1·42, 95% CI 1·12, 1·78) compared with a 'regular meal pattern'. Individuals with a 'moderate-to-fast eating rate' were more likely to have CUD compared with those who had a 'moderate eating rate' (OR 1·42, 95% CI 1·15, 1·75). Patterns of the 'meal-to-sleep interval' and 'intra-meal fluid intake' were not significantly associated with CUD. In conclusion, the 'irregular meal pattern' and the 'moderate-to-fast eating rate' were significantly associated with a greater odds of CUD. Further prospective investigations are warranted to confirm this association.

DOI10.1017/S0007114514004140
2015Talley NJ, Locke GR, Saito YA, Almazar AE, Bouras EP, Howden CW, et al., 'Effect of Amitriptyline and Escitalopram on Functional Dyspepsia: a Multi-Center, Randomized, Controlled Study.', Gastroenterology, (2015)
DOI10.1053/j.gastro.2015.04.020
2015Knight JR, Locke GR, Zinsmeister AR, Schleck CD, Talley NJ, 'Family history of mental illness or alcohol abuse and the irritable bowel syndrome', Journal of Psychosomatic Research, 78 237-241 (2015)

We have observed that many patients with IBS drink very little alcohol and postulated that this may reflect membership in families affected by alcoholism and mental illness. We ai... [more]

We have observed that many patients with IBS drink very little alcohol and postulated that this may reflect membership in families affected by alcoholism and mental illness. We aimed to evaluate whether a family history of substance or alcohol abuse, or psychiatric illness, is associated with IBS. Methods: A valid GI questionnaire was mailed to a randomly selected population-based cohort to identify IBS and healthy controls. The electronic medical record was reviewed to record the subjects' self-reported personal and family health histories. Results: A total of 2300 subjects responded (response rate 55%; IBS 13%, n = 287); 230 subjects with IBS and 318 controls were eligible. Family history of alcohol/substance abuse was reported by 33% of cases and 25% of controls (OR = 1.4, 95% CI = 1.0-2.1, p = 0.06). Family history of psychiatric illness was reported by 37% of cases and 22% of controls (OR = 2.0, 95% CI = 1.3-2.9, p < 0.001). In the absence of a personal history of alcohol use, a family history of alcohol/substance abuse was predictive of IBS status (OR adjusted for age and gender = 1.5, 95% CI = 1.0-2.3, p = 0.05). In the absence of a personal history of alcohol use, reporting both a family history of alcohol/substance abuse and anxiety/depression/mental illness was clearly predictive of IBS status (OR = 2.5, 95% CI = 1.4-4.5; p < 0.005). Substance abuse as a child was associated with an increased risk of IBS (OR = 2.3, 95% CI = 1.1-4.8; p < 0.03). Conclusion: IBS is independently associated with a family history of psychiatric illness and may be linked to a family history of alcohol/substance abuse.

DOI10.1016/j.jpsychores.2014.11.021
2015Herrick LM, Locke GR, Schleck CD, Zinsmeister AR, Treder V, Talley NJ, 'Dyspepsia in the community: value of a community-based mailed survey to identify potential participants for a randomized clinical trial.', Scandinavian journal of gastroenterology, 50 959-964 (2015)
DOI10.3109/00365521.2014.980317
2015Crowell MD, Umar SB, Lacy BE, Jones MP, DiBaise JK, Talley NJ, 'Multi-Dimensional Gastrointestinal Symptom Severity Index: Validation of a Brief GI Symptom Assessment Tool', Digestive Diseases and Sciences, (2015)

Abstract: Few instruments have been developed and validated for the evaluation of multi-dimensional GI symptoms. The Gastrointestinal Symptoms Severity Index (GISSI), a multi-dime... [more]

Abstract: Few instruments have been developed and validated for the evaluation of multi-dimensional GI symptoms. The Gastrointestinal Symptoms Severity Index (GISSI), a multi-dimensional, self-report instrument, was designed as a brief measure of the frequency, severity, and bothersomeness of individual GI and pelvic floor/urogynecologic symptoms. Aim: To report the psychometric properties of the GISSI subscales, including factorial structure, validity, and internal consistency. Methods: The GISSI included 32 items that assessed upper and lower GI symptoms and seven items related to pelvic floor/urogynecologic symptoms. A total of 934 patients presenting for upper and lower GI complaints completed the questionnaire between January 2013 and December 2013. The sample was randomly split into derivation (n = 466) and validation datasets (n = 468). A non-patient sample of 200 was collected separately. Results: Exploratory factor analysis supported a six-factor model for the derivation sample that accounted for 69.3 % of the total variance. The six GI symptom clusters were labeled as constipation/difficult defecation (five items), abdominal pain/discomfort (four items), dyspepsia (four items), diarrhea/anal incontinence (four items), GERD/chest symptoms (four items), and nausea/vomiting (two items). Inclusion of additional items related to female pelvic floor/urogynecologic symptoms resulted in a separate factor. Confirmatory factor analysis of the validation dataset supported the a priori hypothesized six-factor measurement model (¿2(428) = 1462.98; P < 0.001; GFI = .88; RMSEA = .051). Conclusion: The GISSI demonstrated good to excellent psychometric properties and provided multi-dimensional scaling of prominent GI symptom clusters. Further validation may provide an efficient, valid, and reliable measure of patient-reported clinical outcomes.

DOI10.1007/s10620-015-3647-3
2015Elias MK, Kopacova J, Arora AS, Dierkhising RA, Enders FT, Katzka DA, et al., 'The Diagnosis of Esophageal Eosinophilia is Not Increased in the Summer Months', Dysphagia, 30 67-73 (2015)

Smaller studies have suggested seasonal variation of the diagnosis of eosinophilic esophagitis with more patients being diagnosed in the aeroallergen season. We evaluated a large ... [more]

Smaller studies have suggested seasonal variation of the diagnosis of eosinophilic esophagitis with more patients being diagnosed in the aeroallergen season. We evaluated a large group of adult patients for a seasonal variation of the diagnosis of symptomatic eosinophilic esophageal infiltration. We performed a retrospective review of adult patients from a large Eosinophilic esophagitis database at the Mayo Clinic Rochester. We only included patients from three states in the upper Midwest, who had 15 or more eosinophils per high-power field on esophageal biopsy, symptomatic dysphagia, and were seen, in our Gastroenterology Clinic between 2000 and 2008. Clinical data were abstracted and the month of diagnosis was determined. The Rayleigh circular test and the Chi-square goodness-of-fit test were used to detect seasonality of symptomatic esophageal eosinophilia diagnosis and seasonality corrected for esophagogastroduodenoscopy monthly volume. The diagnosis of symptomatic eosinophilic esophageal infiltration was made in 372 patients. The mean number of eosinophils was 39.6 per high-power field. The December/January and May/June periods seem to have an increased presentation rate (p¿=¿0.014). Of those tested, reactions to any aeroallergen was present in 69¿% (48/70), reactions to >4 aeroallergens in 47¿% (33/70) and reactions to any food allergen in 63¿% (50/80) of patients. There was no evidence of monthly concentration of symptomatic esophageal eosinophilia diagnosis in the subgroups of patients with any positive aeroallergen, >4 positive aeroallergens, or history of atopy. The diagnosis of symptomatic esophageal eosinophilia is not made more frequently in the summer months.

DOI10.1007/s00455-014-9574-1
2015Koloski NA, Jones M, Young M, Talley NJ, 'Differentiation of functional constipation and constipation predominant irritable bowel syndrome based on Rome III criteria: A population-based study', Alimentary Pharmacology and Therapeutics, (2015)

While the Rome III classification recognises functional constipation (FC) and constipation predominant IBS (IBS-C) as distinct disorders, recent evidence has suggested that these ... [more]

While the Rome III classification recognises functional constipation (FC) and constipation predominant IBS (IBS-C) as distinct disorders, recent evidence has suggested that these disorders are difficult to separate in clinical practice. Aim: To identify whether clinical and lifestyle factors differentiate Rome III-defined IBS-C from FC based on gastrointestinal symptoms and lifestyle characteristics. Method: 3260 people randomly selected from the Australian population returned a postal survey. FC and IBS-C were defined according to Rome III. The first model used logistic regression to differentiate IBS-C from FC based on lifestyle, quality-of-life and psychological characteristics. The second approach was data-driven employing latent class analysis (LCA) to identify naturally occurring clusters in the data considering all symptoms involved in the Rome III criteria for IBS-C and FC. Results: We found n = 206 (6.5%; 95% CI 5.7-7.4%) people met strict Rome III FC whereas n = 109 (3.5%; 95% CI 2.8-4.1%) met strict Rome III IBS-C. The case-control approach indicated that FC patients reported an older age at onset of constipation, were less likely to exercise, had higher mental QoL and less health care seeking than IBS-C. LCA yielded one latent class that was predominantly (75%) FC, while the other class was approximately half IBS-C and half FC. The FC-dominated latent class had clearly lower levels of symptoms used to classify IBS (pain-related symptoms) and was more likely to be male (P = 0.046) but was otherwise similar in distribution of lifestyle factors to the mixed class. Conclusion: The latent class analysis approach suggests a differentiation based more on symptom severity rather than the Rome III view.

DOI10.1111/apt.13149
2015Koloski NA, Jones M, Young M, Talley NJ, 'Differentiation of functional constipation and constipation predominant irritable bowel syndrome based on Rome III criteria: A population-based study', Alimentary Pharmacology and Therapeutics, 41 856-866 (2015)

Background: While the Rome III classification recognises functional constipation (FC) and constipation predominant IBS (IBS-C) as distinct disorders, recent evidence has suggested... [more]

Background: While the Rome III classification recognises functional constipation (FC) and constipation predominant IBS (IBS-C) as distinct disorders, recent evidence has suggested that these disorders are difficult to separate in clinical practice. Aim: To identify whether clinical and lifestyle factors differentiate Rome III-defined IBS-C from FC based on gastrointestinal symptoms and lifestyle characteristics. Method: 3260 people randomly selected from the Australian population returned a postal survey. FC and IBS-C were defined according to Rome III. The first model used logistic regression to differentiate IBS-C from FC based on life-style, quality-of-life and psychological characteristics. The second approach was data-driven employing latent class analysis (LCA) to identify naturally occurring clusters in the data considering all symptoms involved in the Rome III criteria for IBS-C and FC. Results: We found n = 206 (6.5%; 95% CI 5.7-7.4%) people met strict Rome III FC whereas n = 109 (3.5%; 95% CI 2.8-4.1%) met strict Rome III IBS-C. The case-control approach indicated that FC patients reported an older age at onset of constipation, were less likely to exercise, had higher mental QoL and less health care seeking than IBS-C. LCA yielded one latent class that was predominantly (75%) FC, while the other class was approximately half IBS-C and half FC. The FC-dominated latent class had clearly lower levels of symptoms used to classify IBS (pain-related symptoms) and was more likely to be male (P = 0.046) but was otherwise similar in distribution of lifestyle factors to the mixed class. Conclusion: The latent class analysis approach suggests a differentiation based more on symptom severity rather than the Rome III view.

DOI10.1111/apt.13149
CitationsScopus - 2
2015Walker MM, Talley NJ, Inganäs L, Engstrand L, Jones MP, Nyhlin H, et al., 'Colonic spirochetosis is associated with colonic eosinophilia and irritable bowel syndrome in a general population in Sweden', Human Pathology, 46 277-283 (2015)

Irritable bowel syndrome (IBS) is a functional disorder defined by symptoms in the absence of overt pathology. Colonic spirochetosis (CS), defined by histologic observation of spi... [more]

Irritable bowel syndrome (IBS) is a functional disorder defined by symptoms in the absence of overt pathology. Colonic spirochetosis (CS), defined by histologic observation of spirochetal strains of Brachyspira in colonic biopsies, is uncommon and considered of doubtful significance. We aimed to determine the prevalence of CS in the general population, identify subtle colon pathologies, and evaluate a link with symptoms of IBS. Colonoscopy was performed in 745 subjects (aged 19-70 years, mean age 51 years, 43% male) with biopsies (ileum and 4 colonic sites) from a random population sample, Stockholm, Sweden, who completed a validated questionnaire of gastrointestinal symptoms; IBS was identified by Rome III criteria. CS was identified by histology and immunohistochemistry. In a general population, 17 individuals (2.28%; 95% confidence interval, 1.2%-3.5%) were diagnosed as having CS by histology; 6 (35%) had IBS. CS was always present in the sigmoid colon, but only 14 rectal biopsies. Eosinophils were increased in colon biopsies in CS cases versus controls, in the transverse (P =.02), sigmoid colon (P =.001), and rectum (P =.0005) with subepithelial eosinophil clusters (P =.053). Lymphoid follicles (at any site) were present in 13 CS (P =.0003). There was a 3-fold increased risk of IBS in CS (odds ratio, 3.59; 95% confidence interval, 1.27-10.11; P =.015). Polyps and diverticular disease were similar in CS cases and controls. The prevalence of CS in a general population is 2% and associated with nonconstipating IBS. Colonic eosinophilia with lymphoid follicles may signify the presence of CS.

DOI10.1016/j.humpath.2014.10.026
CitationsScopus - 2Web of Science - 1
Co-authorsMarjorie Walker
2015Walker MM, Talley NJ, Inganäs L, Engstrand L, Jones MP, Nyhlin H, et al., 'Colonic spirochetosis is associated with colonic eosinophilia and irritable bowel syndrome in a general population in Sweden', Human Pathology, 46 277-283 (2015)
DOI10.1016/j.humpath.2014.10.026
Co-authorsMarjorie Walker
2015Brummond NR, Saito YA, Locke GR, Larson JJ, Atkinson EJ, Romero Y, Talley NJ, 'Letter: Role of GNß3 polymorphisms in oesophageal adenocarcinoma and gastroesophageal reflux disease', Alimentary Pharmacology and Therapeutics, 41 600-601 (2015)
DOI10.1111/apt.13094
2015Cho SY, Choung RS, Saito YA, Schleck CD, Zinsmeister AR, Locke GR, Talley NJ, 'Prevalence and risk factors for dysphagia: A USA community study', Neurogastroenterology and Motility, 27 212-219 (2015) [C1]

Background: Dysphagia is considered an alarm symptom but detailed population-based data on dysphagia are lacking. We aimed to estimate in a representative USA Caucasian population... [more]

Background: Dysphagia is considered an alarm symptom but detailed population-based data on dysphagia are lacking. We aimed to estimate in a representative USA Caucasian population, the prevalence of dysphagia and potential risk factors. Methods: A modified version of the previously validated Bowel Disease Questionnaire was mailed to a population-based cohort (n¿=¿7640) of Olmsted County, MN. Dysphagia was measured by one validated question 'In the last year, how often have you had difficulty swallowing (a feeling that food sticks in your throat or chest)?' The medical records were reviewed for organic causes of dysphagia. The associations of reported frequency of dysphagia with potential risk factors were assessed using logistic regression models. Key Results: The sex-specific, age-adjusted (US White 2000) prevalence for dysphagia experienced at least weekly was 3.0% (95% CI: 2.2, 3.7) in females and 3.0% (95% CI: 2.0, 4.0) in males. Those with frequent heartburn (OR¿=¿5.9 [4.0, 8.6]) and acid regurgitation (OR¿=¿10.6 [6.8, 16.6]) were significantly more likely to report frequent dysphagia. Proton pump inhibitor (PPI) use was significantly associated with frequent (3.1, 95% CI 2.2, 4.4) and infrequent dysphagia (1.5, 955 CI 1.3, 1.8). Gastro-esophageal reflux disease (GERD) was the most common diagnosis in those reporting dysphagia on the medical record; other organic explanations were rare and only found in the frequent dysphagia group. Conclusions & Inferences: Frequent dysphagia is not rare in the community (3%), occurs in both women and men across all adult age groups, and is most likely to indicate underlying GERD.

DOI10.1111/nmo.12467
2015Keshteli AH, Feizi A, Esmaillzadeh A, Zaribaf F, Feinle-Bisset C, Talley NJ, Adibi P, 'Patterns of dietary behaviours identified by latent class analysis are associated with chronic uninvestigated dyspepsia.', Br J Nutr, 113 803-812 (2015)
DOI10.1017/S0007114514004140Author URL
2015Brummond NR, Locke GR, Choung RS, Chang JY, Schleck CD, Zinsmeister AR, Talley NJ, 'Effects of Birth Cohorts on the Irritable Bowel Syndrome Support Early-Life Risk Factors.', Dig Dis Sci, 60 2112-2118 (2015)
DOI10.1007/s10620-015-3565-4Author URL
2015Elias MK, Kopacova J, Arora AS, Dierkhising RA, Enders FT, Katzka DA, et al., 'The diagnosis of esophageal eosinophilia is not increased in the summer months.', Dysphagia, 30 67-73 (2015)
DOI10.1007/s00455-014-9574-1Author URL
2015Zala AV, Walker MM, Talley NJ, 'Emerging drugs for functional dyspepsia.', Expert Opin Emerg Drugs, 20 221-233 (2015)
DOI10.1517/14728214.2015.1009827Author URL
CitationsScopus - 1
Co-authorsMarjorie Walker
2015Aro P, Talley NJ, Johansson SE, Agréus L, Ronkainen J, 'Anxiety Is Linked to New-Onset Dyspepsia in the Swedish Population: A 10-Year Follow-up Study.', Gastroenterology, 148 928-937 (2015)
DOI10.1053/j.gastro.2015.01.039Author URL
2015Knight JR, Locke GR, Zinsmeister AR, Schleck CD, Talley NJ, 'Family history of mental illness or alcohol abuse and the irritable bowel syndrome.', J Psychosom Res, 78 237-241 (2015)
DOI10.1016/j.jpsychores.2014.11.021Author URL
2015Holtmann G, Talley NJ, 'Herbal medicines for the treatment of functional and inflammatorybowel disorders', Clinical Gastroenterology and Hepatology, 13 422-432 (2015)

In many parts of the world, there continues to be a long-standing tradition of prescribing herbal products for a range of gastrointestinal conditions. Scientific evidence supporti... [more]

In many parts of the world, there continues to be a long-standing tradition of prescribing herbal products for a range of gastrointestinal conditions. Scientific evidence supporting the use of all herbal preparations is imperfect, however, and available studies are plagued by methodological limitations. For functional gastrointestinal disorders, there is limited evidence supporting the use of some well-characterized preparations. A number of herbals have immunomodulatory activity, and in inflammatory bowel disease there are limited positive placebo-controlled trials; other studies used active controls with suboptimal doses of the comparators. Like all drugs, herbals can lead to serious adverse events (eg, hepatic failure). Quality control is a serious issue to consider when prescribing herbal medicines. Many herbal preparations are marketed without evidence for stringent adherence to good manufacturing practice guidelines. Unpredictable environmental conditions may affect the composition and the concentration of the active ingredients of plant extracts. Further, commercial herbal products usually combine a variable plethora ofchemical families with possible medicinal utility. While some of these ingredients might be of benefit, the concentration and dose of these constituents needs to be closely monitored. Physicians and regulators need to remain very cautious about the use of herbal remedies. Appropriate scientific evidence for the claimed clinical benefits should become mandatory worldwide, and the standards for production and safety monitoring should comply with established standards for chemically defined products. If these principles were adopted, the full value of herbal remedies may come to light, particularly as the individually bioactive compounds present in these preparations become recognized.

DOI10.1016/j.cgh.2014.03.014
CitationsScopus - 1
2015Koloski NA, Jones M, Young M, Talley NJ, 'Differentiation of functional constipation and constipation predominant irritable bowel syndrome based on Rome III criteria: a population-based study', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 41 856-866 (2015)
DOI10.1111/apt.13149Author URL
CitationsWeb of Science - 2
2015Cho SY, Choung RS, Saito YA, Schleck CD, Zinsmeister AR, Locke GR, Talley NJ, 'Prevalence and risk factors for dysphagia: a USA community study', NEUROGASTROENTEROLOGY AND MOTILITY, 27 212-219 (2015) [C1]
DOI10.1111/nmo.12467Author URL
2015Aro P, Talley NJ, Johansson S-E, Agréus L, Ronkainen J, 'Anxiety is linked to new-onset dyspepsia in the Swedish population: A 10-year follow-up study', Gastroenterology, 148 928-937 (2015)

Background & Aims Functional dyspepsia (FD) is associated with anxiety but it is not clear if one causes the other. We investigated whether anxiety and depression precede the onse... [more]

Background & Aims Functional dyspepsia (FD) is associated with anxiety but it is not clear if one causes the other. We investigated whether anxiety and depression precede the onset of FD (based on the modified Rome III criteria) and gastroesophageal reflux symptoms (GERS) in a population-based follow-up study. Methods Participants from the Kalixanda study (n = 3000), randomly selected from the national population register of Sweden, were given the validated Abdominal Symptom Questionnaire 1998-2001; 1000 of these participants then were selected randomly to undergo esophagogastroduodenoscopy and were given the Abdominal Symptom Questionnaire along with the Hospital Anxiety and Depression Scale questionnaire. All eligible subjects who underwent endoscopy (n = 887) were invited to participate in a follow-up study in June-August 2010 and were given the same questionnaires. Data were analyzed by logistic regression. Results Of the 703 subjects who completed the follow-up questionnaires (79.3%); 110 were found to have FD at baseline (15.6%) and 93 at the follow-up examination (13.3%); 48 of these were new cases of FD. GERS without organic disease was reported by 273 individuals (38.8%) at baseline and by 280 at follow-up examination (39.8%); 93 cases were new. Major anxiety was associated with FD at the follow-up evaluation (odds ratio [OR], 6.30; 99% confidence interval [CI], 1.64-24.16). Anxiety was associated with postprandial distress syndrome at baseline (OR, 4.83; 99% CI, 1.24-18.76) and at the follow-up examination (OR, 8.12; 99% CI, 2.13-30.85), but not with epigastric pain syndrome. Anxiety at baseline was associated with new-onset FD at the follow-up examination (OR, 7.61; 99% CI, 1.21-47.73), but not with GERS. Conclusions In a study of the Swedish population, anxiety at baseline, but not depression, increased the risk for development of FD by 7.6-fold in the next 10 years. Anxiety did not affect risk for GERS.

DOI10.1053/j.gastro.2015.01.039
2015Forsberg A, Kjellstrom L, Andreasson A, Jaramillo E, Rubio CA, Bjorck E, et al., 'Colonoscopy findings in high-risk individuals compared to an average-risk control population', SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 50 866-874 (2015)
DOI10.3109/00365521.2014.966317Author URL
2015Talley NJ, Koloski NA, Jones MP, 'Editorial: differentiating chronic idiopathic constipation from constipation-predominant irritable bowel syndrome - possible and important? - Authors' reply', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 41 1300-1300 (2015)
DOI10.1111/apt.13219Author URL
2015Choung RS, Rubio-Tapia A, Lahr BD, Kyle RA, Camilleri MJ, Locke GR, et al., 'Evidence Against Routine Testing of Patients with Functional Gastrointestinal Disorders for Celiac Disease: A Population-based Study.', Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, (2015)
DOI10.1016/j.cgh.2015.05.014
2015Talley NJ, Zwi KJ, 'Let the children go - advocacy for children in detention by the Royal Australasian College of Physicians.', Med J Aust, 202 555-557 (2015)
Author URL
2015Talley NJ, Holtmann G, Walker MM, 'Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology.', J Gastroenterol, 50 601-613 (2015)
DOI10.1007/s00535-015-1076-xAuthor URL
Co-authorsMarjorie Walker
2015Herrick LM, Locke GR, Schleck CD, Zinsmeister AR, Treder V, Talley NJ, 'Dyspepsia in the community: Value of a community-based mailed survey to identify potential participants for a randomized clinical trial', Scandinavian Journal of Gastroenterology, 50 959-964 (2015)

Objective. To assess the usefulness of a community-based mailed survey to identify participants with functional dyspepsia (FD) for a clinical trial. Material and methods. In 2008,... [more]

Objective. To assess the usefulness of a community-based mailed survey to identify participants with functional dyspepsia (FD) for a clinical trial. Material and methods. In 2008, a valid self-report questionnaire of gastrointestinal symptoms required for diagnosis of FD was mailed to randomly selected cohorts of Olmsted County, Minnesota, residents. From survey responses (54%), FD cases and controls were identified. Phone calls were completed in 2010 and 2011 to 54% of respondents offering participation to those meeting criteria. Results. Of 937 people identified from the survey, 189 cases and 265 controls were contacted by phone using four questions similar to the written survey resulting in a moderate level of agreement (Kappa 0.43, 95% CI: 0.35-0.51; p = 0.11). The proportion reporting FD symptoms by survey was 42%, while the proportion by phone was 38%. Comparing classification of cases and controls, 118 (62%) survey cases had dyspepsia symptoms on phone screening while 53 (20%) of the survey controls reported FD symptoms. Of 171 who had symptoms, 60 (35%) declined, 33 (19%) were over study age limit, 24 (14%) had inadequate symptom levels and 36 (21%) had comorbidities. Of survey respondents contacted, six (3%) people were enrolled with two screen fails resulting in four (1%) randomized. Conclusion. Agreement between survey and phone questions was modest. Classifications between case and control changed. People eligible and willing to participate were a fraction of people reporting symptoms. People participating in clinical trials do not broadly represent those in the population.

DOI10.3109/00365521.2014.980317
2014Holliday EG, Attia J, Hancock S, Koloski N, McEvoy M, Peel R, et al., 'Genome-wide association study identifies two novel genomic regions in irritable bowel syndrome', American Journal of Gastroenterology, 109 770-772 (2014) [C1]
DOI10.1038/ajg.2014.56
CitationsScopus - 2Web of Science - 1
Co-authorsLiz Holliday, Rodney Scott, Roseanne Peel, John Attia
2014Gururatsakul M, Holloway RH, Bellon M, Bartholomeusz D, Talley NJ, Holtmann GJ, 'Complicated and uncomplicated peptic ulcer disease: Altered symptom response to a nutrient challenge linked to gastric motor dysfunction', Digestion, 89 239-246 (2014) [C1]

Background: Bleeding peptic ulcer (BPU) frequently occurs in the absence of preceding dyspeptic symptoms. We have observed that patients with BPU had a diminished symptom response... [more]

Background: Bleeding peptic ulcer (BPU) frequently occurs in the absence of preceding dyspeptic symptoms. We have observed that patients with BPU had a diminished symptom response to nutrient challenge test compared to uncomplicated peptic ulcer disease (uPUD). We postulated that more symptoms are manifest in patients with uPUD than BPU because there are greater derangements in gastric motor function. Aim: To assess gastric emptying in patients with BPU, uPUD and healthy controls (HC). Methods: We studied 17 patients with BPU, 10 with uPUD, and 15 HC. After an 8-hour fast, subjects ingested 200 ml of an enteral feeding solution, containing 5 MBq 99mTc-rhenium sulphide colloid, every 5 min up to a cumulative volume of 800 ml. Gastric emptying was measured by scintigraphy for the total, proximal and distal stomach. Results: Patients with uPUD had significantly higher gastric retention in the proximal and total stomach at 100 min than HC and BPU, while BPU had similar percent retention to HC. Patients with uPUD had significantly higher cumulative symptom response to the nutrient challenge than did HC and BPU, while BPU had similar symptom responses to HC. Conclusions: Patients with uPUD have significantly delayed gastric emptying compared to HC and BPU. Data suggest that in addition to alterations of visceral sensory function, altered gastric motor function occurs during a nutrient challenge in uPUD but not BPU. Gastric motor function may contribute to the manifestation of dyspeptic symptoms in PUD. © 2014 S. Karger AG, Basel.

DOI10.1159/000360635
CitationsScopus - 2Web of Science - 1
2014Barboza JL, Talley NJ, Moshiree B, 'Current and emerging pharmacotherapeutic options for irritable bowel syndrome', Drugs, 74 1849-1870 (2014)
DOI10.1007/s40265-014-0292-7
2014Beyder A, Mazzone A, Strege PR, Tester DJ, Saito YA, Bernard CE, et al., 'Loss-of-function of the voltage-gated sodium channel NaV1.5 (Channelopathies) in patients with irritable bowel syndrome', Gastroenterology, 146 1659-1668 (2014) [C1]

Background & Aims SCN5A encodes the a-subunit of the voltage-gated sodium channel NaV1.5. Many patients with cardiac arrhythmias caused by mutations in SCN5A also have symptoms of... [more]

Background & Aims SCN5A encodes the a-subunit of the voltage-gated sodium channel NaV1.5. Many patients with cardiac arrhythmias caused by mutations in SCN5A also have symptoms of irritable bowel syndrome (IBS). We investigated whether patients with IBS have SCN5A variants that affect the function of NaV1.5. Methods We performed genotype analysis of SCN5A in 584 persons with IBS and 1380 without IBS (controls). Mutant forms of SCN5A were expressed in human embryonic kidney-293 cells, and functions were assessed by voltage clamp analysis. A genome-wide association study was analyzed for an association signal for the SCN5A gene, and replicated in 1745 patients in 4 independent cohorts of IBS patients and controls. Results Missense mutations were found in SCN5A in 13 of 584 patients (2.2%, probands). Diarrhea-predominant IBS was the most prevalent form of IBS in the overall study population (25%). However, a greater percentage of individuals with SCN5A mutations had constipation-predominant IBS (31%) than diarrhea-predominant IBS (10%; P <.05). Electrophysiologic analysis showed that 10 of 13 detected mutations disrupted NaV1.5 function (9 loss-of-function and 1 gain-of-function function). The p. A997T-NaV1.5 had the greatest effect in reducing NaV1.5 function. Incubation of cells that expressed this variant with mexiletine restored their sodium current and administration of mexiletine to 1 carrier of this mutation (who had constipation-predominant IBS) normalized their bowel habits. In the genome-wide association study and 4 replicated studies, the SCN5A locus was strongly associated with IBS. Conclusions About 2% of patients with IBS carry mutations in SCN5A. Most of these are loss-of-function mutations that disrupt Na V1.5 channel function. These findings provide a new pathogenic mechanism for IBS and possible treatment options. © 2014 by the AGA Institute.

DOI10.1053/j.gastro.2014.02.054
CitationsScopus - 5Web of Science - 2
2014Collison AM, Sokulsky LA, Sherrill JD, Nightingale S, Hatchwell L, Talley NJ, et al., 'TNF-related apoptosis-inducing ligand (TRAIL) regulates midline-1, thymic stromal lymphopoietin, inflammation, andremodeling in experimental eosinophilic esophagitis', Journal of Allergy and Clinical Immunology, (2014)

Background: Eosinophilic esophagitis (EoE) is an inflammatory disorder of the esophagus defined by eosinophil infiltration and tissue remodeling with resulting symptoms of esophag... [more]

Background: Eosinophilic esophagitis (EoE) is an inflammatory disorder of the esophagus defined by eosinophil infiltration and tissue remodeling with resulting symptoms of esophageal dysfunction. TNF-related apoptosis-inducing ligand (TRAIL) promotes inflammation through upregulation of the E3 ubiquitin-ligase midline-1 (MID1), which binds to and deactivates the catalytic subunit of protein phosphatase 2Ac, resulting in increased nuclear factor ¿B activation. Objective: We sought to elucidate the role of TRAIL in EoE. Methods: We used Aspergillus fumigatus to induce EoE in TRAIL-sufficient (wild-type) and TRAIL-deficient (TRAIL-/-) mice and targeted MID1 in the esophagus with small interfering RNA. We also treated mice with recombinant thymic stromal lymphopoietin (TSLP) and TRAIL. Results: TRAIL deficiency and MID1 silencing with small interfering RNA reduced esophageal eosinophil and mast cell numbers and protected against esophageal circumference enlargement, muscularis externa thickening, and collagen deposition. MID1 expression and nuclear factor ¿B activation were reduced in TRAIL-/- mice, whereas protein phosphatase 2Ac levels were increased compared with those seen in wild-type control mice. This was associated with reduced expression of CCL24, CCL11, CCL20, IL-5, IL-13, IL-25, TGFB, and TSLP. Treatment with TSLP reconstituted hallmark features of EoE in TRAIL-/- mice and recombinant TRAIL induced esophageal TSLP expression invivo in the absence of allergen. Post hoc analysis of gene array data demonstrated significant upregulation of TRAIL and MID1 in a cohort of children withEoE compared with that seen in controls. Conclusion: TRAIL regulates MID1 and TSLP, inflammation, fibrosis, smooth muscle hypertrophy, and expression ofinflammatory effector chemokines and cytokines inexperimental EoE.

DOI10.1016/j.jaci.2015.03.031
Co-authorsMarjorie Walker
2014Gupta M, Beebe TJ, Dunagan KT, Schleck CD, Zinsmeister AR, Talley NJ, et al., 'Screening for Barrett's esophagus: Results from a population-based survey', Digestive Diseases and Sciences, 59 1831-1850 (2014) [C1]

Background: Screening for Barrett's esophagus (BE) and adenocarcinoma (EAC) is controversial, but interest remains in finding the optimal method. Attitudes on screening within the... [more]

Background: Screening for Barrett's esophagus (BE) and adenocarcinoma (EAC) is controversial, but interest remains in finding the optimal method. Attitudes on screening within the community are unknown. We aimed to assess these attitudes via a survey. Study: A mixed-mode survey was conducted in adults >50 years to assess awareness regarding BE, willingness to participate in screening, and preferences regarding method of screening. Methods evaluated were sedated endoscopy (sEGD), unsedated transnasal endoscopy (uTNE) and video capsule (VCE). Results: A total of 136 from 413 (33 %) adults responded [47 % males, mean (SD) age 63 (10.2) years], and 26 % of responders knew of BE at baseline. After reading the information on BE, 72 % were interested in screening. A history of undergoing screening tests and GI symptoms were predictive of interest. Unsedated techniques were preferred by 64 % (VCE: 56 % and uTNE: 8 %) versus sEGD (36 %). Conclusions: The majority of adults were willing to undergo screening for BE/EAC, with a preference for unsedated techniques. © 2014 Springer Science+Business Media.

DOI10.1007/s10620-014-3092-8
CitationsScopus - 3Web of Science - 1
2014Chang JY, Locke GR, Schleck CD, Zinsmeister AR, Talley NJ, 'Lack of Familial Aggregation in Chronic Constipation Excluding Irritable Bowel Syndrome: A Population-Based Study', Digestive Diseases and Sciences, (2014)
DOI10.1007/s10620-014-3475-x
CitationsScopus - 1
2014Taha F, Lipsitz JD, Galea S, Demmer RT, Talley NJ, Goodwin RD, 'Anxiety disorders and risk of self-reported ulcer: A 10-year longitudinal study among US adults', General Hospital Psychiatry, 36 674-679 (2014) [C1]

Objective: Previous epidemiologic studies have documented a link between anxiety disorders and ulcer among adults. Few studies have examined these associations over time and littl... [more]

Objective: Previous epidemiologic studies have documented a link between anxiety disorders and ulcer among adults. Few studies have examined these associations over time and little is understood about the pathways underlying these relationships. Method: Data were drawn from n= 2101 adult participants in the Midlife Development in the United States I and II. Data on ulcer diagnoses were collected through self-report: among participants in the current sample, 38 reported ulcer at Waves 1 and 2 (prevalent ulcer), and 18 reported ulcer at Wave 2 but not at Wave 1 (incident ulcer). Panic attacks and generalized anxiety disorder at Wave 1 (1994) were examined in relation to prevalent (past 12 months) and incident ulcer approximately 10 years later at Wave 2 (2005). Results: Anxiety disorders at Wave 1 were associated with increased prevalence of ulcer [odds ratio (OR)=4.1, 95% confidence interval (CI)=2.0-8.4], increased risk of incident ulcer at Wave 2 (OR=4.1, 95% CI=1.4-11.7) and increased risk of treated ulcer at Wave 2 (OR=4.7, 95% CI=2.3-9.9) compared with those without anxiety. Conclusions: In this large population sample of adults, anxiety disorders were associated with an increased risk of ulcer over a 10-year period. These relationships do not appear to be explained by confounding or mediation by a wide range of factors. Future studies should address potential mechanisms underlying the relationship between anxiety and ulcer.

DOI10.1016/j.genhosppsych.2014.07.005
2014Taha F, Lipsitz JD, Galea S, Demmer RT, Talley NJ, Goodwin RD, 'Anxiety disorders and risk of self-reported ulcer: a 10-year longitudinal study among US adults', General Hospital Psychiatry, 36 674-679 (2014) [C1]
DOI10.1016/j.genhosppsych.2014.07.005
2014Choung RS, Locke GR, Schleck CD, Zinsmeister AR, Talley NJ, 'The effects of ageing on the onset and disappearance of unexplained abdominal pain: a population-based study', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 39 217-225 (2014) [C1]
DOI10.1111/apt.12557Author URL
2014Jones MP, Chey WD, Singh S, Gong H, Shringarpure R, Hoe N, et al., 'A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 39 426-437 (2014) [C1]
DOI10.1111/apt.12608Author URL
CitationsScopus - 9Web of Science - 7
2014Ford AC, Talley NJ, Walker MM, Jones MP, 'Increased prevalence of autoimmune diseases in functional gastrointestinal disorders: case-control study of 23 471 primary care patients', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 40 827-834 (2014) [C1]
DOI10.1111/apt.12903Author URL
CitationsScopus - 1Web of Science - 1
Co-authorsMarjorie Walker
2014Achem SR, Talley NJ, 'Letter: PPI-responsive oesophageal eosinophilia - From initial skepticism to consistent prospective data; Authors' reply', Alimentary Pharmacology and Therapeutics, 39 230-231 (2014) [C3]
DOI10.1111/apt.12570
2014Walker MM, Talley NJ, 'Review article: Bacteria and pathogenesis of disease in the upper gastrointestinal tract - Beyond the era of Helicobacter pylori', Alimentary Pharmacology and Therapeutics, 39 767-779 (2014)
DOI10.1111/apt.12666
CitationsScopus - 3
Co-authorsMarjorie Walker
2014Walker MM, Talley NJ, 'Review article: Bacteria and pathogenesis of disease in the upper gastrointestinal tract - Beyond the era of Helicobacter pylori', Alimentary Pharmacology and Therapeutics, 39 767-779 (2014) [C1]

Background Study of the upper gastrointestinal microbiome has shown that other bacteria besides Helicobacter pylori flourish despite the hostile environment. Whilst H. pylori is t... [more]

Background Study of the upper gastrointestinal microbiome has shown that other bacteria besides Helicobacter pylori flourish despite the hostile environment. Whilst H. pylori is the most studied bacteria in this region with a defined role in inflammation and neoplasia, it is apparent that other bacteria may contribute to UGI disease. Aim To review current knowledge of bacteria inhabiting the oesophagus, stomach and duodenum. Methods Published studies on the upper gastrointestinal microbiome (extracted from PubMed during the last 20 years). Results The stomach is a hostile environment for bacteria; however, recent studies categorising the microbiota have shown surprising results. Helicobacter pylori has been intensively studied since 1984 and recent sequencing analysis of other gastric microbiota shows that H. pylori is not alone. Composition can be influenced by acid suppression, gastritis and abundance of H. pylori. Eradication of H. pylori, whilst decreasing gastric cancer is associated with an increase in asthma, reflux and obesity. A future approach may be to selectively eradicate bacteria which predispose to inflammation and cancer as opposed to a comprehensive knockout policy. In the oesophagus, viridans streptococci are the most common bacteria influenced by both oral and gastric bacteria. Oesophagitis and Barrett's oesophagus are characterised by a significant decrease in Gram-positive bacteria and an increase in Gram-negative bacteria. An inverse association of H. pylori and oesophageal adenocarcinoma is described. The duodenal microbiome has been shown to influence small intestinal bacterial overgrowth, irritable bowel syndrome and coeliac disease. The numbers of bacteria recoverable by culture are variable in the stomach mucosa and gastric juice, typically 102-104 colony-forming units (CFU)/g or mL and in the oesophagus, up to 104 bacteria per mm2 mucosal surface. In the small bowel, in health, 103 CFU/mL are normal. Conclusion This review highlights current knowledge of upper gastrointestinal bacteria and associations with disease. © 2014 John Wiley & Sons Ltd.

DOI10.1111/apt.12666
CitationsScopus - 7Web of Science - 5
Co-authorsMarjorie Walker
2014Lender N, Talley NJ, Enck P, Haag S, Zipfel S, Morrison M, Holtmann GJ, 'Review article: Associations between Helicobacter pylori and obesity - An ecological study', Alimentary Pharmacology and Therapeutics, 40 24-31 (2014) [C1]

Background There is emerging debate over the effect of Helicobacter pylori infection on body mass index (BMI). A recent study demonstrated that individuals who underwent H. pylori... [more]

Background There is emerging debate over the effect of Helicobacter pylori infection on body mass index (BMI). A recent study demonstrated that individuals who underwent H. pylori eradication developed significant weight gain as compared to subjects with untreated H. pylori colonisation. Aim To elucidate the association between H. pylori colonisation and the prevalence of overweight and obesity in developed countries. Methods The literature was searched for publications reporting data on H. pylori prevalence rates and obesity prevalence rates. Studies selected reported H. pylori prevalence in random population samples with sample sizes of more than 100 subjects in developed countries (GDP >25 000 US$/person/year). Corresponding BMI distributions for corresponding countries and regions were identified. Nonparametric tests were used to compare the association between H. pylori and overweight and obesity rates. Results Forty-nine studies with data from 10 European countries, Japan, the US and Australia were identified. The mean H. pylori rate was 44.1% (range 17-75%), the mean rates for obesity and overweight were 46.6 (±16)% and 14.2 (±8.9)%. The rate of obesity and overweight were inversely and significantly (r = 0.29, P < 0.001) correlated with the prevalence of H. pylori infection. Conclusions There is an inverse correlation between H. pylori prevalence and rate of overweight/obesity in countries of the developed world. Thus, the gradual decrease of the H. pylori colonisation that has been observed in recent decades (or factors associated with decrease of) could be causally related to the obesity endemic observed in the Western world. © 2014 John Wiley & Sons Ltd.

DOI10.1111/apt.12790
CitationsScopus - 8Web of Science - 8
2014Lender N, Talley NJ, Enck P, Haag S, Zipfel S, Morrison M, Holtmann GJ, 'Review article: Associations between Helicobacter pylori and obesity - An ecological study', Alimentary Pharmacology and Therapeutics, 40 24-31 (2014)
DOI10.1111/apt.12790
CitationsScopus - 2
2014Guérin A, Mody R, Fok B, Lasch KL, Zhou Z, Wu EQ, et al., 'Risk of developing colorectal cancer and benign colorectal neoplasm in patients with chronic constipation', Alimentary Pharmacology and Therapeutics, 40 83-92 (2014) [C1]

Background Chronic constipation (CC) is a highly prevalent health problem, potentially associated with increased risk of colorectal cancer (CRCancer). Aim To investigate the assoc... [more]

Background Chronic constipation (CC) is a highly prevalent health problem, potentially associated with increased risk of colorectal cancer (CRCancer). Aim To investigate the association between CC, its severity, and CRCancer by estimating the relative risk of developing CRCancer and benign colorectal neoplasm (BCN) among severity-stratified patients with and without CC. Methods Chronic constipation patients from a large retrospective US claims database were matched 1:3 with CC-free controls by demographic characteristics. CRCancer and BCN prevalence were measured over 1 year. In pre-index CRCancer- and BCN-free patients, incidence rate ratios (IRRs) of new CRCancer and BCN were calculated. Multivariate regression models adjusted for comorbidities and family history. CC patients' disease severity was rated based on CC-related resource use. IRRs for new CRCancer and BCN were estimated for CC severity groups and controls. Results Chronic constipation (N = 28 854) and CC-free (N = 86 562) patients had mean age 61.9 years; 66.7% were female. One-year CRCancer prevalence was 2.7% and 1.7%, and BCN prevalence was 24.8% and 11.9% for CC and CC-free patients, respectively. Adjusted IRRs between CC and CC-free patients were 1.59 [95% confidence interval (CI): 1.43-1.78] and 2.60 [95% CI: 1.51-2.70] for CRCancer and BCN, respectively. Patients with severe and very severe CC had significantly greater incidence of CRCancer and BCN. At =2 and =5 years of observation, CRCancer and BCN incidence remained consistently and significantly higher for CC patients. Conclusions Patients with chronic constipation are associated with significantly higher prevalence and incidence of colorectal cancer and benign colorectal neoplasm than matched chronic constipation-free patients. These risks increase with the severity of chronic constipation. © 2014 John Wiley & Sons Ltd.

DOI10.1111/apt.12789
CitationsScopus - 4Web of Science - 5
2014Jones MP, Walker MM, Ford AC, Talley NJ, 'The overlap of atopy and functional gastrointestinal disorders among 23 471 patients in primary care', Alimentary Pharmacology and Therapeutics, 40 382-391 (2014)
DOI10.1111/apt.12846
CitationsScopus - 5
Co-authorsMarjorie Walker
2014Talley NJ, 'Editorial: Adequate management may reduce the colorectal cancer risk associated with constipation? Author's reply', Alimentary Pharmacology and Therapeutics, 40 564-565 (2014) [C3]
DOI10.1111/apt.12885
2014Holtmann GJ, Talley NJ, Morrison M, 'Letter: Inverse correlation between Helicobacter pylori and obesity - A conclusion too early? Authors' reply', Alimentary Pharmacology and Therapeutics, 40 1120-1120 (2014) [C3]
DOI10.1111/apt.12967
2014Jones MP, Walker MM, Ford AC, Talley NJ, 'Editorial: The overlap of atopy and functional gastrointestinal disorders in primary care - Authors' reply', Alimentary Pharmacology and Therapeutics, 40 1244-1245 (2014) [C3]
DOI10.1111/apt.12961
Co-authorsMarjorie Walker
2014Gentile N, Katzka D, Ravi K, Trenkner S, Enders F, Killian J, et al., 'Oesophageal narrowing is common and frequently under-appreciated at endoscopy in patients with oesophageal eosinophilia', Alimentary Pharmacology and Therapeutics, 40 1333-1340 (2014) [C1]

Background: Estimation of the prevalence of oesophageal narrowing and its clinical relevance in patients with oesophageal eosinophilia is probably underestimated by endoscopy. Aim... [more]

Background: Estimation of the prevalence of oesophageal narrowing and its clinical relevance in patients with oesophageal eosinophilia is probably underestimated by endoscopy. Aims: To determine the sensitivity and specificity of oesophagogastroduodenoscopy (EGD) for oesophageal narrowing when compared to a structured oesophagram. Methods: We conducted a retrospective chart review at Mayo Clinic, Rochester of adult patients with eosinophilic oesophageal infiltration of >15 eosinophils/ hpf with symptomatic dysphagia, who underwent a structured barium oesophagram. The sensitivity and specificity of EGD were evaluated against the gold standard of oesophagram. Demographic and multiple clinical factors were evaluated as potential predictors of oesophageal narrowing. Results: Of the 58 patients identified, 34 (58.6%) had a narrowed oesophageal diameter (<21 mm). EGD had poor sensitivity (14.7%, 95% CI 5.0-31.1%) for detection of a narrowed oesophagus and only modest specificity (79.2%, 95% CI 57.8-92.9%). Even at a cut-off diameter of EDmax = 15 mm, EGD had a sensitivity of only 25.0% (95% CI 5.5- 57.2%) for narrowed oesophagus. A history of >5 food impaction episodes, endoscopic rings, and female sex were the best predictors of oesophageal narrowing. 86% (6/7) patients with persistent dysphagia despite remission of histological eosinophilia responded to oesophageal dilation all of whom had radiological oesophageal narrowing and 71% of whom had no perceived oesophageal narrowing at EGD. Conclusions: Symptomatic oesophageal narrowing identified by barium oesophagography is common and under-recognised at endoscopy in patients with oesophageal eosinophilia.

DOI10.1111/apt.12977
CitationsScopus - 1
2014Mody R, Guérin A, Fok B, Lasch KL, Zhou Z, Wu EQ, et al., 'Prevalence and risk of developing comorbid conditions in patients with chronic constipation', Current Medical Research and Opinion, 30 2505-2513 (2014) [C1]
DOI10.1185/03007995.2014.964854
2014Walker MM, Aggarwal KR, Shim LSE, Bassan M, Kalantar JS, Weltman MD, et al., 'Duodenal eosinophilia and early satiety in functional dyspepsia: Confirmation of a positive association in an Australian cohort', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 29 474-479 (2014) [C1]
DOI10.1111/jgh.12419Author URL
CitationsScopus - 3Web of Science - 1
Co-authorsMarjorie Walker
2014Kjellstrom L, Molinder H, Agreus L, Nyhlin H, Talley NJ, Andreasson A, 'A randomly selected population sample undergoing colonoscopy: prevalence of the irritable bowel syndrome and the impact of selection factors', EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 26 268-275 (2014) [C1]
DOI10.1097/MEG.0000000000000024Author URL
CitationsScopus - 4Web of Science - 2
2014Halland M, Almazar A, Lee R, Atkinson E, Larson J, Talley NJ, Saito YA, 'A case-control study of childhood trauma in the development of irritable bowel syndrome', NEUROGASTROENTEROLOGY AND MOTILITY, 26 990-998 (2014) [C1]
DOI10.1111/nmo.12353Author URL
2014Choung RS, Locke GR, Francis DD, Katzka D, Winkle PJ, Orr WC, et al., 'Novel partial 5HT3 agonist pumosetrag reduces acid reflux events in uninvestigated GERD patients after a standard refluxogenic meal: A randomized, double-blind, placebo-controlled pharmacodynamic study', Neurogastroenterology and Motility, 26 13-20 (2014)
DOI10.1111/nmo.12214
2014Choung RS, Locke GR, Francis DD, Katzka D, Winkle PJ, Orr WC, et al., 'Novel partial 5HT3 agonist pumosetrag reduces acid reflux events in uninvestigated GERD patients after a standard refluxogenic meal: A randomized, double-blind, placebo-controlled pharmacodynamic study', Neurogastroenterology and Motility, 26 13-20 (2014) [C1]

Background: Low basal lower esophageal sphincter (LES) pressure and transient LES relaxations are major causes of gastroesophageal reflux disease (GERD). Pumosetrag, a novel selec... [more]

Background: Low basal lower esophageal sphincter (LES) pressure and transient LES relaxations are major causes of gastroesophageal reflux disease (GERD). Pumosetrag, a novel selective partial 5HT3 receptor agonist, showed a promising effect on reducing reflux events in health. We aimed to evaluate the effect of pumosetrag on changes in reflux episodes, lower esophageal sphincter pressure (LESP), and specific symptoms in patients with GERD receiving a refluxogenic meal. Methods: Patients with GERD, who developed heartburn and/or regurgitation after ingestion of a refluxogenic meal, were randomized to 1 of 3 dose levels of pumosetrag (0.2, 0.5, or 0.8¿mg) or placebo. Before and after 7¿days of treatment, patients underwent manometry, intraesophageal multichannel, intraluminal impedance and pH after a standard refluxogenic meal. Key Results: A total of 223 patients with GERD [125 (56%) women, mean (SD) age¿=¿36 (12) years] were enrolled. No overall treatment effects were detected for the total number of reflux episodes (acidic and weakly acidic) (p¿>¿0.5); however, significant treatment effects (p¿<¿0.05) on the number of acid reflux episodes were observed with lower values on pumosetrag 0.2¿mg (10.8¿±¿1.1), 0.5¿mg (9.5¿±¿1.1), and 0.8¿mg (9.9¿±¿1.1) compared with placebo (13.3¿±¿1.1). Significant treatment effects (p¿<¿0.05) were also observed for the percentage of time pH was <4, with less time for pumosetrag at 0.5¿mg (10%) and 0.8¿mg (10%) compared with placebo (16%). Conclusions & Inferences: In GERD, the partial 5HT3 agonist pumosetrag significantly reduced the rate of acid reflux events but did not result in a significant change in LESP or symptomatic improvement over a 1-week treatment period. © 2013 John Wiley & Sons Ltd.

DOI10.1111/nmo.12214
2014Pleyer C, Bittner H, Locke GR, Choung RS, Zinsmeister AR, Schleck CD, et al., 'Overdiagnosis of gastro-esophageal reflux disease and underdiagnosis of functional dyspepsia in a USA community', Neurogastroenterology and Motility, 26 1163-1171 (2014)
DOI10.1111/nmo.12377
2014Pleyer C, Bittner H, Locke GR, Choung RS, Zinsmeister AR, Schleck CD, et al., 'Overdiagnosis of gastro-esophageal reflux disease and underdiagnosis of functional dyspepsia in a USA community', Neurogastroenterology and Motility, 26 1163-1171 (2014) [C1]

Background: There is symptom overlap between gastro-esophageal reflux disease (GERD) and functional dyspepsia (FD). We aimed to test the hypothesis that FD cases are now more like... [more]

Background: There is symptom overlap between gastro-esophageal reflux disease (GERD) and functional dyspepsia (FD). We aimed to test the hypothesis that FD cases are now more likely mislabeled as GERD. Methods: In subjects from Olmsted County, MN seen at Mayo Clinic: (i) Investigation of GERD and FD diagnosis rates between 1985 and 2009. (ii) Assessment of survey-based upper gastrointestinal symptoms between 1988 and 2009. (iii) Analysis of patients reporting GERD and/or FD symptoms and subsequently receiving a consistent diagnosis of GERD and/or FD during a medical encounter. (iv) Assess the association between PPI use and GERD and/or FD symptoms and between actual diagnoses received. Key Results: (i) Yearly GERD diagnosis rates rose between 1985 and 2009 (325-1866 per 100 000). FD diagnosis rates rose from 45 in 1985, to 964 in 1999 but decreased to 452 per 100 000 in 2009. (ii) Reported GERD symptoms did not significantly change between three survey waves in the years 1988-2009 (p = 0.052), whereas FD symptoms slightly increased (p = 0.01). (iii) 62.9% of subjects reporting GERD symptoms received a GERD diagnosis, however only 12.5% of subjects reporting FD symptoms received a FD diagnosis. (iv) PPI use was associated with documented GERD diagnosis (p < 0.001), however there was no significant association between GERD symptoms and PPI use (p = 0.078). Conclusions & Inferences: We have found evidence supporting a systematic bias away from diagnosing FD, favoring a GERD diagnosis. © 2014 John Wiley & Sons Ltd.

DOI10.1111/nmo.12377
CitationsScopus - 2
2014Williams D, Conn J, Talley N, Attia J, 'Reviewing the evidence base for the peripheral sensory examination', International Journal of Clinical Practice, 68 756-760 (2014) [C1]

Background Many students find the peripheral sensory examination confusing. We set out to summarise the evidence base in order to provide guidance on the most useful manoeuvres. M... [more]

Background Many students find the peripheral sensory examination confusing. We set out to summarise the evidence base in order to provide guidance on the most useful manoeuvres. Methods We performed a literature review starting with 5 secondary sources, supplemented by a literature search on MEDLINE. Results A useful approach to neuropathy is to divide these into large fibre sensory neuropathy (LFSN) in which vibration and proprioception are affected, and small fibre sensory neuropathy (SFSN) in which pain and temperature are affected. Positive sensory symptoms such as burning, electric or sunburn pain point to a SFSN; negative symptoms such as loss of sensation, numbness or deep pain point to a LFSN. If LFSN is suspected, the most reproducible and best studied physical examination is a 10g monofilament, but vibration sense is also useful. There is much less data on the best physical examination for a SFSN. The most appropriate diagnostic test for SFSN is quantitative sensory testing, whereas for LFSN a nerve conduction study is indicated. Conclusions A modest amount of evidence is available to guide peripheral sensory examination but more research is needed. © 2014 John Wiley & Sons Ltd.

DOI10.1111/ijcp.12389
Co-authorsJohn Attia
2014Williams D, Conn J, Talley N, Attia J, 'Reviewing the evidence base for the peripheral sensory examination', International Journal of Clinical Practice, 68 756-760 (2014)
DOI10.1111/ijcp.12389
Co-authorsJohn Attia
2014Holtmann G, Talley NJ, 'Herbal Medicines for the Treatment of Functional and Inflammatory Bowel Disorders', Clinical Gastroenterology and Hepatology, (2014)

In many parts of the world, there continues to be a long-standing tradition of prescribing herbal products for a range of gastrointestinal conditions. Scientific evidence supporti... [more]

In many parts of the world, there continues to be a long-standing tradition of prescribing herbal products for a range of gastrointestinal conditions. Scientific evidence supporting the use of all herbal preparations is imperfect, however, and available studies are plagued by methodological limitations. For functional gastrointestinal disorders, there is limited evidence supporting the use of some well-characterized preparations. A number of herbals have immunomodulatory activity, and in inflammatory bowel disease there are limited positive placebo-controlled trials; other studies used active controls with suboptimal doses of the comparators. Like all drugs, herbals can lead to serious adverse events (eg, hepatic failure). Quality control is a serious issue to consider when prescribing herbal medicines. Many herbal preparations are marketed without evidence for stringent adherence to good manufacturing practice guidelines. Unpredictable environmental conditions may affect the composition and the concentration of the active ingredients of plant extracts. Further, commercial herbal products usually combine a variable plethora of¿chemical families with possible medicinal utility. While some of these ingredients might be of benefit, the concentration and dose of these constituents needs to be closely monitored. Physicians and regulators need to remain very cautious about the use of herbal remedies. Appropriate scientific evidence for the claimed clinical benefits should become mandatory worldwide, and the standards for production and safety monitoring should comply with established standards for chemically defined products. If these principles were adopted, the full value of herbal remedies may come to light, particularly as the individually bioactive compounds present in these preparations become recognized. © 2014 AGA Institute.

DOI10.1016/j.cgh.2014.03.014
CitationsWeb of Science - 1
2014Talley NJ, 'DECADE IN REVIEW-FGIDS 'Functional' gastrointestinal disorders-a paradigm shift', NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 11 649-650 (2014) [C3]
DOI10.1038/nrgastro.2014.163Author URL
CitationsScopus - 2Web of Science - 1
2014Barboza JL, Talley NJ, Moshiree B, 'Current and emerging pharmacotherapeutic options for irritable bowel syndrome', Drugs, 74 1849-1870 (2014) [C1]

Treatment of irritable bowel syndrome (IBS) is challenging for both primary care physicians and gastroenterologists because of the heterogeneity of the patient population and the ... [more]

Treatment of irritable bowel syndrome (IBS) is challenging for both primary care physicians and gastroenterologists because of the heterogeneity of the patient population and the multifactorial pathophysiologies responsible for the symptoms in IBS. This review focuses on the current and emerging pharmacological treatments for IBS. Many of the current medications used to treat this disorder have distinct properties such as efficacy for different symptoms, safety profiles, contraindications, costs, dosing regimens, treatment duration and long-term data. All of these factors, in addition to patient preference and cognitive, food and environmental triggers, must be considered prior to any medication selection. This review will focus on randomized controlled trials with a general uniformity in study design, a rigorous patient selection and appropriate treatment durations. We will also discuss other exciting emerging treatments for IBS such as the µ-opioid receptor (agonists and antagonists), selective ¿-opioid receptor agonists, anti-inflammatory drugs, serotonergic agents, bile acid modulators and intestinal bile acid transporters, which may prove promising in treating our patients.

DOI10.1007/s40265-014-0292-7
CitationsScopus - 1
2014Jones MP, Walker MM, Ford AC, Talley NJ, 'The overlap of atopy and functional gastrointestinal disorders among 23 471 patients in primary care', Alimentary Pharmacology and Therapeutics, 40 382-391 (2014) [C1]

Background Activation of the immune system has been demonstrated in atopy and functional gastrointestinal disorders (FGIDs). Previous data from our group have suggested a connecti... [more]

Background Activation of the immune system has been demonstrated in atopy and functional gastrointestinal disorders (FGIDs). Previous data from our group have suggested a connection between immune dysregulation, FGIDs and mood disorders. Aim To investigate if these data translate to clinical practice and examine connections from the perspective of FGIDs to determine whether atopy and FGIDs are connected via mood disorders. Methods Evidence of irritable bowel syndrome (IBS), functional dyspepsia (FD) and constipation was sought from the medical records of 30 000 primary care records over a minimum 5 year period. The same records yielded diagnoses of four atopic conditions (asthma, eczema, allergic rhinitis/hay fever and conjunctivitis). Results Atopic conditions were found in excess among all FGID groups considered when compared with controls. In the groups with IBS alone (OR = 1.43, 1.29-1.58), FD alone (OR = 1.41, 1.26-1.58) and those with multiple FGIDs (OR = 1.92, 1.75-2.12) there was elevated prevalence of asthma compared with controls without a FGID. Across disorders the excess was generally highest among patients diagnosed with multiple FGIDs (rhinitis/hay fever OR = 3.74, 3.32-4.20; conjunctivitis OR = 3.00, 2.49-3.62) and was only partly explained by a common association between both FGIDs and atopic conditions with mood disorders, although not for every atopic/FGID combination (rhinitis/hay fever OR = 2.60, 2.29-2.96, conjunctivitis OR = 2.34, 1.90-2.87). Conclusions Irritable bowel syndrome, functional dyspepsia and constipation share an association with atopy that is only partly explained via a common connection with mood disorders. These data have important implications for understanding both the pathophysiology of functional gastrointestinal disorders and development of new treatments. © 2014 John Wiley & Sons Ltd.

DOI10.1111/apt.12846
CitationsScopus - 6Web of Science - 5
Co-authorsMarjorie Walker
2014Talley NJ, Napthali KE, 'Endoscopy in symptomatic gastroesophageal reflux disease: Scoping out whomto target', JAMA Internal Medicine, 174 465-466 (2014) [C3]
DOI10.1001/jamainternmed.2013.12992
2014Holtmann G, Talley NJ, 'The stomach-brain axis.', Best Pract Res Clin Gastroenterol, 28 967-979 (2014) [C1]
DOI10.1016/j.bpg.2014.10.001Author URL
CitationsScopus - 1Web of Science - 1
2014Walker MM, Powell N, Talley NJ, 'Atopy and the gastrointestinal tract--a review of a common association in unexplained gastrointestinal disease.', Expert Rev Gastroenterol Hepatol, 8 289-299 (2014) [C1]
DOI10.1586/17474124.2014.881716Author URL
CitationsScopus - 5Web of Science - 5
Co-authorsMarjorie Walker
2014Ek WE, Reznichenko A, Ripke S, Niesler B, Zucchelli M, Rivera NV, et al., 'Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts.', Gut, (2014)
DOI10.1136/gutjnl-2014-307997Author URL
Co-authorsLiz Holliday
2013Talley NJ, 'Foreword', Irritable Bowel Syndrome: Diagnosis and Clinical Management, (2013) [C3]
DOI10.1002/9781118444689
2013Talley NJ, Walker MM, 'Novel insights into the pathology of upper gut symptoms: new syndromes, new diseases.', Med J Aust, 199 440-441 (2013) [C3]
Author URL
Co-authorsMarjorie Walker
2013Flook NW, Moayyedi P, Dent J, Talley NJ, Persson T, Karlson BW, Ruth M, 'Acid-Suppressive Therapy With Esomeprazole for Relief of Unexplained Chest Pain in Primary Care: A Randomized, Double-Blind, Placebo-Controlled Trial', AMERICAN JOURNAL OF GASTROENTEROLOGY, 108 56-64 (2013) [C1]
DOI10.1038/ajg.2012.369Author URL
CitationsScopus - 2Web of Science - 1
2013Talley NJ, 'Functional (Non-Ulcer) Dyspepsia and Gastroesophageal Reflux Disease: One Not Two Diseases ?', AMERICAN JOURNAL OF GASTROENTEROLOGY, 108 775-777 (2013) [C3]
DOI10.1038/ajg.2013.102Author URL
CitationsScopus - 4Web of Science - 4
2013Power AM, Talley NJ, Ford AC, 'Association Between Constipation and Colorectal Cancer: Systematic Review and Meta-Analysis of Observational Studies', AMERICAN JOURNAL OF GASTROENTEROLOGY, 108 894-903 (2013) [C1]
DOI10.1038/ajg.2013.52Author URL
CitationsScopus - 11Web of Science - 11
2013Koloski NA, Jones M, Wai R, Gill RS, Byles J, Talley NJ, 'Impact of Persistent Constipation on Health-Related Quality of Life and Mortality in Older Community-Dwelling Women', AMERICAN JOURNAL OF GASTROENTEROLOGY, 108 1152-1158 (2013) [C1]
DOI10.1038/ajg.2013.137Author URL
CitationsScopus - 11Web of Science - 10
Co-authorsJulie Byles
2013Ford AC, Talley NJ, 'The Role of Diagnostic Colonoscopy in Constipation: A Quality Improvement Project Response', AMERICAN JOURNAL OF GASTROENTEROLOGY, 108 1930-1930 (2013) [C3]
DOI10.1038/ajg.2013.338Author URL
2013Halland M, Koloski NA, Jones M, Byles J, Chiarelli P, Forder P, Talley NJ, 'Prevalence Correlates and Impact of Fecal Incontinence Among Older Women', DISEASES OF THE COLON & RECTUM, 56 1080-1086 (2013) [C1]
DOI10.1097/DCR.0b013e31829203a9Author URL
CitationsScopus - 6Web of Science - 4
Co-authorsJulie Byles, Peta Forder, Pauline Chiarelli
2013Pimentel M, Talley NJ, Quigley EMM, Hani A, Sharara A, Mahachai V, 'Report From the Multinational Irritable Bowel Syndrome Initiative 2012', GASTROENTEROLOGY, 144 E1-E5 (2013) [C3]
DOI10.1053/j.gastro.2013.04.049Author URL
CitationsScopus - 9Web of Science - 9
2013Talley NJ, 'C.J. Hawkey, Jaime Bosch, Joel E. Richter, Guadalupe Garcia-Tsao, Francis K.L. Chan (Eds.). (2012) Textbook of Clinical Gastroenterology and Hepatology, 2nd edition. Wiley, New York, New York. ISBN: 978-1-4051-9182-1', Gastroenterology, 145 484 (2013) [C3]
DOI10.1053/j.gastro.2013.06.014Author URL
2013Talley NJ, 'Essentials of Gastroenterology. Shanthi V. Sitaraman and Lawrence S. Friedman, editors. 480 pp. New York, New York, Wiley, 2012 [Book Review]', Gastroenterology, 144 853 (2013) [C3]
DOI10.1053/j.gastro.2013.02.021Author URL
2013Quince C, Lundin EE, Andreasson AN, Greco D, Rafter J, Talley NJ, et al., 'The impact of Crohn's disease genes on healthy human gut microbiota: a pilot study', GUT, 62 952-954 (2013) [C3]
DOI10.1136/gutjnl-2012-304214Author URL
CitationsScopus - 11Web of Science - 9
2013Leggett CL, Nelsen EM, Tian J, Schleck CB, Zinsmeister AR, Dunagan KT, et al., 'Metabolic syndrome as a risk factor for barrett esophagus: A population-based case-control study', Mayo Clinic Proceedings, 88 157-165 (2013) [C1]

Objectives: To assess the association between Barrett esophagus (BE) and the metabolic syndrome in patients with and without reflux symptoms and to determine whether this associat... [more]

Objectives: To assess the association between Barrett esophagus (BE) and the metabolic syndrome in patients with and without reflux symptoms and to determine whether this association is reflux independent and metabolically driven. Patients and Methods: Case patients with BE and controls were residents of Olmsted County, Minnesota (1999-2006). Two control groups (one with and one without symptoms of gastroesophageal reflux) were identified from a cohort of patients who had responded to a validated gastrointestinal symptom questionnaire. Cases and controls were individually matched by age, sex, and duration of follow-up. Controls did not have a known diagnosis of BE. The association of the metabolic syndrome and its individual components with BE was assessed using univariate and multivariate conditional logistic regression separately for each control group. Results: A total of 309 patients were included (103 BE cases, 103 controls with reflux symptoms, and 103 controls without reflux symptoms). A total of 64% of cases, 47% of controls with reflux symptoms, and 50% of controls without reflux symptoms had the metabolic syndrome. The metabolic syndrome was associated with a 2-fold increased risk of BE relative to those with (odds ratio, 2.00; 95% CI, 1.10-3.65; P=.02) and without (odds ratio, 1.90; 95% CI, 1.03-3.60; P=.04) reflux symptoms. This association was independent of smoking, alcohol consumption, and body mass index and remained robust with sensitivity analysis. Conclusion: The metabolic syndrome is associated with BE independent of reflux symptoms, which may reflect a reflux-independent pathway of BE pathogenesis. © 2013 Mayo Foundation for Medical Education and Research.

DOI10.1016/j.mayocp.2012.09.017
CitationsScopus - 7Web of Science - 5
2013Symonds IM, Talley NJ, 'Can professionalism be taught?: Yes, but a more strategic approach should replace didactic methods', Medical Journal of Australia, 199 380-381 (2013) [C3]
DOI10.5694/mja13.10656
CitationsScopus - 5Web of Science - 1
Co-authorsIan Symonds
2013Shim L, Talley NJ, Boyce P, Tennant C, Jones M, Kellow JE, 'Stool characteristics and colonic transit in irritable bowel syndrome: evaluation at two time points', SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 48 295-301 (2013) [C1]
DOI10.3109/00365521.2012.758767Author URL
2013Ludvigsson JF, Aro P, Walker MM, Vieth M, Agreus L, Talley NJ, et al., 'Celiac disease, eosinophilic esophagitis and gastroesophageal reflux disease, an adult population-based study', SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 48 808-814 (2013) [C1]
DOI10.3109/00365521.2013.792389Author URL
CitationsScopus - 10Web of Science - 8
Co-authorsMarjorie Walker
2013Lacy BE, Crowell MD, Talley NJ, 'Letter: East-West differences in the economic impact of functional dyspepsia - authors' reply', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 38 656-656 (2013) [C3]
DOI10.1111/apt.12448Author URL
2013Vazquez-Elizondo G, Ngamruengphong S, Khrisna M, DeVault KR, Talley NJ, Achem SR, 'The outcome of patients with oesophageal eosinophilic infiltration after an eight-week trial of a proton pump inhibitor', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 38 1312-1319 (2013) [C1]
DOI10.1111/apt.12513Author URL
CitationsScopus - 11Web of Science - 10
2013Lacy BE, Weiser KT, Kennedy AT, Crowell MD, Talley NJ, 'Functional dyspepsia: The economic impact to patients', Alimentary Pharmacology and Therapeutics, 38 170-177 (2013) [C1]

Background Although highly prevalent, little is known about the economic impact of functional dyspepsia (FD). Aims To quantify FD patients' health care utilisation patterns and to... [more]

Background Although highly prevalent, little is known about the economic impact of functional dyspepsia (FD). Aims To quantify FD patients' health care utilisation patterns and to estimate direct and indirect costs of FD to patients. Methods ICD-9 codes identified adult patients with dyspepsia. A validated questionnaire was mailed to patients who met Rome III criteria for FD. Results Three hundred and fifty-five patients met all inclusion criteria. The response rate was 63%. The respondents' mean age was 50 (14) years; 75% were women; 52% of respondents rated their FD as moderate. Patients reported 3 visits (mean) to their PCP over 12 months; 75% reported having blood work, 92% an EGD, 59% an ultrasound and 40% a CT scan. The direct cost of testing using Medicare reimbursement rates per patient was $582. To treat FD symptoms, 89% tried dietary changes, 89% over-the-counter medications, 87% prescription medications and 25% alternative therapies. Mean patient expenditure over the last year was $246 for OTC medications (range $0-12,000), $290 for co-payments (range $0-9,000) and $110 for alternative treatments (range $0-3,741). Total mean direct cost yearly to patients was $699. In the 7 days prior to completing the questionnaire, respondents reported a mean of 1.4 h absence from work. Extrapolating the results to the US population, we conservatively calculate the costs of FD were $18.4 billion in 2009. Conclusions Functional dyspepsia patients incur significant direct and indirect costs and work productivity is impaired by dyspeptic symptoms. © 2013 John Wiley & Sons Ltd.

DOI10.1111/apt.12355
CitationsScopus - 12
2013Choung RS, Locke III GR, Schleck CD, Ziegenfuss JY, Beebe TJ, Zinsmeister AR, Talley NJ, 'A low response rate does not necessarily indicate non-response bias in gastroenterology survey research: A population-based study', Journal of Public Health (Germany), 21 87-95 (2013) [C1]

Aim: To estimate the potential for response bias in standard mailed questionnaires used in surveys of GI symptoms in a community. Subjects and methods: Validated self-report tools... [more]

Aim: To estimate the potential for response bias in standard mailed questionnaires used in surveys of GI symptoms in a community. Subjects and methods: Validated self-report tools have been developed to measure functional gastrointestinal (GI) disorders but response rates in community surveys have been rapidly declining in many parts of the world. Whether a lower community response rate introduces significant response bias in GI survey research is unknown. A questionnaire was mailed to a total of 5,069 randomly selected subjects. The overall response rate was 52 %. A random sample of 723 of these subjects (428 responders and 295 non-responders, stratified by age and gender) was selected for medical record abstraction (including both inpatient and outpatient history). Results: The odds for response increased in those with a higher body mass index (odds ratio (OR):1.02 [95 % CI: 1.01, 1.03]), more health care seeking behavior for non-GI problems (OR: 1.97 [95 % CI: 1.43, 2.72]), and for those who had responded to a previous survey (OR: 4.84 [95 % CI: 2.84, 8.26]). Responder status was not significantly associated with any GI symptoms or a diagnosis of GI or non-GI disease (with two exceptions, diverticulosis and skin disease). Conclusions: Despite a response rate of only 52 %, the results of a community-based GI survey do not appear to be impacted by non-response bias in a major way. A low survey response rate does not necessarily indicate non-response bias. © 2012 Springer-Verlag.

DOI10.1007/s10389-012-0513-z
CitationsScopus - 8
2013Tavakkoli A, Sayed BA, Talley NJ, Moshiree B, 'Acid and non-acid reflux in patients refractory to proton pump inhibitor therapy: Is gastroparesis a factor?', WORLD JOURNAL OF GASTROENTEROLOGY, 19 6193-6198 (2013) [C1]
DOI10.3748/wjg.v19.i37.6193Author URL
2013Talley N, Ofner E, Lynch A, 'Statement on the health of people seeking asylum', Journal of Paediatrics and Child Health, 49 989-990 (2013) [C3]
DOI10.1111/jpc.12434
2013Jones MP, Eley D, Lampe L, Coulston CM, Malhli GS, Wilson I, et al., 'Role of personality in medical students' initial intention to become rural doctors', AUSTRALIAN JOURNAL OF RURAL HEALTH, 21 80-89 (2013) [C1]
DOI10.1111/ajr.12013Author URL
Co-authorsBrian Kelly
2013Goodwin RD, Talley NJ, Hotopf M, Cowles RA, Galea S, Jacobi F, 'A link between physician-diagnosed ulcer and anxiety disorders among adults', ANNALS OF EPIDEMIOLOGY, 23 189-192 (2013) [C1]
DOI10.1016/j.annepidem.2013.01.003Author URL
CitationsScopus - 5Web of Science - 4
2013Choung RS, Locke GR, Schleck CD, Zinsmeister AR, Talley NJ, 'Associations between medication use and functional gastrointestinal disorders: a population-based study', NEUROGASTROENTEROLOGY AND MOTILITY, 25 (2013) [C1]
DOI10.1111/nmo.12082Author URL
CitationsScopus - 5Web of Science - 4
2013Walter SA, Jones MP, Talley NJ, Kjellstrom L, Nyhlin H, Andreasson AN, Agreus L, 'Abdominal pain is associated with anxiety and depression scores in a sample of the general adult population with no signs of organic gastrointestinal disease', NEUROGASTROENTEROLOGY AND MOTILITY, 25 741-E576 (2013) [C1]
DOI10.1111/nmo.12155Author URL
CitationsScopus - 5Web of Science - 3
2013Talley NJ, 'STW5 (Iberogast) herbal therapy and functional gastrointestinal symptoms', Medicine Today, 14 71-73 (2013) [C3]
CitationsScopus - 1
2013Moshiree B, Barboza J, Talley N, 'An update on current pharmacotherapy options for dyspepsia', Expert Opinion on Pharmacotherapy, 14 1737-1753 (2013) [C1]
DOI10.1517/14656566.2013.809063Author URL
CitationsScopus - 6Web of Science - 4
2013Gupta K, Dhawan A, Abel C, Talley N, Attia J, 'A re-evaluation of the scratch test for locating the liver edge', BMC GASTROENTEROLOGY, 13 (2013) [C1]
DOI10.1186/1471-230X-13-35Author URL
CitationsScopus - 1Web of Science - 1
Co-authorsJohn Attia
2013Topazian M, Camilleri M, Enders FT, Clain JE, Gleeson FC, Levy MJ, et al., 'Gastric Antral Injections of Botulinum Toxin Delay Gastric Emptying but Do Not Reduce Body Weight', CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 11 145-+ (2013) [C1]
DOI10.1016/j.cgh.2012.09.029Author URL
CitationsScopus - 3Web of Science - 4
2013Halland M, Talley NJ, 'New treatments for IBS', NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 10 13-23 (2013) [C1]
DOI10.1038/nrgastro.2012.207Author URL
CitationsScopus - 11Web of Science - 8
2013Tack J, Talley NJ, 'Functional dyspepsia-symptoms, definitions and validity of the Rome III criteria', NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 10 134-141 (2013) [C1]
DOI10.1038/nrgastro.2013.14Author URL
CitationsScopus - 27Web of Science - 21
2013Koloski NA, Jones M, Eslick G, Talley NJ, 'Predictors of Response Rates to a Long Term Follow-Up Mail out Survey', PLOS ONE, 8 (2013) [C1]
DOI10.1371/journal.pone.0079179Author URL
CitationsWeb of Science - 1
2013Jones MP, Oudenhove LV, Koloski N, Tack J, Talley NJ, 'Early life factors initiate a 'vicious circle' of affective and gastrointestinal symptoms: a longitudinal study', United European Gastroenterology Journal, 1 394-402 (2013) [C1]
DOI10.1177/2050640613498383Author URL
CitationsWeb of Science - 4
2012Choung RS, Locke Iii GR, Schleck CD, Zinsmeister AR, Melton Iii LJ, Talley NJ, 'Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population', American Journal of Gastroenterology, 107 82-88 (2012) [C1]
CitationsScopus - 36Web of Science - 24
2012Ford AC, Khan KJ, Talley NJ, Moayyedi P, 'Response to Doherty and Moss', American Journal of Gastroenterology, 107 487-488 (2012) [C3]
2012Herrick LM, Locke Iii GR, Zinsmeister AR, Talley NJ, 'Challenges and lessons learned in conducting comparative-effectiveness trials', American Journal of Gastroenterology, 107 644-649 (2012) [C1]
CitationsScopus - 1Web of Science - 1
2012Tack J, Talley NJ, 'Gastroduodenal disorders', Arquivos de Gastroenterologia, 49 21-27 (2012) [C1]
DOI10.1590/S0004-28032012000500005
CitationsScopus - 1
2012Bennett C, Vakil N, Bergman J, Harrison R, Odze R, Vieth M, et al., 'Consensus statements for management of Barrett's Dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process', Gastroenterology, 143 336-346 (2012) [C1]
CitationsScopus - 128Web of Science - 98
2012Rajan E, Gostout CJ, Aimore Bonin E, Moran EA, Locke RG, Szarka LA, et al., 'Endoscopic full-thickness biopsy of the gastric wall with defect closure by using an endoscopic suturing device: Survival porcine study', Gastrointestinal Endoscopy, 76 1014-1019 (2012) [C1]
CitationsScopus - 7Web of Science - 7
2012Ronkainen J, Walker MM, Aro P, Storskrubb T, Talley NJ, Ahmed ZB, et al., 'Lymphocytic oesophagitis, a condition in search of a disease?', GUT, 61 (2012) [C3]
DOI10.1136/gutjnl-2012-302329Author URL
CitationsWeb of Science - 3
Co-authorsMarjorie Walker
2012Koloski NA, Jones M, Kalantar J, Weltman M, Zaguirre J, Talley NJ, 'The brain-gut pathway in functional gastrointestinal disorders is bidirectional: A 12-year prospective population-based study', Gut, 61 1284-1290 (2012) [C1]
CitationsScopus - 65Web of Science - 48
2012Koloski NA, Jones M, Talley NJ, 'Authors' response', Gut, 61 1776-1777 (2012) [C3]
CitationsScopus - 5Web of Science - 2
Co-authorsMarjorie Walker
2012Koloski NA, Jones M, Kalantar J, Weltman M, Zaguirre J, Talley NJ, 'Psychological impact and risk factors associated with new onset fecal incontinence', Journal of Psychosomatic Research, 73 464-468 (2012) [C1]
CitationsScopus - 4Web of Science - 4
2012Forsberg AM, Kjellstrom L, Agreus L, Andreasson AN, Nyhlin H, Talley NJ, Bjorck E, 'Prevalence of colonic neoplasia and advanced lesions in the normal population: A prospective population-based colonoscopy study', Scandinavian Journal of Gastroenterology, 47 184-190 (2012) [C1]
CitationsScopus - 11Web of Science - 11
2012Rayner CK, Talley NJ, Horowitz M, 'Stomach bugs and diabetes: An astounding observation or just confounding?', Diabetes Care, 35 463-464 (2012) [C3]
CitationsScopus - 1
2012Brook RA, Kleinman NL, Choung RS, Smeeding JE, Talley NJ, 'Excess comorbidity prevalence and cost associated with functional dyspepsia in an employed population', Digestive Diseases and Sciences, 57 109-118 (2012) [C1]
CitationsScopus - 7Web of Science - 6
2012Saito YA, Larson JJ, Atkinson EJ, Ryu E, Almazar AE, Petersen GM, Talley NJ, 'The role of 5-HTT LPR and GN beta 3 825C > T polymorphisms and gene-environment interactions in Irritable Bowel Syndrome (IBS)', Digestive Diseases and Sciences, 57 2650-2657 (2012) [C1]
CitationsScopus - 13Web of Science - 11
2012Thompson JS, Lebwohl B, Reilly NR, Talley NJ, Bhagat G, Green PHR, 'Increased incidence of eosinophilic esophagitis in children and adults with celiac disease', Journal of Clinical Gastroenterology, 46 E6-E11 (2012) [C1]
CitationsScopus - 15Web of Science - 15
2012Halland M, Talley NJ, 'Fecal incontinence: Mechanisms and management', Current Opinion in Gastroenterology, 28 57-62 (2012) [C1]
CitationsScopus - 15Web of Science - 10
2012Pounder RE, Talley NJ, 'Untitled', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 35 1-2 (2012) [C3]
DOI10.1111/j.1365-2036.2011.04952.xAuthor URL
2012Lacy BE, Talley NJ, Locke Iii GR, Bouras EP, Dibaise JK, El-Serag HB, et al., 'Review article: Current treatment options and management of functional dyspepsia', Alimentary Pharmacology & Therapeutics, 36 3-15 (2012) [C1]
CitationsScopus - 54Web of Science - 39
2012Koloski NA, Jones M, Talley NJ, 'Commentary: Psychological disorders linked to functional dyspepsia', Alimentary Pharmacology & Therapeutics, 36 1099-1100 (2012) [C3]
CitationsScopus - 1Web of Science - 1
2012Pounder RE, Talley NJ, 'Letter: The ethics of using inferior regimens in H. pylori randomised trials - Editors' reply', Alimentary Pharmacology and Therapeutics, 35 858 (2012) [C3]
CitationsWeb of Science - 4
2012Waseem S, Islam S, Kahn G, Moshiree B, Talley NJ, 'Spectrum of gastroparesis in children', Journal of Pediatric Gastroenterology and Nutrition, 55 166-172 (2012) [C1]
CitationsScopus - 10Web of Science - 6
2012Myasoedova E, Matteson EL, Talley NJ, Crowson CS, 'Increased incidence and impact of upper and lower gastrointestinal events in patients with rheumatoid arthritis in Olmsted County, Minnesota: A longitudinal population-based study', Journal of Rheumatology, 39 1355-1362 (2012) [C1]
CitationsScopus - 2Web of Science - 3
2012Koloski NA, Boyce PM, Jones MP, Talley NJ, 'What level of IBS symptoms drives impairment in health-related quality of life in community subjects with irritable bowel syndrome? Are current IBS symptom thresholds clinically meaningful?', Quality of Life Research, 21 829-836 (2012) [C1]
CitationsScopus - 9Web of Science - 9
2012Choung RS, Locke Iii GR, Lee RM, Schleck CD, Zinsmeister AR, Talley NJ, 'Cyclic vomiting syndrome and functional vomiting in adults: Association with cannabinoid use in males', Neurogastroenterology and Motility, 24 20-E1 (2012) [C1]
CitationsScopus - 8Web of Science - 7
2012Choung RS, Locke Iii GR, Schleck CD, Zinsmeister AR, Talley NJ, 'Overlap of dyspepsia and gastroesophageal reflux in the general population: One disease or distinct entities?', Neurogastroenterology and Motility, 24 229-E106 (2012) [C1]
CitationsScopus - 10Web of Science - 10
2012Alexander JA, Jung KW, Arora AS, Enders F, Katzka DA, Kephardt GM, et al., 'Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis', Clinical Gastroenterology and Hepatology, 10 742-749 (2012) [C1]
CitationsScopus - 66Web of Science - 46
2012Choung RS, Locke Iii GR, Rey E, Schleck CD, Baum C, Zinsmeister AR, Talley NJ, 'Factors associated with persistent and nonpersistent chronic constipation, over 20 years', Clinical Gastroenterology and Hepatology, 10 494-500 (2012) [C1]
CitationsScopus - 9Web of Science - 6
2012Lee J, Huprich J, Kujath C, Ravi K, Enders F, Smyrk TC, et al., 'Esophageal diameter is decreased in some patients with eosinophilic esophagitis and might increase with topical corticosteroid therapy', Clinical Gastroenterology and Hepatology, 10 481-486 (2012) [C1]
CitationsScopus - 22Web of Science - 20
2012Talley NJ, 'Advances in nutrition: Dietary modification as a treatment for irritable bowel syndrome', Clinical Advances in Hematology and Oncology, 10 552-554 (2012) [C1]
CitationsScopus - 1
2012Talley NJ, Locke Iii GR, Herrick LM, Silvernail VM, Prather CM, Lacy BE, et al., 'Functional Dyspepsia Treatment Trial (FDTT): A double-blind, randomized, placebo-controlled trial of antidepressants in functional dyspepsia, evaluating symptoms, psychopathology, pathophysiology and pharmacogenetics', Contemporary Clinical Trials, 33 523-533 (2012) [C1]
CitationsScopus - 20Web of Science - 14
2012Talley NJ, 'Dietary modification as a treatment for irritable bowel syndrome', Gastroenterology and Hepatology, 8 552-554 (2012) [C3]
2012Adibi P, Keshteli AH, Esmaillzadeh A, Afshar H, Roohafza H, Bagherian-Sararoudi R, et al., 'The study on the epidemiology of psychological, alimentary health and nutrition (SEPAHAN): Overview of methodology', Journal of Research in Medical Sciences, 17 S291-S298 (2012) [C1]
CitationsScopus - 21Web of Science - 8
2012Gill RS, Collins JS, Talley NJ, 'Management of noncardiac chest pain in women', Women's Health, 8 131-145 (2012) [C1]
CitationsScopus - 2
2012Ford AC, Talley NJ, 'Laxatives for chronic constipation in adults', British Medical Journal, 345 e6168 (2012) [C2]
CitationsScopus - 6Web of Science - 3
2012Ford AC, Talley NJ, 'Irritable bowel syndrome', British Medical Journal, 345 37-42 (2012) [C1]
CitationsScopus - 31Web of Science - 21
2012Keely S, Talley NJ, Hansbro PM, 'Pulmonary-intestinal cross-talk in mucosal inflammatory disease', Mucosal Immunology, 5 7-18 (2012) [C1]
CitationsScopus - 26Web of Science - 27
Co-authorsSimon Keely, Philip Hansbro
2012Rey E, Choung RS, Schleck CD, Zinsmeister AR, Talley NJ, Locke Iii GR, 'Prevalence of hidden gastroparesis in the community: The gastroparesis 'iceberg'', Journal of Neurogastroenterology and Motility, 18 34-42 (2012) [C1]
CitationsScopus - 19Web of Science - 14
2011Walker MM, Warwick A, Ung C, Talley NJ, 'The role of eosinophils and mast cells in intestinal functional disease', Current Gastroenterology Reports, 13 323-330 (2011) [C1]
DOI10.1007/s11894-011-0197-5
CitationsScopus - 24
Co-authorsMarjorie Walker
2011Talley NJ, 'Rumination syndrome', Gastroenterology and Hepatology, 7 117-118 (2011) [C3]
CitationsScopus - 2
2011Myasoedova E, Talley NJ, Manek NJ, Crowson CS, 'Prevalence and risk factors of gastrointestinal disorders in patients with rheumatoid arthritis: Results from a population-based survey in Olmsted County, Minnesota', Gastroenterology Research and Practice, 2011 1-7 (2011) [C1]
DOI10.1155/2011/745829
CitationsScopus - 4Web of Science - 3
2011Ford AC, Talley NJ, 'IBS in 2010: Advances in pathophysiology, diagnosis and treatment', Nature Reviews Gastroenterology and Hepatology, 8 76-78 (2011) [C3]
DOI10.1038/nrgastro.2010.216
CitationsScopus - 15Web of Science - 10
2011Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, et al., 'Antibiotic Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis (vol 106, pg 661, 2011)', AMERICAN JOURNAL OF GASTROENTEROLOGY, 106 1014-1014 (2011) [C3]
Author URL
2011Katz KD, Rashtak S, Lahr BD, Melton LJ, Krause PK, Maggi K, et al., 'Screening for Celiac Disease in a North American Population: Sequential Serology and Gastrointestinal Symptoms', AMERICAN JOURNAL OF GASTROENTEROLOGY, 106 1333-1339 (2011) [C1]
DOI10.1038/ajg.2011.21Author URL
CitationsScopus - 44Web of Science - 42
2011Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, et al., 'Erratum: Antibiotic therapy in inflammatory bowel disease: A systematic review and meta-analysis (American Journal of Gastroenterology (2011) 106 (661-673) DOI: 10.1038/ajg.2011.72)', American Journal of Gastroenterology, 106 1014-1014 (2011) [C3]
DOI10.1038/ajg.2011.131
2011Talley NJ, Abreu MT, Achkar J-P, Bernstein CN, Dubinsky MC, Hanauer SB, et al., 'An evidence-based systematic review on medical therapies for inflammatory bowel disease', American Journal of Gastroenterology, 106 S2-S25 (2011) [C1]
DOI10.1038/ajg.2011.58
CitationsScopus - 100Web of Science - 79
2011Ford AC, Kane SV, Khan KJ, Achkar J-P, Talley NJ, Marshall JK, Moayyedi P, 'Efficacy of 5-aminosalicylates in Crohn's disease: Systematic review and meta-analysis', American Journal of Gastroenterology, 106 617-629 (2011) [C1]
DOI10.1038/ajg.2011.71
CitationsScopus - 67Web of Science - 40
2011Ford AC, Achkar J-P, Khan KJ, Kane SV, Talley NJ, Marshall JK, Moayyedi P, 'Efficacy of 5-aminosalicylates in ulcerative colitis: Systematic review and meta-analysis', American Journal of Gastroenterology, 106 601-616 (2011) [C1]
DOI10.1038/ajg.2011.67
CitationsScopus - 65Web of Science - 49
2011Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P, 'Efficacy of biological therapies in inflammatory bowel disease: Systematic review and meta-analysis', American Journal of Gastroenterology, 106 644-659 (2011) [C1]
DOI10.1038/ajg.2011.73
CitationsScopus - 176Web of Science - 155
2011Khan KJ, Dubinsky MC, Ford AC, Ullman TA, Talley NJ, Moayyedi P, 'Efficacy of immunosuppressive therapy for inflammatory bowel disease: A systematic review and meta-analysis', American Journal of Gastroenterology, 106 630-642 (2011) [C1]
DOI10.1038/ajg.2011.64
CitationsScopus - 85Web of Science - 71
2011Ford AC, Bernstein CN, Khan KJ, Abreu MT, Marshall JK, Talley NJ, Moayyedi P, 'Glucocorticosteroid therapy in inflammatory bowel disease: Systematic review and meta-analysis', American Journal of Gastroenterology, 106 590-599 (2011) [C1]
DOI10.1038/ajg.2011.70
CitationsScopus - 67Web of Science - 55
2011Liebregts T, Adam B, Bredack C, Gururatsakul M, Pilkington KR, Brierley SM, et al., 'Small bowel homing T cells are associated with symptoms and delayed gastric emptying in functional dyspepsia', American Journal of Gastroenterology, 106 1089-1098 (2011) [C1]
DOI10.1038/ajg.2010.512
CitationsScopus - 24Web of Science - 20
2011Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, et al., 'Antibiotic therapy in inflammatory bowel disease: A systematic review and meta-analysis', American Journal of Gastroenterology, 106 661-673 (2011) [C1]
DOI10.1038/ajg.2011.72
CitationsScopus - 129Web of Science - 110
2011Jung KW, Talley NJ, Romero Y, Katzka DA, Schleck CD, Zinsmeister AR, et al., 'Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: A population-based study', American Journal of Gastroenterology, 106 1447-1455 (2011) [C1]
DOI10.1038/ajg.2011.130
CitationsScopus - 45Web of Science - 37
2011Ford AC, Khan KJ, Talley NJ, Moayyedi P, '5-aminosalicylates prevent relapse of Crohn's Disease after surgically induced remission: Systematic review and meta-analysis', American Journal of Gastroenterology, 106 413-420 (2011) [C1]
DOI10.1038/ajg.2010.317
CitationsScopus - 35Web of Science - 22
2011Ford AC, Talley NJ, Moayyedi P, 'Reply to Akobeng - Efficacy of 5-Aminosalicylates for the maintenance of remission in Crohn's Disease', American Journal of Gastroenterology, 106 1857-1858 (2011) [C3]
DOI10.1038/ajg.2011.218
2011Ronkainen J, Talley NJ, Storskrubb T, Johansson S-E, Lind T, Vieth M, et al., 'Erosive esophagitis is a risk factor for Barrett's esophagus: A community-based endoscopic follow-up study', American Journal of Gastroenterology, 106 1946-1952 (2011) [C1]
DOI10.1038/ajg.2011.326
CitationsScopus - 21Web of Science - 14
2011Ford AC, Talley NJ, Moayyedi P, 'Response to Atreja et al', American Journal of Gastroenterology, 106 2046 (2011) [C3]
DOI10.1038/ajg.2011.274
2011Ford AC, Talley NJ, Moayyedi P, 'Response to Yang et al', American Journal of Gastroenterology, 106 2044 (2011) [C3]
DOI10.1038/ajg.2011.246
2011Talley NJ, 'Rifaximin relieved global symptoms and bloating in the irritable bowel syndrome without constipation', Annals of Internal Medicine, 154 6 (2011) [C3]
2011Talley NJ, 'Quadruple-drug therapy was better than triple-drug therapy for eradicating Helicobacter pylori in adults', Annals of Internal Medicine, 154 1 (2011) [C3]
2011Talley NJ, 'ACP Journal Club. Quadruple-drug therapy was better than triple-drug therapy for eradicating Helicobacter pylori in adults.', Annals of internal medicine, 154 JC6-JC2 (2011) [C3]
DOI10.7326/0003-4819-154-12-201106210-02002
2011Talley NJ, 'Irritable bowel syndrome: Rational therapy', Consultant, 51 341-347 (2011) [C2]
2011Talley NJ, Fodor AA, 'Bugs, stool, and the irritable bowel syndrome: Too much is as bad as too little?', Gastroenterology, 141 1555-1559 (2011) [C3]
DOI10.1053/j.gastro.2011.09.019
CitationsScopus - 8Web of Science - 6
2011Jung KW, Gundersen N, Kopacova J, Arora AS, Romero Y, Katzka D, et al., 'Occurrence of and risk factors for complications after endoscopic dilation in eosinophilic esophagitis', Gastrointestinal Endoscopy, 73 15-21 (2011) [C1]
DOI10.1016/j.gie.2010.09.036
CitationsScopus - 40Web of Science - 31
2011Jones M, Koloski N, Boyce P, Talley NJ, 'Pathways connecting cognitive behavioral therapy and change in bowel symptoms of IBS', Journal of Psychosomatic Research, 70 278-285 (2011) [C1]
DOI10.1016/j.jpsychores.2010.10.004
CitationsScopus - 20Web of Science - 16
2011Chang JY, Talley NJ, Locke GR, Katzka DA, Schleck CD, Zinsmeister AR, et al., 'Population Screening for Barrett Esophagus: A Prospective Randomized Pilot Study', MAYO CLINIC PROCEEDINGS, 86 1174-1180 (2011) [C1]
DOI10.4065/mcp.2011.0396Author URL
CitationsScopus - 10Web of Science - 10
2011Beebe TJ, Ziegenfuss JY, St Sauver JL, Jenkins SM, Haas L, Davern ME, Talley NJ, 'Health Insurance Portability and Accountability Act (HIPAA) Authorization and Survey Nonresponse Bias', MEDICAL CARE, 49 365-370 (2011) [C1]
DOI10.1097/MLR.0b013e318202ada0Author URL
CitationsScopus - 5Web of Science - 5
2011Eslick GD, Koloski NA, Talley NJ, 'Sexual, physical, verbal/emotional abuse and unexplained chest pain', Child Abuse and Neglect, 35 601-605 (2011) [C1]
DOI10.1016/j.chiabu.2011.04.007
2011Pittock SJ, Lennon VA, Dege CL, Talley NJ, Locke GR, 'Neural Autoantibody Evaluation in Functional Gastrointestinal Disorders: A Population-Based Case-Control Study', DIGESTIVE DISEASES AND SCIENCES, 56 1452-1459 (2011) [C1]
DOI10.1007/s10620-010-1514-9Author URL
CitationsScopus - 5Web of Science - 3
2011Ravi K, Talley NJ, Smyrk TC, Katzka DA, Kryzer L, Romero Y, et al., 'Low grade esophageal eosinophilia in adults: An unrecognized part of the spectrum of eosinophilic esophagitis?', Digestive Diseases and Sciences, 56 1981-1986 (2011) [C1]
DOI10.1007/s10620-011-1594-1
CitationsScopus - 14Web of Science - 11
2011Walter SA, Kjellstrom L, Talley NJ, Andreasson AN, Nyhlin H, Agreus L, 'Prospective diary evaluation of unexplained abdominal pain and bowel dysfunction: A population-based colonoscopy study', Digestive Diseases and Sciences, 56 1444-1451 (2011) [C1]
DOI10.1007/s10620-010-1468-y
CitationsScopus - 3Web of Science - 3
2011Wang YR, Talley NJ, Picco MF, 'Overlap: Irritable bowel syndrome, inflammatory bowel disease, and diverticular disease', Journal of Clinical Gastroenterology, 45 S36-S42 (2011) [C1]
DOI10.1097/MCG.0b013e3182107824
2011Chang JY, Talley NJ, 'An update on irritable bowel syndrome: From diagnosis to emerging therapies', Current Opinion in Gastroenterology, 27 72-78 (2011) [C2]
DOI10.1097/mog.0b013e3283414065
CitationsScopus - 21Web of Science - 13
2011Pounder RE, Talley NJ, 'Untitled', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 33 1-2 (2011) [C3]
DOI10.1111/j.1365-2036.2010.04527.xAuthor URL
2011Aro P, Talley NJ, Agreus L, Johansson SE, Bolling-Sternevald E, Storskrubb T, Ronkainen J, 'Functional dyspepsia impairs quality of life in the adult population', Alimentary Pharmacology & Therapeutics, 33 1215-1224 (2011) [C1]
DOI10.1111/j.1365-2036.2011.04640.x
CitationsScopus - 30Web of Science - 25
2011Ford AC, Suares NC, Talley NJ, 'Meta-analysis: the epidemiology of noncardiac chest pain in the community', Alimentary Pharmacology & Therapeutics, 34 172-180 (2011) [C1]
DOI10.1111/j.1365-2036.2011.04702.x
CitationsScopus - 10Web of Science - 7
2011Achem SR, Almansa C, Krishna M, Heckman MG, Wolfsen HC, Talley NJ, Devault KR, 'Eosinophilic oesophagitis in noncardiac chest pain: Authors' reply', Alimentary Pharmacology & Therapeutics, 34 110 (2011) [C3]
DOI10.1111/j.1365-2036.2011.04698.x
CitationsScopus - 1
2011Achem SR, Almansa C, Krishna M, Heckman MG, Wolfsen HC, Talley NJ, Devault KR, 'Oesophageal eosinophilic infiltration in patients with noncardiac chest pain', Alimentary Pharmacology & Therapeutics, 33 1194-1201 (2011) [C1]
DOI10.1111/j.1365-2036.2011.04652.x
CitationsScopus - 12Web of Science - 9
2011Ang D, Talley NJ, Simren M, Janssen P, Boeckxstaens G, Tack J, 'Review article: Endpoints used in functional dyspepsia drug therapy trials', Alimentary Pharmacology & Therapeutics, 33 634-649 (2011) [C1]
DOI10.1111/j.1365-2036.2010.04566.x
CitationsScopus - 13Web of Science - 11
2011Choung RS, Branda ME, Chitkara D, Shah ND, Katusic SK, Locke Iii GR, Talley NJ, 'Longitudinal direct medical costs associated with constipation in women', Alimentary Pharmacology & Therapeutics, 33 251-260 (2011) [C1]
DOI10.1111/j.1365-2036.2010.04513.x
CitationsScopus - 22Web of Science - 16
2011Veldhuyzen Van Zanten S, Wahlqvist P, Talley NJ, Halling K, Vakil N, Lauritsen K, et al., 'Randomised clinical trial: The burden of illness of uninvestigated dyspepsia before and after treatment with esomeprazole - Results from the STARS II study', Alimentary Pharmacology & Therapeutics, 34 714-723 (2011) [C1]
DOI10.1111/j.1365-2036.2011.04789.x
CitationsScopus - 3Web of Science - 3
2011Choung RS, Ruff KC, Malhotra A, Herrick L, Locke Iii GR, Harmsen WS, et al., 'Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture', Alimentary Pharmacology and Therapeutics, 33 1059-1067 (2011) [C1]
DOI10.1111/j.1365-2036.2011.04625.x
CitationsScopus - 35Web of Science - 26
2011Choung RS, Shah ND, Chitkara D, Branda ME, Van Tilburg MA, Whitehead WE, et al., 'Direct Medical Costs of Constipation From Childhood to Early Adulthood: A Population-based Birth Cohort Study', JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 52 47-54 (2011) [C1]
DOI10.1097/MPG.0b013e3181e67058Author URL
CitationsScopus - 13Web of Science - 10
2011Spergel JM, Book WM, Mays E, Song L, Shah SS, Talley NJ, Bonis PA, 'Variation in Prevalence, Diagnostic Criteria, and Initial Management Options for Eosinophilic Gastrointestinal Diseases in the United States', JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 52 300-306 (2011) [C1]
DOI10.1097/MPG.0b013e3181eb5a9fAuthor URL
CitationsScopus - 74Web of Science - 60
2011Walker MM, Talley NJ, 'Clinical value of duodenal biopsies - Beyond the diagnosis of coeliac disease', Pathology Research and Practice, 207 538-544 (2011) [C2]
DOI10.1016/j.prp.2011.08.001
CitationsScopus - 10Web of Science - 8
Co-authorsMarjorie Walker
2011Ford AC, Talley NJ, 'Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: A systematic review', Journal of Gastroenterology, 46 421-431 (2011) [C1]
DOI10.1007/s00535-011-0379-9
CitationsScopus - 47Web of Science - 38
2011Dinning PG, Jones M, Hunt L, Fuentealba SE, Kalanter J, King DW, et al., 'Factor analysis identifies subgroups of constipation', World Journal of Gastroenterology, 17 1468-1474 (2011) [C1]
DOI10.3748/wjg.v17.i11.1468
CitationsScopus - 5Web of Science - 4
2010Chang JY, Choung RS, Lee RM, Locke GR, Schleck CD, Zinsmeister AR, et al., 'A shift in the clinical spectrum of eosinophilic gastroenteritis toward the mucosal disease type', Clinical Gastroenterology and Hepatology, 8 669-675 (2010) [C1]
DOI10.1016/j.cgh.2010.04.022
CitationsScopus - 31Web of Science - 18
2010Brook RA, Kleinman NL, Choung RS, Melkonian AK, Smeeding JE, Talley NJ, 'Functional Dyspepsia Impacts Absenteeism and Direct and Indirect Costs', Clinical Gastroenterology and Hepatology, 8 498-503 (2010) [C1]
DOI10.1016/j.cgh.2010.03.003
CitationsScopus - 54Web of Science - 39
2010Rubio-Tapia A, Talley NJ, Gurudu SR, Wu T, Murray JA, 'Gluten-Free Diet and Steroid Treatment Are Effective Therapy for Most Patients With Collagenous Sprue', Clinical Gastroenterology and Hepatology, 8 344-349 (2010) [C1]
DOI10.1016/j.cgh.2009.12.023
CitationsScopus - 24Web of Science - 20
2010Talley NJ, Herrick L, Locke GR, 'Antidepressants in functional dyspepsia', EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 4 5-8 (2010) [C3]
DOI10.1586/EGH.09.73Author URL
CitationsScopus - 18Web of Science - 11
2010Ford AC, Moayyedi P, Talley NJ, 'Irritable Bowel Syndrome 355-376 (2010)
DOI10.1002/9781444314403.ch21
2010Chang JY, Talley NJ, 'Eosinophilic Gastroenteritis 392-396 (2010) [B2]

Eosinophilic gastroenteritis (EG) is a rare and heterogeneous disorder characterized by gastrointestinal (GI) symptoms and eosinophilic infiltration of the GI tract. Symptoms are ... [more]

Eosinophilic gastroenteritis (EG) is a rare and heterogeneous disorder characterized by gastrointestinal (GI) symptoms and eosinophilic infiltration of the GI tract. Symptoms are dependent upon site of the GI tract involved and depth of involvement. The diagnostic criteria includes: 1) the presence of GI symptoms, 2) histopathology demonstrating predominant eosinophilic infiltration, 3) the absence of other conditions that cause eosinophilia, and 4) no eosinophilic involvement of organs outside the GI tract. Diagnosis requires a clinical history, physical exam, and documentation of any history of atopic disorders, allergies, and drug allergies. Laboratory evaluation includes a complete blood count with differential to evaluate for peripheral eosinophilia. Endoscopic evaluation with random biopsies remains the cornerstone for diagnosis. Histopathologic diagnosis typically requires an infiltration level of >20 eosinophils per high power field. Management strategies are based upon severity of symptoms and include anti-diarrheals, dietary adjustments, and steroid therapy. © 2010 Blackwell Publishing Ltd.

DOI10.1002/9781444327311.ch50
2010Jung H-K, Choung RS, Talley NJ, 'Irritable Bowel Syndrome and Diverticular Disease: Association or Misdiagnosis? Response', AMERICAN JOURNAL OF GASTROENTEROLOGY, 105 2293-2294 (2010) [C3]
DOI10.1038/ajg.2010.197Author URL
2010Lacy BE, Talley NJ, Camilleri M, 'Functional Dyspepsia: Time to Change Clinical Trial Design?', AMERICAN JOURNAL OF GASTROENTEROLOGY, 105 2525-2529 (2010) [C1]
DOI10.1038/ajg.2010.266Author URL
CitationsScopus - 6Web of Science - 3
2010Chang JY, Locke GR, McNally MA, Halder SL, Schleck CD, Zinsmeister AR, Talley NJ, 'Impact of functional gastrointestinal disorders on survival in the community', American Journal of Gastroenterology, 105 822-832 (2010) [C1]
DOI10.1038/ajg.2010.40
CitationsScopus - 38Web of Science - 30
2010Saito YA, Petersen GM, Larson JJ, Atkinson EJ, Fridley BL, De Andrade M, et al., 'Familial aggregation of irritable bowel syndrome: A family case-control study', American Journal of Gastroenterology, 105 833-841 (2010) [C1]
DOI10.1038/ajg.2010.116
CitationsScopus - 32Web of Science - 27
2010Rey E, Choung RS, Schleck CD, Zinsmeister AR, Locke GR, Talley NJ, 'Onset and risk factors for fecal incontinence in a US community', American Journal of Gastroenterology, 105 412-419 (2010) [C1]
DOI10.1038/ajg.2009.594
CitationsScopus - 29Web of Science - 24
2010Kephart GM, Alexander JA, Arora AS, Romero Y, Smyrk TC, Talley NJ, Kita H, 'Marked deposition of eosinophil-derived neurotoxin in adult patients with eosinophilic esophagitis', American Journal of Gastroenterology, 105 298-307 (2010) [C1]
DOI10.1038/ajg.2009.584
CitationsScopus - 43Web of Science - 36
2010Jung HK, Choung RS, Locke GR, Schleck CD, Zinsmeister AR, Talley NJ, 'Diarrhea-predominant irritable bowel syndrome is associated with diverticular disease: A population-based study', American Journal of Gastroenterology, 105 652-661 (2010) [C1]
DOI10.1038/ajg.2009.621
CitationsScopus - 51Web of Science - 39
2010Saito YA, Rey E, Almazar-Elder AE, Harmsen WS, Zinsmeister AR, Locke GR, Talley NJ, 'A randomized, double-blind, placebo-controlled trial of st john's wort for treating irritable bowel syndrome', American Journal of Gastroenterology, 105 170-177 (2010) [C1]
CitationsScopus - 20Web of Science - 12
2010Ford AC, Guyatt GH, Talley NJ, Moayyedi P, 'Errors in the conduct of systematic reviews of pharmacological interventions for irritable bowel syndrome', American Journal of Gastroenterology, 105 280-288 (2010) [C1]
CitationsScopus - 17Web of Science - 20
2010Talley NJ, Tack J, 'Gastroduodenal disorders', American Journal of Gastroenterology, 105 757-763 (2010) [C1]
CitationsScopus - 27Web of Science - 22
2010Moayyedi P, Ford AC, Quigley EMM, Foxx-Orenstein AE, Chey WD, Talley NJ, Brandt LJ, 'The American College of Gastroenterology Irritable Bowel Syndrome Monograph: Translating Systematic Review Data to Clinical Practice', GASTROENTEROLOGY, 138 789-791 (2010) [C3]
DOI10.1053/j.gastro.2009.09.077Author URL
CitationsScopus - 3Web of Science - 2
2010Walker M, Murray JA, Ronkainen J, Aro P, Storskrubb T, D'Amato M, et al., 'Detection of Celiac Disease and Lymphocytic Enteropathy by Parallel Serology and Histopathology in a Population-Based Study', Gastroenterology, 139 112-119 (2010) [C1]
DOI10.1053/j.gastro.2010.04.007
CitationsScopus - 92Web of Science - 82
Co-authorsMarjorie Walker
2010Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, Quigley EM, 'The efficacy of probiotics in the treatment of irritable bowel syndrome: A systematic review', Gut, 59 325-332 (2010) [C1]
CitationsScopus - 275Web of Science - 202
2010Leise MD, Locke GR, Dierkhising RA, Zinsmeister AR, Reeder GS, Talley NJ, 'Patients dismissed from the hospital with a diagnosis of noncardiac chest pain: Cardiac outcomes and health care utilization', Mayo Clinic Proceedings, 85 323-330 (2010) [C1]
DOI10.4065/mcp.2009.0428
CitationsScopus - 11Web of Science - 8
2010Walter SA, Kjellstrom L, Nyhlin H, Talley NJ, Agreus L, 'Assessment of normal bowel habits in the general adult population: The Popcol study', Scandinavian Journal of Gastroenterology, 45 556-566 (2010) [C1]
DOI10.3109/00365520903551332
CitationsScopus - 11Web of Science - 8
2010Chang JY, Talley NJ, 'Current and emerging therapies in irritable bowel syndrome: from pathophysiology to treatment', TRENDS IN PHARMACOLOGICAL SCIENCES, 31 326-334 (2010) [C3]
DOI10.1016/j.tips.2010.04.008Author URL
CitationsScopus - 22Web of Science - 19
2010McElhiney J, Lohse MR, Arora AS, Peloquin JM, Geno DM, Kuntz MM, et al., 'The Mayo Dysphagia Questionnaire-30: Documentation of reliability and validity of a tool for interventional trials in adults with esophageal disease', Dysphagia, 25 221-230 (2010) [C1]
DOI10.1007/s00455-009-9246-8
CitationsScopus - 16Web of Science - 14
2010Yamini D, Pimentel M, 'Irritable Bowel Syndrome and Small Intestinal Bacterial Overgrowth', JOURNAL OF CLINICAL GASTROENTEROLOGY, 44 672-675 (2010) [C3]
DOI10.1097/MCG.0b013e3181d7a368Author URL
CitationsWeb of Science - 9
2010Choung RS, Herrick LM, Locke GR, Zinsmeister AR, Talley NJ, 'Irritable bowel syndrome and chronic pelvic pain: A population-based study', Journal of Clinical Gastroenterology, 44 696-701 (2010) [C1]
DOI10.1097/MCG.0b013e3181d7a368
CitationsScopus - 12Web of Science - 7
2010Saito YA, Choung RS, Zinsmeister AR, Talley NJ, 'Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture: Authors' reply', Alimentary Pharmacology & Therapeutics, 33 1379-1380 (2010) [C3]
DOI10.1111/j.1365-2036.2011.04669.x
2010Pounder RE, Talley NJ, 'Letter from the editors', Alimentary Pharmacology and Therapeutics, 31 3-4 (2010) [C3]
DOI10.1111/j.1365-2036.2009.04193.x
2010Rey E, Locke GR, Jung HK, Malhorta A, Beebe TJ, Schleck CD, et al., 'Measurement of abdominal symptoms by validated questionnaire: A 3-month recall timeframe as recommended by Rome III is not superior to a 1-year recall timeframe', Alimentary Pharmacology and Therapeutics, 31 1237-1247 (2010) [C1]
DOI10.1111/j.1365-2036.2010.04288.x
CitationsScopus - 10Web of Science - 8
2010Hart J, Hawkey CJ, Lanas A, Naesdal J, Talley NJ, Thompson AB, Yeomans ND, 'Predictors of gastroduodenal erosions in patients taking low-dose aspirin', Alimentary Pharmacology and Therapeutics, 31 143-149 (2010) [C1]
DOI10.1111/j.1365-2036.2009.04133.x
CitationsScopus - 24Web of Science - 19
2010Walker M, Salehian SS, Murray CE, Rajendran A, Hoare JM, Negus R, et al., 'Implications of eosinophilia in the normal duodenal biopsy - An association with allergy and functional dyspepsia', Alimentary Pharmacology and Therapeutics, 31 1229-1236 (2010) [C1]
DOI10.1111/j.1365-2036.2010.04282.x
CitationsScopus - 34Web of Science - 25
Co-authorsMarjorie Walker
2010Cremonini F, Camilleri M, Clark MM, Beebe TJ, Locke GR, Zinsmeister AR, et al., 'Associations among binge eating behavior patterns and gastrointestinal symptoms: a population-based study (vol 33, pg 342, 2009)', INTERNATIONAL JOURNAL OF OBESITY, 34 214-214 (2010) [C3]
DOI10.1038/ijo.2009.214Author URL
2010Tack J, Talley NJ, 'Gastroduodenal disorders', Revista de Gastroenterologia de Mexico, 75 463-471 (2010) [C1]
2010Aro P, Ronkainen J, Storskrubb T, Vieth M, Engstrand L, Johansson SE, et al., 'Use of tobacco products and gastrointestinal morbidity: An endoscopic population-based study (the Kalixanda study)', European Journal of Epidemiology, 25 741-750 (2010) [C1]
DOI10.1007/s10654-010-9495-8
CitationsScopus - 11Web of Science - 7
2010Gururatsakul M, Holloway RH, Talley NJ, Hotlmann GJ, 'Association between clinical manifestations of complicated and uncomplicated peptic ulcer and visceral sensory dysfunction', Journal of Gastroenterology and Hepatology, 25 1162-1169 (2010) [C1]
DOI10.1111/j.1440-1746.2010.06269.x
CitationsScopus - 5Web of Science - 5
2010Talley NJ, Lindor KD, Vargas HE, 'Practical Gastroenterology and Hepatology: Liver and Biliary Disease', Practical Gastroenterology and Hepatology: Liver and Biliary Disease, (2010) [A3]

This comprehensive resource for fellows/trainees and candidates for recertification in gastroenterology summarizes the field in a modern, fresh format. Prominent experts from arou... [more]

This comprehensive resource for fellows/trainees and candidates for recertification in gastroenterology summarizes the field in a modern, fresh format. Prominent experts from around the globe write on their areas of expertise, and each chapter follows a uniform structure. The focus is on key knowledge, with the most important clinical facts highlighted in boxes. Color illustrations reinforce the text. © 2010 Blackwell Publishing Ltd.

DOI10.1002/9781444325249
2010Ziegenfuss JY, Beebe TJ, Rey E, Schleck C, Locke GR, Talley NJ, 'Internet Option in a Mail Survey More Harm Than Good?', EPIDEMIOLOGY, 21 585-586 (2010) [C3]
DOI10.1097/EDE.0b013e3181e09657Author URL
CitationsScopus - 9Web of Science - 8
2010Clark K, Currow DC, Talley NJ, 'The Use of Digital Rectal Examinations in Palliative Care Inpatients', JOURNAL OF PALLIATIVE MEDICINE, 13 797-797 (2010) [C3]
DOI10.1089/jpm.2010.0019Author URL
CitationsScopus - 2Web of Science - 1
2010Gathaiya N, Locke GR, Camilleri M, Schleck CD, Zinsmeister AR, Talley NJ, 'Novel associations with dyspepsia: a community-based study of familial aggregation, sleep dysfunction and somatization (vol 21, pg 922, 2009)', NEUROGASTROENTEROLOGY AND MOTILITY, 22 226-226 (2010) [C3]
Author URL
2010Gathaiya N, Locke GR, Camilleri M, Schleck CD, Zinsmeister AR, Talley NJ, 'Erratum: Novel associations with dyspepsia: A community-based study of familial aggregation, sleep dysfunction and somatization (Neurogastroenterol Motil (2009) 21 (922-e69))', Neurogastroenterology and Motility, 22 226-226 (2010) [C3]
DOI10.1111/j.1365-2982.2009.01457.x
2010Haag S, Senf W, Tagay S, Heuft G, Gerken G, Talley NJ, Holtmann G, 'Is there any association between disturbed gastrointestinal visceromotor and sensory function and impaired quality of life in functional dyspepsia?', Neurogastroenterology and Motility, 22 262-270 (2010) [C1]
DOI10.1111/j.1365-2982.2009.01415.x
CitationsScopus - 10Web of Science - 6
2010Gururatsakul M, Holloway RH, Adam B, Liebregts T, Talley NJ, Holtmann GJ, 'The ageing gut: Diminished symptom response to a standardized nutrient stimulus', Neurogastroenterology and Motility, 22 246-251 (2010) [C1]
DOI10.1111/j.1365-2982.2009.01413.x
CitationsScopus - 5Web of Science - 4
2010Talley NJ, Locke RG, Beebe TJ, Rey E, Ziegenfuss JY, Jenkins S, Lackore K, 'Shortening a survey and using alternative forms of prenotification: Impact on response rate and quality', BMC Medical Research Methodology, 10 50-50 (2010) [C1]
DOI10.1186/1471-2288-10-50
CitationsScopus - 9Web of Science - 10
2009Talley NJ, Choung RS, 'Functional (Non-Ulcer) Dyspepsia and Gastroparesis-Differentiating These Conditions and Practical Management Approaches', REVIEWS IN GASTROENTEROLOGICAL DISORDERS, 9 E48-E53 (2009) [C3]
DOI10.3909/rigd.0345Author URL
CitationsScopus - 1
2009Talley NJ, Lasch KL, Baum CL, 'A Gap in Our Understanding: Chronic Constipation and Its Comorbid Conditions.', Clinical Gastroenterology and Hepatology, 7 9-19 (2009) [C1]
DOI10.1016/j.cgh.2008.07.005
CitationsScopus - 15Web of Science - 13
2009Prasad GA, Alexander JA, Schleck CD, Zinsmeister AR, Smyrk TC, Elias RM, et al., 'Epidemiology of Eosinophilic Esophagitis Over Three Decades in Olmsted County, Minnesota', Clinical Gastroenterology and Hepatology, 7 1055-1061 (2009) [C1]
DOI10.1016/j.cgh.2009.06.023
CitationsScopus - 167Web of Science - 140
2009Pilichiewicz AN, Horowitz M, Holtmann GJ, Talley NJ, Feinle-Bisset C, 'Relationship Between Symptoms and Dietary Patterns in Patients With Functional Dyspepsia', Clinical Gastroenterology and Hepatology, 7 317-322 (2009) [C1]
DOI10.1016/j.cgh.2008.09.007
CitationsScopus - 24Web of Science - 23
2009Vakil N, Talley NJ, Van Zanten SV, Flook N, Persson T, Björck E, et al., 'Cost of Detecting Malignant Lesions by Endoscopy in 2741 Primary Care Dyspeptic Patients Without Alarm Symptoms', Clinical Gastroenterology and Hepatology, 7 756-761 (2009) [C1]
DOI10.1016/j.cgh.2009.03.031
CitationsScopus - 18Web of Science - 15
2009Ford AC, Spiegel BM, Talley NJ, Moayyedi P, 'Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: Systematic Review and Meta-analysis', Clinical Gastroenterology and Hepatology, 7 1279-1286 (2009) [C1]
CitationsScopus - 133Web of Science - 99
2009Talley NJ, 'Irritable Bowel Syndrome: Novel views on the epidemiology and potential risk factors', Digestive and Liver Disease, 41 772-780 (2009) [C1]
DOI10.1016/j.dld.2009.07.005
CitationsScopus - 45Web of Science - 40
2009Devault KR, Talley NJ, 'Insights into the future of gastric acid suppression', Nature Clinical Practice Gastroenterology and Hepatology, 6 524-532 (2009) [C1]
DOI10.1038/nrgastro.2009.125
CitationsScopus - 24Web of Science - 18
2009Talley NJ, Holtmann G, 'Approach to the Patient with Dyspepsia and Related Functional Gastrointestinal Complaints 38-61 (2009) [B2]
DOI10.1002/9781444300758.ch4
2009Talley NJ, 'Evolution of Training in Gastroenterology and Hepatology: Working Together Is the Solution RESPONSE', AMERICAN JOURNAL OF GASTROENTEROLOGY, 104 11-12 (2009) [C3]
DOI10.1038/ajg.2008.130Author URL
2009Talley NJ, 'Should We Examine the Prostate Prior to Colonoscopy?', AMERICAN JOURNAL OF GASTROENTEROLOGY, 104 247-247 (2009) [C3]
DOI10.1038/ajg.2008.50Author URL
CitationsScopus - 1Web of Science - 1
2009Brandt LJ, Chey WD, Foxx-Orenstein AE, Quigley EMM, Schiller LR, Schoenfeld PS, et al., 'An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome (vol 104, pg S1, 2009)', AMERICAN JOURNAL OF GASTROENTEROLOGY, 104 1072-1072 (2009) [C3]
Author URL
2009Talley NJ, 'Green Light from the FDA for New Drug Development in Irritable Bowel Syndrome and Functional Dyspepsia', AMERICAN JOURNAL OF GASTROENTEROLOGY, 104 1339-1341 (2009) [C3]
DOI10.1038/ajg.2009.295Author URL
CitationsScopus - 7Web of Science - 5
2009Talley NJ, Richter J, 'At Last, Time for the Next Transformation', AMERICAN JOURNAL OF GASTROENTEROLOGY, 104 2883-2884 (2009) [C3]
DOI10.1038/ajg.2009.460Author URL
2009Talley NJ, 'The FDA and IBS Drug Development Reply', AMERICAN JOURNAL OF GASTROENTEROLOGY, 104 3106-3106 (2009) [C3]
DOI10.1038/ajg.2009.447Author URL
2009Richter JE, Talley NJ, 'A new publisher and soon a new editorial team', American Journal of Gastroenterology, 104 268-269 (2009) [C1]
DOI10.1038/ajg.2008.153
2009Jankowski JA, Talley NJ, 'Dissecting GI phenotype-genotype relationships in GERD and dyspepsia: An SNP here and an SNP there!', American Journal of Gastroenterology, 104 286-288 (2009) [C1]
DOI10.1038/ajg.2008.129
CitationsScopus - 5
2009Saito YA, Talley NJ, 'AJG Series: Molecular Biology for Clinicians', American Journal of Gastroenterology, 104 2583-2587 (2009) [C1]
DOI10.1038/ajg.2009.319
CitationsScopus - 2Web of Science - 2
2009Almansa C, Krishna M, Buchner AM, Ghabril MS, Talley NJ, Devault KR, et al., 'Seasonal distribution in newly diagnosed cases of eosinophilic esophagitis in adults', American Journal of Gastroenterology, 104 828-833 (2009) [C1]
DOI10.1038/ajg.2008.169
CitationsScopus - 91Web of Science - 74
2009Choung RS, Locke GR, Zinsmeister AR, Schleck CD, Talley NJ, 'Psychosocial distress and somatic symptoms in community subjects with irritable bowel syndrome: A psychological component is the rule', American Journal of Gastroenterology, 104 1772-1779 (2009) [C1]
DOI10.1038/ajg.2009.239
CitationsScopus - 63Web of Science - 55
2009Choung RS, Locke GR, Zinsmeister AR, Schleck CD, Talley NJ, 'Opioid bowel dysfunction and narcotic bowel syndrome: A population-based study', American Journal of Gastroenterology, 104 1199-1204 (2009) [C1]
DOI10.1038/ajg.2009.71
CitationsScopus - 20Web of Science - 15
2009Jones M, Talley NJ, 'Minimum clinically important difference for the nepean dyspepsia index, a validated quality of life scale for functional dyspepsia', American Journal of Gastroenterology, 104 1483-1488 (2009) [C1]
DOI10.1038/ajg.2009.136
CitationsScopus - 8Web of Science - 8
2009Ford AC, Chey WD, Talley NJ, Malhotra A, Spiegel BM, Moayyedi P, 'Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome systematic review and meta-analysis', Archives of Internal Medicine, 169 651-658 (2009) [C1]
DOI10.1001/archinternmed.2009.22
CitationsScopus - 110Web of Science - 91
2009Ford AC, Talley NJ, Quigley EMM, Moayyedi P, 'Efficacy of Probiotics in Irritable Bowel Syndrome: A Meta-Analysis of Randomized, Controlled Trials', DISEASES OF THE COLON & RECTUM, 52 1805-1805 (2009) [C3]
DOI10.1007/DCR.0b013e3181ae0ab8Author URL
CitationsScopus - 4Web of Science - 4
2009Aro P, Talley NJ, Ronkainen J, Storskrubb T, Vieth M, Johansson S, et al., 'Anxiety Is Associated With Uninvestigated and Functional Dyspepsia (Rome III Criteria) in a Swedish Population-Based Study', Gastroenterology, 137 94-100 (2009) [C1]
DOI10.1053/j.gastro.2009.03.039
CitationsScopus - 73Web of Science - 61
2009Jung H, Choung RS, Locke Iii GR, Schleck CD, Zinsmeister AR, Szarka LA, et al., 'The Incidence, Prevalence, and Outcomes of Patients With Gastroparesis in Olmsted County, Minnesota, From 1996 to 2006', Gastroenterology, 136 1225-1233 (2009) [C1]
DOI10.1053/j.gastro.2008.12.047
CitationsScopus - 91Web of Science - 79
2009Spiegel B, Camilleri M, Bolus R, Andresen V, Chey WD, Fehnel S, et al., 'Psychometric Evaluation of Patient-Reported Outcomes in Irritable Bowel Syndrome Randomized Controlled Trials: A Rome Foundation Report', Gastroenterology, 137 1944-1953 (2009) [C1]
DOI10.1053/j.gastro.2009.08.047
CitationsScopus - 32Web of Science - 29
2009Ford AC, van Zanten SJOV, Rodgers CC, Talley NJ, Vakil NB, Moayyedi P, 'Alarm features of colorectal cancer Reply', GUT, 58 1026-1027 (2009) [C3]
Author URL
2009Ford AC, Veldhuyzen Van Zanten SJO, Rodgers CC, Talley NJ, Vakil NB, Moayyedi P, 'Authors' reply', Gut, 58 1026-1027 (2009) [C3]
2009Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P, 'Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: Systematic review and meta-analysis', Gut, 58 367-378 (2009) [C1]
DOI10.1136/gut.2008.163162
CitationsScopus - 275Web of Science - 218
2009Talley NJ, 'Risks of proton-pump inhibitors: what every doctor should know', MEDICAL JOURNAL OF AUSTRALIA, 190 109-110 (2009) [C3]
Author URL
CitationsScopus - 10Web of Science - 7
2009Talley NJ, Dimoska A, Gan K, 'Risks of proton-pump inhibitors: what every doctor should know REPLY', MEDICAL JOURNAL OF AUSTRALIA, 190 653-653 (2009) [C3]
Author URL
2009Talley NJ, Dimoska A, Gan K, 'In reply', Medical Journal of Australia, 190 653-653 (2009) [C3]
2009Goodwin RD, Keyes KM, Stein MB, Talley NJ, 'Peptic ulcer and mental disorders among adults in the community: The role of nicotine and alcohol use disorders', Psychosomatic Medicine, 71 463-468 (2009) [C1]
DOI10.1097/PSY.0b013e3181988137
CitationsScopus - 16Web of Science - 13
2009Agréus L, Storskrubb T, Aro P, Ronkainen J, Talley NJ, Sipponen P, 'Clinical use of proton-pump inhibitors but not H2-blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen i and pepsinogen II in a random adult population', Scandinavian Journal of Gastroenterology, 44 564-570 (2009) [C1]
DOI10.1080/00365520902745062
CitationsScopus - 17Web of Science - 13
2009Chitkara DK, Talley NJ, Schleck C, Zinsmeister AR, Shah ND, Locke GR, 'Recollection of childhood abdominal pain in adults with functional gastrointestinal disorders', Scandinavian Journal of Gastroenterology, 44 301-307 (2009) [C1]
DOI10.1080/00365520802555975
CitationsScopus - 13Web of Science - 12
2009Ford AC, Talley NJ, Moayyedi P, 'In reply', JAMA - Journal of the American Medical Association, 301 1126-1126 (2009) [C3]
DOI10.1001/jama.2009.273
2009Ford AC, Talley NJ, Moayyedi P, 'Testing for Celiac Disease in Patients With Symptoms of Irritable Bowel Syndrome Reply', JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 301 1126-1126 (2009) [C3]
Author URL
2009Ford AC, Talley NJ, van ZSJO, Vakil NB, Simel DL, Moayyedi P, 'Will the History and Physical Examination Help Establish That Irritable Bowel Syndrome Is Causing This Patient's Lower Gastrointestinal Tract Symptoms? (vol 300, pg 1793, 2008)', JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 301 1544-1544 (2009) [C3]
Author URL
2009Eslick GD, Talley NJ, 'Dysphagia: Epidemiology, risk factors and impact on quality of life - A population-based study', Dysphagia, 24 121-122 (2009) [C3]
DOI10.1007/s00455-008-9191-y
2009Talley NJ, 'Pathogenesis of Irritable Bowel Syndrome Are Genes a SERT-ainty?', JOURNAL OF CLINICAL GASTROENTEROLOGY, 43 902-904 (2009) [C3]
Author URL
2009Eslick GD, Talley NJ, 'Gastroesophageal reflux disease (GERD): Risk factors, and impact on quality of life - A population-based study', Journal of Clinical Gastroenterology, 43 111-117 (2009) [C1]
DOI10.1097/MCG.0b013e31815ea27b
CitationsScopus - 34Web of Science - 28
2009Kennedy AT, Weiser KT, Crowell MD, Talley NJ, Lacy BE, 'Functional dyspepsia: Validation and results of a novel survey instrument to evaluate patient knowledge and perceptions', Journal of Clinical Gastroenterology, 43 933-940 (2009) [C1]
DOI10.1097/MCG.0b013e3181945a32
CitationsScopus - 3Web of Science - 3
2009Saito YA, Strege PR, Tester DJ, Locke Iii GR, Talley NJ, Bernard CE, et al., 'Sodium channel mutation in irritable bowel syndrome: Evidence for an ion channelopathy', American Journal of Physiology: Gastrointestinal and Liver Physiology, 296 211-218 (2009) [C1]
DOI10.1152/ajpgi.90571.2008
CitationsScopus - 46Web of Science - 40
2009Ford AC, Talley NJ, Moayyedi P, '10-biomarker algorithm to identify irritable bowel syndrome', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 30 95-96 (2009) [C3]
DOI10.1111/j.1365-2036.2009.04007.xAuthor URL
CitationsScopus - 4Web of Science - 2
2009Pounder RE, Talley NJ, Rhodes JM, Martin P, Colombel J-F, Sung JJY, Fennerty MB, 'Alimentary Pharmacology & Therapeutics - Editors' declarations of interest', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 31 1-2 (2009) [C3]
DOI10.1111/j.1365-2036.2009.04192.xAuthor URL
2009Jiang X, Locke GR, Zinsmeister AR, Schleck CD, Talley NJ, 'Health care seeking for abdominal bloating and visible distention', Alimentary Pharmacology and Therapeutics, 30 775-783 (2009) [C1]
DOI10.1111/j.1365-2036.2009.04080.x
CitationsScopus - 4Web of Science - 4
2009Walker M, Talley NJ, Prabhakar M, Pennaneac'H CJ, Aro P, Ronkainen J, et al., 'Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia', Alimentary Pharmacology and Therapeutics, 29 765-773 (2009) [C1]
DOI10.1111/j.1365-2036.2009.03937.x
CitationsScopus - 75Web of Science - 64
Co-authorsMarjorie Walker
2009Cremonini F, Camilleri M, Clark MM, Beebe TJ, Locke GR, Zinsmeister AR, et al., 'Associations among binge eating behavior patterns and gastrointestinal symptoms: A population-based study', International Journal of Obesity, 33 342-353 (2009) [C1]
DOI10.1038/ijo.2008.272
CitationsScopus - 19Web of Science - 17
2009Zhang L, Eslick GD, Xia HH, Wu C, Phung N, Talley NJ, 'Relationship between alcohol consumption and active Helicobacter pylori infection', Alcohol and Alcoholism, 45 89-94 (2009) [C1]
DOI10.1093/alcalc/agp068
CitationsScopus - 6Web of Science - 4
2009Talley NJ, Choung RS, 'Whither dyspepsia? A historical perspective of functional dyspepsia and concepts of pathogenesis and therapy in 2009', Journal of Gastroenterology and Hepatology, 24 20-28 (2009) [C1]
DOI10.1111/j.1440-1746.2009.06067.x
CitationsScopus - 19Web of Science - 12
2009Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, et al., 'Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection', Journal of Gastroenterology and Hepatology, 24 1587-1600 (2009) [C1]
DOI10.1111/j.1440-1746.2009.05982.x
CitationsScopus - 229Web of Science - 199
2009Money ME, Hofmann AF, Hagey LR, Walkowiak J, Talley NJ, 'Treatment of Irritable Bowel Syndrome-Diarrhea With Pancrealipase or Colesevelam and Association With Steatorrhea', PANCREAS, 38 232-233 (2009) [C3]
Author URL
CitationsScopus - 8Web of Science - 6
2009Talley NJ, Tangalos EG, 'Gastroenterology in the Elderly Preface', GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 38 XI-XII (2009) [C3]
DOI10.1016/j.gtc.2009.07.001Author URL
2009Ford AC, Talley NJ, 'Does Helicobacter pylori really cause duodenal ulcers? Yes.', BMJ: British Medical Journal, 339 542-543 (2009) [C1]
DOI10.1136/bmj.b2784
CitationsScopus - 2Web of Science - 3
2009Talley NJ, 'So you aspire to be a Professor?', WORLD JOURNAL OF GASTROENTEROLOGY, 15 5626-5627 (2009) [C3]
DOI10.3748/wjg.15.5626Author URL
2009Bisschops R, Karamanolis G, Arts J, Talley NJ, 'Relationship between symptoms and ingestion;of a meal in functional dyspepsia', Ceska a Slovenska Gastroenterologie a Hepatologie, 63 74-75 (2009) [C1]
2009Emmanuel AV, Tack J, Quigley EM, Talley NJ, 'Pharmacological management of constipation', NEUROGASTROENTEROLOGY AND MOTILITY, 21 41-54 (2009) [C3]
DOI10.1111/j.1365-2982.2009.01403.xAuthor URL
CitationsScopus - 33Web of Science - 24
2009Cremonini F, Camilleri M, Zinsmeister AR, Herrick LM, Beebe T, Talley NJ, 'Sleep disturbances are linked to both upper and lower gastrointestinal symptoms in the general population', Neurogastroenterology and Motility, 21 128-135 (2009) [C1]
DOI10.1111/j.1365-2982.2008.01181.x
CitationsScopus - 19Web of Science - 20
2009Gathaiya N, Locke Iii GR, Camilleri M, Schleck CD, Zinsmeister AR, Talley NJ, 'Novel associations with dyspepsia: A community-based study of familial aggregation, sleep dysfunction and somatization', Neurogastroenterology and Motility, 21 922-e69 (2009) [C1]
DOI10.1111/j.1365-2982.2009.01320.x
CitationsScopus - 14Web of Science - 12
2009Chang JY, Locke Iii GR, Schleck CD, Zinsmeister AR, Talley NJ, 'Risk factors for chronic diarrhoea in the community in the absence of irritable bowel syndrome', Neurogastroenterology and Motility, 21 1060-1067 (2009) [C1]
DOI10.1111/j.1365-2982.2009.01328.x
CitationsScopus - 6Web of Science - 3
2009Cook IJ, Talley NJ, Benninga MA, Rao SS, Scott SM, 'Chronic constipation: Overview and challenges', Neurogastroenterology and Motility, 21 1-8 (2009) [C1]
CitationsScopus - 44Web of Science - 33
2009Talley NJ, 'Step-up and step-down treatment strategies did not differ for symptom relief at 6 months in new onset dyspepsia', Evidence-Based Medicine, 14 114-114 (2009) [C3]
DOI10.1136/ebm.14.4.114
2009Eslick GD, Kalantar JS, Talley NJ, 'Rectal bleeding: Epidemiology, associated risk factors, and health care seeking behaviour: A population-based study', Colorectal Disease, 11 921-926 (2009) [C1]
DOI10.1111/j.1463-1318.2008.01721.x
CitationsScopus - 9Web of Science - 7
2008Talley NJ, 'Lansoprazole was not effective in young dyspeptic patients without Helicobacter pylori.', ACP journal club, 148 10 (2008) [C3]
2008Talley NJ, 'Functional gastrointestinal disorders as a public health problem', Neurogastroenterology and Motility, 20 121-129 (2008) [C1]
DOI10.1111/j.1365-2982.2008.01097.x
CitationsScopus - 92Web of Science - 76
2008Talley NJ, Stevens JE, Russo A, Maddox AF, Rayner CK, Phillips L, et al., 'Effect of itopride on gastric emptying in longstanding diabetes mellitus', Neurogastroenterology and Motility, 20 456-463 (2008) [C1]
CitationsScopus - 23Web of Science - 14
2008Choung RS, Cremonini F, Thapa P, Zinsmeister AR, Talley NJ, 'The effect of short-term, low-dose tricyclic and tetracyclic antidepressant treatment on satiation, postnutrient load gastrointestinal symptoms and gastric emptying: A double-blind, randomized, placebo-controlled trial', Neurogastroenterology and Motility, 20 220-227 (2008) [C1]
DOI10.1111/j.1365-2982.2007.01029.x
CitationsScopus - 27Web of Science - 24
2008Saito YA, Zimmerman JM, Harmsen WS, De Andrade M, Locke Iii GR, Petersen GM, Talley NJ, 'Irritable bowel syndrome aggregates strongly in families: A family-based case-control study', Neurogastroenterology and Motility, 20 790-797 (2008) [C1]
DOI10.1111/j.1365-2982.2007.01077.x
CitationsScopus - 33Web of Science - 25
2008Eslick GD, Talley NJ, 'Natural history and predictors of outcome for non-cardiac chest pain: A prospective 4-year cohort study', Neurogastroenterology and Motility, 20 989-997 (2008) [C1]
DOI10.1111/j.1365-2982.2008.01133.x
CitationsScopus - 33Web of Science - 28
2008Kaptchuk TJ, Talley NJ, 'Placebo acupuncture improved symptoms and quality of life in irritable bowel syndrome', Evidence-Based Medicine, 13 180-180 (2008) [C3]
DOI10.1136/ebm.13.6.180
2008Talley NJ, 'Chronic unexplained diarrhea: What to do when the initial workup is negative?', Reviews in Gastroenterological Disorders, 8 178-185 (2008) [C1]
CitationsScopus - 1
2008Choung RS, Talley NJ, 'Epidemiology and clinical presentation of stress-related peptic damage and chronic peptic ulcer', CURRENT MOLECULAR MEDICINE, 8 253-257 (2008) [C3]
DOI10.2174/156652408784533823Author URL
CitationsScopus - 25Web of Science - 17
2008Talley NJ, 'Newer antidepressants in Irritable Bowel Syndrome: What is the evidence?', Archives of Medical Science, 4 77-78 (2008) [C3]
CitationsScopus - 2Web of Science - 3
2008Talley NJ, Bunch TJ, Packer DL, Jahangir A, Locke GR, Gersh BJ, et al., 'Long-Term Risk of Atrial Fibrillation With Symptomatic Gastroesophageal Reflux Disease and Esophagitis', American Journal of Cardiology, 102 1207-1211 (2008) [C1]
DOI10.1016/j.amjcard.2008.06.048
CitationsScopus - 23Web of Science - 16
2008Crane SJ, Locke GR, Romero Y, Zinsmeister AR, Talley NJ, 'Adenocarcinoma of the esophagogastric junction may arise from short-segment Barrett's esophagus', AMERICAN JOURNAL OF GASTROENTEROLOGY, 103 493-494 (2008) [C3]
DOI10.1111/j.1572-0241.2007.01646_14.xAuthor URL
2008Richter JE, Talley NJ, 'The American Journal of Gastroenterology 2007: Building on Success', AMERICAN JOURNAL OF GASTROENTEROLOGY, 103 507-509 (2008) [C3]
DOI10.1111/j.1572-0241.2008.01855.xAuthor URL
2008Talley NJ, 'Separation of Specialty Training in Hepatology and Gastroenterology: The Imminent Divorce of Gastroenterology and Hepatology?', AMERICAN JOURNAL OF GASTROENTEROLOGY, 103 2421-2422 (2008) [C3]
DOI10.1111/j.1572-0241.2008.02057.xAuthor URL
CitationsScopus - 3Web of Science - 3
2008Talley NJ, 'Improving the Adequacy of the Rectal Examination in Gastroenterology Response', AMERICAN JOURNAL OF GASTROENTEROLOGY, 103 2940-2940 (2008) [C3]
Author URL
2008Talley NJ, 'Rectal Examination Reply', AMERICAN JOURNAL OF GASTROENTEROLOGY, 103 2940-2941 (2008) [C3]
Author URL
2008Talley NJ, 'Reply to Dr. Kittisupamongkol', American Journal of Gastroenterology, 103 2940-2941 (2008) [C3]
DOI10.1111/j.1572-0241.2008.02094_4.x
2008Talley NJ, 'Response to the letter by Dr. Marshall', American Journal of Gastroenterology, 103 2940-2940 (2008) [C3]
DOI10.1111/j.1572-0241.2008.02094_2.x
2008Achkar E, Richter JE, Talley NJ, 'Conflict of interest policy of the American Journal of Gastroenterology: New and improved', American Journal of Gastroenterology, 103 259-259 (2008) [C1]
DOI10.1111/j.1572-0241.2007.01763.x
2008Achkar E, Richter JE, Talley NJ, 'American Journal of Gastroenterology conflict of interest policy', American Journal of Gastroenterology, 103 260-261 (2008) [C1]
DOI10.1111/j.1572-0241.2007.01799.x
CitationsScopus - 1
2008Talley NJ, 'How to do and interpret a rectal examination in gastroenterology', American Journal of Gastroenterology, 103 820-822 (2008) [C1]
DOI10.1111/j.1572-0241.2008.01832.x
CitationsScopus - 25Web of Science - 20
2008Saito YA, Talley NJ, 'Genetics of irritable bowel syndrome.', American Journal of Gastroenterology, 103 2100-2104 (2008) [C1]
DOI10.1111/j.1572-0241.2008.02048.x
CitationsScopus - 40Web of Science - 35
2008Talley NJ, Fock KM, Moayyedi P, Moayyedi P, 'Gastric cancer concensus conference recommends H. pylori screening and treatment in asymptomatic persons from high risk populations to prevent gastric cancer', American Journal of Gastroenterology, 103 510-514 (2008) [C1]
DOI10.1111/j.1572-0241.2008.01819.x
CitationsScopus - 57Web of Science - 52
2008Talley NJ, Vakil N, Laine L, Talley NJ, Zakko SF, Tack J, et al., 'Tegaserod treatment for dysmotility-like functional dyspepsia: Results of two randomized, controlled trials', American Journal of Gastroenterology, 103 1906-1919 (2008) [C1]
DOI10.1111/j.1572-0241.2008.01953.x
CitationsScopus - 45Web of Science - 33
2008Shah ND, Chitkara DK, Locke GR, Meek PD, Talley NJ, 'Ambulatory care for constipation in the United States, 1993-2004', American Journal of Gastroenterology, 103 1746-1753 (2008) [C1]
DOI10.1111/j.1572-0241.2008.01910.x
CitationsScopus - 39Web of Science - 32
2008Pilichiewicz AN, Feltrin KL, Horowitz M, Holtmann G, Wishart JM, Jones KL, et al., 'Functional dyspepsia is associated with a greater symptomatic response to fat but not carbohydrate, increased fasting and postprandial CCK, and diminished PYY', American Journal of Gastroenterology, 103 2613-2623 (2008) [C1]
DOI10.1111/j.1572-0241.2008.02041.x
CitationsScopus - 41Web of Science - 34
2008Tuteja AK, Talley NJ, Joos SK, Tolman KG, Hickam DH, 'Abdominal bloating in employed adults: Prevalence, risk factors, and association with other bowel disorders', American Journal of Gastroenterology, 103 1241-1248 (2008) [C1]
DOI10.1111/j.1572-0241.2007.01755.x
CitationsScopus - 24Web of Science - 20
2008Bouras EP, Talley NJ, Camilleri M, Burton DD, Heckman MG, Crook JE, Richelson E, 'Effects of amitriptyline on gastric sensorimotor function and postprandial symptoms in healthy individuals: A randomized, double-blind, placebo-controlled trial', American Journal of Gastroenterology, 103 2043-2050 (2008) [C1]
DOI10.1111/j.1572-0241.2008.02021.x
CitationsScopus - 18Web of Science - 19
2008Quan C, Talley NJ, Jones MP, Howell S, Horowitz M, 'Gain and loss of gastrointestinal symptoms in diabetes mellitus: Associations with psychiatric disease, glycemic control, and autonomic neuropathy over 2 years of follow-up', American Journal of Gastroenterology, 103 2023-2030 (2008) [C1]
DOI10.1111/j.1572-0241.2008.01943.x
CitationsScopus - 17Web of Science - 14
2008Talley NJ, Locke Iii RG, McNally M, Schleck CD, Zinsmeister AR, Melton Iii JL, 'Impact of gastroesophageal reflux on survival in the community', American Journal of Gastroenterology, 103 12-19 (2008) [C1]
DOI10.1111/j.1572-0241.2007.01546.x
CitationsScopus - 10Web of Science - 6
2008Jones MP, Talley NJ, Eslick GD, Dubois D, 'Community subgroups in dyspepsia and their association with weight loss', American Journal of Gastroenterology, 103 2051-2060 (2008) [C1]
DOI10.1111/j.1572-0241.2008.01935.x
CitationsScopus - 9Web of Science - 9
2008Brandt LJ, Chey WD, Foxx-Orenstein AE, Quigley AE, Schiller LR, Schoenfield PS, et al., 'An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome', American Journal of Gastroenterology, 104 1-35 (2008) [C1]
CitationsScopus - 286Web of Science - 232
2008Talley NJ, Gabriel SE, Harmsen WS, Zinsmeister AR, Evans RW, 'IBS Is Big Bucks!', GASTROENTEROLOGY, 135 1821-1822 (2008) [C3]
Author URL
2008Rajan E, Gostout CJ, Lurken MS, Talley NJ, Locke GR, Szarka LA, et al., 'Endoscopic "no hole" full-thickness biopsy of the stomach to detect myenteric ganglia', Gastrointestinal Endoscopy, 68 301-307 (2008) [C1]
DOI10.1016/j.gie.2007.10.017
CitationsScopus - 21Web of Science - 22
2008Rajan E, Gostout CJ, Lurken MS, Talley NJ, Locke GR, Szarka LA, et al., 'Evaluation of endoscopic approaches for deep gastric-muscle-wall biopsies: what works?', Gastrointestinal Endoscopy, 67 297-303 (2008) [C1]
DOI10.1016/j.gie.2007.06.024
CitationsScopus - 12Web of Science - 12
2008Talley N, 'Subdividing functional dyspepsia: A paradigm shift?', Gut, 57 1487-1489 (2008) [C1]
DOI10.1136/gut.2008.155788
CitationsWeb of Science - 1
2008Talley NJ, Tack J, Ptak T, Gupta R, Giguere M, 'Itopride in functional dyspepsia: Results of two phase III multicentre, randomised, double-blind, placebo-controlled trials', Gut, 57 740-746 (2008) [C1]
DOI10.1136/gut.2007.132449
CitationsScopus - 69Web of Science - 60
2008Ford AC, Veldhuyzen Van Zanten SJ, Rodgers CC, Talley NJ, Vakil NB, Moayyedi P, 'Diagnostic utility of alarm features for colorectal cancer: Systematic review and meta-analysis', Gut, 57 1545-1552 (2008) [C1]
DOI10.1136/gut.2008.159723
CitationsScopus - 51Web of Science - 38
2008Jiang X, Locke Iii GR, Choung RS, Zinsmeister AR, Schleck CD, Talley NJ, 'Prevalence and risk factors for abdominal bloating and visible distention: A population-based study', Gut, 57 756-763 (2008) [C1]
DOI10.1136/gut.2007.142810
CitationsScopus - 33Web of Science - 30
2008Crane SJ, Locke Iii GR, Harmsen WS, Zinsmeister AR, Romero Y, Talley NJ, 'Survival trends in patients with gastric and esophageal adenocarcinomas: A population-based study', Mayo Clinic Proceedings, 83 1087-1094 (2008) [C1]
DOI10.4065/83.10.1087
CitationsScopus - 28Web of Science - 29
2008Storskrubb T, Aro P, Ronkainen J, Sipponen P, Nyhlin H, Talley NJ, et al., 'Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: The Kalixanda study', Scandinavian Journal of Gastroenterology, 43 1448-1455 (2008) [C1]
DOI10.1080/00365520802273025
CitationsScopus - 50Web of Science - 47
Co-authorsMarjorie Walker
2008Ford AC, Talley NJ, Veldhuyzen Van Zanten SJ, Vakil NB, Simel DL, Moayyedi P, 'Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms?', JAMA: Journal of the American Medical Association, 300 1793-1805 (2008) [C1]
DOI10.1001/jama.300.15.1793
CitationsScopus - 53Web of Science - 41
2008Talley NJ, 'Is it time to screen and treat H pylori to prevent gastric cancer?', Lancet, 372 350-352 (2008) [C1]
DOI10.1016/S0140-6736(08)61136-8
CitationsScopus - 8Web of Science - 6
2008Tuteja AK, Talley NJ, Gelman SS, Alder SC, Thompson C, Tolman K, Hale DC, 'Development of functional diarrhea, constipation, irritable bowel syndrome, and dyspepsia during and after traveling outside the USA (Digestive Diseases and Sciences (2007) DOI: 10.1007/s10620-007-9853-x)', Digestive Diseases and Sciences, 53 870-870 (2008) [C3]
DOI10.1007/s10620-007-9913-2
2008Talley NJ, Kellow JE, Boyce P, Tennant C, Huskic S, Jones M, 'Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: A double-blind, randomized, placebo-controlled trial', Digestive Diseases and Sciences, 53 108-115 (2008) [C1]
DOI10.1007/s10620-007-9830-4
CitationsScopus - 60Web of Science - 46
2008Tuteja AK, Talley NJ, Gelman SS, Adler SC, Thompson C, Tolman K, Hale DC, 'Development of functional diarrhea, constipation, irritable bowel syndrome, and dyspepsia during and after traveling outside the USA', Digestive Diseases and Sciences, 53 271-276 (2008) [C1]
DOI10.1007/s10620-007-9853-x
CitationsScopus - 27Web of Science - 25
2008Hammer J, Talley NJ, 'Value of different diagnostic criteria for the irritable bowel syndrome among men and women', Journal of Clinical Gastroenterology, 42 160-166 (2008) [C1]
DOI10.1097/MCG.0b013e3181574d48
CitationsScopus - 19Web of Science - 14
2008Bolling-Sternevald E, Aro P, Ronkainen J, Storskrubb T, Talley NJ, Junghard O, Agréus L, 'Do gastrointestinal symptoms fluctuate in the short-term perspective? The Kalixanda study', Digestive Diseases: clinical reviews, 26 256-263 (2008) [C1]
DOI10.1159/000121356
CitationsScopus - 18Web of Science - 18
2008Agreus L, Talley NJ, Sheen A, Johansson S, Jones MP, Svardsudd K, 'Predictors and non-predictors of symptom relief in dyspepsia consultations in primary care', Digestive Diseases: clinical reviews, 26 248-255 (2008) [C1]
DOI10.1159/000121355
CitationsScopus - 3Web of Science - 3
2008Talley NJ, Ruff K, Jiang X, Jung HK, 'The Rome III classification of dyspepsia: Will it help research?', DIGESTIVE DISEASES, 26 203-209 (2008) [C3]
DOI10.1159/000121347Author URL
CitationsScopus - 17Web of Science - 8
2008Moayyedi P, Akhtardanesh N, Talley NJ, Jankowski J, 'Mortality risks associated with Barrett's oesophagus: authors' reply', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 27 853-854 (2008) [C3]
DOI10.1111/j.1365-2036.2008.03651.xAuthor URL
CitationsScopus - 1Web of Science - 1
2008Moayyedi P, Burch N, Akhtar-Danesh N, Enaganti SK, Harrison R, Talley NJ, Jankowski J, 'Mortality rates in patients with Barrett's oesophagus', Alimentary Pharmacology and Therapeutics, 27 316-320 (2008) [C1]
DOI10.1111/j.1365-2036.2007.03582.x
CitationsScopus - 55Web of Science - 48
2008Eslick GD, Talley NJ, 'Dysphagia: Epidemiology, risk factors and impact on quality of life - A population-based study', Alimentary Pharmacology and Therapeutics, 27 971-979 (2008) [C1]
DOI10.1111/j.1365-2036.2008.03664.x
CitationsScopus - 45Web of Science - 40
2008Talley NJ, Choung RS, Camilleri M, Dierkhising RA, Zinsmeister AR, 'Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsia', Alimentary Pharmacology and Therapeutics, 27 1122-1131 (2008) [C1]
DOI10.1111/j.1365-2036.2008.03676.x
CitationsScopus - 23Web of Science - 20
2008Haag S, Senf W, Hauser W, Tagay S, Grandt D, Heuft G, et al., 'Impairment of health-related quality of life in functional dyspepsia and chronic liver disease: The influence of depression and anxiety', Alimentary Pharmacology and Therapeutics, 27 561-571 (2008) [C1]
DOI10.1111/j.1365-2036.2008.03619.x
CitationsScopus - 19Web of Science - 16
2008Choung RS, Ferguson DD, Murray JA, Kammer PP, Dierkhising RA, Zinsmeister AR, et al., 'A novel partial 5HT3 agonist DDP733 after a standard refluxogenic meal reduces reflux events: A randomized, double-blind, placebo-controlled pharmacodynamic study', Alimentary Pharmacology and Therapeutics, 27 404-411 (2008) [C1]
DOI10.1111/j.1365-2036.2007.03591.x
CitationsScopus - 10Web of Science - 8
2008Monally MA, Locke GR, Zinsmeister AR, Schieck CD, Peterson J, Talley NJ, 'Biliary events and an increased risk of new onset irritable bowel syndrome: A population-based cohort study', Alimentary Pharmacology and Therapeutics, 28 334-343 (2008) [C1]
DOI10.1111/j.1365-2036.2008.03715.x
CitationsScopus - 7Web of Science - 5
2008Talley NJ, Barton PM, Moayyedi P, Vakil NB, Delaney BC, 'A second-order simulation model of the cost-effectiveness of managing dyspepsia in the United States', Medical Decision Making, 28 44-55 (2008) [C1]
DOI10.1177/0272989X07309644
CitationsScopus - 16Web of Science - 12
2008Talley NJ, 'Genetics and functional bowel disease', Journal of Pediatric Gastroenterology and Nutrition, 47 680-682 (2008) [C1]
DOI10.1097/01.mpg.0000338957.89673.e8
CitationsScopus - 4Web of Science - 2
2008Fock KM, Talley NJ, Fass R, Goh KL, Katelaris P, Hunt R, et al., 'Asia-Pacific consensus on the management of gastroesophageal reflux disease (vol 22, pg 8, 2007)', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 23 504-504 (2008) [C3]
Author URL
CitationsScopus - 2Web of Science - 1
2008Fock KM, Talley NJ, Moayyedi P, Hunt R, Azuma T, Sugano K, et al., 'Asia-Pacific consensus guidelines on gastric cancer prevention', Journal of Gastroenterology and Hepatology, 23 351-365 (2008) [C1]
DOI10.1111/j.1440-1746.2008.05314.x
CitationsScopus - 144Web of Science - 129
2008Fock KM, Talley NJ, Fass R, Goh KL, Katelaris P, Hunt R, et al., 'Asia-Pacific consensus on the management of gastroesophageal reflux disease: Update', Journal of Gastroenterology and Hepatology, 23 8-22 (2008) [C1]
DOI10.1111/j.1440-1746.2007.05249.x
CitationsScopus - 98Web of Science - 76
2008Talley NJ, 'Gut eosinophilia in food allergy and systemic and autoimmune diseases', Gastroenterology Clinics of North America, 37 307-332 (2008) [C1]
DOI10.1016/j.gtc.2008.02.008
CitationsScopus - 7Web of Science - 4
2008Talley NJ, 'Preface', Gastroenterology Clinics of North America, 37 xi-xii (2008) [C1]
DOI10.1016/j.gtc.2008.03.003
2008Prasad GA, Talley NJ, 'Eosinophilic esophagitis in adults', Gastroenterology Clinics of North America, 37 349-368 (2008) [C1]
DOI10.1016/j.gtc.2008.03.002
CitationsScopus - 18Web of Science - 13
2008Quan C, Talley NJ, Jones MP, Howell S, Horowitz M, 'Gastrointestinal symptoms and glycemic control in diabetes mellitus: A longitudinal population study', European Journal of Gastroenterology and Hepatology, 20 888-897 (2008) [C1]
DOI10.1097/MEG.0b013e3282f5f734
CitationsScopus - 12Web of Science - 8
2008Talley NJ, 'Commentary: Controversies in NICE guidance on irritable bowel syndrome', BMJ: British Medical Journal, 336 558-559 (2008) [C1]
DOI10.1136/bmj.39504.409329.AD
CitationsScopus - 2
2008Talley NJ, Ford AC, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, Moayyedi P, 'Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: Systematic review and meta-analysis', BMJ: British Medical Journal, 337 1388-1392 (2008) [C1]
CitationsScopus - 208Web of Science - 137
2008Topazian M, Camilleri M, De La Mora-Levy J, Enders FB, Foxx-Orenstein AE, Levy MJ, et al., 'Endoscopic ultrasound-guided gastric botulinum toxin injections in obese subjects: A pilot study', Obesity Surgery, 18 401-407 (2008) [C1]
DOI10.1007/s11695-008-9442-x
CitationsScopus - 12Web of Science - 9
2007Talley NJ, 'Functional nausea and vomiting', Australian Family Physician, 36 694-697 (2007) [C1]
DOI10.1038/ncpgasthep1094
CitationsScopus - 24Web of Science - 13
2007Crane SJ, Talley NJ, 'Chronic gastrointestinal symptoms in the elderly', CLINICS IN GERIATRIC MEDICINE, 23 721-+ (2007)
DOI10.1016/j.cger.2007.06.003Author URL
CitationsScopus - 33Web of Science - 20
2007Talley NJ, 'The role of endoscopy in dyspepsia', ASGE Clinical Update, 15 1-4 (2007)

Commentary: In practice, dyspepsia is commonly used as an indication for endoscopy to exclude upper-gut mucosal abnormalities. However, in this review, Dr Nicholas J. Talley offer... [more]

Commentary: In practice, dyspepsia is commonly used as an indication for endoscopy to exclude upper-gut mucosal abnormalities. However, in this review, Dr Nicholas J. Talley offers a much more pragmatic approach for the diagnosis and management of dyspepsia. By using several systematic reviews, meta-analyses, and recently proposed practice guidelines for dyspepsia, Dr Talley provides a convincing argument that upper endoscopy in subjects younger than 55 years with dyspepsia but without alarm symptoms is a low-yield diagnostic strategy. In contrast, subjects with dyspepsia and who are older than 55 years and/or with alarm symptoms would benefit from upper endoscopy as the initial evaluative strategy. An easy-to-follow (and remember) diagnostic algorithm for uninvestigated dyspepsia is offered at the end of the monograph. - Ronnie Fass, MD, Editor. © 2007 American Society for Gastrointestinal Endoscopy.

DOI10.1016/j.clinup.2007.06.001
2007Liebregts T, Adam B, Bertel A, Lackner C, Neumann J, Talley NJ, et al., 'Psychological stress and the severity of post-inflammatory visceral hyperalgesia', European Journal of Pain, 11 216-222 (2007) [C1]
DOI10.1016/j.ejpain.2006.02.007
CitationsScopus - 21Web of Science - 19
2007McNally MA, Talley NJ, 'Current treatments in functional dyspepsia', Current Treatment Options in Gastroenterology, 10 157-168 (2007)

By nature of the definition of functional dyspepsia (FD), organic causes have to be ruled out before therapy can be directed. However, in uninvestigated dyspepsia in the absence o... [more]

By nature of the definition of functional dyspepsia (FD), organic causes have to be ruled out before therapy can be directed. However, in uninvestigated dyspepsia in the absence of alarm features, Helicobacter pylori "test and treat" or an empiric trial of acid suppression therapy for 4 to 8 weeks is reasonable. If alarm symptoms or signs are present, or if the dyspepsia symptoms first occur in those aged greater than 55 years, prompt esophagogastroduodenoscopy is mandatory to exclude serious disease and positively diagnose FD. Empiric acid suppression with H2-receptor antagonists or proton-pump inhibitors is superior to placebo in treatment of FD, but those patients with meal-related symptoms are least likely to respond. Helicobacter pylori eradication in FD benefits a minority of cases but is worthwhile, as response may be maintained. There is increasing evidence that some prokinetics may be superior to placebo in treatment of FD, but probably only a minority respond; those with meal-related symptoms may have the best response. Antidepressant therapy may have a place in management of difficult cases, but adequate randomized controlled trials are unavailable. Copyright © 2007 by Current Medicine Group LLC.

DOI10.1007/s11938-007-0068-1
CitationsScopus - 6
2007Halder SLS, Talley NJ, 'Functional dyspepsia: A new Rome III paradigm', Current Treatment Options in Gastroenterology, 10 259-272 (2007)

Functional dyspepsia (FD) is a condition commonly seen in gastroenterological practice. With the introduction of Rome III criteria in 2006, a new approach for categorizing patient... [more]

Functional dyspepsia (FD) is a condition commonly seen in gastroenterological practice. With the introduction of Rome III criteria in 2006, a new approach for categorizing patients has been recommended. The diagnostic criteria suggest that meal-related and pain-predominant symptom groupings that presumably have distinct pathophysiologic mechanisms and potentially different therapeutic targets exist. The new classification is in the early stages of testing; in the meantime, the umbrella term of FD should continue to be utilized in clinical practice. Treatment of FD remains a major challenge. Unfortunately, most of the agents used in practice have limited or no evidence of efficacy, and the results typically are short-lived once therapy is ceased. Appropriate therapy currently is based on a consideration of putative pathophysiologic mechanisms. Testing for and eradicating Helicobacter pylori is a first-line strategy irrespective of the symptom pattern. In patients who have epigastric pain, antisecretory agents are recommended. Antacids, bismuth, and sucralfate seem to be no better than placebo. For meal-related symptoms such as postprandial fullness or early satiety, prokinetics may confer some benefit. However, few choices are available, and the efficacy for those drugs on the market is limited at best. Antidepressants are of uncertain efficacy but are widely used. Psychological therapies seem promising and may confer benefits on both pain and meal-related symptoms. Efficacy of complementary medicines has been suggested in controlled trials, but more data are needed. Emerging treatments include gastric funclus relaxors and visceral analgesics, although their application in FD is still in the preliminary stages. Copyright © 2007 by Current Medicine Group LLC.

DOI10.1007/s11938-007-0069-0
CitationsScopus - 16
2007Wallander MA, Wahlqvist P, Kleinman N, Campbell S, Talley NJ, Brook R, 'Comorbidities during the year following diagnosis for persons with and without gerd using the agency for health research and quality (AHRQ) 261 specific categories', VALUE IN HEALTH, 10 A147-A147 (2007)
DOI10.1016/S1098-3015(10)68984-XAuthor URL
2007Grudell AB, Alexander JA, Enders FB, Pacifico R, Fredericksen M, Wise JL, et al., 'Validation of the Mayo Dysphagia Questionnaire', Diseases of the Esophagus, 20 202-205 (2007) [C1]
DOI10.1111/j.1442-2050.2007.00670.x
CitationsScopus - 22Web of Science - 19
2007Choung RS, Locke GR, Zinsmeister AR, Fett S, Talley NJ, 'Impact of irritable bowel syndrome (IBS) on sexual function: A population-based study', NEUROGASTROENTEROLOGY AND MOTILITY, 19 62-62 (2007)
Author URL
2007Choung RS, Cremonini F, Locke GR, Thapa P, Zinsmeister AR, Talley NJ, 'The effect of short-term antidepressant treatment on gastric emptying: A double-blind, randomized, placebo-controlled trial', NEUROGASTROENTEROLOGY AND MOTILITY, 19 63-64 (2007)
Author URL
2007Saito YA, Locke Iii GR, Zimmerman JM, Holtmann G, Slusser JP, De Andrade M, et al., 'A genetic association study of 5-HTT LPR and GNß3 C825T polymorphisms with irritable bowel syndrome', Neurogastroenterology and Motility, 19 465-470 (2007) [C1]
DOI10.1111/j.1365-2982.2007.00905.x
CitationsScopus - 49Web of Science - 40
2007Talley NJ, Choung RS, Peterson J, Camilleri M, Burton D, Harmsen WS, Zinsmeister AR, 'A double-blind, randomized, placebo-controlled trial of itopride (100 and 200 mg three times daily) on gastric motor and sensory function in healthy volunteers', Neurogastroenterology and Motility, 19 180-187 (2007) [C1]
DOI10.1111/j.1365-2982.2006.00869.x
CitationsScopus - 24Web of Science - 19
2007Chang JY, Locke GR, Schleck CD, Zinsmeister AR, Talley NJ, 'Risk factors for chronic constipation and a possible role of analgesics', Neurogastroenterology and Motility, 19 905-911 (2007) [C1]
DOI10.1111/j.1365-2982.2007.00974.x
CitationsScopus - 25Web of Science - 19
2007Kalantar JS, Talley NJ, 'Towards a diagnosis of functional dyspepsia', Medicine Today, 8 45-50 (2007)

¿ Functional dyspepsia is characterised by a history of at least three months of chronic dyspeptic symptoms in the absence of any relevant organic disease. ¿ Individual dyspepti... [more]

¿ Functional dyspepsia is characterised by a history of at least three months of chronic dyspeptic symptoms in the absence of any relevant organic disease. ¿ Individual dyspeptic symptoms or groups of symptoms cannot be used to help distinguish organic dyspesia (ie. that caused by chronic peptic ulcer disease, gastro-oesophageal reflux or malignancy) from functional dyspepsia. Therefore it is often difficult to distinguish between these conditions without investigations. ¿ Empirical therapy for dyspepsia involves testing for Helicobacter pylori and treating if infected, followed by acid suppression with a proton pump inhibitor (PPI) if symptoms remain, or if negative for H. pylori a trial of PPI therapy. ¿ Endoscopy should be performed before H. pylori testing and treatment in patients with new symptoms who are older than 55 years or who have alarm symptoms. ¿ If acid suppression fails in a patient in whom H. pylori has been excluded or eradicated, the symptoms and diagnosis should be reappraised. Prokinetics, antidepressants, psychological therapies or complementary therapies may be helpful. ¿ Alarm features (red flags) for upper gastrointestinal malignancy include onset of dyspepsia at an older age (over 55 years), a family history of upper gastrointestinal cancer or symptoms such as unexplained weight loss, recurrent vomiting or progressive dysphagia.

2007Hawkey CJ, Talley NJ, Scheiman JM, Jones RH, Långström G, Næsdal J, et al., 'Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: The NASA2 and SPACE2 studies', Arthritis Research and Therapy, 9 R17-R17 (2007) [C1]
DOI10.1186/ar2124
CitationsScopus - 15Web of Science - 12
2007Talley NJ, 'Introducing Expert Review of Gastroenterology and Hepatology.', Expert review of gastroenterology & hepatology, 1 1-2 (2007)
2007Talley NJ, Li Z, 'Helicobacter pylori: testing and treatment.', Expert review of gastroenterology & hepatology, 1 71-79 (2007)

Helicobacter pylori is an important pathogen worldwide. Accurate diagnosis and appropriate therapy is important in clinical practice. Invasive tests that accurately identify curre... [more]

Helicobacter pylori is an important pathogen worldwide. Accurate diagnosis and appropriate therapy is important in clinical practice. Invasive tests that accurately identify current infection include the biopsy urease test and histology. The best noninvasive tests for diagnosis include the urea breath test and stool antigen testing. Proton pump inhibitor therapy can lead to false-negative H. pylori test results, and treatment should be stopped for 1-2 weeks prior to testing if possible. In the setting of bleeding peptic ulcer disease, urea breath testing is recommended to rule out a false-negative biopsy test result if needed. The current recommendations for when to test for H. pylori vary around the world. Well-accepted indications include active and past ulcer disease, and gastric-mucosa associated lymphoid tissue lymphoma. There is no universal agreement regarding whether all patients with functional dyspepsia should be tested and treated, although this is an evidence-based recommendation. There is also evidence that H. pylori eradication prevents peptic ulcer disease in those starting NSAIDs long term. Primary treatment remains triple therapy with 10-14 days probably being superior to shorter courses of therapy. Quadruple therapy is recommended if standard triple therapy fails. Salvage therapies with levofloxacin, rifabutin or furazolidone have been identified. Novel approaches to treatment include sequential therapy and use of adjuvants.

CitationsScopus - 6
2007Cash BD, Chang E, Talley NJ, Wald A, 'Fresh perspectives in chronic constipation and other functional bowel disorders', REVIEWS IN GASTROENTEROLOGICAL DISORDERS, 7 116-133 (2007)
Author URL
CitationsScopus - 5Web of Science - 2
2007Hanauer SB, Sandborn WJ, Vakil N, Katz PO, Talley NJ, Rex DK, et al., 'Best of DDW 2007: Highlights from the 2007 digestive disease week May 19-24, 2007, Washington, DC', Reviews in Gastroenterological Disorders, 7 134-166 (2007)
2007Talley NJ, 'Functional gastrointestinal disorders in 2007 and Rome III: something new, something borrowed, something objective', Reviews in Gastroenterological Disorders, 7 97-105 (2007) [C1]
CitationsScopus - 23Web of Science - 19
2007Talley NJ, Chitkara DK, Weaver AL, Katusic SK, De Schepper H, Rucker MJ, Locke Iii GR, 'Incidence of Presentation of Common Functional Gastrointestinal Disorders in Children From Birth to 5 Years: A Cohort Study', Clinical Gastroenterology and Hepatology, 5 186-191 (2007) [C1]
DOI10.1016/j.cgh.2006.06.012
CitationsScopus - 20Web of Science - 18
2007Talley NJ, Chitkara DK, Locke Iii GR, Weaver AL, Katusic SK, De Schepper H, Rucker MJ, 'Medical presentation of constipation from childhood to early adulthood: a population-based cohort study.', Clinical Gastroenterology and Hepatology, 5 1059-1064 (2007) [C1]
DOI10.1016/j.cgh.2007.04.028
CitationsScopus - 11Web of Science - 9
2007Camilleri M, Mangel AW, Fehnel SE, Drossman DA, Mayer EA, Talley NJ, 'Primary Endpoints for Irritable Bowel Syndrome Trials: A Review of Performance of Endpoints', Clinical Gastroenterology and Hepatology, 5 534-540 (2007) [C1]
CitationsScopus - 52Web of Science - 49
2007Ronkainen J, Storskrubb T, Hindley LA, Harmsen WS, Zinsmeister AR, Agreus L, et al., 'Non-ulcer Dyspepsia and Duodenal Eosinophilia: An Adult Endoscopic Population-Based Case-Control Study', Clinical Gastroenterology and Hepatology, 5 1175-1183 (2007) [C1]
DOI10.1016/j.cgh.2007.05.015
CitationsScopus - 80Web of Science - 71
Co-authorsMarjorie Walker
2007Richter JE, Talley NJ, 'American Journal of Gastroenterology 2006: The best clinical GI journal in the world', AMERICAN JOURNAL OF GASTROENTEROLOGY, 102 229-231 (2007)
DOI10.1111/j.1572-0241.2007.00002.xAuthor URL
CitationsScopus - 1Web of Science - 1
2007Harrison R, Perry I, Haddadin W, McDonald S, Bryan R, Abrams K, et al., 'Detection of intestinal metaplasia in Barrett's esophagus', AMERICAN JOURNAL OF GASTROENTEROLOGY, 102 2353-2354 (2007)
DOI10.1111/j.1572-0241.2007.01353_6.xAuthor URL
2007Harrison R, Perry I, Haddadin W, McDonald S, Bryan R, Sampliner R, et al., 'Detection of intestinal metaplasia in Barrett's Esophagus: An observational comparator study suggests the need for a minimum of eight biopsies', American Journal of Gastroenterology, 102 1154-1161 (2007) [C1]
DOI10.1111/j.1572-0241.2007.01230.x
CitationsScopus - 99Web of Science - 75
2007Prasad GA, Talley NJ, Romero Y, Arora AS, Kryzer LA, Smyrk TC, Alexander JA, 'Prevalence and predictive factors of eosinophilic esophagitis in patients presenting with dysphagia: A prospective study', American Journal of Gastroenterology, 102 2627-2632 (2007) [C1]
DOI10.1111/j.1572-0241.2007.01512.x
CitationsScopus - 138Web of Science - 117
2007Choung RS, Locke GR, Schleck CD, Zinsmeister AR, Talley NJ, 'Do distinct dyspepsia subgroups exist in the community? A population-based study', American Journal of Gastroenterology, 102 1983-1989 (2007) [C1]
DOI10.1111/j.1572-0241.2007.01381.x
CitationsScopus - 45Web of Science - 42
2007Crane SJ, Locke Iii GR, Harmsen WS, Diehl NN, Zinsmeister AR, Melton Iii LJ, et al., 'Subsite-specific risk factors for esophageal and gastric adenocarcinoma', American Journal of Gastroenterology, 102 1596-1602 (2007) [C1]
DOI10.1111/j.1572-0241.2007.01234.x
CitationsScopus - 25Web of Science - 18
2007Levy RL, Finch EA, Crowell MD, Talley NJ, Jeffery RW, 'Behavioral intervention for the treatment of obesity: Strategies and effectiveness data', American Journal of Gastroenterology, 102 2314-2321 (2007) [C1]
CitationsScopus - 44Web of Science - 35
2007Talley NJ, 'Irritable bowel syndrome: Rational therapy', Consultant, 47 81-92 (2007)

Irritable bowel syndrome (IBS) is characterized by abdominal pain or discomfort, bloating, and constipation or diarrhea; the pain is typically relieved by defecation. The diagnosi... [more]

Irritable bowel syndrome (IBS) is characterized by abdominal pain or discomfort, bloating, and constipation or diarrhea; the pain is typically relieved by defecation. The diagnosis is not one of exclusion; it can be made based on the answers to a few key questions and the absence of "alarm" symptoms. Fiber therapy, the elimination of particular foods, and regulation of bowel function can help relieve symptoms. Tegaserod or polyethylene glycol can be used to treat IBS with constipation. Loperamide and alosetron are of benefit in IBS with diarrhea (although the latter carries a small risk of ischemic colitis). Low-dose tricyclic antidepressants may be used to treat the abdominal pain associated with IBS. Probiotic therapy or rifaximin may help reduce bloating. Psychological therapies seem to improve well-being in patients with IBS.

2007Liebregts T, Adam B, Bredack C, Roth A, Heinzel S, Lester S, et al., 'Immune Activation in Patients With Irritable Bowel Syndrome', Gastroenterology, 132 913-920 (2007) [C1]
DOI10.1053/j.gastro.2007.01.046
CitationsScopus - 264Web of Science - 228
2007Halder SL, Locke Iii GR, Schleck CD, Zinsmeister AR, Melton Iii LJ, Talley NJ, 'Natural History of Functional Gastrointestinal Disorders: A 12-year Longitudinal Population-Based Study', Gastroenterology, 133 799-807 (2007) [C1]
DOI10.1053/j.gastro.2007.06.010
CitationsScopus - 116Web of Science - 99
2007Ronkainen J, Talley NJ, Aro P, Storskrubb T, Johansson S-E, Lind T, et al., 'Prevalence of oesophageal eosinophils and eosinophilic oesophagitis in adults: The population-based Kalixanda study', Gut, 56 615-620 (2007) [C1]
DOI10.1136/gut.2006.107714
CitationsScopus - 155Web of Science - 126
Co-authorsMarjorie Walker
2007Beebe TJ, Talley NJ, Camilleri M, Jenkins SM, Anderson KJ, Locke Iii RG, 'The HIPAA authorization form and effects on survey response rates, nonresponse Bias, and data quality A randomized community study', Medical Care, 45 959-965 (2007) [C1]
CitationsScopus - 16Web of Science - 17
2007Talley NJ, 'Managing chronic constipation from constipating medicines', Southern Medical Journal, 100 1070-1071 (2007) [C1]
DOI10.1097/SMJ.0b013e318157ec3d
CitationsWeb of Science - 1
2007Talley NJ, Jung HK, Jiang X, Locke GR, 'Is there an increased risk of hip fracture in patients on long-term PPI therapy?', NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 4 420-421 (2007)
DOI10.1038/ncpgasthep0870Author URL
CitationsScopus - 3Web of Science - 3
2007Talley NJ, 'How to manage the difficult-to-treat dyspeptic patient', Nature Clinical Practice Gastroenterology and Hepatology, 4 35-42 (2007) [C1]
DOI10.1038/ncpgasthep0685
CitationsScopus - 12Web of Science - 11
2007Vakil N, Van Zanten SV, Kahrilas P, Dent J, Jones R, Group GC, Talley NJ, 'The Montreal definition and classification of gastroesophageal reflux disease: A global, evidence-based consensus paper', Zeitschrift fuer Gastroenterologie, 45 1125-1140 (2007) [C1]
DOI10.1055/s-2007-963633
CitationsScopus - 16
2007Singh M, Skelly MM, Hawkey CJ, Yeomans ND, Lanas AI, Talley NJ, et al., 'Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin', Alimentary Pharmacology and Therapeutics, 22 795-801 (2007) [C1]
DOI10.1111/j.1365-2036.2005.02649.x
CitationsScopus - 157Web of Science - 119
2007Lembo A, Zaman M, Jones M, Talley NJ, 'Influence of genetics on irritable bowel syndrome, gastrooesophageal reflux and dyspepsia: A twin study', Alimentary Pharmacology and Therapeutics, 25 1343-1350 (2007) [C1]
DOI10.1111/j.1365-2036.2007.03326.x
CitationsScopus - 61Web of Science - 46
2007Crane SJ, Locke Iii GR, Harmsen WS, Diehl NN, Zinsmeister AR, Melton Iii J, et al., 'The changing incidence of oesophageal and gastric adenocarcinoma by anatomic sub-site', Alimentary Pharmacology and Therapeutics, 25 447-453 (2007) [C1]
DOI10.1111/j.1365-2036.2006.03229.x
CitationsScopus - 40Web of Science - 38
2007Talley NJ, Vakil N, Lauritsen K, Van Zanten SV, Flook N, Bolling-Sternevald E, et al., 'Randomized-controlled trial of esomeprazole in functional dyspepsia patients with epigastric pain or burning: Does a 1-week trial of acid suppression predict symptom response?', Alimentary Pharmacology and Therapeutics, 26 673-682 (2007) [C1]
DOI10.1111/j.1365-2036.2007.03410.x
CitationsScopus - 20Web of Science - 18
2007Haag S, Senf W, Tagay S, Langkafel M, Braun-Lang U, Pietsch A, et al., 'Is there a benefit from intensified medical and psychological interventions in patients with functional dyspepsia not responding to conventional therapy?', Alimentary Pharmacology and Therapeutics, 25 973-986 (2007) [C1]
DOI10.1111/j.1365-2036.2007.03277.x
CitationsScopus - 31Web of Science - 20
2007Choung RS, Locke Iii GR, Zinsmeister AR, Schleck CD, Talley NJ, 'Epidemiology of slow and fast colonic transit using a scale of stool form in a community', Alimentary Pharmacology and Therapeutics, 26 1043-1050 (2007) [C1]
DOI10.1111/j.1365-2036.2007.03456.x
CitationsScopus - 20Web of Science - 17
2007Talley NJ, Van Zanten SV, Flook N, Vakil N, Lauritsen K, Bolling-Sternevald E, et al., 'One-week acid suppression trial in uninvestigated dyspepsia patients with epigastric pain or burning to predict response to 8 weeks' treatment with esomeprazole: A randomized, placebo-controlled study', Alimentary Pharmacology and Therapeutics, 26 665-672 (2007) [C1]
DOI10.1111/j.1365-2036.2007.03409.x
CitationsScopus - 13Web of Science - 13
2007Talley NJ, Hawkey CJ, Jones RH, Yeomans ND, Scheiman JM, Goldstein JL, et al., 'Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs', Alimentary Pharmacology and Therapeutics, 25 813-821 (2007) [C1]
DOI10.1111/j.1365-2036.2006.03210.x
CitationsScopus - 16Web of Science - 12
2007Jung HK, Halder S, McNally M, Locke Iii GR, Schleck CD, Zinsmeister AR, Talley NJ, 'Overlap of gastro-oesophageal reflux disease and irritable bowel syndrome: Prevalence and risk factors in the general population', Alimentary Pharmacology and Therapeutics, 26 453-461 (2007) [C1]
CitationsScopus - 55Web of Science - 46
2007Choung RS, Locke Iii GR, Schleck CD, Zinsmeister AR, Talley NJ, 'Cumulative incidence of chronic constipation: a population-based study 1988-2003', Alimentary Pharmacology and Therapeutics, 26 1521-1528 (2007) [C1]
DOI10.1111/j.1365-2036.2007.03540.x
CitationsScopus - 41Web of Science - 29
2006Holtmann G, Liebregts T, Talley NJ, 'Itopride for functional dyspepsia - Reply', NEW ENGLAND JOURNAL OF MEDICINE, 354 2392-2392 (2006)
Author URL
2006Chitkara DK, Bredenoord AJ, Talley NJ, Whitehead WE, 'Aerophagia and rumination: Recognition and therapy', Current Treatment Options in Gastroenterology, 9 305-313 (2006)

Aerophagia and rumination syndrome are functional upper gastrointestinal disorders that are becoming increasingly recognized in otherwise-healthy children and adults. Aerophagia i... [more]

Aerophagia and rumination syndrome are functional upper gastrointestinal disorders that are becoming increasingly recognized in otherwise-healthy children and adults. Aerophagia is primarily characterized by troublesome repetitive belching and abdominal symptoms that result from air sucking and swallowing. Rumination syndrome is primarily characterized by regurgitation occurring shortly after meal intake. Physiologic studies suggest that both disorders are a result of habitual behavior with associated esophageal and gastric physiologic deviations. However, the underlying etiology of these disorders remains unclear. Studies examining optimal treatments are lacking. However, therapeutic approaches utilizing biofeedback may be helpful in alleviating symptoms for patients with these conditions. Copyright © 2006 by Current Science Inc.

DOI10.1007/s11938-006-0012-9
CitationsScopus - 12
2006Holtmann G, Talley NJ, Liebregts T, Adam B, Parow C, 'A placebo-controlled trial of itopride in functional dyspepsia (vol 354, pg 832, 2005)', NEW ENGLAND JOURNAL OF MEDICINE, 355 429-429 (2006)
Author URL
CitationsWeb of Science - 1
2006Holtmann G, Liebregts T, Talley NJ, 'The authors reply [13]', New England Journal of Medicine, 354 2392-2392 (2006)
DOI10.1056/NEJMc060843
2006Howell S, Quine S, Talley NJ, 'Low social class is linked to upper gastrointestinal symptoms in an Australian sample of urban adults', Scandinavian Journal of Gastroenterology, 41 657-666 (2006) [C1]
DOI10.1080/00365520500442567
CitationsScopus - 9Web of Science - 8
2006Moayyedi P, Talley NJ, Fennerty MB, Vakil N, 'Distinguishing organic and functional dyspepsia by history - Reply', JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 296 1352-1353 (2006)
DOI10.1001/jama.296.11.1352-bAuthor URL
2006Moayyedi P, Talley NJ, Fennerty MB, Vakil N, 'Can the clinical history distinguish between organic and functional dyspepsia?', JAMA: Journal of the American Medical Association, 295 1566-1576 (2006) [C1]
CitationsScopus - 75Web of Science - 47
2006Moayyedi P, Talley NJ, Fennerty MB, Vakil N, 'In reply [8]', Journal of the American Medical Association, 296 1352-1353 (2006)
2006Moayyedi P, Talley NJ, 'Helicobacter pylori and gastro-oesophageal reflux disease - Reply', LANCET, 368 986-987 (2006)
DOI10.1016/S0140-6736(06)69406-3Author URL
CitationsScopus - 11Web of Science - 1
2006Moayyedi P, Talley NJ, 'Gastro-oesophageal reflux disease', Lancet, 367 2086-2100 (2006) [C1]
DOI10.1016/S0140-6736(06)68932-0
CitationsScopus - 222Web of Science - 189
2006Malfertheiner P, Fass R, Quigley EM, Modlins IM, Malagelada JR, Moss SF, et al., 'Review Article: From gastrin to gastrooesophageal reflux disease - a century of acid suppression', Alimentary Pharmacology and Therapeutics, 23 683-690 (2006) [C1]
DOI10.1111/j.1365-2036.2006.02817.x
CitationsScopus - 14Web of Science - 8
2006Ronkainen J, Aro P, Storskrubb T, Lind T, Bolling-Sternevald E, Junghard O, et al., 'Gastro-oesophageal reflux symptoms and health-related quality of life in the adult general population - The Kalixanda study', Alimentary Pharmacology and Therapeutics, 23 1725-1733 (2006) [C1]
DOI10.1111/j.1365-2036.2006.02952.x
CitationsScopus - 80Web of Science - 75
2006Talley NJ, Locke GR, Lahr BD, Zinsmeister AR, Cohard-Radice M, D'Ella TV, et al., 'Predictors of the placebo response in functional dyspepsia', Alimentary Pharmacology and Therapeutics, 23 923-936 (2006) [C1]
DOI10.1111/j.1365-2036.2006.02845.x
CitationsScopus - 59Web of Science - 48
2006Talley NJ, Vakil N, Stolte M, Sundin M, Junghard O, Bolling-Sternevald E, 'Patterns of gastritis and the effect of eradicating Helicobacter pylorion gastro-oesophageal reflux disease in Western patients with non-ulcer dyspepsia', Alimentary Pharmacology and Therapeutics, 24 55-63 (2006) [C1]
DOI10.1111/j.1365-2036.2006.02964.x
CitationsScopus - 21Web of Science - 19
2006Talley NJ, Camilleri M, Burton D, Thomforde G, Koch K, Rucker MJ, et al., 'Double-blind, randomized, placebo-controlled study to evaluate the effects of tegaserod on gastric motor, sensory and myoelectric function in healthy volunteers', Alimentary Pharmacology and Therapeutics, 24 859-867 (2006) [C1]
DOI10.1111/j.1365-2036.2006.03049.x
CitationsScopus - 17Web of Science - 15
2006Choung RS, Locke Iii GR, Zinsmeister AR, Melton Iii LJ, Talley NJ, 'Alternating bowel pattern: What do people mean?', Alimentary Pharmacology and Therapeutics, 23 1749-1755 (2006) [C1]
DOI10.1111/j.1365-2036.2006.02953.x
CitationsScopus - 2Web of Science - 2
2006Talley NJ, Armstrong D, Junghard O, Wiklund I, 'Predictors of treatment response in patients with non-erosive reflux disease', Alimentary Pharmacology and Therapeutics, 24 371-376 (2006) [C1]
DOI10.1111/j.1365-2036.2006.02983.x
CitationsScopus - 39Web of Science - 33
2006Hammer J, Talley NJ, 'Disturbed bowel habits in patients with non-ulcer dyspepsia', Alimentary Pharmacology and Therapeutics, 24 405-410 (2006) [C1]
DOI10.1111/j.1365-2036.2006.02992.x
CitationsScopus - 3Web of Science - 2
2006Stolte M, Muller H, Talley NJ, O'Morain C, Bolling-Sternevald E, Sundin M, et al., 'In patients with Helicobacter pylori gastritis and functional dyspepsia, a biopsy from the incisura angularis provides useful diagnostic information', Pathology Research and Practice, 202 405-413 (2006) [C1]
DOI10.1016/j.prp.2006.01.011
CitationsScopus - 6Web of Science - 4
2006Koloski NA, Boyce PM, Talley NJ, 'Somatization an independent psychosocial risk factor for irritable bowel syndrome but not dyspepsia: A population-based study', European Journal of Gastroenterology and Hepatology, 18 1101-1109 (2006) [C1]
DOI10.1097/01.meg.0000231755.42963.c6
CitationsScopus - 23Web of Science - 16
2006Fajardo NR, Cremonini F, Talley NJ, 'Management of constipation in patients with cancer', American Journal of Cancer, 5 319-330 (2006)

In patients with cancer, constipation is a common complication. However, unlike in the general population, the impact of the symptoms of constipation on the quality of life in can... [more]

In patients with cancer, constipation is a common complication. However, unlike in the general population, the impact of the symptoms of constipation on the quality of life in cancer patients is often greater. More importantly, in patients who are in the more advanced stages of the disease, constipation may also be suggestive of disease progression. Constipation as a symptom in this population is of significant importance as it may lead to life-threatening complications, i.e. bowel perforation due to fecal impaction. Therefore, in this regard, this problem deserves particular attention, as early recognition and management of complications may prevent further physical deterioration. This review aims to provide an overview of the management of constipation in patients with cancer. A symptom-based criteria definition for chronic constipation and prevalence of the problem in cancer patients provides a brief introduction. For the initial assessment and evaluation of constipation in cancer patients, an algorithm is described. The different possible etiologies of constipation in cancer patients are also discussed. Regarding therapeutic management, guidelines and recommendations for the use of different types of laxatives, stool softeners, suppositories and rectal enemas, prokinetic agents, antidepressant medications, and miscellaneous agents are succinctly discussed. Management of fecal impaction and opioid-induced bowel dysfunction are also described. Lastly, a brief overview of the management of acute colonic pseudo-obstruction and surgical or endoscopic options for large bowel obstruction are described. © 2006 Adis Data Information BV. All rights reserved.

DOI10.2165/00024669-200605050-00003
CitationsScopus - 1
2006Choung RS, Talley NJ, 'Novel mechanisms in functional dyspepsia', World Journal of Gastroenterology, 12 673-677 (2006) [C1]
CitationsScopus - 25Web of Science - 17
2006Cremonini F, Locke Iii GR, Schleck CD, Zinsmeister AR, Talley NJ, 'Relationship between upper gastrointestinal symptoms and changes in body weight in a population-based cohort', Neurogastroenterology and Motility, 18 987-994 (2006) [C1]
DOI10.1111/j.1365-2982.2006.00816.x
CitationsScopus - 33Web of Science - 24
2006Halder SL, Locke Iii GR, Schleck CD, Zinsmeister AR, Talley NJ, 'Influence of alcohol consumption on IBS and dyspepsia', Neurogastroenterology and Motility, 18 1001-1008 (2006) [C1]
DOI10.1111/j.1365-2982.2006.00815.x
CitationsScopus - 17Web of Science - 15
2006Boyce PM, Talley NJ, Burke C, Koloski NA, 'Epidemiology of the functional gastrointestinal disorders diagnosed according to Rome II criteria: An Australian population-based study', Internal Medicine Journal, 36 28-36 (2006) [C1]
DOI10.1111/j.1445-5994.2006.01006.x
CitationsScopus - 54Web of Science - 45
2006Talley NJ, 'Irritable bowel syndrome', Internal Medicine Journal, 36 724-728 (2006) [C1]
CitationsScopus - 69Web of Science - 55
2006Hancox RJ, Poulton R, Taylor DR, Greene JM, McLachlan CR, Cowan JO, et al., 'Associations between respiratory symptoms, lung function and gastro-oesophageal reflux symptoms in a population-based birth cohort', Respiratory Research, 7 142-142 (2006) [C1]
DOI10.1186/1465-9921-7-142
CitationsScopus - 34Web of Science - 29
2006Aghazahedi M, Moayyedi P, Talley NJ, 'Endoscopic therapy for patients with gastro-esophageal reflux disease (GORD)', Cochrane Database of Systematic Reviews, (2006)

This is the protocol for a review and there is no abstract. The objectives are as follows: (1) To assess the effectiveness of endoscopic suturing devices in patients with GORD com... [more]

This is the protocol for a review and there is no abstract. The objectives are as follows: (1) To assess the effectiveness of endoscopic suturing devices in patients with GORD compared with no treatment or anti-secretory therapy. (2) To evaluate the incidence of adverse effects associated with endoscopic therapies. (3) To assess the effectiveness of radio-frequency energy in patients with GORD compared with no treatment or anti-secretory therapy. (4) To evaluate the incidence of adverse effects associated with radio-frequency energy to the cardia. (5) To assess the effectiveness of endoscopic injecting devices in patients with GORD compared with no treatment or anti-secretory therapy. (6) To evaluate the incidence of adverse effects associated with endoscopic injecting devices. (7) To assess the overall effectiveness of endoscopic therapies in GORD compared with no treatment or antisecretory therapies. Copyright © 2006 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

DOI10.1002/14651858.CD006284
2006Talley NJ, 'Chronic constipation and irritable bowel syndrome: Epidemiology, presentation, and diagnosis', Advanced Studies in Medicine, 6 (2006)

An estimated 15% of the US population is affected by chronic constipation and irritable bowel syndrome (IBS), a prevalence that exceeds chronic conditions, such as asthma and diab... [more]

An estimated 15% of the US population is affected by chronic constipation and irritable bowel syndrome (IBS), a prevalence that exceeds chronic conditions, such as asthma and diabetes. Chronic constipation and IBS have somewhat overlapping symptoms that suggest some commonality in pathophysiology. Diagnosis often is complicated by the disconnect between physician and patient definitions of constipation. From a formal perspective, the American College of Gastroenterology (ACG) has set forth arguably the simplest, most straightforward criteria for defining constipation. Diagnosis of constipation is based primarily on the medical history and physical examination. The ACG has found no published evidence to support the routine use of any specific diagnostic test. For patients with chronic constipation but no alarm symptoms, empiric therapy is recommended by the ACG. Several criteria have been set forth to define IBS, and the most appropriate definition remains open to discussion. The basic diagnostic approach consists of symptom assessment, a check for red flags, and a limited screen for organic disease, as indicated by the history and examination. Patients with alarm features or red flags, such as anemia, persistent diarrhea, or rectal bleeding, require further evaluation.

CitationsScopus - 2
2006Rex DK, Hanauer SB, Sandborn WJ, Katz PO, Talley NJ, 'Report from the ACG. Highlights of the 70th Annual Scientific Meeting of the American College of Gastroenterology October 28-November 2, 2005, Honolulu, HI', Reviews in Gastroenterological Disorders, 6 35-47 (2006)
2006Hanauer SB, Sandborn WJ, Vakil N, Katz PO, Talley NJ, Rex DK, et al., 'Best of DDW 2006', Reviews in Gastroenterological Disorders, 6 153-189 (2006)
CitationsScopus - 1
2006Rex DK, Talley NJ, Katz PO, Hanauer SB, Sandborn WJ, 'Report from the ACG: Highlights of the 71st Annual Scientific Meeting of the American College of Gastroenterology, October 20-25, Las Vegas, NV', Reviews in Gastroenterological Disorders, 6 227-242 (2006)
2006Hanauer SB, Sandborn WJ, Vakil N, Katz PO, Talley NJ, Rex DK, et al., 'Highlights from the 2006 Digestive Disease Week May 20- 25, 2006, Los Angeles, CA', Reviews in Gastroenterological Disorders, 6 153-189 (2006) [C1]
2006Talley NJ, 'A unifying hypothesis for the functional gastrointestinal disorders: really multiple diseases or one irritable gut?', Reviews in Gastrointestinal Disorders, 6 72-78 (2006) [C1]
CitationsScopus - 25Web of Science - 23
2006Choung RS, Talley NJ, 'Food allergy and intolerance in IBS', Gastroenterology and Hepatology, 2 756-760 (2006)

Irritable bowel syndrome (IBS) is a very common functional gastrointestinal disorder. IBS is likely to be a multifactorial condition resulting from a number of different mechanism... [more]

Irritable bowel syndrome (IBS) is a very common functional gastrointestinal disorder. IBS is likely to be a multifactorial condition resulting from a number of different mechanisms such as disordered motility, visceral hypersensitivity, abnormal central processing, psychological factors, genetic factors, gut inflammation, and dietary factors. Many patients with IBS give a history of adverse food reactions, but the foods identified to be relevant have been highly variable. Food hypersensitivity can be mediated by immunoglobulin E-dependent and -independent mechanisms involving mast cells, eosinophils, and other immune cells. Recent clinical and experimental studies suggest that there is a possible role for food hypersensitivity in IBS, with improvement of IBS symptom severity in a subset of patients on elimination diets, but the underlying mechanisms in IBS have yet to be fully understood. This review considers the evidence for the role of food hypersensitivity in IBS, based on the available epidemiologic and pathophysiologic data, and the clinical implications.

CitationsScopus - 3
2006Talley NJ, 'How effective is fluoxetine for the treatment of pain and constipation-predominant irritable bowel syndrome?', Nature Clinical Practice Gastroenterology and Hepatology, 3 196-197 (2006) [C1]
DOI10.1038/ncpgasthep0444
CitationsScopus - 1Web of Science - 1
2006Aro P, Storskrubb T, Ronkainen J, Bolling-Sternevald E, Engstrand L, Veith M, et al., 'Peptic ulcer disease in a general adult population: The kalixanda study: A random population-based study', American Journal of Epidemiology, 163 1025-1034 (2006) [C1]
DOI10.1093/aje/kwj129
CitationsScopus - 80Web of Science - 70
2006Richter JE, Talley NJ, 'AJG year in review - American Journal of Gastroenterology 2005: Another great year', AMERICAN JOURNAL OF GASTROENTEROLOGY, 101 683-685 (2006)
DOI10.1111/j.1572-0241.2006.00569.xAuthor URL
2006Saito YA, Locke GR, Talley NJ, 'Diet and dyspepsia: To believe patients or studies? Response to Drs. Thomas and Kareem', AMERICAN JOURNAL OF GASTROENTEROLOGY, 101 2163-2163 (2006)
DOI10.1111/j.1572-0241.2006.00763_2.xAuthor URL
2006Crowell MD, Decker GA, Levy R, Jeffrey R, Talley NJ, 'Gut-brain neuropeptides in the regulation of ingestive behaviors and obesity', AMERICAN JOURNAL OF GASTROENTEROLOGY, 101 2848-2856 (2006)
DOI10.1111/j.1572-0241.2006.00832.xAuthor URL
CitationsScopus - 12Web of Science - 11
2006Talley NJ, Schoenfeld P, 'When is adequate relief satisfactory or when is satisfactory relief adequate?', AMERICAN JOURNAL OF GASTROENTEROLOGY, 101 2886-2887 (2006)
DOI10.1111/j.1572-0241.2006.00867_3.xAuthor URL
2006Schoenfeld P, Talley NJ, 'Measuring successful treatment of irritable bowel syndrome: Is "Satisfactory Relief" enough?', American Journal of Gastroenterology, 101 1066-1068 (2006) [C1]
DOI10.1111/j.1572-0241.2006.00519.x
CitationsScopus - 13Web of Science - 12
2006Holtmann G, Talley NJ, 'Hypothesis driven research and molecular mechanisms in functional dyspepsia: the beginning of a beautiful friendship in research and practice', American Journal of Gastroenterology, 101 593-595 (2006) [C1]
DOI10.1111/j.1572-0241.2006.00480.x
CitationsScopus - 11Web of Science - 10
2006Saito YA, Talley NJ, De Andrade M, Petersen GM, 'Case-control genetic association studies in gastrointestinal disease: Review and recommendations', American Journal of Gastroenterology, 101 1379-1389 (2006) [C1]
DOI10.1111/j.1572-0241.2006.00587.x
CitationsScopus - 19Web of Science - 14
2006Chitkara D, Van Tilburg M, Whitehead WE, Talley NJ, 'Teaching diaphragmatic breathing for rumination syndrome', American Journal of Gastroenterology, 101 2449-2452 (2006) [C1]
DOI10.1111/j.1572-0241.2006.00801.x
CitationsScopus - 28Web of Science - 19
2006Talley NJ, Richter J, 'Declaring conflicts of interest in the American Journal of Gastroenterology: Not just smoke and mirrors.', American Journal of Gastroenterology, 101 2677-2678 (2006) [C1]
DOI10.1111/j.1572-0241.2006.00971.x
CitationsScopus - 2Web of Science - 2
2006Scheiman JM, Yeomans ND, Talley NJ, Vakil N, Chan FK, Tulassay Z, et al., 'Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors', American Journal of Gastroenterology, 101 701-710 (2006) [C1]
DOI10.1111/j.1572-0241.2006.00499.x
CitationsScopus - 166Web of Science - 124
2006Storskrubb T, Aro P, Ronkainen J, Wreiber K, Nyhlin H, Bolling-Sternevald E, et al., 'Antimicrobial susceptibility of Helicobacter pylori strains in a random adult Swedish population', Helicobacter (Oxford), 11 224-230 (2006) [C1]
DOI10.1111/j.1523-5378.2006.00414.x
CitationsScopus - 26Web of Science - 22
2006Ronkainen J, Vieth M, Talley NJ, 'Prevalence of Barrett's esophagus - Reply', GASTROENTEROLOGY, 130 1374-1375 (2006)
DOI10.1053/j.gastro.2006.02.048Author URL
2006Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada J, Stanghellini V, 'Functional gastroduodenal disorders. (vol 130, pg 1466, 2006)', GASTROENTEROLOGY, 131 336-336 (2006)
Author URL
CitationsWeb of Science - 4
2006Irvine EJ, Whitehead WE, Chey WD, Matsueda K, Shaw M, Talley NJ, Veldhuyzen Van Zanten SJ, 'Design of treatment trials for functional gastrointestinal disorders', Gastroenterology, 130 1538-1551 (2006) [C1]
DOI10.1053/j.gastro.2005.11.058
CitationsScopus - 160Web of Science - 138
2006Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada J-R, Stanghelini V, 'Functional Gastroduodenal Disorders', Gastroenterology, 130 1466-1479 (2006) [C1]
DOI10.1053/j.gastro.2005.11.059
CitationsScopus - 817Web of Science - 637
2006Vakil N, Moayyedi P, Fennerty MB, Talley NJ, 'Limited Value of Alarm Features in the Diagnosis of Upper Gastrointestinal Malignancy: Systematic Review and Meta-analysis', Gastroenterology, 131 390-401 (2006) [C1]
DOI10.1053/j.gastro.2006.04.029
CitationsScopus - 98Web of Science - 79
2006Talley NJ, Andresen V, Camilleri M, Kim HJ, Stephens DA, Saito YA, et al., 'Is There an Association Between GNß3-C825T Genotype and Lower Functional Gastrointestinal Disorders?', Gastroenterology, 130 1985-1994 (2006) [C1]
DOI10.1053/j.gastro.2006.03.017
CitationsScopus - 47Web of Science - 40
2006Rajan E, Gostout CJ, Lurken MS, Locke GR, Talley NJ, Szarka LJ, et al., 'Novel Endoscopic Full Thickness Biopsy of the Stomach to Detect Myenteric Ganglia: A Pilot Study in a Porcine Model', GASTROINTESTINAL ENDOSCOPY, 63 AB233-AB233 (2006)
Author URL
2006Rajan E, Gostout CJ, Lurken MS, Locke GR, Talley NJ, Szarka LA, et al., 'Endoscopic Full Thickness Biopsy of the Stomach: What Works?', GASTROINTESTINAL ENDOSCOPY, 63 AB233-AB233 (2006)
Author URL
2006Fajardo N, Wise J, Locke GR, Talley NJ, 'Esophageal perforation after placement of wireless Bravo pH probe.', Gastrointestinal Endoscopy, 63 184-185 (2006) [C1]
DOI10.1016/j.gie.2005.07.035
CitationsScopus - 24Web of Science - 20
2006Talley NJ, Locke GR, 'Does delayed gastric emptying really cause symptoms in functional dyspepsia? We still doubt it!', GUT, 55 1674-1674 (2006)
DOI10.1136/gut.2005.105601Author URL
CitationsScopus - 8Web of Science - 7
2006Talley NJ, 'Genes and environment in irritable bowel syndrome: one step forward', GUT, 55 1694-1696 (2006)
DOI10.1136/gut.2006.108837Author URL
CitationsScopus - 10Web of Science - 9
2006Talley NJ, Locke Iii GR, Lahr BD, Zinsmeister AR, Tougas G, Ligozio G, et al., 'Functional dyspepsia, delayed gastric emptying, and impaired quality of life', Gut, 55 933-939 (2006) [C1]
DOI10.1136/gut.2005.078634
CitationsScopus - 116Web of Science - 99
2005Locke GR, Lin SC, Talley NJ, 'Psychiatric disease and functional GI disorders in the community: More evidence for a casual link?', AMERICAN JOURNAL OF GASTROENTEROLOGY, 100 248-249 (2005)
DOI10.1111/j.1572-0241.2005.41277_3.xAuthor URL
CitationsScopus - 3Web of Science - 2
2005Kamm MA, Muller-Lissner S, Talley NJ, 'Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. (vol 100, pg 362, 2005)', AMERICAN JOURNAL OF GASTROENTEROLOGY, 100 735-735 (2005)
Author URL
CitationsWeb of Science - 3
2005Richter JE, Talley NJ, 'American Journal of Gastroenterology: 2004 in review', AMERICAN JOURNAL OF GASTROENTEROLOGY, 100 737-739 (2005)
DOI10.1111/j.1572-0241.2005.50054.xAuthor URL
2005Brandt LJ, Schoenfeld P, Prather CM, Quigley EMM, Schiller LR, Talley NJ, 'Evidence-based position statement on the management of chronic constipation in North America', AMERICAN JOURNAL OF GASTROENTEROLOGY, 100 (2005)
DOI10.1111/j.1572-0241.2005.50613.xAuthor URL
CitationsWeb of Science - 1
2005Nandurkar S, Locke GR, Murray JA, Melton LJ, Zinsmeister AR, Dierkhising R, Talley NJ, 'Rates of endoscopy and endoscopic findings among people with frequent symptoms of gastroesophageal reflux in the community', AMERICAN JOURNAL OF GASTROENTEROLOGY, 100 1459-1465 (2005)
DOI10.1111/j.1572-0241.2005.41115.xAuthor URL
CitationsScopus - 21Web of Science - 19
2005Richter JE, Talley NJ, Achkar E, 'The GI match is back!', AMERICAN JOURNAL OF GASTROENTEROLOGY, 100 1664-1664 (2005)
DOI10.1111/j.1572-0241.2005.50881.xAuthor URL
2005Kamm MA, Müller-Lissner S, Talley NJ, 'Erratum: Tegaserod for the treatment of chronic constipation: A randomized, double-blind, placebo-controlled multinational study (American Journal of Gastroenterology (2005) 100 (362-372))', American Journal of Gastroenterology, 100 735-735 (2005)
DOI10.1111/j.1572-0241.2005.20050228.x
CitationsScopus - 1
2005Moayyedi P, Talley N, 'Gambling with gastroesophageal reflux disease: should we worry about the QALY?', American Journal of Gastroenterology, 100 534-536 (2005) [C1]
DOI10.1111/j.1572-0241.2005.41779.x
CitationsScopus - 5Web of Science - 4
2005Chitkara D, Rawat D, Talley N, 'The epidemiology of childhood recurrent abdominal pain in Western countries: A systematic review', American Journal of Gastroenterology, 100 1868-1875 (2005) [C1]
DOI10.1111/j.1572-0241.2005.41893.x
CitationsScopus - 153Web of Science - 124
2005Brandt LJ, Prather CM, Quigley EM, Schiller LR, Schoenfeld P, Talley N, 'Systematic review on the management of chronic constipation in North America', American Journal of Gastroenterology, 100 5-22 (2005) [C1]
DOI10.1111/j.1572-0241.2005.50613_2.x
CitationsScopus - 191Web of Science - 130
2005Brandt LJ, Prather CM, Quigley EM, Schiller LR, Schoenfeld P, Talley NJ, 'An evidence-based approach to the management of chronic constipation in North America.', American Journal of Gastroenterology, 100 1-4 (2005) [C1]
DOI10.1111/j.1572-0241.2005.50613_1.x
2005Talley NJ, 'Nobel Prize in Medicine awarded to a gastroenterologist in 2005', American Journal of Gastroenterology, 101 211-211 (2005) [C1]
DOI10.1111/j.1572-0241.2006.00388.x
CitationsScopus - 2
2005Kamm MA, Müller-Lissner S, Talley NJ, Tack J, Boeckxstaens G, Minushkin ON, et al., 'Tegaserod for the treatment of chronic constipation: A randomized, double-blind, placebo-controlled multinational study', American Journal of Gastroenterology, 100 362-372 (2005) [C1]
DOI10.1111/j.1572-0241.2005.40749.x
CitationsScopus - 142Web of Science - 95
2005Cremonini F, Wise J, Moayyedi P, Talley NJ, 'Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: A metaanalysis', American Journal of Gastroenterology, 100 1226-1232 (2005) [C1]
DOI10.1111/j.1572-0241.2005.41657.x
CitationsScopus - 99Web of Science - 79
2005Talley NJ, Hawkey C, Yeomans ND, Jones R, Sung JJ, Langstrom G, et al., 'Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors', American Journal of Gastroenterology, 100 1028-1036 (2005) [C1]
DOI10.1111/j.1572-0241.2005.41465.x
CitationsScopus - 78Web of Science - 57
2005Saito YA, Locke Iii GR, Weaver AL, Zinsmeister AR, Talley NJ, 'Diet and functional gastrointestinal disorders: A population-based case-control study', American Journal of Gastroenterology, 100 2743-2748 (2005) [C1]
DOI10.1111/j.1572-0241.2005.00288.x
CitationsScopus - 72Web of Science - 54
2005Tuteja AK, Talley NJ, Joos SK, Woehl JV, Hickam DH, 'Is constipation associated with decreased physical activity in normally active subjects?', American Journal of Gastroenterology, 100 124-129 (2005) [C1]
DOI10.1111/j.1572-0241.2005.40516.x
CitationsScopus - 45Web of Science - 25
2005Howell S, Poulton R, Talley NJ, 'The natural history of childhood abdominal pain and its association with adult irritable bowel syndrome: Birth-cohort study', American Journal of Gastroenterology, 100 2071-2078 (2005) [C1]
DOI10.1111/j.1572-0241.2005.41753.x
CitationsScopus - 42Web of Science - 33
2005Talley NJ, Vakil N, 'Guidelines for the management of dyspepsia', American Journal of Gastroenterology, 100 2324-2337 (2005) [C1]
CitationsScopus - 267Web of Science - 197
2005Revicki D, Talley NJ, 'Reflux questionnaire (ReQuest (TM))', DIGESTION, 71 173-173 (2005)
DOI10.1159/000086139Author URL
2005Talley NJ, Camilleri M, Chitkara DK, Bouras E, Locke Iii GR, Burton D, et al., 'Effects of desipramine and escitalopram on postprandial symptoms induced by the nutrient drink test in healthy volunteers: A randomized, double-blind, placebo-controlled study', Digestion: international journal of gastroenterology, 72 97-103 (2005) [C1]
DOI10.1159/000088363
CitationsScopus - 14Web of Science - 16
2005Koloski NA, Talley NJ, Boyce PM, 'A history of abuse in community subjects with irritable bowel syndrome and functional dyspepsia: The role of other psychosocial variables', Digestion: international journal of gastroenterology, 72 86-96 (2005) [C1]
DOI10.1159/000087722
CitationsScopus - 41Web of Science - 33
2005Moayyedi P, Delaney B, Vakil N, Forman D, Talley N, 'Nonulcer dyspepsia and proton pump inhibitors - Reply', GASTROENTEROLOGY, 128 805-806 (2005)
DOI10.1053/j.gastro.2005.01.025Author URL
CitationsScopus - 1
2005Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, et al., 'Prevalence of Barrett's esophagus in the general population: An endoscopic study', Gastroenterology, 129 1825-1831 (2005) [C1]
DOI10.1053/j.gastro.2005.08.053
CitationsScopus - 432Web of Science - 354
2005Talley NJ, Vakil NB, Moayyedi P, 'American gastroenterological association technical review on the evaluation of dyspepsia', Gastroenterology, 129 1756-1780 (2005) [C1]
CitationsScopus - 230
2005Talley NJ, Aro P, Ronkainen J, Storskrubb T, Bolling-Sternevald E, Agreus L, 'Body mass index and chronic unexplained gastrointestinal symptoms: An adult endoscopic population based study', Gut, 54 1377-1383 (2005) [C1]
DOI10.1136/gut.2004.057497
CitationsScopus - 48Web of Science - 33
2005Koloski NA, Boyce PM, Talley NJ, 'Is health care seeking for irritable bowel syndrome and functional dyspepsia a socially learned response to illness?', Digestive Diseases and Sciences, 50 153-162 (2005) [C1]
DOI10.1007/s10620-005-1294-9
CitationsScopus - 17Web of Science - 14
2005Saito YA, Cremonini F, Talley NJ, 'Association of the 1438G/A and 102T/C polymorphism of the 5-HT2A receptor gene with irritable bowel syndrome 5-HT2A gene polymorphism in irritable bowel syndrome', JOURNAL OF CLINICAL GASTROENTEROLOGY, 39 835-835 (2005)
DOI10.1097/01.mcg.0000177239.90005.b5Author URL
CitationsScopus - 4Web of Science - 5
2005Burton DD, Kim HJ, Camilleri M, Stephens DA, Mullan BP, O'Connor MK, Talley NJ, 'Relationship of gastric emptying and volume changes after a solid meal in humans', American Journal of Physiology: Gastrointestinal and Liver Physiology, 289 261-266 (2005) [C1]
DOI10.1152/ajpgi.00052.2005
CitationsScopus - 34Web of Science - 28
2005Ahlawat SK, Locke GR, Weaver AL, Farmer SA, Yawn BP, Talley NJ, 'Dyspepsia consulters and patterns of management: A population-based study', Alimentary Pharmacology and Therapeutics, 22 251-259 (2005) [C1]
DOI10.1111/j.1365-2036.2005.02525.x
CitationsScopus - 18Web of Science - 14
2005Chitkara DK, Bredenoord AJ, Rucker MJ, Talley NJ, 'Aerophagia in adults: A comparison with functional dyspepsia', Alimentary Pharmacology and Therapeutics, 22 855-858 (2005) [C1]
DOI10.1111/j.1365-2036.2005.02651.x
CitationsScopus - 21Web of Science - 16
2005Wise JL, Locke GR, Zinsmeister AR, Talley NJ, 'Risk factors for non-cardiac chest pain in the community', Alimentary Pharmacology and Therapeutics, 22 1023-1031 (2005) [C1]
DOI10.1111/j.1365-2036.2005.02666.x
CitationsScopus - 13Web of Science - 7
2005Talley NJ, 'Epidemiology, severity, and impact of irritable bowel syndrome', Practical Gastroenterology, 29 4-12 (2005)
2005Talley NJ, 'Irritable bowel syndrome - Preface', GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 34 XI-XII (2005)
DOI10.1016/j.gtc.2005.04.001Author URL
2005Cremonini F, Talley NJ, 'Irritable bowel syndrome: Epidemiology, natural history, health care seeking and emerging risk factors', Gastroenterology Clinics of North America, 34 189-204 (2005) [C1]
DOI10.1016/j.gtc.2005.02.008
CitationsScopus - 130Web of Science - 93
2005Talley N, Wiklund I, 'Patient reported outcomes in gastroesophageal reflux disease: an overview of available measures', Quality of Life Research, 14 21-33 (2005) [C1]
DOI10.1007/s11136-004-0613-5
CitationsScopus - 22Web of Science - 21
2005Fawcett JP, Barbezat GO, Poulton R, Milne BJ, Xia HH, Talley NJ, 'Helicobacter pylori serology in a birth cohort of New Zealanders from age 11 to 26', World Journal of Gastroenterology, 11 3273-3276 (2005) [C1]
CitationsScopus - 7Web of Science - 7
2005Talley NJ, 'Review: prompt endoscopy is not a cost-effective strategy for initial management of dyspepsia.', ACP journal club, 143 76 (2005)
2005Halder SLS, Talley NJ, 'Treatment of functional dyspepsia', Current Treatment Options in Gastroenterology, 8 325-336 (2005)

Functional dyspepsia (FD) is a common reason a patient presents with upper gastrointestinal symptoms for medical care. Although treatment of FD remains expensive, the agents are r... [more]

Functional dyspepsia (FD) is a common reason a patient presents with upper gastrointestinal symptoms for medical care. Although treatment of FD remains expensive, the agents are rarely used in a systematic manner; the majority of treatments are empirical and the results short lived once therapy is ceased. This is partly due to the lack of consistent pathophysiologic markers in FD, so therapy is symptom driven. This review appraises the best evidence on available interventions. A structured scheme for deciding on appropriate therapies is to consider the possible putative pathophysiologic mechanisms. Eradicating Helicobacter pylori, if present, is a first-line strategy. In patients who have symptoms suggesting excessive gastric acid secretion, particularly epigastric pain, antisecretory agents are recommended. Prokinetics may confer benefits on symptoms suggestive of upper gastrointestinal dysmotility, like fullness or early satiety. However, their use is limited due to availability issues. The expanding field of psychologic therapies provides a promising avenue of treatment. Complementary medicines are now widely use and their benefits have been suggested in recent controlled trials. Emerging treatments include cholecystokinin 1 blockers, opioid receptor agonists, and serotonergic agents, although their application in FD is in the preliminary stages. Copyright © 2005 by Current Science Inc.

CitationsScopus - 11
2005Wahlqvist P, Bergenheim K, Persson T, Brun J, Flook N, Lauritsen K, et al., 'Esomeprazole treatment in patients with uninvestigated non-GERD dyspepsia leads to significant improvements in productivity while at work and in daily activities - Results from a randomised, placebo-controlled clinical study', VALUE IN HEALTH, 8 A125-A125 (2005)
DOI10.1016/S1098-3015(10)67530-4Author URL
2005Chitkara DK, Bredenoord AJ, Wang M, Rucker MJ, Talley NJ, 'Aerophagia in children: characterization of a functional gastrointestinal disorder (vol 17, pg 518, 2005)', NEUROGASTROENTEROLOGY AND MOTILITY, 17 773-773 (2005)
DOI10.1111/j.1365-2982.2005.714.xAuthor URL
2005Locke Iii GR, Zinsmeister AR, Fett SL, Melton Iii LJ, Talley NJ, 'Overlap of gastrointestional symptom complexes in a US community', Neurogastroenterology and Motility, 17 29-34 (2005) [C1]
DOI10.1111/j.1365-2982.2004.00581.x
CitationsScopus - 135Web of Science - 114
2005Chitkara DK, Bredenood AJ, Wang M, Rucker MJ, Talley NJ, 'Aerophagia in children: Characterization of a functional gastrointestinal disorder', Neurogastroenterology and Motility, 17 518-522 (2005) [C1]
DOI10.1111/j.1365-2982.2005.00682.x
CitationsScopus - 11Web of Science - 10
2005Talley NJ, 'Review: prompt endoscopy is not a cost effective strategy for initial management of dyspepsia.', Evidence-Based medicine, 143 143-176 (2005) [C1]
DOI10.1136/ebm.10.6.185
2005Cuddihy MT, Locke Iii GR, Wahner-Roedler D, Dierkhising R, Zinsmeister AR, Long KH, Talley NJ, 'Dyspepsia management in primary care: A management trial', International Journal of Clinical Practice, 59 194-201 (2005) [C1]
DOI10.1111/j.1742-1241.2005.00372.x
CitationsScopus - 2Web of Science - 1
2005Talley N, 'Helicobacter pylori infection in Indigenous Australians: a serious health issue?', Medical Journal of Australia, 182 205-206 (2005) [C3]
CitationsWeb of Science - 1
2005Fajardo NR, Cremonini F, Talley NJ, 'Frontiers in functional dyspepsia', Current Gastroenterology Reports, 7 289-296 (2005)

Functional dyspepsia (FD) refers to unexplained pain or discomfort in the upper abdomen and is commonly seen in gastroenterology practice. The underlying pathophysiologic mechanis... [more]

Functional dyspepsia (FD) refers to unexplained pain or discomfort in the upper abdomen and is commonly seen in gastroenterology practice. The underlying pathophysiologic mechanisms associated with FD are unclear, although traditionally, delayed gastric emptying, visceral hypersensitivity to acid or mechanical distention, and impaired gastric accommodation have been implicated as putative physiologic disturbances. It also remains uncertain whether FD and irritable bowel syndrome are different presentations of the same disorder. Recent data on pathophysiologic mechanisms of FD have focused on postprandial motor disturbances (accelerated gastric emptying, antral-fundic incoordination, and abnormal phasic contractions), alterations of neurohormonal mechanisms in response to a meal, and previous acute infection. Pharmacologic therapies for FD may be guided by these novel mechanisms, as current available therapeutic options are limited. Novel prokinetics and gastric accommodation modulators, visceral analgesics, and agents targeting the neurohormonal response to food ingestion are the next therapeutic frontiers in FD. This review summarizes traditional knowledge and more recent advances in the pathophysiology of FD and potential therapeutic opportunities. Copyright © 2005 by Current Science Inc.

CitationsScopus - 5
2005Moayyedi P, Delancy BC, Vakil N, Forman D, Talley NJ, Speigel B, Dulai G, 'Proton pump inhibitors in nonulcer dyspepsia: Still working after all these years', Evidence-Based Gastroenterology, 6 36-37 (2005)
DOI10.1097/01.ebg.0000163172.48492.91
2005Rex DK, Sandborn WJ, Hanauer SB, Katz PO, Talley NJ, 'Report from the ACG', Reviews in Gastroenterological Disorders, 5 31-46 (2005)
2005Talley NJ, 'Environmental versus genetic risk factors for irritable bowel syndrome: Clinical and therapeutic implication', Reviews in Gastroenterological Disorders, 5 82-88 (2005) [C1]
CitationsScopus - 9
2005Talley NJ, 'Differentiating functional constipation from constipation-predominant irritable bowel syndrome: Management implications', Reviews in Gastroenterological Disorders, 5 1-9 (2005) [C1]
CitationsScopus - 18
2005Rex DK, Sandborn WJ, Hanauer SB, Katz PO, Talley NJ, 'Highlights from the 69th Annual Scientific Meeting of the American College of Gastroenterology, October 29-November 3, 2004', Reviews in Gastroenterological Disorders, 5 31-46 (2005) [C1]
2005Talley NJ, 'Functional GI Disorders. In: Best of DDW 2005', Reviews in Gastroenterological Disorders, 5 152-154 (2005) [C1]
2005Saito YA, Petersen GM, Locke GR, Talley NJ, 'The genetics of irritable bowel syndrome', CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 3 1057-1065 (2005)
DOI10.1053/S1542-3565(05)00184-9Author URL
CitationsScopus - 46Web of Science - 40
2005Camilleri M, Dubois D, Coulie B, Jones M, Kahrilas PJ, Rentz AM, et al., 'Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: Results of the US upper gastrointestinal study', Clinical Gastroenterology and Hepatology, 3 543-552 (2005) [C1]
DOI10.1016/S1542-3565(05)00153-9
CitationsScopus - 169Web of Science - 150
2005Cremonini F, Talley N, 'Treatments targeting putative mechanisms in the irritable bowel syndrome', Nature Clinical Practice Gastroenterology and Hepatology, 2 82-88 (2005) [C1]
DOI10.1038/ncpgasthep0096
CitationsScopus - 19Web of Science - 16
2005Eslcik GD, Coulshed DS, Talley NJ, 'Diagnosis and treatment of noncardiac chest pain', Nature Clinical Practice Gastroenterology and Hepatology, 2 463-472 (2005) [C1]
DOI10.1038/ncpgasthep0284
CitationsScopus - 21Web of Science - 18
2005Holtmann G, Talley NJ, Liebregts T, Adam B, Parow C, 'A placebo-controlled trial of itopride in functional dyspepsia', New England Journal of Medicine, 354 832-840 (2005) [C1]
DOI10.1056/NEJMoa052639
CitationsScopus - 130Web of Science - 106
2005Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, et al., 'High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: A Kalixanda study report', Scandinavian Journal of Gastroenterology, 40 275-285 (2005) [C1]
DOI10.1080/00365520510011579
CitationsScopus - 220Web of Science - 192
2005Storskrubb T, Aro P, Ronkainen J, Veith M, Stolte M, Wreiber K, et al., 'A negative Helicobacter pylori serology test is more reliable for exclusion of premalignant gastric conditions than a negative test for current H. pylori infection: A report on histology and H. pylori detection in the general adult population', Scandinavian Journal of Gastroenterology, 40 302-311 (2005) [C1]
DOI10.1080/00365520410010625
CitationsScopus - 35Web of Science - 34
2004Mearin F, Roset M, Badia X, Balboa A, Baro E, Ponce J, et al., 'Splitting irritable bowel syndrome: From original Rome to Rome II criteria', AMERICAN JOURNAL OF GASTROENTEROLOGY, 99 122-130 (2004)
DOI10.1046/j.1572-0241.2003.04024.xAuthor URL
CitationsScopus - 39Web of Science - 31
2004Locke GR, Weaver AL, Melton LJ, Talley NJ, 'Psychosocial factors are linked to functional gastrointestinal disorders: A population based nested case-control study', AMERICAN JOURNAL OF GASTROENTEROLOGY, 99 350-357 (2004)
DOI10.1111/j.1572-0241.2004.04043.xAuthor URL
CitationsScopus - 193Web of Science - 155
2004Talley NJ, Dennis EH, Schettler-Duncan VA, Lacy BE, Olden KW, Crowell MD, 'Overlapping symptoms in IBS: Reply', AMERICAN JOURNAL OF GASTROENTEROLOGY, 99 1192-1192 (2004)
DOI10.1111/j.1572-0241.2004.40463.xAuthor URL
2004Howell S, Talley NJ, Quine S, Poulton R, 'The irritable bowel syndrome has origins in the childhood socioeconomic environment', AMERICAN JOURNAL OF GASTROENTEROLOGY, 99 1572-1578 (2004)
DOI10.1111/j.1572-0241.2004.40188.xAuthor URL
CitationsScopus - 40Web of Science - 29
2004Delgado-Aros S, Locke GR, Camilleri M, Talley NJ, Fett S, Zinsmeister AR, Melton LJ, 'Obesity is associated with increased risk of gastrointestinal symptoms: A population-based study', AMERICAN JOURNAL OF GASTROENTEROLOGY, 99 1801-1806 (2004)
DOI10.1111/j.1572-0241.2004.30887.xAuthor URL
CitationsScopus - 128Web of Science - 115
2004Talley NJ, Howell S, Poulton R, 'Obesity and chronic gastrointestinal tract symptoms in young adults: A birth cohort study', AMERICAN JOURNAL OF GASTROENTEROLOGY, 99 1807-1814 (2004)
DOI10.1111/j.1572-0241.2004.30388.xAuthor URL
CitationsScopus - 91Web of Science - 79
2004Rohrbock RBK, Hammer J, Vogelsang H, Talley NJ, Hammer HF, 'Acupuncture has a placebo effect on rectal perception but not on distensibility and spatial summation: A study in health and IBS', AMERICAN JOURNAL OF GASTROENTEROLOGY, 99 1990-1997 (2004)
DOI10.1111/j.1572-0241.2004.30028.xAuthor URL
CitationsScopus - 24Web of Science - 18
2004Richter JE, Talley NJ, 'ACG Action Plan', American Journal of Gastroenterology, 99 573-573 (2004)
DOI10.1111/j.1572-0241.2004.4108a.x
2004Mann NS, Talley NJ, Dennis EH, Schettler-Duncan VA, Lacy BE, Olden KW, Crowell MD, 'Upper GI symptoms in patients with irritable bowel syndrome [1] (multiple letters)', American Journal of Gastroenterology, 99 1191-1192 (2004)
DOI10.1111/j.1572-0241.2004.40240.x
CitationsScopus - 1
2004Talley N, Richter JE, Achkar E, 'What's hot in the journal: Editors' comments', American Journal of Gastroenterology, 99 1411-1411 (2004)
CitationsScopus - 1
2004Richter J, Talley N, 'American Journal of Gastroenterology 2004: A new look, editorial team, and publishers.', American Journal of Gastroenterology, 99 3-5 (2004) [C1]
DOI10.1046/j.1572-0241.2003.04028.x
CitationsScopus - 1Web of Science - 1
2004Feinle-Bisset C, Vozzo R, Horowitz M, Talley N, 'Diet, food intake and disturbed physiology in the pathogenesis of symptoms in functional dyspepsia', American Journal of Gastroenterology, 99 170-181 (2004)
DOI10.1046/j.1572-0241.2003.04003.x
CitationsScopus - 72Web of Science - 59
2004Talley N, 'Antidepressants in IBS: Are we deluding ourselves?', American Journal of Gastroenterology, 99 921-923 (2004) [C1]
DOI10.1111/j.1572-0241.2004.04128.x
CitationsScopus - 19Web of Science - 18
2004Talley NJ, Richter JE, 'The Journal's Impact Increases!', American Journal of Gastroenterology, 99 1867-1868 (2004) [C1]
DOI10.1111/j.1572-0241.2004.41073.x
CitationsScopus - 2
2004Talley N, Richter JE, Achkar E, 'Editors' comments. GI fellowship matching program.', The American journal of gastroenterology, 99 1411-1411 (2004)
CitationsScopus - 1
2004Peura DA, Kovacs TOG, Metz DC, Siepman N, Pilmer BL, Talley NJ, 'Lansoprazole in the treatment of functional dyspepsia: Two double-blind, randomized, placebo-controlled trials', AMERICAN JOURNAL OF MEDICINE, 116 740-748 (2004)
DOI10.1016/j.amjmed.2004.01.008Author URL
CitationsScopus - 78Web of Science - 69
2004Koloski NA, Pachana N, Talley NJ, 'Psychological characteristics of older versus younger persons with a functional gastrointestinal disorder (FGID)', AUSTRALIAN JOURNAL OF PSYCHOLOGY, 56 198-198 (2004)
Author URL
2004Crowell MD, Lacy BE, Schettler VA, Dineen TN, Olden KW, Talley NJ, 'Subtypes of anal incontinence associated with bowel dysfunction: Clinical, physiologic, and psychosocial characterization', DISEASES OF THE COLON & RECTUM, 47 1627-1635 (2004)
DOI10.1007/s10350-004-0646-4Author URL
CitationsScopus - 6Web of Science - 5
2004Holtmann G, Siffert W, Haag S, Mueller N, Langkafel M, Senf W, et al., 'G-protein beta 3 subunit 825 CC genotype is associated with unexplained (functioncal) dyspepsia', GASTROENTEROLOGY, 126 971-979 (2004)
DOI10.1053/j.gastro.2004.01.006Author URL
CitationsScopus - 156Web of Science - 130
2004Talley NJ, 'Proteinase activated receptor 2: A protean effector comes of age', GASTROENTEROLOGY, 126 1907-1909 (2004)
Author URL
2004Moayyedi P, Delany B, Vakil N, Forman D, Talley N, 'The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis', Gastroenterology, 127 1329-1337 (2004) [C1]
DOI10.1053/j.gastro.2004.08.026
CitationsScopus - 144Web of Science - 104
2004Talley NJ, 'Unnecessary abdominal and back surgery in irritable bowel syndrome: Time to stem the flood now?', Gastroenterology, 126 1899-1903 (2004) [C1]
DOI10.1053/j.gastro.2004.04.029
CitationsScopus - 14Web of Science - 11
2004Hammer J, Eslick GD, Howell SC, Altiparmak E, Talley NJ, 'Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia', GUT, 53 666-672 (2004)
DOI10.1136/gut.2003.021857Author URL
CitationsScopus - 105Web of Science - 72
2004Howell SC, Eslick GD, Talley NJ, 'Cluster's last stand', GUT, 53 773-774 (2004)
Author URL
CitationsWeb of Science - 1
2004Haag S, Talley NJ, Holtmann G, 'Symptom patterns in functional dyspepsia and irritable bowel syndrome: relationship to disturbances in gastric emptying and response to a nutrient challenge in consulters and non-consulters', GUT, 53 1445-1451 (2004)
DOI10.1136/gut.2003.030049Author URL
CitationsScopus - 38Web of Science - 27
2004Dent J, Armstrong D, Delaney B, Moayyedi P, Talley N, Vakil N, 'Symptom evaluation in reflux disease: workshop background, process, terminology, recommendations, and discussion outputs', Gut, 53 1-24 (2004) [C1]
DOI10.1136/gut.2003.034272
CitationsScopus - 96Web of Science - 79
2004Locke GR, Murray JA, Zinsmeister AR, Melton LJ, Talley NJ, 'Celiac disease serology in irritable bowel syndrome and dyspepsia: A population-based case-control study', MAYO CLINIC PROCEEDINGS, 79 476-482 (2004)
Author URL
CitationsScopus - 72Web of Science - 61
2004Locke GR, Talley NJ, Murray JA, Zinsmeister AR, Melton LJ, 'Celiac disease serology and irritable bowel syndrome: Does the relationship merit further evaluation? Reply', MAYO CLINIC PROCEEDINGS, 79 1210-1210 (2004)
Author URL
CitationsScopus - 6
2004Vege SS, Locke GR, Weaver AL, Farmer SA, Melton LJ, Talley NJ, 'Functional gastrointestinal disorders among people with sleep disturbances: A population-based study', MAYO CLINIC PROCEEDINGS, 79 1501-1506 (2004)
Author URL
CitationsScopus - 37Web of Science - 30
2004Cremonini F, Talley N, 'Diagnostic and therapeutic strategies in the irritable bowel syndrome', Minerva Medica, 95 427-441 (2004) [C1]
CitationsScopus - 15
2004Aro P, Ronkainen J, Storskrubb T, Bolling-Sternevald E, Svardsudd K, Talley NJ, et al., 'Validation of the translation and cross-cultural adaptation into Finnish of the Abdominal Symptom Questionnaire, the Hospital Anxiety and Depression Scale and the Complaint Score Questionnaire', SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 39 1201-1208 (2004)
DOI10.1080/00365520410008132Author URL
CitationsScopus - 19Web of Science - 19
2004Aro P, Ronkainen J, Storskrubb T, Bolling-Sternevald E, Carlsson R, Johansson SE, et al., 'Valid symptom reporting at upper endoscopy in a random sample of the Swedish adult general population: the Kalixanda study', SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 39 1280-1288 (2004)
DOI10.1080/00365520410008141Author URL
CitationsScopus - 56Web of Science - 54
2004Talley N, Vakil N, Delaney B, Marshall B, Bytzer P, Engstrand L, et al., 'Management issues in dyspepsia: current consensus and controversies', Scandinavian Journal of Gastroenterology, 39 913-918 (2004) [C1]
DOI10.1080/00365520410003452
CitationsScopus - 20Web of Science - 16
2004Holtmann G, Kutscher SU, Haag S, Langkafel M, Heuft G, Neufang-Hueber J, et al., 'Clinical presentation and personality factors are predictors of the response to treatment in patients with functional dyspepsia - A randomized, double-blind placebo-controlled crossover study', DIGESTIVE DISEASES AND SCIENCES, 49 672-679 (2004)
DOI10.1023/B:DDAS.0000026317.00071.75Author URL
CitationsScopus - 28Web of Science - 27
2004Eslick GD, Howell SC, Hammer J, Talley NJ, 'Empirically derived symptom sub-groups correspond poorly with diagnostic criteria for functional dyspepsia and irritable bowel syndrome. A factor and cluster analysis of a patient sample', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 19 133-140 (2004)
DOI10.1046/j.1365-2036.2003.01805.xAuthor URL
CitationsScopus - 30Web of Science - 20
2004Halder SLS, Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ, 'Impact of functional gastrointestinal disorders on health-related quality of life: a population-based case-control study', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 19 233-242 (2004)
DOI10.1111/j.0269-2813.2004.01807.xAuthor URL
CitationsScopus - 112Web of Science - 91
2004Locke GR, Yawn BP, Wollan PC, Melton LJ, Lydick E, Talley NJ, 'Incidence of a clinical diagnosis of the irritable bowel syndrome in a United States population', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 19 1025-1031 (2004)
DOI10.1111/j.1365-2036.2004.01938.xAuthor URL
CitationsScopus - 44Web of Science - 24
2004Armstrong D, Talley NJ, Lauritsen K, Moum B, Lind T, Tunturi-Hihnala H, et al., 'The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 20 413-421 (2004)
DOI10.1111/j.1365-2036.2004.02085.xAuthor URL
CitationsScopus - 67Web of Science - 60
2004Nandurkar S, Locke GR, Fett S, Zinsmeister AR, Cameron AJ, Talley NJ, 'Relationship between body mass index, diet, exercise and gastro-oesophageal reflux symptoms in a community', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 20 497-505 (2004)
DOI10.1111/j.1365-2036.2004.02156.xAuthor URL
CitationsScopus - 89Web of Science - 62
2004Eslick GD, Talley NJ, 'Non-cardiac chest pain: predictors of health care seeking, the types of health care professional consulted, work absenteeism and interruption of daily activities', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 20 909-915 (2004)
DOI10.1111/j.1365-2036.2004.02175.xAuthor URL
CitationsScopus - 51Web of Science - 42
2004Talley N, 'What the physician needs to know for correct management of gastroesophageal reflux disease and dyspepsia.', Alimentary Pharmacology and Therapeutics, 20 23-30 (2004) [C1]
CitationsScopus - 11Web of Science - 11
2004Dent J, Talley N, 'Clinical strategies-interactive case discussions', Alimentary Pharmacology and Therapeutics, 20 97-104 (2004) [C1]
DOI10.1111/j.1365-2036.2004.02141.x
2004Talley N, 'Practical examples: trials and conclusions - an interactive segment', Alimentary Pharmacology and Therapeutics, 20 9-13 (2004) [C1]
DOI10.1111/j.1365-2036.2004.02137.x
2004Talley N, 'Gastro-esophageal reflux disease: how wide is its span?', Alimentary Pharmacology and Therapeutics, 20 27-37 (2004) [C1]
CitationsWeb of Science - 13
2004El-Serag H, Talley N, 'Prevalence and clinical course of functional dyspepsia: A systematic review', Alimentary Pharmacology and Therapeutics, 19 643-654 (2004) [C1]
DOI10.1111/j.1365-2036.2004.01897.x
CitationsScopus - 174Web of Science - 137
2004Cremonini F, Talley N, 'The overlap between functional dyspepsia and irritable bowel syndrome: a tale of one or two disorders?', Alimentary Pharmacology and Therapeutics, 20 40-49 (2004) [C1]
DOI10.1111/j.1365-2036.2004.02184.x
CitationsScopus - 64Web of Science - 38
2004Xia HHX, Wong BCY, Zhang GS, Yang Y, Wyatt JM, Adams S, et al., 'Antralization of gastric incisura is topographically associated with increased gastric epithelial apoptosis and proliferation, but not with CagA seropositivity', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 19 1257-1263 (2004)
DOI10.1111/j.1400-1746.2004.03489.xAuthor URL
CitationsScopus - 5Web of Science - 4
2004Fock K, Talley N, Hunt R, Fass R, Nandurkar S, Lam S, et al., 'Report of the Asia- Pacific consensus on the management of gastroesophageal reflux disease', Journal of Gastroenterology and Hepatology, 19 357-367 (2004) [C1]
DOI10.1111/j.1440-1746.2004.03419.x
CitationsScopus - 76Web of Science - 67
2004Friedrich WN, Whiteside SP, Talley NJ, 'Noncoercive sexual contact with similarly aged individuals - What is the impact?', JOURNAL OF INTERPERSONAL VIOLENCE, 19 1075-1084 (2004)
DOI10.1177/0886260504267583Author URL
CitationsScopus - 3Web of Science - 2
2004Haag S, Tagay S, Hauser W, Langkafel M, Grandt D, Heuft G, et al., 'Quality of life in chronic illness - Comparison of functional dyspepsia and chronic liver disease', PSYCHOTHERAPIE PSYCHOSOMATIK MEDIZINISCHE PSYCHOLOGIE, 54 93-93 (2004)
Author URL
2004Talley N, 'Critical evaluation - Clinical trials and practice: Discussion', Alimentary Pharmacology and Therapeutics, Supplement, 20 38-39 (2004)
2004Talley NJ, 'Review article: Gastro-oesophageal reflux disease - How wide is its span?', Alimentary Pharmacology and Therapeutics, Supplement, 20 27-37 (2004)

Symptoms of gastro-oesophageal reflux disease are highly prevalent in Western countries; however, it is less certain how many individuals with heartburn have clinically relevant d... [more]

Symptoms of gastro-oesophageal reflux disease are highly prevalent in Western countries; however, it is less certain how many individuals with heartburn have clinically relevant disease. Although the prevalence of gastro-oesophageal reflux disease in Asia is substantially lower, the incidence may be increasing. How much of this increase is explained by the increasing recognition of heartburn in clinical practice, dietary changes and increasing obesity, or the eradication of Helicobacter pylori, remains unclear. There has been speculation that endoscopy-negative reflux disease represents a separate entity from reflux oesophagitis (as defined by the Los Angeles classification), but the evidence that might support this proposal is unconvincing. Patients with chronic reflux symptoms have a higher risk of Barrett's oesophagus, and the increased risk of developing oesophageal adenocarcinoma in individuals with a long history of heartburn is also well documented, but whether this always occurs via Barrett's oesophagus is debatable. Moreover, treatment with standard-dose antisecretory therapies and anti-reflux surgery seems unlikely, based on current evidence, to reduce the cancer risk in patients with Barrett's oesophagus. Gastro-oesophageal reflux disease has also been implicated in an increasing array of other conditions, but arguably in these settings it is often over-diagnosed.

CitationsScopus - 13
2004Revicki DA, Rentz AM, Dubois D, Kahrilas P, Stanghellini V, Talley NJ, Tack J, 'Gastroparesis Cardinal Symptom Index (GCSI): Development and validation of a patient reported assessment of severity of gastroparesis symptoms', QUALITY OF LIFE RESEARCH, 13 833-844 (2004)
DOI10.1023/B:QURE.0000021689.86296.e4Author URL
CitationsScopus - 87Web of Science - 82
2004Rentz AM, Kahrilas P, Stanghellini V, Tack J, Talley NJ, de la Loge C, et al., 'Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders', QUALITY OF LIFE RESEARCH, 13 1737-1749 (2004)
DOI10.1007/s11136-004-9567-xAuthor URL
CitationsScopus - 70Web of Science - 66
2004de la Loge C, Trudeau E, Marquis P, Kahrilas P, Stanghellini V, Talley NJ, et al., 'Cross-cultural development and validation of a patient self-administered questionnaire to assess quality of life in upper gastrointestinal disorders: The PAGI-QOL (c)', QUALITY OF LIFE RESEARCH, 13 1751-1762 (2004)
DOI10.1007/s11136-004-8751-3Author URL
CitationsScopus - 36Web of Science - 29
2004Talley N, 'Irritable bowel syndrome remains a difficult condition to manage', Drug Benefit Trends, 16 313-322 (2004) [C1]
CitationsScopus - 1
2004Delgado-Aros S, Cremonini F, Talley N, 'Treatment of functional dyspepsia', Current Treatment Options in Gastroenterology, 7 121-131 (2004) [C1]
CitationsScopus - 9
2004Talley NJ, Quan C, Jones MP, Horowitz M, 'Association of upper and lower gastrointestinal tract symptoms with body mass index in an Australian cohort', NEUROGASTROENTEROLOGY AND MOTILITY, 16 413-419 (2004)
DOI10.1111/j.1365-2982.2004.00530.xAuthor URL
CitationsScopus - 53Web of Science - 44
2004Camilleri M, Talley N, 'Pathophysiology as a basis for understanding symptom complexes and therapeutic targets', Neurogastroenterology and Motility, 16 135-142 (2004) [C1]
DOI10.1111/j.1365-2982.2004.00516.x
CitationsScopus - 60Web of Science - 49
2004Crowell MD, Shetzline MA, Moses PL, Mawe GM, Talley NJ, 'Enterochromaffin cells and 5-HT signaling in the pathophysiology of disorders of gastrointestinal function', Current Opinion in Investigational Drugs, 5 55-60 (2004)

Disorders of gastrointestinal function are common and significantly reduce quality-of-life, as well as negatively impacting healthcare costs. Consequently, there is much interest ... [more]

Disorders of gastrointestinal function are common and significantly reduce quality-of-life, as well as negatively impacting healthcare costs. Consequently, there is much interest in understanding the pathogenesis of these disorders. Increasing, albeit as yet limited, evidence has implicated alterations in 5-hydroxytryptamine (5-HT) release, and the subsequent interaction of 5-HT with specific 5-HT receptor subtypes, in the altered gut function of patients with irritable bowel syndrome (IBS) and other functional bowel diseases. Alterations to enterochromaffin cells and/or 5-HT signaling can result in gastrointestinal dysmotility, visceral hypersensitivity and secretomotor abnormalities in the gut. Evidence is beginning to link disturbed 5-HT physiology with the pathophysiology of diarrhea and constipation in IBS, and with slow-transit constipation. This review discusses the current evidence on the pathobiology of these systems. © Thomson Scientific.

CitationsScopus - 50
2004Crowell M, Shetzline M, Moses P, Mawe G, Talley N, 'Enterochromaffin cells and serotonin signaling in the pathophysiology of disorders of gastrointestinal function', Current Opinions in Investigational Drugs., 5 55-60 (2004) [C1]
2004Cremonini F, Delgado-Aros S, Talley N, 'Functional dyspepsia: drugs for new (and old) therapeutic targets', Best Practice and Research: Clinical Gastroenterology, 18 717-733 (2004) [C1]
DOI10.1016/j.bpg.2004.04.003
CitationsScopus - 26Web of Science - 21
2004Hanauer SB, Sandborn WJ, Davis GL, Keeffe EB, Vakil N, Katz PO, et al., 'Best of DDW 2004: Highlights from the 2004 Digestive Disease Week', Reviews in Gastroenterological Disorders, 4 129-161 (2004)
CitationsScopus - 1
2004Talley N, 'Management of chronic constipation', Reviews in Gastroenterological Disorders, 4 18-24 (2004) [C1]
CitationsScopus - 21
2004Talley N, 'Chronic constipation', Reviews in Gastroenterological Disorders, 4 18-24 (2004) [C3]
CitationsScopus - 1
2004Talley N, 'Functional gastrointestinal disorders', Reviews in Gastroenterological Disorders, 4 144-146 (2004) [C1]
2004Talley N, 'Definitions, epidemiology and impact of chronic constipation', Reviews in Gastroenterological Disorders, 4 3-10 (2004) [C1]
CitationsScopus - 88
2004Revicki DA, Rentz AM, Tack J, Stanghellini V, Talley NJ, Kahrilas P, et al., 'Responsiveness and Interpretation of a Symptom Severity Index Specific to Upper Gastrointestinal Disorders', CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2 769-777 (2004)
DOI10.1053/S1542-3565(04)00348-9Author URL
CitationsScopus - 39Web of Science - 35
2004de la Loge C, Trudeau E, Marquis P, Revicki DA, Rentz AM, Stanghellini V, et al., 'Responsiveness and Interpretation of a Quality of Life Questionnaire Specific to Upper Gastrointestinal Disorders', CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2 778-786 (2004)
DOI10.1053/S1542-3565(04)00349-0Author URL
CitationsScopus - 26Web of Science - 23
2003Saito YA, Talley NJ, Melton LJ, Fett S, Zinsmeister AR, Locke GR, 'The effect of new diagnostic criteria for irritable bowel syndrome on community prevalence estimates', NEUROGASTROENTEROLOGY AND MOTILITY, 15 687-694 (2003)
DOI10.1046/j.1350-1925.2003.00441.xAuthor URL
CitationsScopus - 57Web of Science - 43
2003Weltman M, Talley N, 'Chronic hepatitis C infection: a review and update on treatment strategies', ADF Health, 4 27-33 (2003) [C1]
2003Wiklund I, Talley N, 'Update on health-related quality of life in patients with gastroesophageal reflux disease (GERD)', Expert Review of Pharmacoeconomics and Outcomes Research: informing decision-making in the delivery of cost-effective healthcare, 3 341-350 (2003) [C1]
DOI10.1586/14737167.3.3.341
CitationsScopus - 35
2003Katelaris PH, Forbes GM, Talley NJ, Peek Jr RM, 'The superiority of proton pump inhibitor-based regimens for Helicobacter pylori eradication: Comment', Evidence-Based Gastroenterology, 4 46-47 (2003)
DOI10.1097/00132579-200305000-00006
2003Hanauer SB, Hawes RH, Katz PO, Sandborn WJ, Talley NJ, Vakil N, 'Highlights from the 2003 digestive disease week. Best of DDW 2003', Reviews in Gastroenterological Disorders, 3 158-179 (2003)
2003Talley N, 'Establishing irritable bowel syndrome as a clinical diagnosis', Reviews in Gastroenterological Disorders, 3 1-2 (2003) [C1]
2003Talley N, 'When to conduct testing in patients with suspected irritable bowel syndrome', Reviews in Gastroenterological Disorders, 3 18-24 (2003) [C1]
CitationsScopus - 12
2003Talley N, 'Best of DDW 2003. New insights on treatment of irritable bowel syndrome and functional dyspepsia', Reviews in Gastroenterological Disorders, 3 172-175 (2003) [C1]
2003Talley N, 'Update on the Role of Drug Therapy in Non-Ulcer Dyspepsia', Reviews in Gastroenterological Disorders, 3 25-30 (2003) [C1]
CitationsScopus - 15
2003Talley NJ, 'Target the brain to get the gain?', Reviews in gastroenterological disorders, 3 182-184 (2003)
2003Talley N, 'SSRIs in IBS: sensing a dash of disappointment', Clinical Gastroenterology and Hepatology, 1 155-159 (2003) [C1]
DOI10.1053/jcgh.2003.50023
CitationsScopus - 15Web of Science - 10
2003Talley N, 'Functional Disorders. Target the brain to get the gain?', Reviews in Gastrointestinal Disorders, 3 182-184 (2003) [C1]
2003Hammer J, Howell S, Bytzer P, Horowitz M, Talley NJ, 'Symptom clustering in subjects with and without diabetes mellitus: A population-based study of 15,000 Australian adults', AMERICAN JOURNAL OF GASTROENTEROLOGY, 98 391-398 (2003)
DOI10.1016/S0002-9270(02)05904-XAuthor URL
CitationsScopus - 20Web of Science - 23
2003Talley NJ, Jones M, Nuyts G, Dubois D, 'Risk factors for chronic constipation based on a general practice sample', AMERICAN JOURNAL OF GASTROENTEROLOGY, 98 1107-1111 (2003)
DOI10.1016/S0002-9270(03)00239-9Author URL
CitationsScopus - 100Web of Science - 71
2003Talley NJ, Dennis EH, Schettler-Duncan VA, Lacy BE, Olden KW, Crowell MD, 'Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea', AMERICAN JOURNAL OF GASTROENTEROLOGY, 98 2454-2459 (2003)
DOI10.1016/S0002-9270(03)00705-6Author URL
CitationsScopus - 151Web of Science - 121
2003Talley N, 'Diabetic gastropathy and prokinetics', American Journal of Gastroenterology, 98 264-271 (2003) [C1]
DOI10.1016/S0002-9270(02)05936-1
CitationsScopus - 59Web of Science - 46
2003Moayyedi P, Deeks J, Talley N, Delaney B, Forman D, 'An update of the Cochrane systematic review of Helicobactor pylori eradication therapy in non-ulcer dyspepsia. Resolving the discrepancy between systematic reviews', American Journal of Gastroenterology, 98 2621-2626 (2003) [C1]
DOI10.1016/j.amjgastroenterol.2003.07.003
CitationsScopus - 139Web of Science - 102
2003Talley NJ, 'Pharmacologic therapy for the irritable bowel syndrome.', American Journal of Gastroenterology, 750-758 (2003) [C1]
DOI10.1016/S0002-9270(02)06028-8
CitationsScopus - 71Web of Science - 49
2003Boyce PM, Talley NJ, Balaam B, Koloski NA, Truman G, 'A Randomized Controlled Trial of Cognitive Behavior Therapy, Relaxation Training, and Routine Clinical Care for the Irritable Bowel Syndrome', American Journal of Gastroenterology, 98 2209-2218 (2003) [C1]
DOI10.1111/j.1572-0241.2003.07716.x
CitationsScopus - 80Web of Science - 63
2003Koloski NA, Talley NJ, Boyce PM, 'Does psychological distress modulate functional gastrointestinal symptoms and health care seeking? A prospective, community cohort study', American Journal of Gastroenterology, 98 789-797 (2003) [C1]
DOI10.1111/j.1572-0241.2003.07388.x
CitationsScopus - 62Web of Science - 52
2003Chitkara D, Talley NJ, 'Differential p38 mitogen-activated protein kinase target phosphorylation in responders and nonresponders to infliximab - Reply', GASTROENTEROLOGY, 125 635-636 (2003)
DOI10.1016/S0016-5085(03)00980-6Author URL
2003Chitkara D, Talley NJ, 'Hypnotherapy for functional dyspepsia: Do the results add up?', GASTROENTEROLOGY, 125 636-636 (2003)
DOI10.1016/S0016-5085(03)00981-8Author URL
CitationsScopus - 1Web of Science - 1
2003Katelaris PH, Forbes GM, Talley NJ, Crotty B, 'The QUADRATE study: A proposal for a change in the reporting of pharmaceutical supported trials - Reply', GASTROENTEROLOGY, 125 640-641 (2003)
DOI10.1016/S0016-5085(03)00985-5Author URL
2003Chitkara DK, Cremonini F, Talley NJ, 'Psychotherapy and paroxetine: Cost effective for severe IBS, or a waste of resources', GASTROENTEROLOGY, 125 1554-1555 (2003)
DOI10.1053/S0016-5085(03)01403-3Author URL
CitationsScopus - 4Web of Science - 2
2003Graham DY, Dore MP, Katelaris PH, Forbes GM, Talley NJ, Crotty B, 'The QUADRATE study: A proposal for a change in the reporting of pharmaceutical supported trials [8] (multiple letters)', Gastroenterology, 125 639-641 (2003)
DOI10.1016/S0016-5085(03)00984-3
CitationsScopus - 2
2003Talley N, 'Dyspepsia.', Gastroenterology, 125 1219-1226 (2003) [C1]
DOI10.1016/j.gastro.2003.07.001
CitationsScopus - 34Web of Science - 19
2003Locke GR, Zinsmeister AR, Talley NJ, 'Can symptoms predict endoscopic findings in GERD?', GASTROINTESTINAL ENDOSCOPY, 58 661-670 (2003)
DOI10.1016/S0016-5107(03)02011-XAuthor URL
CitationsScopus - 58Web of Science - 53
2003Talley N, 'Yield of endoscopy in dyspepsia and concurrent treatment with proton pump inhibitors: the blind leading the blind?', Gastrointestinal Endoscopy, 58 89-92 (2003) [C1]
DOI10.1067/mge.2003.302
CitationsScopus - 4Web of Science - 2
2003Kalantar JS, Locke GR, Zinsmeister AR, Beighley CM, Talley NJ, 'Familial aggregation of irritable bowel syndrome: a prospective study', GUT, 52 1703-1707 (2003)
DOI10.1136/gut.52.12.1703Author URL
CitationsScopus - 99Web of Science - 85
2003Howell S, Poulton R, Caspi A, Talley NJ, 'Relationship between abdominal pain subgroups in the community and psychiatric diagnosis and personality - A birth cohort study', JOURNAL OF PSYCHOSOMATIC RESEARCH, 55 179-187 (2003)
DOI10.1016/S0022-3999(02)00599-8Author URL
CitationsScopus - 3Web of Science - 4
2003Howell SC, Quine S, Talley NJ, 'Ethics review and use of reminder letters in postal surveys: are current practices compromising an evidence-based approach?', MEDICAL JOURNAL OF AUSTRALIA, 178 43-43 (2003)
Author URL
CitationsScopus - 9Web of Science - 7
2003Talley NJ, Dent J, 'Chairmen's introduction: extending the opportunities for better clinical outcomes', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 17 V-V (2003)
DOI10.1046/j.1365-2036.17.s1.11.xAuthor URL
2003Xia HHX, Talley NJ, Blum AL, O'Morain CA, Stolte M, Bolling-Sternevald E, Mitchell HM, 'Clinical and pathological implications of IgG antibody responses to Helicobacter pylori and its virulence factors in non-ulcer dyspepsia', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 17 935-943 (2003)
DOI10.1046/j.0269-2813.2003.01525.xAuthor URL
CitationsScopus - 8Web of Science - 9
2003Eslick GD, Jones MP, Talley NJ, 'Non-cardiac chest pain: prevalence, risk factors, impact and consulting - a population-based study', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 17 1115-1124 (2003)
DOI10.1046/j.0269-2813.2003.01557.xAuthor URL
CitationsScopus - 137Web of Science - 109
2003Westbrook JI, Talley NJ, 'Diagnostic investigation rates and use of prescription and non-prescription medications amongst dyspeptics: a population-based study of 2300 Australians', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 17 1171-1178 (2003)
DOI10.1046/j.0269-2813.2003.01555.xAuthor URL
CitationsScopus - 13Web of Science - 9
2003Quan C, Talley NJ, Cross S, Jones M, Hammer J, Giles N, Horowitz M, 'Development and validation of the Diabetes Bowel Symptom Questionnaire', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 17 1179-1187 (2003)
DOI10.1046/j.0269-2813.2003.01553.xAuthor URL
CitationsScopus - 11Web of Science - 12
2003Kalantar JS, Locke GR, Talley NJ, Zinsmeister AR, Fett SL, Melton LJ, 'Is irritable bowel syndrome more likely to be persistent in those with relatives who suffer from gastrointestinal symptoms? A population-based study at three time points', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 17 1389-1397 (2003)
DOI10.1046/j.1365-2036.2003.01591.xAuthor URL
CitationsScopus - 17Web of Science - 11
2003Bolling-Sternevald E, Lauritsen K, Talley NJ, Junghard O, Glise H, 'Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia?', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 18 117-124 (2003)
DOI10.1046/j.0269-2813.2003.01651.xAuthor URL
CitationsScopus - 30Web of Science - 24
2003Revicki DA, Rentz AM, Dubois D, Kahrilas P, Stanghellini V, Talley NJ, Tack J, 'Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 18 141-150 (2003)
DOI10.1046/j.0269-2813.2003.01612.xAuthor URL
CitationsScopus - 125Web of Science - 105
2003El-Serag H, Talley N, 'Systematic review: health-related quality of life in functional dyspepsia', Alimentary Pharmacology and Therapeutics, 18 387-393 (2003) [C1]
DOI10.1046/j.0269-2813.2003.01706.x
CitationsScopus - 79Web of Science - 68
2003Dent J, Talley N, 'Overview: initial and long-term management of gastro-oesophageal reflux disease', Alimentary Pharmacology and Therapeutics, 17 53-57 (2003) [C1]
DOI10.1046/j.1365-2036.17.s1.10.x
CitationsScopus - 20Web of Science - 12
2003Koloski NA, Talley NJ, Huskic SS, Boyce PM, 'Predictors of conventional and alternative health care seeking for irritable bowel syndrome and functional dyspepsia', Alimentary Pharmacology and Therapeutics, 17 841-851 (2003) [C1]
DOI10.1046/j.1365-2036.2003.01498.x
CitationsScopus - 78Web of Science - 55
2003Talley NJ, 'Evaluation of drug treatment in irritable bowel syndrome (vol 56, pg 362, 2003)', BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 56 584-584 (2003)
Author URL
2003Talley N, 'Evaluation of drug treatment in irritable bowel syndrome', British Journal of Clinical Pharmacology, 56 362-369 (2003) [C1]
DOI10.1046/j.1365-2125.2003.01966.x
CitationsScopus - 48Web of Science - 33
2003Talley N, 'Helicobacter pylori management: how to improve the therapeutic confusion in practice', Canadian Journal of Gastroenterology, 17 21-24 (2003) [C1]
CitationsScopus - 2
2003Muller-Lissner S, Koch G, Talley NJ, Drossman D, Rueegg P, Dunger-Baldauf C, Lefkowitz M, 'Subject's Global Assessment of Relief: An appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials', JOURNAL OF CLINICAL EPIDEMIOLOGY, 56 310-316 (2003)
DOI10.1016/S0895-4356(03)00027-1Author URL
CitationsScopus - 46Web of Science - 37
2003Mearin F, Balboa A, Badia X, Baro E, Caldwell E, Cucala M, et al., 'Irritable bowel syndrome subtypes according to bowel habit: revisiting the alternating subtype', EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 15 165-172 (2003)
DOI10.1097/01.meg.0000049985.90403.87Author URL
CitationsScopus - 80Web of Science - 60
2003Talley NJ, 'Omeprazole was effective in the short term for uninvestigated dyspepsia.', ACP journal club, 138 70 (2003)
2003Weltman M, Talley N, 'An approach to recurrent, non-identifiable GI bleeding', New Ethics Journal, - 57-63 (2003) [C1]
2002Talley NJ, 'Dyspepsia management in the millennium: The death of test and treat?', GASTROENTEROLOGY, 122 1521-1525 (2002)
DOI10.1053/gast.2002.33370Author URL
CitationsScopus - 26Web of Science - 18
2002Halder SLS, Locke G, Talley NJ, Weaver AL, Fett SL, Zinsmeister AR, 'The impact of functional gastrointestinal disorders on health-related quality of life: A population-based case-control study', GASTROENTEROLOGY, 122 A91-A91 (2002)
Author URL
2002Ronkainen JA, Aro P, Storskrubb T, Vieth M, Lind T, Graffner H, et al., 'Prevalence of esophagitis and endoscopy-negative reflux disease in a population. A report from the Kalixanda study', GASTROENTEROLOGY, 122 A213-A213 (2002)
Author URL
CitationsWeb of Science - 7
2002Holtmann G, Saadat-Gilani K, Buenger L, Gschossmann JM, Gerken G, Talley NJ, 'Disturbed opioidergic antinociceptive pathways in patients with functional dyspepsia', GASTROENTEROLOGY, 122 A312-A312 (2002)
Author URL
CitationsWeb of Science - 1
2002Eslick GD, Kalantar JS, Talley NJ, 'Prevalence, risk factors, and health care seeking for rectal bleeding: A population-based study', GASTROENTEROLOGY, 122 A446-A446 (2002)
Author URL
2002Eslick GD, Jones MP, Talley NJ, 'Stability of gastrointestinal symptoms, psychological and quality of life risk factors among patients with non-cardiac chest pain (NCCP): A prospective cohort study', GASTROENTEROLOGY, 122 A466-A466 (2002)
Author URL
CitationsWeb of Science - 2
2002Agreus L, Talley NJ, Aro P, Storskrubb T, Ronkainen J, Bolling-Sternevald E, 'The Rome II dyspepsia definition using both pain and discomfort as descriptors seems relevant in population based studies.', GASTROENTEROLOGY, 122 A472-A472 (2002)
Author URL
2002Koloski NA, Talley NJ, Huskic SS, Boyce PM, 'Is a history of abuse or psychological distress more important in explaining irritable bowel syndrome (IBS)/functional dyspepsia (FD)?', GASTROENTEROLOGY, 122 A503-A503 (2002)
Author URL
2002Howell S, Talley NJ, Poulton R, 'Does a history of stomach and bowel complaints over the first 21 years of life predict Manning Criteria IBS at age 26?', GASTROENTEROLOGY, 122 A504-A504 (2002)
Author URL
2002Eslick GD, Howell SC, Hammer J, Talley NJ, 'Predictors of irritable bowel syndrome (IBS) and non-ulcer dyspepsia (NUD) in patients: A non-hierarchical cluster analysis model', GASTROENTEROLOGY, 122 A504-A505 (2002)
Author URL
2002Koloski NA, Talley NJ, Huskic SS, Boyce PM, 'Are irritable bowel syndrome (IBS) subgroups stable over time?', GASTROENTEROLOGY, 122 A507-A507 (2002)
Author URL
2002Aro PT, Ronkainen JA, Storskrubb T, Bolling-Sternevald E, Talley NJ, Agreus L, 'Findings at upper endoscopy in a random adult population. A report from the Kalixanda study.', GASTROENTEROLOGY, 122 A568-A568 (2002)
Author URL
CitationsWeb of Science - 6
2002Howell S, Talley NJ, 'Socioeconomic class predicts membership of GI symptom cluster groups: A population based study of 15,000 Australian adults.', GASTROENTEROLOGY, 122 A571-A571 (2002)
Author URL
2002Quan C, Talley NJ, Jones L, Howell S, Bernays S, Lewis J, Horowitz M, 'A longitudinal population study of gastrointestinal symptoms and glycemic control in diabetes mellitus', GASTROENTEROLOGY, 122 A571-A571 (2002)
Author URL
2002Tuteja AK, Joos SK, Talley NJ, Hickam DH, 'Association between functional dyspepsia and non-strenuous physical activity: A population based study', GASTROENTEROLOGY, 122 A571-A572 (2002)
Author URL
2002Bolling-Sternevald E, Aro P, Ronkainen J, Storskrubb T, Talley NJ, Junghard O, Agreus L, 'Short-term symptom fluctuation in a random adult population. A report from the Kalixanda study', GASTROENTEROLOGY, 122 A572-A572 (2002)
Author URL
2002Holtmann G, Gschossmann J, Buenger L, Gerken G, Talley NJ, 'Do changes in visceral sensory function determine the development of dyspepsia during treatment with aspirin?', GASTROENTEROLOGY, 123 1451-1458 (2002)
DOI10.1053/gast.2002.36556Author URL
CitationsScopus - 42Web of Science - 33
2002Katelaris PH, Forbes GM, Talley NJ, Crotty B, 'A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE study', GASTROENTEROLOGY, 123 1763-1769 (2002)
DOI10.1053/gast.2002.37051Author URL
CitationsScopus - 111Web of Science - 100
2002Talley NJ, Verlinden M, 'Motilin agonists and dyspepsia: throwing out the baby with the bath water - Reply', GUT, 51 612-613 (2002)
Author URL
CitationsScopus - 15Web of Science - 1
2002Axon ATR, Talley NJ, Veldhuyzen Van Zanten SJO, 'pH-Hp: Implications for dyspepsia management', Gut, 50 iv1-iv1 (2002) [C1]
2002Kalantar JS, Howell S, Talley NJ, 'Prevalence of faecal incontinence and associated risk factors', MEDICAL JOURNAL OF AUSTRALIA, 176 54-57 (2002)
Author URL
CitationsScopus - 126Web of Science - 98
2002Talley NJ, Moore MG, Sprogis A, Katelaris P, 'Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care', MEDICAL JOURNAL OF AUSTRALIA, 177 423-427 (2002)
Author URL
CitationsScopus - 14Web of Science - 15
2002Westbrook JI, Talley NJ, 'Empiric clustering of dyspepsia into symptom subgroups: a population-based study', SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 37 917-923 (2002)
DOI10.1080/003655202760230874Author URL
CitationsScopus - 38Web of Science - 32
2002Abeygunasekera SC, Talley NJ, 'Management of Dyspepsia', Comprehensive Therapy, 28 182-189 (2002) [C1]
2002Talley NJ, Spiller R, 'Irritable bowel syndrome: a little understood organic bowel disease?', LANCET, 360 555-564 (2002)
DOI10.1016/S0140-6736(02)09712-XAuthor URL
CitationsScopus - 186Web of Science - 154
2002Jones KL, Wishart JM, Berry M, Russo A, Xia HHX, Talley NJ, Horowitz M, 'Helicobacter pylori infection is not associated with delayed gastric emptying or upper gastrointestinal symptoms in diabetes mellitus', DIGESTIVE DISEASES AND SCIENCES, 47 704-709 (2002)
DOI10.1023/A:1014763210890Author URL
CitationsScopus - 18Web of Science - 14
2002Jones MP, Talley NJ, Nuyts G, Dubois D, 'Lack of objective evidence of efficacy of laxatives in chronic constipation', DIGESTIVE DISEASES AND SCIENCES, 47 2222-2230 (2002)
DOI10.1023/A:1020131126397Author URL
CitationsScopus - 94Web of Science - 62
2002Eslick GD, Coulshed DS, Talley NJ, 'Review article: The burden of illness of non-cardiac chest pain', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 16 1217-1223 (2002)
DOI10.1046/j.1365-2036.2002.01296.xAuthor URL
CitationsScopus - 75Web of Science - 65
2002Holtmann G, Gschossmann J, Mayr P, Talley NJ, 'A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 16 1641-1648 (2002)
DOI10.1046/j.1365-2036.2002.01322.xAuthor URL
CitationsScopus - 54Web of Science - 39
2002Eslick GD, Yan P, Xia HHX, Murray H, Spurrett B, Talley NJ, 'Foetal intrauterine growth restrictions with Helicobacter pylori infection', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 16 1677-1682 (2002)
DOI10.1046/j.1365-2036.2002.01333.xAuthor URL
CitationsScopus - 36Web of Science - 30
2002Weltman MD, Talley NJ, 'An approach to recurrent, non-identifiable GI bleeding', Current Therapeutics, 43 27-30+32 (2002)

Gastrointestinal tract bleeding is a common problem in clinical practice. Although the cause is usually identifiable, the source of bleeding still goes undetected in up to 30% of ... [more]

Gastrointestinal tract bleeding is a common problem in clinical practice. Although the cause is usually identifiable, the source of bleeding still goes undetected in up to 30% of patients in whom adequate and timely gastroscopy and colonoscopy have been performed. This article will concentrate on unexplained or occult gastrointestinal bleeding from the upper gastrointestinal tract and small bowel.

2002Katelaris P, Holloway R, Talley N, Gotley D, Williams S, Dent J, 'Gastro-oesophageal reflux disease in adults: Guidelines for clinicians', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 17 825-833 (2002)
Author URL
CitationsScopus - 44Web of Science - 32
2002Talley NJ, 'Natural history of reflux oesophagitis: What is the risk of progression and does it matter clinically?', Journal of Gastroenterology and Hepatology, 17 1247-1249 (2002) [C1]
CitationsScopus - 2Web of Science - 2
2002Talley NJ, Venables TL, Green JRB, Armstrong D, O'Kane KPJ, Giaffer M, et al., 'Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months', EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 14 857-863 (2002)
DOI10.1097/00042737-200208000-00008Author URL
CitationsScopus - 103Web of Science - 77
2002Waldum HL, Brenna E, Alberti HP, Jones R, Dent JM, Kahrilas PJ, Talley NJ, 'Gastro-oesophageal reflux disease in general practice [3] (multiple letters)', BMJ: British Medical Journal, 324 485-486 (2002) [C1]
CitationsScopus - 1
2002Coulshed DS, Eslick GD, Talley NJ, 'Non-cardiac chest pain - Patients need diagnoses', BRITISH MEDICAL JOURNAL, 324 915-915 (2002)
DOI10.1136/bmj.324.7342.915Author URL
CitationsScopus - 11Web of Science - 12
2002Coulshed DS, Eslick GD, Talley NJ, Mackenzie GM, 'Non-cardiac chest pain [5] (multiple letters)', British Medical Journal, 324 915-915 (2002)
CitationsScopus - 2
2002Westbrook JI, Talley NJ, Westbrook MT, 'Gender differences in the symptoms and physical and mental well-being of dyspeptics: A population based study', QUALITY OF LIFE RESEARCH, 11 283-291 (2002)
DOI10.1023/A:1015239020403Author URL
CitationsScopus - 28Web of Science - 24
2002Xia HHX, Wong BCY, Talley NJ, Lam SK, 'Alternative and rescue treatment regimens for Helicobacter pylori eradication', Expert Opinion on Pharmacotherapy, 3 1301-1311 (2002) [C1]
CitationsScopus - 40
2002Talley NJ, 'New and emerging treatments for irritable bowel syndrome and functional dyspepsia', Expert Opinion on Emerging Drugs, 7 91-98 (2002)

The symptomatic management of irritable bowel syndrome (IBS) and functional dyspepsia, which often overlap, can be frustrating and difficult. Education and reassurance remain cent... [more]

The symptomatic management of irritable bowel syndrome (IBS) and functional dyspepsia, which often overlap, can be frustrating and difficult. Education and reassurance remain central for management although controlled trials are lacking. Psychological interventions may be useful in select patients but methodological inadequacies in clinical trials limit their interpretability. For symptom exacerbations, drug treatment is reasonable but no current treatment successfully targets the full symptom complex. Bulking agents are not of proven efficacy in IBS; they may improve constipation but worsen bloating and pain. Anticholinergics are of uncertain value in IBS. A meta-analysis of trials of smooth muscle relaxants for IBS has been reported to be positive but the quality of the trials included was poor. Antidepressants for IBS and functional dyspepsia appear to be efficacious based on the limited published evidence; both global symptoms and abdominal pain improve. Selective serotonin reuptake inhibitors (SSRIs) are of uncertain efficacy but anecdotally appear to be useful. Laxatives are not of proven efficacy in IBS. Loperamide improves diarrhea, but not abdominal pain in IBS. No drug is of proven efficacy for bloating. Acid suppression remains the mainstay of therapy for functional dyspepsia but the majority of patients do not have an adequate response. Promising drugs include new prokinetics for constipation-predominant IBS (e.g., tegaserod, a partial 5-HT4 agonist, prucalopride, a full 5-HT4 agonist, and dexloxiglumide, a cholecystokinin1 antagonist), agents for diarrhea-predominant IBS (e.g., 5-HT3 antagonists, a2 receptor agonists and corticotrophin receptor-1 antagonists), other visceral analgesics (e.g. tachykinin antagonists, opioid agonists) and in dyspepsia fundus relaxing agents (e.g., 5-HT1, agonists, tegaserod).

DOI10.1517/14728214.7.1.91
CitationsScopus - 7
2002Bennett G, Talley NJ, 'Irritable Bowel Syndrome in the Elderly', Best Practice and Research: Clinical Gastroenterology, 16 63-76 (2002) [C1]
CitationsScopus - 19Web of Science - 12
2002Daneshjoo R, J Talley N, 'Eosinophilic gastroenteritis.', Current gastroenterology reports, 4 366-372 (2002)

Eosinophilic gastroenteritis is a rare gastrointestinal (GI) disorder of undetermined cause characterized by infiltration of eosinophils in the GI tract. Eosinophils accumulate in... [more]

Eosinophilic gastroenteritis is a rare gastrointestinal (GI) disorder of undetermined cause characterized by infiltration of eosinophils in the GI tract. Eosinophils accumulate in tissues and may release highly cytotoxic granular proteins, which cause severe tissue damage characteristic of eosinophilic gastroenteritis. Eotaxin may play a role in the recruitment of eosinophils into tissue in combination with chemoattractants and cytokines, including interleukin 3 and 5 and granulocyte-macrophage colony-stimulating factor. Food allergy, especially in children, can be a triggering factor, and an amino acid-based diet may be helpful. Accumulation of eosinophils in the gut is a common feature in food-induced GI disorders that can be regulated through a complex molecular network involving Th2 cells, various cytokines, and chemokines. Eosinophilic gastroenteritis has a wide spectrum of clinical presentation depending on the site of involvement. It may be confused with irritable bowel syndrome or dyspepsia and, rarely, mimics pancreatitis or appendicitis. Diagnosis is important and is usually made by a pathologist. Eosinophilic gastroenteritis is a treatable disease; patients generally respond to steroid therapy, although relapse is common. Non-enteric-coated budesonide, a locally acting corticosteroid with little risk of adrenal suppression, may be substituted, although more experience is needed. Promising new drugs for eosinophilic gastroenteritis include montelukast, a selective leukotriene receptor antagonist, and suplaplast tosilate, a selective Th2 cytokine inhibitor with inhibitory effects on allergy-induced eosinophilic infiltration and IgE production. Although it is likely a separate disease, more experience has accumulated, and an elimination or specific amino acid-based diet appears to be helpful in treatment.

CitationsScopus - 40
2002Talley NJ, Abeygunasekera S, 'Bile reflux and Barrett's oesophagus: innocent bystander or sinister companion? (vol 34, pg 246, 2002)', DIGESTIVE AND LIVER DISEASE, 34 534-534 (2002)
Author URL
2002Talley NJ, Abeygunasekara S, 'Erratum: Bile reflux and Barrett's oesophagus: Innocent bystander or sinister companion? (Digestive and Liver Disease (2002) vol. 34 (246-248))', Digestive and Liver Disease, 34 534-534 (2002)
2002Talley NJ, 'Bile reflux and Barrett's oesophagus: innocent bystander or sinister companion?', Digestive and Liver Disease, 34 246-248 (2002) [C1]
CitationsScopus - 2Web of Science - 4
2002Badia X, Mearin F, Balboa A, Baro E, Caldwell E, Cucala M, et al., 'Burden of illness in irritable bowel syndrome comparing Rome I and Rome II criteria', PHARMACOECONOMICS, 20 749-758 (2002)
DOI10.2165/00019053-200220110-00004Author URL
CitationsScopus - 59Web of Science - 47
2002Barbezat GO, Poulton R, Milne B, Howell S, Fawcett JP, Talley N, 'Prevalence and correlates of irritable bowel symptoms in a New Zealand birth cohort', New Zealand Medical Journal, 115 (2002)

Aim: To determine the prevalence and correlates of bowel symptoms and the irritable bowel syndrome (IBS) in a birth cohort of young New Zealanders. Methods: Participants in the Du... [more]

Aim: To determine the prevalence and correlates of bowel symptoms and the irritable bowel syndrome (IBS) in a birth cohort of young New Zealanders. Methods: Participants in the Dunedin Multidisciplinary Health and Development Study at age 26 completed a validated Bowel Disease Questionnaire expressing their experience of clearly defined symptoms over the previous 12 months. Results: 980 participants (499 male, 481 female, comprising 96% of the birth cohort) completed the questionnaire. Sixty four per cent had at least one of the measured symptoms; abdominal pain was reported in 46.5%, chronic constipation in 9.1%, and chronic diarrhoea in 17.1%. A diagnosis of IBS could be made by using two or more of Manning's diagnostic criteria in 18.8%, three or more criteria in 10.3%, and more than three in 3.3%. Symptoms were more than twice as frequent and severe in females than males. Conclusions: Bowel-related abdominal symptoms, including those required for a diagnosis of IBS, are very common in 26-year-old New Zealanders; the prevalence of these symptoms is very similar to that recorded previously in Europe and the USA. © NZMA.

CitationsScopus - 21
2002Bytzer P, Talley NJ, Hammer J, Young LJ, Jones MP, Horowitz M, 'GI symptoms in diabetes mellitus are associated with both poor glycemic control and diabetic complications', AMERICAN JOURNAL OF GASTROENTEROLOGY, 97 604-611 (2002)
Author URL
CitationsScopus - 72Web of Science - 53
2002Koloski NA, Talley NJ, Boyce PM, 'Epidemiology and health care seeking in the functional G1 disorders: A population-based study', AMERICAN JOURNAL OF GASTROENTEROLOGY, 97 2290-2299 (2002)
Author URL
CitationsScopus - 140Web of Science - 123
2002Talley NJ, Armstrong D, Junghard O, Wiklund I, 'Predictors of treatment response in patients with endoscopy-negative reflux disease (ENRD)', AMERICAN JOURNAL OF GASTROENTEROLOGY, 97 S12-S12 (2002)
DOI10.1016/S0002-9270(02)04469-6Author URL
CitationsWeb of Science - 1
2002Tuteja AK, Joos SK, Talley NJ, Hickam DH, 'Physical activity improves health perception in subjects with irritable bowel syndrome', AMERICAN JOURNAL OF GASTROENTEROLOGY, 97 S282-S282 (2002)
Author URL
2002Tuteja AK, Joos SK, Talley NJ, Hickam DH, 'Functional bowel disorders: A population based study of prevalence and risk factors', AMERICAN JOURNAL OF GASTROENTEROLOGY, 97 S282-S283 (2002)
Author URL
2002Brandt LJ, Bjorkman D, Fennerty MB, Locke GR, Olden K, Peterson W, et al., 'Systematic review on the management of irritable bowel syndrome in North America', AMERICAN JOURNAL OF GASTROENTEROLOGY, 97 S7-S26 (2002)
Author URL
CitationsScopus - 251Web of Science - 163
2002Xia HHX, Zhang GS, Talley NJ, Wong BCY, Yang Y, Henwood C, et al., 'Topographic association of gastric epithelial expression of Ki-67, Bax, and Bcl-2 with antralization in the gastric incisura, body, and fundus', AMERICAN JOURNAL OF GASTROENTEROLOGY, 97 3023-3031 (2002)
Author URL
CitationsScopus - 16Web of Science - 18
2002Talley NJ, Howell S, Jones MP, Horowitz M, 'Predictors of turnover of lower gastrointestinal symptoms in diabetes mellitus', AMERICAN JOURNAL OF GASTROENTEROLOGY, 97 3087-3094 (2002)
Author URL
CitationsScopus - 15Web of Science - 12
2002Brandt LJ, Locke GR, Olden K, Quigley E, Schoenfeld P, Schuster M, Talley N, 'An evidence-based approach to the management of irritable bowel syndrome in North America', American Journal of Gastroenterology, 97 (2002)
DOI10.1016/S0002-9270(02)05656-3
CitationsScopus - 61
2002Quan C, Talley NJ, 'Management of peptic ulcer disease not related to Helicobacter pylori or NSAIDs', American Journal of Gastroenterology, 97 2950-2961 (2002) [C1]
CitationsScopus - 61Web of Science - 44
2002Bytzer P, Talley NJ, 'Prevalence of gastrointestinal symptoms in patients with type 2 diabetes: A population-based study - In reply', ARCHIVES OF INTERNAL MEDICINE, 162 1069-1069 (2002)
Author URL
2002Icks A, Haastert B, Rathmann W, Wareham N, Bytzer P, Talley NJ, 'Prevalence of gastrointestinal symptoms in patients with type 2 diabetes: A population-based study [2] (multiple letters)', Archives of Internal Medicine, 162 1067-1069 (2002)
CitationsScopus - 6
2001Xia HHX, Talley NJ, 'Apoptosis in gastric epithelium induced by Helicobacter pylori infection: Implications in gastric carcinogenesis', AMERICAN JOURNAL OF GASTROENTEROLOGY, 96 16-26 (2001)
DOI10.1016/S0002-9270(00)02240-1Author URL
CitationsScopus - 161Web of Science - 145
2001Talley NJ, Young L, Bytzer P, Hammer J, Leemon M, Jones M, Horowitz M, 'Impact of chronic gastrointestinal symptoms in diabetes mellitus on health-related quality of life', AMERICAN JOURNAL OF GASTROENTEROLOGY, 96 71-76 (2001)
Author URL
CitationsScopus - 91Web of Science - 71
2001Koloski NA, Talley NJ, Boyce PM, 'Predictors of health care seeking for irritable bowel syndrome and nonulcer dyspepsia: A critical review of the literature on symptom and psychosocial factors', AMERICAN JOURNAL OF GASTROENTEROLOGY, 96 1340-1349 (2001)
DOI10.1016/S0002-9270(01)02352-8Author URL
CitationsScopus - 134Web of Science - 102
2001Talley NJ, Bytezer P, Hammer J, Young L, Jones M, Horowitz M, 'Psychological distress is linked to gastrointestinal symptoms in diabetes mellitus', American Journal of Gastroenterology, 96 1033-1038 (2001) [C1]
CitationsScopus - 46Web of Science - 16
2001Shaw MJ, Talley NJ, Beebe TJ, Rockwood T, Carlsson R, Adlis S, et al., 'Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease', American Journal of Gastroenterology, 96 52-57 (2001) [C1]
CitationsScopus - 222Web of Science - 207
2001Veldhyzen Van Zanten SJ, Jones MJ, Verlinden M, Talley NJ, 'Efficacy of cisapride and domperidone in functional (non-ulcer) dyspepsia: a meta-analysis', American Journal of Gastroenterology, 96 689-696 (2001) [C1]
CitationsScopus - 113Web of Science - 84
2001McManis PG, Newall D, Talley NJ, 'Abdominal wall muscle activity in the irritable bowel syndrome with bloating', American Journal of Gastroenterology, 96 1139-1142 (2001) [C1]
CitationsScopus - 24Web of Science - 18
2001Talley NJ, Howell S, Poulton R, 'The irritable bowel syndrome and psychiatric disorders in the community: is there a link?', American Journal of Gastroenterology, 96 1072-1079 (2001) [C1]
CitationsScopus - 51Web of Science - 37
2001Talley NJ, Verlinden M, Jones M, 'Can symptoms discriminate among those with delayed or normal gastric emptying in dysmotility-like dyspepsia?', American Journal of Gastroenterology, 96 1422-1428 (2001) [C1]
CitationsScopus - 121Web of Science - 108
2001Shaw MJ, Fendrick AM, Kane RL, Adlis SA, Talley NJ, 'Self-reported effectiveness and physician consultation rate in users of over-the-counter histamine-2 receptor antagonists', American Journal of Gastroenterology, 96 673-676 (2001) [C1]
CitationsScopus - 16Web of Science - 11
2001Xia H, Talley NJ, Kam E, Young LJ, Hammer J, Horowitz M, 'Helicobacter pylori infection is not associated with diabetes mellitus, nor with upper gastrointestinal symptoms in diabetes mellitus', American Journal of Gastroenterology, 96 1039-1046 (2001) [C1]
CitationsScopus - 59Web of Science - 39
2001Talley NJ, Fullerton S, Junghard O, Wiklund I, 'Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments', American Journal of Gastroenterology, 96 1998-2004 (2001) [C1]
CitationsScopus - 144Web of Science - 124
2001Agreus L, Svardsudd K, Talley NJ, Jones MP, Tibblin G, 'Natural history of gastroesophageal reflux disease and functional abdominal disorders: a population-based study', American Journal of Gastroenterology, 96 2905-2914 (2001) [C1]
CitationsScopus - 172Web of Science - 149
2001Bytzer P, Talley NJ, 'Dyspepsia', ANNALS OF INTERNAL MEDICINE, 134 815-822 (2001)
Author URL
CitationsWeb of Science - 39
2001Bytzer P, Talley NJ, 'Dyspepsia', Annals of Internal Medicine, 134 815-822 (2001)

Dyspepsia refers to pain or discomfort centered in the upper abdomen. This symptom is remarkably common, with 1-year prevalence rates averaging 25% in the community. Symptoms sugg... [more]

Dyspepsia refers to pain or discomfort centered in the upper abdomen. This symptom is remarkably common, with 1-year prevalence rates averaging 25% in the community. Symptoms suggestive of the irritable bowel syndrome and reflux disease frequently overlap but do not form part of the definition of dyspepsia. Electrical and other stimuli can cause similar or different symptoms in various patients, and even the site to which symptoms are referred varies considerably. Dyspeptic symptoms are therefore a relatively poor guide to the origin or nature of any "disturbances" in the gut. Identification of patients who require further investigation to rule out serious structural disease, such as peptic ulcer disease or cancer, is a key issue because unaided clinical diagnosis is unreliable. The use of an age threshold (typically 45 years) and the identification of alarm features, including weight loss, repeated vomiting, and signs of bleeding, seem to be valid on the basis of the limited evidence available. Dyspeptic symptoms fall into distinct subgroups resembling the perceived clinical entities of ulcer-like and dysmotility-like dyspepsia. Unfortunately, because of overlap with reflux symptoms and between the subgroups, the clinical significance of these groups remains highly questionable. A focus on symptom predominance may be more rewarding. Lack of validated outcome measures has hampered clinical studies and has led to the development of complex outcome measures that integrate and weigh different symptoms or other indirect indicators of outcome into a general score. Further testing and validation are in progress.

CitationsScopus - 54
2001Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M, 'Prevalence of gastrointestinal symptoms associated with diabetes mellitus: A population-based survey of 15000 adults', Archives of Internal Medicine, 161 1989-1996 (2001)

Background: Gastrointestinal symptoms are reportedly common in diabetes, but a causal link is controversial and adequate population control data are lacking. Objective: To determi... [more]

Background: Gastrointestinal symptoms are reportedly common in diabetes, but a causal link is controversial and adequate population control data are lacking. Objective: To determine whether gastrointestinal symptoms are more frequent in persons with diabetes, particularly in those with poor glycemic control. Methods: Fifteen thousand adults were mailed a questionnaire (response rate, 60.0%) containing validated questions on the frequency of troublesome gastrointestinal symptoms within the past 3 months, diabetic status, and self-reported glycemic control. The prevalence of 16 symptoms and 5 symptom complexes, reported to occur often or very often, was compared using logistic regression analysis, adjusting for age and sex. Results: Overall, 8657 eligible subjects responded; 423 (4.9%) reported having diabetes. Most (94.8%) had type 2 diabetes mellitus. Adjusting for age and sex, all 16 symptoms and the 5 symptom complexes were significantly more frequent in subjects with diabetes compared with controls. An increased prevalence rate of symptoms was significantly associated with poorer levels of glycemic control but not with duration of diabetes or type of diabetic treatment. Conclusions: Diabetes mellitus is associated with an increased prevalence of upper and lower gastrointestinal symptoms. This effect may be linked to poor glycemic control but not to duration of diabetes or type of treatment.

CitationsScopus - 101
2001Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M, 'Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults', Archives of Internal Medicine, 161 1989-1996 (2001) [C1]
CitationsScopus - 161Web of Science - 207
2001Hammer J, Howell SC, Talley NJ, 'Alarm features do not discriminate organic disease from functional gastrointestinal illness.', GASTROENTEROLOGY, 120 A51-A51 (2001)
Author URL
2001Lembo T, Zaman MS, Chavez NF, Krueger R, Jones MP, Talley NJ, 'Concordance of IBS among monozygotic and dizygotic twins', GASTROENTEROLOGY, 120 A66-A67 (2001)
Author URL
CitationsWeb of Science - 4
2001Holtmann G, Buenger L, Saadat-Gilani K, Gerken G, Pietsch A, Talley NJ, 'Opiodergic antinociceptive pathways modulate gastric mechanosensory function in healthy subjects', GASTROENTEROLOGY, 120 A81-A81 (2001)
Author URL
CitationsWeb of Science - 1
2001Howell SC, Poulton R, Talley NJ, 'Is psychiatric illness, personality or both a predictor of IBS in young adults? Results from a birth cohort study in New Zealand.', GASTROENTEROLOGY, 120 A114-A114 (2001)
Author URL
CitationsWeb of Science - 1
2001Boyce PM, Talley NJ, Koloski NA, Balaam B, Nandurkar S, 'A randomized controlled trial of cognitive behavioural therapy, relaxation therapy and routine medical care for irritable bowel syndrome (IBS)', GASTROENTEROLOGY, 120 A115-A115 (2001)
Author URL
CitationsWeb of Science - 3
2001Tuteja AK, Joos SK, Talley NJ, Woehl JV, Hickam DH, 'Association between constipation and physical activity in a population of employed adults', GASTROENTEROLOGY, 120 A230-A230 (2001)
Author URL
2001Aro P, Ronkainen J, Storskrubb T, Bolling E, Talley NJ, Agrous L, 'Prevalence of symptoms and upper endoscopic findings in a random adult population. The Kalixanda study.', GASTROENTEROLOGY, 120 A231-A231 (2001)
DOI10.1016/S0016-5085(08)81148-1Author URL
CitationsWeb of Science - 1
2001Bytzer P, Howell S, Leemon M, Young LJ, Jones MP, Talley NJ, 'Low socioeconomic class is a risk factor for upper and lower gastrointestinal symptoms. A population based study in 15,000 adults', GASTROENTEROLOGY, 120 A231-A231 (2001)
Author URL
2001Talley NJ, Jones MP, Horowitz M, 'Onset and disappearance of gastrointestinal symptoms in diabetes: Influence of psychosocial factors, disease duration and glycemic control', GASTROENTEROLOGY, 120 A232-A232 (2001)
DOI10.1016/S0016-5085(01)81151-3Author URL
CitationsWeb of Science - 2
2001Hammer J, Howell SC, Horowitz M, Talley NJ, 'Glycemic control and treatment predict symptom clustering in diabetes mellitus (DM).', GASTROENTEROLOGY, 120 A232-A232 (2001)
Author URL
2001Talley NJ, Hammer J, Giles N, Jones MP, Horowitz M, 'Measuring gastrointestinal symptoms in diabetes: Development and validation of the Diabetes Bowel Symptom Questionnaire', GASTROENTEROLOGY, 120 A232-A232 (2001)
DOI10.1016/S0016-5085(01)81151-3Author URL
CitationsWeb of Science - 2
2001Ronkainen J, Aro P, Storskrubb T, Vieth MWR, Carlsson R, Graffner H, et al., 'How persistent is short segment Barrett's esophagus in the general population? A report from the Kalixanda study.', GASTROENTEROLOGY, 120 A232-A233 (2001)
Author URL
2001Vakil NB, Talley NJ, Bolling-Sternevald E, Junghard O, Carlsson R, 'Resolution of H-pylori antrum, corpus or pan-gastritis does not induce heartburn in patients with functional dyspepsia', GASTROENTEROLOGY, 120 A237-A238 (2001)
Author URL
2001Rohrboeck RB, Hammer J, Vogelsang H, Talley NJ, Hammer HF, 'Spatial summation is present in the rectum of healthy and IBS individuals: Is there an effect of acupuncture?', GASTROENTEROLOGY, 120 A398-A398 (2001)
Author URL
2001Zaman MS, Hur C, Jones MP, Krueger RF, Chavez NF, Talley NJ, Lembo T, 'Concordance of reflux among monozygotic and dizygotic twins', GASTROENTEROLOGY, 120 A418-A418 (2001)
Author URL
CitationsWeb of Science - 6
2001Talley NJ, Junghard O, Wiklund IK, 'Why do patients with gastroesophageal reflux disease (GERD) have a poor health-related quality of life (HRQL)?', GASTROENTEROLOGY, 120 A423-A423 (2001)
DOI10.1016/S0016-5085(08)82097-5Author URL
CitationsWeb of Science - 10
2001Nandurkar S, Talley NJ, Martin CJ, Xia HHX, Wyatt JM, Adams S, Cheung K, 'Distribution of cagA positive H-pylori and patterns of gastritis in patients with gastroesophageal reflux disease (GERD) and controls: Does cagA protect against GERD?', GASTROENTEROLOGY, 120 A426-A426 (2001)
Author URL
2001Zaman MS, Chavez NF, Krueger R, Talley NJ, Lembo T, 'Extra-intestinal symptoms in patients with irritable bowel syndrome (IBS)', GASTROENTEROLOGY, 120 A636-A636 (2001)
DOI10.1016/S0016-5085(08)83160-5Author URL
CitationsWeb of Science - 7
2001Zhang GS, Talley NJ, Henwood C, Wyatt JM, Adams S, Wong BC, et al., 'Topographic association of Ki-67 and Bcl-2 expression with H-pylori infection, gastric atrophy, intestinal metaplasia: A role for antralization in gastric carcinogenesis?', GASTROENTEROLOGY, 120 A656-A656 (2001)
Author URL
2001Storskrubb T, Aro P, Ronkainen J, Vieth MWR, Engstrand L, Talley NJ, Agrzus L, 'Helicobacter pylori and symptoms in a random adult population evaluated by endoscopy. A report from the Kalixanda study.', GASTROENTEROLOGY, 120 A738-A738 (2001)
Author URL
2001Koloski NA, Talley NJ, Matheson M, Boyce PM, 'Psychosocial predictors of irritable bowel syndrome (IBS) and functional dyspepsia (FD) in the general population', GASTROENTEROLOGY, 120 A758-A758 (2001)
Author URL
2001Gangarosa L, Shanahan F, Talley NJ, Targan S, Winter H, 'American gastroenterological association medical position statement: Guidelines for the evaluation of food allergies', Gastroenterology, 120 1023-1025 (2001)
CitationsScopus - 32
2001Gangarosa L, Shanahan F, Talley NJ, Targan S, Winter H, 'AGA technical review on the evaluation of food allergy in gastrointestinal disorders', Gastroenterology, 120 1026-1040 (2001)
CitationsScopus - 98
2001Levy RL, Jones KR, Whitehead WE, Feld SI, Talley NJ, Corey LA, 'Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology', Gastroenterology, 121 799-804 (2001) [C1]
CitationsScopus - 240Web of Science - 192
2001Boyce P, Burke C, Talley NJ, 'Epidemiology of the functional gastrointestinal disorders diagnosed according to Rome II criteria: An Australian population-based study', GUT, 48 A45-A46 (2001)
Author URL
2001Boyce PM, Talley NJ, Truman G, Balaam B, Nandurkar S, 'Cognitive behavioural therapy and relaxation therapy are no better than good routine medical care for managing Irritable Bowel Syndrome', GUT, 48 A46-A47 (2001)
Author URL
CitationsWeb of Science - 3
2001Talley NJ, 'H pylori and functional dyspepsia', GUT, 49 738-739 (2001)
Author URL
2001Bytzer P, Howell S, Leemon M, Young LJ, Talley NJ, 'Low socioeconomic class is a risk factor for upper and lower gastrointestinal symptoms: a population based study in 15,000 Australian adults', Gut, 49 66-72 (2001) [C1]
CitationsScopus - 56Web of Science - 50
2001Talley NJ, Verlinden M, Geenen DJ, Hogan RB, Riff D, McCallum RW, Mack RJ, 'Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial', Gut, 49 395-401 (2001) [C1]
CitationsScopus - 109Web of Science - 100
2001Talley NJ, Eslick GD, 'Non-cardiac chest pain - Reply', MEDICAL JOURNAL OF AUSTRALIA, 174 483-483 (2001)
Author URL
2001Mearin F, Badia X, Balboa A, Baro E, Caldwell E, Cucala M, et al., 'Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria: comparison of Rome II versus previous criteria in a general population', Scandinavian Journal of Gastroenterology, 36 1155-1161 (2001) [C1]
CitationsScopus - 170Web of Science - 140
2001Talley NJ, 'Serotoninergic neuroenteric modulators', LANCET, 358 2061-2068 (2001)
DOI10.1016/S0140-6736(01)07103-3Author URL
CitationsScopus - 143Web of Science - 93
2001Xia H, Phung N, Altiparmak E, Berry A, Matheson M, Talley NJ, 'Reduction of peptic ulcer disease and Helicobacter pylori infection but increase of reflux esophagitis in Western Sydney between 1990 and 1998', Digestive Diseases and Sciences, 46 2716-2723 (2001) [C1]
CitationsScopus - 44Web of Science - 28
2001Holtmann G, Gschossmann J, Holtmann M, Talley NJ, 'H. pylori and functional dyspepsia: increased serum antibodies as an independent risk factor?', Digestive Diseases and Sciences, 46 1550-1557 (2001) [C1]
CitationsScopus - 16Web of Science - 11
2001Talley NJ, 'Therapeutic options in nonulcer dyspepsia', JOURNAL OF CLINICAL GASTROENTEROLOGY, 32 286-293 (2001)
DOI10.1097/00004836-200104000-00004Author URL
CitationsScopus - 30Web of Science - 19
2001Hammer J, Talley NJ, 'Nonulcer dyspepsia', CURRENT OPINION IN GASTROENTEROLOGY, 17 518-522 (2001)
DOI10.1097/00001574-200111000-00007Author URL
CitationsScopus - 2Web of Science - 1
2001Talley NJ, Verlinden M, Jones M, 'Quality of life in functional dyspepsia: responsiveness of the Nepean Dyspepsia Index and development of a new 10-item short form', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 15 207-216 (2001)
DOI10.1046/j.1365-2036.2001.00900.xAuthor URL
CitationsScopus - 51Web of Science - 40
2001Bytzer P, Talley NJ, Jones MP, Horowitz M, 'Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus', Alimentary Pharmacology and Therapeutics, 15 137-142 (2001) [C1]
CitationsScopus - 33Web of Science - 29
2001Talley NJ, Lauritsen K, Tunturi-Hihnala H, Lind T, Moum B, Bang C, et al., 'Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastrooesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months', Alimentary Pharmacology and Therapeutics, 15 347-354 (2001) [C1]
CitationsScopus - 170Web of Science - 128
2001Talley NJ, Van Zanten SV, Saez LR, Dukes G, Perschy T, Heath M, et al., 'A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia', Alimentary Pharmacology and Therapeutics, 15 525-537 (2001) [C1]
CitationsScopus - 84Web of Science - 62
2001Shaw MJ, Beebe TJ, Adlis SA, Talley NJ, 'Reliability and validity of the digestive health status instrument in samples of community, primary care, and gastroenterology patients', Alimentary Pharmacology and Therapeutics, 15 981-987 (2001) [C1]
CitationsScopus - 16Web of Science - 15
2001Talley NJ, Riff DS, Schwartz H, Marcuard SP, 'Double-blind placebo-controlled mulitcentre studies of rebamipide, a gastroprotective drug, in the treatment of functional dyspepsia with or without Helicobacter pylori infection', Alimentary Pharmacology and Therapeutics, 15 1603-1611 (2001) [C1]
CitationsScopus - 21Web of Science - 17
2001Talley NJ, Daneshjoo R, 'Chronic indigestion: Causes and treatment', Current Therapeutics, 42 59-66 (2001)

Chronic indigestion is a common problem in Australia, with up to one-third of Australians experiencing upper gastrointestinal distress. The reported prevalence of dyspepsia in Wes... [more]

Chronic indigestion is a common problem in Australia, with up to one-third of Australians experiencing upper gastrointestinal distress. The reported prevalence of dyspepsia in Western countries generally ranges from 25-40%.[1,2] Dyspepsia is associated with significant work absenteeism, impaired health-related quality of life and increased medical costs. It accounts for 10% of GP consultations and about 20-30%[1,2] of gastroenterology consultations.

CitationsScopus - 1
2001Koloski NA, Talley NJ, Boyce PM, Morris-Yates AD, 'The effects of questionnaire length and lottery ticket inducement on the response rate in mail surveys', PSYCHOLOGY & HEALTH, 16 67-75 (2001)
DOI10.1080/08870440108405490Author URL
CitationsScopus - 14Web of Science - 16
2001Kahrilas PJ, Lagergren J, Laine LA, Talley NJ, Jones R, Kahrilas PJ, Vakil N, 'Introduction: Evolution of management strategies and opportunities for esomeprazole (Nexium®)', European Journal of Gastroenterology and Hepatology, 13 (2001)
2001Vakil N, Talley N, Malfertheiner P, Fass R, Tytgat GNJ, Laine LA, et al., 'Session 4: Long-term medical management', European Journal of Gastroenterology and Hepatology, 13 (2001)
CitationsScopus - 1
2001Talley NJ, Phung N, Kalantar JS, 'ABC of the upper gastrointestinal tract - Indigestion: When is it functional?', BRITISH MEDICAL JOURNAL, 323 1294-1297 (2001)
DOI10.1136/bmj.323.7324.1294Author URL
CitationsScopus - 12Web of Science - 7
2001Deng J, Jones R, Kahrilas P, Talley NJ, 'Management of gastro-oesophageal reflux disease in general practice', BRITISH MEDICAL JOURNAL, 322 344-347 (2001)
Author URL
CitationsScopus - 97
2001Talley NJ, 'Drug therapy options for patients with irritable bowel syndrome', American Journal of Managed Care, 7 (2001)

Existing pharmacotherapeutic options for the treatment of patients with irritable bowel syndrome (IBS) are limited in treating the multiple symptoms associated with the disorder. ... [more]

Existing pharmacotherapeutic options for the treatment of patients with irritable bowel syndrome (IBS) are limited in treating the multiple symptoms associated with the disorder. There is much interest in the use of serotonin agents as new therapeutics. Acting primarily through 5-HT3 and 5-HT4 receptors, serotonin elicits changes in motor function and possibly visceral sensation. Two serotonin agents were developed specifically for IBS: tegaserod, a 5-HT4 receptor partial agonist, and alosetron, a 5-HT3 receptor antagonist (which is no longer available). Phase III clinical trial data show that during a 12-week treatment period with tegaserod, IBS patients with abdominal pain and discomfort, bloating, and constipation experienced significant global relief (ie, improvement in overall well-being, abdominal pain, and bowel habit) compared with placebo. Improvement in bowel movement frequency and consistency was achieved and pain was relieved by 1 week. During 12 weeks of treatment, alosetron was shown to elicit significant relief of abdominal pain and discomfort compared with placebo or mebeverine in female IBS patients with diarrhea. Alosetron slowed colonic transit and treatment efficacy was apparent after a week of treatment. Another 5-HT4 receptor agonist, prucalopride, which is being developed for chronic constipation, accelerates colonic transit and increases stool frequency. Therefore, this agent may be of benefit in IBS patients with constipation.

CitationsScopus - 18
2001Bensoussan A, Chang SW, Menzies RG, Talley NJ, 'Application of the general health status questionnaire SF36 to patients with gastrointestinal dysfunction: initial validation and validation as a measure of change', Australian and New Zealand Journal of Public Health, 25 71-77 (2001) [C1]
CitationsScopus - 16Web of Science - 14
2001Talley NJ, 'Commentary', Evidence-Based Medicine, 6 88-88 (2001)
DOI10.1136/ebm.6.3.88
2001Talley NJ, 'Commentary', Evidence-Based Medicine, 6 189-189 (2001)
DOI10.1136/ebm.6.6.189
2001Boyce P, Hickey A, Gilchrist J, Talley NJ, 'The development of a brief personality scale to measure vulnerability to postnatal depression', Archives of Women s Mental Health, 3 147-153 (2001) [C1]
CitationsScopus - 40
2001Xia HH-X, Wong BCY, Talley NJ, Lam SK, 'Helicobacter pylori infection - Current treatment practice', Expert Opinion on Pharmacotherapy, 2 253-266 (2001)

Helicobacter pylori infection, which is present in 30-60% of the population in developed countries and in more than 60% in developing countries, is established to be a major cause... [more]

Helicobacter pylori infection, which is present in 30-60% of the population in developed countries and in more than 60% in developing countries, is established to be a major cause of gastritis, peptic ulcer disease and gastric cancer. Eradication therapy has been incorporated into clinical practice over the past 15 years. Treatment regimens include a 2 week bismuth-based triple therapy (a bismuth compound plus metronidazole, tetracycline or amoxycillin), a 1 week proton-pump inhibitor (PPI)-based triple therapy and a 1 week ranitidine bismuth citrate (RBC)-based triple therapy (a PPI or RBC plus any two of the three antibiotics, metronidazole, amoxycillin and clarithromycin). These regimens achieve eradication rates of > 80%. H. pylori resistance to metronidazole and clarithromycin decreases the clinical efficacy of most regimens, despite the high eradication rates for resistant strains achieved by the RBC-triple therapy in some recent trials. The dose of antibiotics (especially clarithromycin) and the duration of treatment may also influence the eradication rate. Doctors' beliefs impact on clinical practice and, thus, influence the clinical application of eradication therapy. Whereas peptic ulcer disease and primary gastric low-grade B-cell mucosa-associated lymphoid tissue lymphoma (MALToma) have become established as definite indications for eradication therapy, there remain controversies surrounding non-ulcer dyspepsia, gastro-oesophageal reflux disease, atrophic gastritis, intestinal metaplasia, use of non-steroidal anti-inflammatory drugs (NSAIDs) and H. pylori-related extradigestive diseases.

DOI10.1517/14656566.2.2.253
CitationsScopus - 7
2001Bytzer P, Talley NJ, 'Current indications for acid suppressants in dyspepsia', BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY, 15 385-400 (2001)
DOI10.1053/bega.2001.0186Author URL
CitationsScopus - 12Web of Science - 9
2001Talley NJ, Thitiphuree S, 'Lump or split dyspepsia? A continuing controversy.', Current gastroenterology reports, 3 175-176 (2001)
2000Reilly WT, Talley NJ, Pemberton JH, Zinsmeister AR, 'Validation of a questionnaire to assess fecal incontinence and associated risk factors - Fecal incontinence questionnaire', DISEASES OF THE COLON & RECTUM, 43 146-153 (2000)
Author URL
CitationsScopus - 63Web of Science - 57
2000Talley NJ, Lauristen K, Tunturi-Hihnala H, Lind T, Moum B, Bang CJ, et al., 'Esomeprazole 20mg maintains symptom control in endoscopy-negative GERD: A randomized placebo-controlled trial of on-demnd therapy for 6 months.', GASTROENTEROLOGY, 118 A21-A21 (2000)
Author URL
CitationsWeb of Science - 10
2000Talley NJ, Kong S, Ferriola PC, Mangel AW, 'Demographic and clinical characteristics of non-constipated female IBS patients in the United States.', GASTROENTEROLOGY, 118 A147-A147 (2000)
Author URL
2000Jones MP, Dubois D, Nuyts G, Talley NJ, 'Medical resource utilization of chronic constipation patients in a large general practice population.', GASTROENTEROLOGY, 118 A212-A212 (2000)
Author URL
2000Wiklund IK, Fullerton S, Junghard O, Talley NJ, 'Interpretability and meaningfulness of quality of life changes in patients with heartburn.', GASTROENTEROLOGY, 118 A220-A220 (2000)
Author URL
CitationsWeb of Science - 1
2000Nandurkar S, Ormsby AH, Talley NJ, Goldblum JR, Richter JE, Rice TW, Gramlich TL, 'Short segment Barrett's or not: Cytokeratin (CK) 7/20 immunoreactivity could be the key!', GASTROENTEROLOGY, 118 A226-A226 (2000)
Author URL
CitationsWeb of Science - 2
2000Nandurkar S, Talley NJ, Martin CJ, Wyatt JM, Adams S, Cheung K, 'Prevalence and associations of cardia epithelium.', GASTROENTEROLOGY, 118 A226-A227 (2000)
Author URL
CitationsWeb of Science - 2
2000Haag S, Holtmann G, Neufang-Heuber J, Gschossmann J, Gerken G, Talley NJ, 'Is there a link between the pattern of functional abdominal symptoms and disturbances of gastric emptying or the response to a nutrient challenge?', GASTROENTEROLOGY, 118 A391-A391 (2000)
Author URL
2000Saito YA, Locke GR, Talley NJ, Zinsmeister AR, Fett SL, Melton LJ, 'The effect of new diagnostic criteria for Irritable Bowel Syndrome on community prevalence estimates.', GASTROENTEROLOGY, 118 A396-A396 (2000)
Author URL
CitationsWeb of Science - 7
2000Koloski NA, Talley NJ, Boyce PM, 'Psychological distress does not predict health care seeking behaviour for gastrointestinal (GI) symptoms over time in community subjects with functional abdominal pain.', GASTROENTEROLOGY, 118 A398-A398 (2000)
Author URL
2000Saito YA, Locke GR, Williams DE, Talley NJ, Zinsmeister AR, Fett SL, Melton LJ, 'The role of psychological distress on symptoms and health care utilization in patients with irritable bowel syndrome.', GASTROENTEROLOGY, 118 A399-A399 (2000)
Author URL
2000Bytzer PM, Hammer J, Talley NJ, Young LJ, Jones MP, Horowitz M, 'Gastrointestinal symptoms in diabetes mellitus are associated with diabetic complications but not with current glycemic control.', GASTROENTEROLOGY, 118 A468-A468 (2000)
Author URL
CitationsWeb of Science - 5
2000Nandurkar S, Talley NJ, Martin CJ, Wyatt JM, Adams S, Cheung K, 'Risk factors for intestinal metaplasia at the gastro-esophageal junction (IMAGE): Is it all H-pylori (HP)?', GASTROENTEROLOGY, 118 A486-A486 (2000)
Author URL
2000Talley NJ, Venables TL, Green JR, Armstrong D, O'Kane KP, Giaffer MH, et al., 'Esomeprazole 40mg and 20mg is efficacious in the long-term management of patients with endoscopy-negative GERD: A placebo-controlled trial of on-demand therapy for 6 months.', GASTROENTEROLOGY, 118 A658-A658 (2000)
Author URL
CitationsWeb of Science - 16
2000Nuyts G, Dubois D, Jones MP, Talley NJ, 'Risk factors for chronic constipation: A case-control study in a large general practice population.', GASTROENTEROLOGY, 118 A693-A693 (2000)
Author URL
2000Kalantar JS, Howell S, Talley NJ, 'The hidden burden of fecal incontinence and its associated risk factors: A population-based study.', GASTROENTEROLOGY, 118 A694-A694 (2000)
Author URL
2000Bytzer PM, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M, 'Diabetes mellitus is associated with an increased of gastrointestinal symptoms: A population-based survey of 15,000 prevalence results from adults.', GASTROENTEROLOGY, 118 A716-A716 (2000)
Author URL
CitationsWeb of Science - 4
2000Koloski NA, Talley NJ, Boyce PM, 'Do changes in gastrointestinal (GI) symptom patterns over time reflect changes in psychological distress levels in community subjects with functional abdominal pain?', GASTROENTEROLOGY, 118 A718-A718 (2000)
Author URL
2000Yan P, Murray H, Spurrett B, Xia HHX, Eslick G, Talley NJ, 'Association between Helicobacter pylori infection and fetal intrauterine growth retardation (IUGR).', GASTROENTEROLOGY, 118 A734-A734 (2000)
Author URL
CitationsWeb of Science - 2
2000Holtmann G, Neufang-Hueber J, Gschossmann J, Gerken G, Talley NJ, 'Is there an influence of gender on mechanosensory function in patients with functional gastrointestinal disorders or in health?', GASTROENTEROLOGY, 118 A843-A843 (2000)
Author URL
2000Talley NJ, Verlinden MH, Snape W, Beker JA, Ducrotte P, Dettmer A, et al., 'Lack of anti-dyspeptic effects of the macrolide gastrokinetic (GK) agent, ABT-229, in functional dyspepsia (FD) and idiopathic gastroparesis (IG).', GASTROENTEROLOGY, 118 A847-A847 (2000)
Author URL
2000Verlinden MH, McCallum RW, Schwartz S, Geenen DJ, Portnoy EB, Mack RJ, Talley NJ, 'The macrolide gastrokinetic (GK) agent, ABT-229, has an adverse effect on postprandial dyspeptic symptoms in patients with insulin-dependent diabetes (DM).', GASTROENTEROLOGY, 118 A848-A848 (2000)
Author URL
CitationsWeb of Science - 1
2000Katelaris PH, Crotty B, Reiner R, Radford-Smith G, Bolin T, Korman M, et al., 'A randomised multicentre comparison of pantoprazole quadruple and trifle therapies versus bismuth triple therapy in H-pylori positive, endoscopy negative dyspepsia.', GASTROENTEROLOGY, 118 A879-A879 (2000)
Author URL
CitationsWeb of Science - 4
2000Shaw MJ, Rockwood T, Adlis SA, Beebe T, Carlsson R, Fendrick AM, Talley NJ, 'Development of a brief reflux disease questionnaire.', GASTROENTEROLOGY, 118 A1096-A1096 (2000)
Author URL
2000Koloski NA, Talley NJ, Boyce PM, 'Do psychological factors predict the new onset of functional gastrointestinal (GI) symptoms in healthy controls in the general population?', GASTROENTEROLOGY, 118 A1182-A1182 (2000)
Author URL
2000Bytzer PM, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M, 'Gastrointestinal symptoms in diabetes are associated with poor glycemic control.', GASTROENTEROLOGY, 118 A1220-A1220 (2000)
Author URL
2000Holtmann G, Neufang-Hueber J, Gerken G, Goebell H, Talley NJ, 'In patients with functional dyspepsia, overlapping of dyspepsia subgroups is a marker for severity.', GASTROENTEROLOGY, 118 A1246-A1246 (2000)
Author URL
2000Junghard O, Carlsson R, Hasselgren G, Talley NJ, Wiklund IK, 'Assessment of clinical significance in endoscopy negative heartburn.', GASTROENTEROLOGY, 118 A1253-A1253 (2000)
Author URL
CitationsWeb of Science - 1
2000Xia HHX, Young LJ, Hammer J, Horowitz M, Talley NJ, 'Does Helicobacter pylori infection explain upper gastrointestinal symptoms in diabetes mellitus?', GASTROENTEROLOGY, 118 A1326-A1326 (2000)
Author URL
2000Xia HHX, Talley NJ, Blum AL, O Morain CA, Bolling-Sternevald E, 'Virulence factors predict long-term clinical efficacy of eradication therapy in nonulcer dyspepsia (NUD).', GASTROENTEROLOGY, 118 A1326-A1326 (2000)
Author URL
2000Holtmann G, Gschossmann J, Neufang-Huber J, Gerken G, Talley NJ, 'Differences in gastric mechanosensory function after repeated ramp distensions in non-consulters with dyspepsia and healthy controls', GUT, 47 332-336 (2000)
DOI10.1136/gut.47.3.332Author URL
CitationsScopus - 65Web of Science - 57
2000Locke GR, Zinsmeister AR, Talley NJ, Fett SL, Melton LJ, 'Familial association in adults with functional gastrointestinal disorders', MAYO CLINIC PROCEEDINGS, 75 907-912 (2000)
Author URL
CitationsScopus - 159Web of Science - 144
2000Eslick GD, Talley NJ, 'Non-cardiac chest pain: squeezing the life out of the Australian healthcare system?', MEDICAL JOURNAL OF AUSTRALIA, 173 233-234 (2000)
Author URL
CitationsScopus - 29Web of Science - 30
2000Xia HHX, Phung N, Kalantar JS, Talley NJ, 'Demographic and endoscopic characteristics of patients with Helicobacter pylori positive and negative peptic ulcer disease', MEDICAL JOURNAL OF AUSTRALIA, 173 515-519 (2000)
Author URL
CitationsScopus - 29Web of Science - 22
2000Talley NJ, Vakil N, Fennerty MB, 'Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. Reply', NEW ENGLAND JOURNAL OF MEDICINE, 342 590-590 (2000)
Author URL
CitationsWeb of Science - 1
2000McColl KEL, Perri F, Andriulli A, Talley NJ, Vakil N, Fennerty MB, 'Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia [3] (multiple letters)', New England Journal of Medicine, 342 589-590 (2000)
DOI10.1056/NEJM200002243420814
CitationsScopus - 11
2000Haque M, Wyeth JW, Stace NH, Talley NJ, Green R, 'Prevalence, severity and associated features of gastro-oesophageal reflux and dyspepsia: a population-based study', NEW ZEALAND MEDICAL JOURNAL, 113 178-181 (2000)
Author URL
CitationsScopus - 95Web of Science - 83
2000Levy RL, Whitehead WE, Bjorling EA, Corey LA, Talley NJ, 'Reported concordance in IBS among monozygotic and dizygotic twins', PSYCHOSOMATIC MEDICINE, 62 97-97 (2000)
Author URL
2000Agreus L, Talley NJ, Svardsudd K, Tibblin G, Jones MP, 'Identifying dyspepsia and irritable bowel syndrome: The value of pain or discomfort, and bowel habit descriptors', SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 35 142-151 (2000)
Author URL
CitationsScopus - 56Web of Science - 49
2000Westbrook JI, McIntosh JH, Talley NJ, 'The impact of dyspepsia definition on prevalence estimates: Considerations for future researchers', SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 35 227-233 (2000)
Author URL
CitationsScopus - 26Web of Science - 24
2000Hammer J, Talley NJ, 'Nonulcer dyspepsia', CURRENT OPINION IN GASTROENTEROLOGY, 16 503-507 (2000)
DOI10.1097/00001574-200011000-00007Author URL
CitationsScopus - 3Web of Science - 3
2000Xia HHX, Kalantar JS, Mitchell HM, Talley NJ, 'Can Helicobacter pylori serology still be applied as a surrogate marker to identify peptic ulcer disease in dyspepsia?', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 14 615-624 (2000)
Author URL
CitationsScopus - 24Web of Science - 23
2000Westbrook JI, Mcintosh J, Talley NJ, 'Factors associated with consulting medical or non-medical practitioners for dyspepsia: an Australian population-based study', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 14 1581-1588 (2000)
DOI10.1046/j.1365-2036.2000.00878.xAuthor URL
CitationsScopus - 28Web of Science - 25
2000Talley NJ, Verlinden M, Snape W, Beker JA, Ducrotte P, Dettmer A, et al., 'Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 14 1653-1661 (2000)
DOI10.1046/j.1365-2036.2000.00868.xAuthor URL
CitationsScopus - 157Web of Science - 141
2000Talley NJ, 'Irritable bowel syndrome. Practical management.', Australian family physician, 29 823-828 (2000)

BACKGROUND: Irritable bowel syndrome (IBS) is a common problem affecting one in six Australians. In any patient complaining of chronic or recurrent abdominal pain, chronic diarrho... [more]

BACKGROUND: Irritable bowel syndrome (IBS) is a common problem affecting one in six Australians. In any patient complaining of chronic or recurrent abdominal pain, chronic diarrhoea or constipation or bloating, IBS should top the list of possibilities. OBJECTIVE: To outline an approach to the practical management of patients with IBS. DISCUSSION: A positive diagnosis can be made if a few simple questions are asked, and the diagnosis can be confirmed by a small number of tests to exclude structural disease. Improved understanding of the differences in gut function in patients with IBS is likely to result in the development of some exciting new therapies.

CitationsScopus - 4
2000Xia HHX, Kalantar JS, Wyatt JM, Adams S, Cheung K, Eslick GD, Talley NJ, 'High sensitivity and specificity of a laboratory-based serological test, pylori DTect ELISA, for detection of Helicobacter pylori infection', DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 36 69-74 (2000)
DOI10.1016/S0732-8893(99)00101-7Author URL
CitationsScopus - 24Web of Science - 23
2000Talley NJ, Vakil N, Ballard II ED, Fennerty MB, 'The dyspepsia dilemma', CMAJ, 163 203-203 (2000)
CitationsScopus - 1
2000Neri M, Laterza F, Howell S, Di Gioacchino M, Festi D, Ballone E, et al., 'Symptoms discriminate irritable bowel syndrome from organic gastrointestinal diseases and food allergy', EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 12 981-988 (2000)
DOI10.1097/00042737-200012090-00003Author URL
CitationsScopus - 18Web of Science - 15
2000Pantoflickova D, Blum AL, Talley NJ, Koelz HR, 'Will eradication of Helicobacter pylori improve symptoms of non-ulcer dyspepsia? Meta-analysis included unreliable studies', BRITISH MEDICAL JOURNAL, 320 1209-1209 (2000)
Author URL
CitationsScopus - 7Web of Science - 5
2000Cates C, Delaney B, Moayyedi P, Soo S, Deeks J, Forman D, et al., 'Will eradication of Helicobacter pylori improve symptoms of non-ulcer dyspepsia? (multiple letters)', British Medical Journal, 320 1208-1210 (2000)
CitationsScopus - 5
2000Thitiphuree S, Talley NJ, 'Esomeprazole, a new proton pump inhibitor: Pharmacological characteristics and clinical efficacy', INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 54 537-541 (2000)
Author URL
CitationsScopus - 21Web of Science - 17
2000Nandurkar S, Talley NJ, 'Epidemiology and natural history of reflux disease', BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY, 14 743-757 (2000)
DOI10.1053/bega.2000.0122Author URL
CitationsScopus - 67Web of Science - 44
2000Koloski NA, Talley NJ, Boyce PM, 'The impact of functional gastrointestinal disorders on quality of life', AMERICAN JOURNAL OF GASTROENTEROLOGY, 95 67-71 (2000)
Author URL
CitationsScopus - 122Web of Science - 92
2000Xia HHX, Kalantar JS, Talley NJ, Wyatt JM, Adams S, Cheung K, Mitchell HM, 'Antral-type mucosa in the gastric incisura, body, and fundus (antralization): A link between Helicobacter pylori infection and intestinal metaplasia?', AMERICAN JOURNAL OF GASTROENTEROLOGY, 95 114-121 (2000)
Author URL
CitationsScopus - 65Web of Science - 60
2000Locke GR, Zinsmeister AR, Talley NJ, Fett SL, Melton LJ, 'Risk factors for irritable bowel syndrome: Role of analgesics and food sensitivities', AMERICAN JOURNAL OF GASTROENTEROLOGY, 95 157-165 (2000)
Author URL
CitationsScopus - 112Web of Science - 93
2000Talley NJ, 'Irritable bowel syndrome and health care seeking: Do we pass our bad habits onto our children?', AMERICAN JOURNAL OF GASTROENTEROLOGY, 95 340-341 (2000)
Author URL
CitationsScopus - 5Web of Science - 3
2000Carpenter HA, Talley NJ, 'The importance of clinicopathological correlation in the diagnosis of inflammatory conditions of the colon: Histological patterns with clinical implications', AMERICAN JOURNAL OF GASTROENTEROLOGY, 95 878-896 (2000)
Author URL
CitationsScopus - 87Web of Science - 54
2000Talley NJ, Holtmann G, Agreus L, Jones M, 'Gastrointestinal symptoms and subjects cluster into distinct upper and lower groupings in the community: A four nations study', AMERICAN JOURNAL OF GASTROENTEROLOGY, 95 1439-1447 (2000)
Author URL
CitationsScopus - 72Web of Science - 65
2000Locke GR, Talley NJ, Nelson DK, Haruma K, Weaver AL, Zinsmeister AR, Melton LJ, 'Helicobacter pylori and dyspepsia: A population-based study of the organism and host', AMERICAN JOURNAL OF GASTROENTEROLOGY, 95 1906-1913 (2000)
Author URL
CitationsScopus - 36Web of Science - 26
2000Hu WHC, Martin CJ, Talley NJ, 'Intraesophageal acid perfusion sensitizes the esophagus to mechanical distension: A barostat study', AMERICAN JOURNAL OF GASTROENTEROLOGY, 95 2189-2194 (2000)
Author URL
CitationsScopus - 54Web of Science - 47
2000Saito YA, Locke GR, Talley NJ, Zinsmeister AR, Fett SL, Melton LJ, 'A comparison of the Rome and manning criteria for case identification in epidemiological investigations of irritable bowel syndrome', AMERICAN JOURNAL OF GASTROENTEROLOGY, 95 2816-2824 (2000)
DOI10.1016/S0002-9270(00)01985-7Author URL
CitationsScopus - 157Web of Science - 128
2000Boyce PM, Koloski NA, Talley NJ, 'Irritable bowel syndrome according to varying diagnostic criteria: Are the new Rome II criteria unnecessarily restrictive for research and practice?', AMERICAN JOURNAL OF GASTROENTEROLOGY, 95 3176-3183 (2000)
Author URL
CitationsScopus - 171Web of Science - 139
2000Boyce P, Gilchrist J, Talley NJ, Rose D, 'Cognitive-behaviour therapy as a treatment for irritable bowel syndrome: a pilot study', AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 34 300-309 (2000)
DOI10.1080/j.1440-1614.2000.00731.xAuthor URL
CitationsScopus - 44Web of Science - 37
1999Roberts RO, Jacobsen SJ, Reilly WT, Pemberton JH, Lieber MM, Talley NJ, 'Prevalence of combined fecal and urinary incontinence: A community-based study', JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 47 837-841 (1999)
Author URL
CitationsScopus - 164Web of Science - 129
1999Nandurkar S, Talley NJ, 'Barrett's esophagus: The long and the short of it (vol 94, pg 30, 1999)', AMERICAN JOURNAL OF GASTROENTEROLOGY, 94 1719-1719 (1999)
Author URL
CitationsWeb of Science - 1
1999Talley NJ, Verlinden M, Jones M, 'Validity of a new quality of life scale for functional dyspepsia: a United States multicenter trial of the Nepean Dyspepsia Index', AMERICAN JOURNAL OF GASTROENTEROLOGY, 94 2390-2397 (1999)
Author URL
CitationsScopus - 92Web of Science - 77
1999Nandurkar S, Talley NJ, 'Barrett's esophagus: The long and the short of it', AMERICAN JOURNAL OF GASTROENTEROLOGY, 94 30-40 (1999)
Author URL
CitationsScopus - 106Web of Science - 90
1999Nandurkar S, Talley NJ, 'Erratum: Barrett's esophagus: (Gastroenterology (January 1999) 94 (30- 40))', American Journal of Gastroenterology, 94 1719-1719 (1999)
1999Eslick GD, Lim L, Byles JE, Talley N, Xia H, 'Association of Helicobacter Pylori Infection with Gastric Carcinoma: a Meta Analysis', American Journal of Gastroenterology, 94 2374-2379 (1999) [C1]
CitationsScopus - 256Web of Science - 222
Co-authorsJulie Byles
1999Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ, 'Risk factors associated with symptoms of gastroesophageal reflux', AMERICAN JOURNAL OF MEDICINE, 106 642-649 (1999)
DOI10.1016/S0002-9343(99)00121-7Author URL
CitationsScopus - 335Web of Science - 304
1999Hammer J, Talley NJ, 'Diagnostic criteria for the irritable bowel syndrome', American Journal of Medicine, 107 5-11 (1999)

The Rome criteria represent a consensus viewpoint based on currently available data, but their development certainly does not establish that the content is truly indicative of a s... [more]

The Rome criteria represent a consensus viewpoint based on currently available data, but their development certainly does not establish that the content is truly indicative of a specific disease process. There is a limit to the repertoire of gastrointestinal symptoms; because of the low specificity of symptoms, it is understandable that symptoms alone are unlikely to be accurate enough. However, in the absence of a reproducible and accepted biological marker, symptoms currently remain the primary means of identifying and recruiting patients for research. All diagnostic criteria will continue to be controversial until the pathophysiology of irritable bowel syndrome (IBS) is better understood and treatment more appropriately targeted to relevant disturbances. The aim of this review is to present the current Rome criteria and critically evaluate the arguments for and against the individual components being included as part of the criteria. Copyright (C) 1999 Excerpta Medica Inc.

DOI10.1016/S0002-9343(99)00276-4
CitationsScopus - 32
1999Oliveria SA, Christos PJ, Talley NJ, Dannenberg AJ, 'Heartburn risk factors, knowledge, and prevention strategies - A population-based survey of individuals with heartburn', ARCHIVES OF INTERNAL MEDICINE, 159 1592-1598 (1999)
DOI10.1001/archinte.159.14.1592Author URL
CitationsScopus - 57Web of Science - 47
1999Xia HHX, Talley NJ, 'Helicobacter pylori eradication in patients with non-ulcer dyspepsia', DRUGS, 58 785-792 (1999)
DOI10.2165/00003495-199958050-00001Author URL
CitationsScopus - 16Web of Science - 11
1999Fullerton SC, Wiklund IK, Hassle A, Talley NJ, Kamm MJ, van Zanten SV, et al., 'Gender differences in self-assessed symptom and quality of life endpoints in clinical studies of upper gastrointestinal disease', GASTROENTEROLOGY, 116 A60-A60 (1999)
Author URL
1999Hammer J, Willson T, Horowitz M, Talley NJ, 'Prevalence and determinants of chronic gastrointestinal symptoms in diabetes mellitus', GASTROENTEROLOGY, 116 A63-A63 (1999)
Author URL
CitationsWeb of Science - 1
1999Jones MP, Talley NJ, Dubois DJ, 'Laxatives in chronic constipation: A statistical meta-analysis', GASTROENTEROLOGY, 116 A67-A67 (1999)
Author URL
CitationsWeb of Science - 2
1999Jones MP, Talley NJ, 'Classification of dyspepsia sub-types: Patient perception v Rome criteria', GASTROENTEROLOGY, 116 A67-A67 (1999)
Author URL
CitationsWeb of Science - 2
1999Junghard O, Wiklund I, Lauritsen K, Talley NJ, 'Validation of 7-graded diary cards for severity of dyspeptic symptoms in patients with non-ulcer dyspepsia (NUD)', GASTROENTEROLOGY, 116 A68-A68 (1999)
Author URL
1999Koloski NA, Talley NJ, Boyce PM, 'Functional gastrointestinal disorders (FGIDs) impair quality of life in consulters and non-consulters', GASTROENTEROLOGY, 116 A71-A71 (1999)
Author URL
1999Koloski NA, Talley NJ, Boyce PM, 'High prevalence and striking overlap of the functional gastrointestinal disorders (FGIDs): Is the current Rome classification worthwhile?', GASTROENTEROLOGY, 116 A72-A72 (1999)
Author URL
1999Talley NJ, Eslick GD, Jones MP, 'Gastro-esophageal reflux disease (GERD) explains most non-cardiac chest pain: A population-based study', GASTROENTEROLOGY, 116 A99-A99 (1999)
Author URL
CitationsWeb of Science - 5
1999Talley NJ, Verlinden M, Jones MP, 'A new quality of life (QOL) impact scale for functional dyspepsia: The nepean dyspepsia index (NDI)', GASTROENTEROLOGY, 116 A99-A99 (1999)
Author URL
CitationsWeb of Science - 5
1999Wiklund I, Allgen U, Mercedes C, Garrigues V, Hamelin B, Talley NJ, Ahlstrom L, 'Predictors of the placebo run-in response in patients with functional dyspepsia', GASTROENTEROLOGY, 116 A104-A104 (1999)
Author URL
1999Wiklund I, Allgen U, Cucala M, Dalvag A, Garrigues V, Hamelin B, et al., 'Predictors of the placebo run in response in patients with functional dysperia', GASTROENTEROLOGY, 116 A104-A104 (1999)
Author URL
1999Bolling-Sternevald E, Talley NJ, Blum A, O'Morain C, Junghard O, Sundin M, et al., 'Does cure of H-pylori infection give different symptomatic response in patients with functional dyspepsia from different parts of the world?', GASTROENTEROLOGY, 116 A126-A126 (1999)
Author URL
CitationsWeb of Science - 1
1999Fullerton SC, Wiklund IK, Talley NJ, Kamm MJ, van Zanten SV, Pare P, et al., 'Patients with upper gastrointestinal symptoms (GI) have a poor quality of life regardless of the presence of esophagitis', GASTROENTEROLOGY, 116 A166-A166 (1999)
Author URL
1999Fullerton SC, Wiklund I, Talley NJ, Kamm M, van Zanten SV, Pare P, et al., 'Patients with upper gastrointestinal symptoms (GI) have a poor quality of life regardless of the presence of esophagitis', GASTROENTEROLOGY, 116 A166-A166 (1999)
Author URL
1999Holtmann G, Neufang-Hueber J, Kaune A, Gschossmann JM, Goebell H, Talley NJ, Gerken G, 'Changes of mechanosensory thresholds during treatment with aspirin and development of dyspeptic symptoms in patients with functional dyspepsia and healthy controls.', GASTROENTEROLOGY, 116 A188-A188 (1999)
Author URL
1999Holtmann G, Kurth T, Neufang-Hueber J, Goebell H, Diener HC, Talley NJ, Gerken G, 'Association between migraine and symptoms of functional gastrointestinal disorders.', GASTROENTEROLOGY, 116 A188-A189 (1999)
Author URL
1999Nandurkar S, Talley NJ, Martin CJ, Christopherson R, 'Short term culture of esophageal squamous epithelium and Barrett's epithelium from endoscopic biopsies', GASTROENTEROLOGY, 116 A264-A264 (1999)
Author URL
1999Nandurkar S, Talley NJ, Martin CJ, Adams S, 'To identify gastroesophageal reflux disease (GERD), don't bother taking an esophageal biopsy', GASTROENTEROLOGY, 116 A264-A265 (1999)
Author URL
1999Nandurkar S, Talley NJ, Martin CJ, Adams S, Wyatt JM, Cheung K, 'Intestinal metaplasia at the gastro-esophageal junction (IMAGE): Look beyond H.pylori (Hp)?', GASTROENTEROLOGY, 116 A265-A265 (1999)
Author URL
1999Xia HHX, Phung N, Kalandar J, Talley NJ, 'Characteristics of Helicobacter pylori positive and negative peptic ulcer disease', GASTROENTEROLOGY, 116 A359-A359 (1999)
Author URL
CitationsWeb of Science - 5
1999Hammer J, Hammer HF, Talley NJ, 'Evidence of a central mechanism of perception, spatial summation, in the rectum', GASTROENTEROLOGY, 116 A1002-A1002 (1999)
Author URL
1999Holtmann G, Neufang-Hueber J, Haag S, Kaune A, Eising EG, Talley NJ, Gerken G, 'Comparison of C-13-octanoic breath test and scintigraphy for the assessment of gastric emptying.', GASTROENTEROLOGY, 116 A1008-A1008 (1999)
Author URL
1999Koloski NA, Talley NJ, Boyce PM, 'Psychological mechanisms are linked to the pathophysiology of functional gastrointestinal disorders (FGIDS), and not just health care seeking', GASTROENTEROLOGY, 116 A1019-A1019 (1999)
Author URL
1999Koloski NA, Talley NJ, Boyce PM, 'High levels of health care utilisation for functional gastrointestinal disorders (FGIDS) in a community', GASTROENTEROLOGY, 116 A1019-A1019 (1999)
Author URL
1999Shaw MJ, Newcomer MK, Adlis SA, Talley NJ, 'A comparsion of the SF-12 and the SF-36 in primary care outpatients with digestive complaints', GASTROINTESTINAL ENDOSCOPY, 49 AB148-AB148 (1999)
Author URL
1999Haag S, Nandurkar S, Talley NJ, 'Regression of Barrett's esophagus: the role of acid suppression, surgery, and ablative methods', GASTROINTESTINAL ENDOSCOPY, 50 229-240 (1999)
DOI10.1016/S0016-5107(99)70230-0Author URL
CitationsScopus - 43Web of Science - 35
1999Dent J, Brun J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, et al., 'An evidence-based appraisal of reflux disease management - the Genval workshop report', GUT, 44 S1-S16 (1999)
Author URL
CitationsScopus - 759Web of Science - 385
1999Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GNJ, 'Functional gastroduodenal disorders', GUT, 45 37-42 (1999)
Author URL
CitationsScopus - 814Web of Science - 453
1999van Zanten SJOV, Talley NJ, Bytzer P, Klein KB, Whorwell PJ, Zinsmeister AR, 'Design of treatment trials for functional gastrointestinal disorders', GUT, 45 69-77 (1999)
Author URL
CitationsScopus - 181Web of Science - 121
1999Blum AL, Talley NJ, Stolte M, 'Helicobacter pylori and nonulcer dyspepsia', NEW ENGLAND JOURNAL OF MEDICINE, 340 1510-1511 (1999)
Author URL
1999Nandurkar S, Talley NJ, 'Gastroesophageal reflux and adenocarcinoma of the esophagus', NEW ENGLAND JOURNAL OF MEDICINE, 341 536-536 (1999)
Author URL
CitationsWeb of Science - 3
1999Talley NJ, Vakil N, Ballard ED, Fennerty MB, 'Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia', NEW ENGLAND JOURNAL OF MEDICINE, 341 1106-1111 (1999)
DOI10.1056/NEJM199910073411502Author URL
CitationsScopus - 265Web of Science - 243
1999Nandukar S, Talley NJ, Heath EI, Holbrook JT, Forastiere AA, Marcus G, et al., 'Gastroesophageal reflux and adenocarcinoma of the esophagus [1] (multiple letters)', New England Journal of Medicine, 341 536-538 (1999)
DOI10.1056/NEJM199908123410714
CitationsScopus - 3
1999Lieber CS, Puspok A, Oberhubek G, Logan RFA, Logan RPH, Ganz PA, et al., 'Helicobacter pylori and nonulcer dyspepsia [1] (multiple letters)', New England Journal of Medicine, 340 1508-1511 (1999)
DOI10.1056/NEJM199905133401912
CitationsScopus - 6
1999Meineche-Schmidt V, Talley NJ, Pap A, Kordecki H, Schmid V, Ohlsson L, et al., 'Impact of functional dyspepsia on quality of life and health care consumption after cessation of antisecretory treatment - A multicentre 3-month follow-up study', SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 34 566-574 (1999)
Author URL
CitationsScopus - 36Web of Science - 34
1999Bensoussan A, Talley NJ, Menzies R, 'Chinese herbal medicine for irritable bowel syndrome - Reply', JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 282 1036-1037 (1999)
Author URL
1999Lu W, Kaptchuk TJ, Wong HCG, Wong JKT, Wong NYY, Bensoussan A, et al., 'Chinese herbal medicine for irritable bowel syndrome [4] (multiple letters)', Journal of the American Medical Association, 282 1035-1037 (1999)
DOI10.1001/jama.282.11.1035
CitationsScopus - 8
1999Hammer J, Talley NJ, 'Nonulcer dyspepsia', CURRENT OPINION IN GASTROENTEROLOGY, 15 492-496 (1999)
DOI10.1097/00001574-199911000-00006Author URL
CitationsScopus - 5Web of Science - 5
1999Talley NJ, Chang FY, Wyatt JMA, Adams S, Lau A, Borody T, et al., 'Nizatidine in combination with amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection. (vol 12, pg 527, 1998)', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 13 841-841 (1999)
Author URL
1999Talley NJ, Axon A, Bytzer P, Holtmann G, Lam SK, van Zanten SV, 'Management of uninvestigated and functional dyspepsia: a working party report for the World Congresses of Gastroenterology 1998', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 13 1135-1148 (1999)
Author URL
CitationsScopus - 95Web of Science - 74
1999Talley NJ, Haque M, Wyeth JW, Stace NH, Tytgat GNJ, Stanghellini V, et al., 'Development of a new dyspepsia impact scale: The Nepean Dyspepsia Index', Alimentary Pharmacology and Therapeutics, 13 225-235 (1999)

Background: There is not at present a suitable disease-specific health-related quality of life instrument for uninvestigated dyspepsia and functional (non-ulcer) dyspepsia. Aim: T... [more]

Background: There is not at present a suitable disease-specific health-related quality of life instrument for uninvestigated dyspepsia and functional (non-ulcer) dyspepsia. Aim: To develop a new multi-dimensional disease-specific instrument. Methods: The Nepean Dyspepsia Index (NDI) was designed to measure impairment of a subject's ability to engage in relevant aspects of their life and also their enjoyment of these aspects; in addition, the individual importance of each aspect is assessed. A 42-item quality of life measure was developed and tested, both in out-patients presenting to general practice with upper gastrointestinal complaints (n = 113) and in a randomly chosen population-based sample (n = 347). Results: Adequate face and content validity was documented by an expert panel. Factor analysis identified four clinically relevant subscales: interference with activities of daily living, work, enjoyment of life and emotional well-being; lack of knowledge and control over the illness: disturbance to eating or drinking; and disturbance to sleep because of dyspepsia. These scales had high internal consistency. Both symptoms and the quality of life scores discriminated dyspepsia from health. Conclusion: The Nepean Dyspepsia Index is a reliable and valid disease-specific index for dyspepsia, measuring symptoms and health-related quality of life.

DOI10.1046/j.1365-2036.1999.00445.x
CitationsScopus - 102
1999Talley NJ, Chang FY, Wyatt JMA, Adams S, Lau A, Borody T, et al., 'Erratum: Nizatidine in combination with amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection (Alimentary Pharmacology and Therapeutics (1998), 12, (527-32))', Alimentary Pharmacology and Therapeutics, 13 841-841 (1999)
DOI10.1046/j.1365-2036.1999.00001.x
1999Mackender D, Talley NJ, 'Cutaneous signs of systemic disease: Part 2. Characteristic lesions of common diseases', Current Therapeutics, 40 83-87 (1999)

The first article of this series (July 1999) focused on nail abnormalities and disorders of pigmentation as signs of systemic disease. In this second article, some characteristic ... [more]

The first article of this series (July 1999) focused on nail abnormalities and disorders of pigmentation as signs of systemic disease. In this second article, some characteristic cutaneous conditions associated with certain diseases or groups of diseases are discussed. A brief overview of cutaneous problems in system-related diseases is also provided. The third article in this series will appear in the September 1999 issue of Current Therapeutics.

1999Mackender D, Talley NJ, 'Cutaneous signs of systemic disease: Part 3. Lesions in rheumatological and connective tissue diseases, HIV infection and miscellaneous conditions', Current Therapeutics, 40 67-73 (1999)

The first two articles in this series focused on (1) nail abnormalities and disorders of pigmentation as signs of systemic disease (July 1999), and (2) characteristic cutaneous co... [more]

The first two articles in this series focused on (1) nail abnormalities and disorders of pigmentation as signs of systemic disease (July 1999), and (2) characteristic cutaneous conditions associated with selected diseases (August 1999). The third and last of this series of articles discusses cutaneous signs of rheumatological and connective tissue disease, HIV infection, metabolic disturbances and miscellaneous systemic conditions.

1999Mackender D, Talley NJ, 'Cutaneous signs of systemic disease', Current Therapeutics, 40 83-89 (1999)
1999Talley NJ, 'Management of dyspepsia and functional dyspepsia: An international perspective', CANADIAN JOURNAL OF GASTROENTEROLOGY, 13 685-687 (1999)
Author URL
CitationsScopus - 3Web of Science - 2
1999Kalantar JS, Talley NJ, 'The effects of lottery incentive and length of questionnaire on health survey response rates: A randomized study', JOURNAL OF CLINICAL EPIDEMIOLOGY, 52 1117-1122 (1999)
DOI10.1016/S0895-4356(99)00051-7Author URL
CitationsScopus - 82Web of Science - 75
1999Howell S, Talley NJ, 'Does fear of serious disease predict consulting behaviour amongst patients with dyspepsia in general practice?', EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 11 881-886 (1999)
DOI10.1097/00042737-199908000-00012Author URL
CitationsScopus - 34Web of Science - 29
1999Tytgat G, Hungin APS, Malfertheiner P, Talley N, Hongo M, McColl K, et al., 'Decision-making in dyspepsia: Controversies in primary and secondary care', European Journal of Gastroenterology and Hepatology, 11 223-230 (1999)
CitationsScopus - 14
1999Talley NJ, Janssens J, Lauritsen K, Rácz I, Bolling-Sternevald E, 'Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group.', BMJ (Clinical research ed.), 318 833-837 (1999)
DOI10.1136/bmj.318.7187.833
1999Talley NJ, Janssens J, Lauritsen K, Racz I, Bolling-Sternevald E, 'Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up', BRITISH MEDICAL JOURNAL, 318 833-837 (1999)
Author URL
CitationsScopus - 242Web of Science - 226
1999Talley NJ, Lauritsen K, Bolling-Sternevald E, 'Eradication of Helicobacter pylori in functional dyspepsia - Reply', BRITISH MEDICAL JOURNAL, 319 451-452 (1999)
Author URL
1999Xia HHX, Fan XG, Talley NJ, 'Clarithromycin resistance in Helicobacter pylori and its clinical relevance', WORLD JOURNAL OF GASTROENTEROLOGY, 5 263-266 (1999)
Author URL
CitationsScopus - 25Web of Science - 14
1999Besoussan A, Talley NJ, Menzies R, Guo A, Ngu M, Brinkhaus B, 'Treatment of irritable bowel syndrome with Chinese herbal medicine', Forschende Komplementarmedizin, 6 157-158 (1999)
1999Xia HHX, Gallagher C, Hyde D, Talley NJ, Keane CT, O'Morain CA, 'Comparison between McCoy cell line and HeLa cell line for detecting Helicobacter pylori cytotoxicity: clinical and pathological relevance', ITALIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 31 663-668 (1999)
Author URL
CitationsScopus - 4Web of Science - 4
1999Hua-Xiang Xia H, Gallagher C, Hyde D, Talley NJ, Keane CT, O'Morain CA, 'Comparison between McCoy cell line and HeLa cell line for detecting Helicobacter pylori cytotoxicity: Clinical and pathological relevance', Italian Journal of Gastroenterology and Hepatology, 31 651-658 (1999)

Background. Cell culture assay is an accurate test for detecting Helicobacter pylori cytotoxicity. Aims. To evaluate McCoy cells for detecting Helicobacter pylori cytotoxicity by ... [more]

Background. Cell culture assay is an accurate test for detecting Helicobacter pylori cytotoxicity. Aims. To evaluate McCoy cells for detecting Helicobacter pylori cytotoxicity by comparing with HeLa cells, and determine the association of cytotoxic strains with endoscopie and histological findings. Methods. Helicobacter pylori isolates from 68 dyspeptic patients and 11 asymptomatic volunteers were tested. 180 ul (1.8 x 10 cells) of grown McCoy or HeLa cell suspension was seeded into each well of a 96-well microtitre tray and the medium was replaced once after 24 hours. Sonicate (20 ul) of each isolate was then added to the wells, in duplicate. After 24 and 48 hours incubation, intracellular vacuolation was assessed by inverted light microscopy. Results. Using McCoy cells 57% of isolates showed cytotoxicity (23% weak and 34% strong), while using HeLa cells 30% of isolates showed strong cytotoxicity. All isolates toxic in HeLa cells were also toxic in McCoy cells. The prevalence of cytotoxic strains was not significantly different benveen the endoscopie findings; 50% in normal endoscopy, 60% in non-ulcer dyspepsia and 59% in peptic ulcer disease. However, cytotoxic strains were more common in subjects with severe histological gastritis than in those with normal mucosa or mild gastritis (66% vs 30%, p<0.01). Similarly, the prevalence of cytotoxic strains was also higher in subjects with active gastritis than in those without (64% vs 23%, p<0.01). Conclusions. McCoy cells are more sensitive than HeLa cells for detecting Helicobacter pylori cytotoxicity in vitro. There is an association between cytotoxic strains and the severity and activity of histological gastritis.

1999Chan FK, Sung JJ, Chung SC, Talley NJ, Eslick GD, 'Eradication of Helicobacter pylori before NSAID treatment prevented ulcers', Enfermedades Infecciosas y Microbiologia, 19 103-104 (1999)
1999Bolin TD, Korman MG, Stanton R, Talley N, Newstead GL, Donnelly N, et al., 'Positive cost effectiveness of early diagnosis of colorectal cancer', Colorectal Disease, 1 113-122 (1999)

Background Studies examining interventional screening have lacked accurate data, because costs of hospital infrastructure, nursing and disinfection have not been included. We comp... [more]

Background Studies examining interventional screening have lacked accurate data, because costs of hospital infrastructure, nursing and disinfection have not been included. We compared all costs of different strategies for screening, including colonoscopy, to provide a rational basis for decisions in early diagnosis. The costs, although based on Australian data, are probably applicable to all developed countries. Methods Comprehensive cost data from Australian private day endoscopy centres, public and private hospitals, physicians, anaesthetists and pathologists were used to assess medical and infrastructure hospital costs for various methods of screening. The data were processed using the Office of Technology Assessment colorectal cancer screening model. Results Annual or triennial faecal occult blood tests (FOBT; Hemoccult®) are cost-effective, particularly with assumed 10-year dwell times (the time taken for an adenoma to become a cancer), the costs per year of life saved being $US 26 015 and $US 24 756, respectively. Colonoscopy at 5- or 10-year intervals is also cost- effective with similar dwell times, and colonoscopy every 10 years with a cost of $27 159 per year saved is comparable to annual or triennial FOBT. Double contrast barium enema at either 3- or 5-year intervals is cost-effective, but ideally should be combined with an annual FOBT, reducing the cost effectiveness of these options. FOBT also is ideally combined with flexible sigmoidoscopy; an annual FOBT and 5-yearly flexible sigmoidoscopy is cost-effective with both 5- and 10-year dwell times, though less than FOBT or colonoscopy. A once-only colonoscopy at age 50 is not cost-effective. Conclusions Annual or triennial FOBT, double contrast barium enema (DCBE) 3 and 5 and colonoscopy 5 and 10 are all cost-effective. There is less value in combining FOBT and flexible sigmoidoscopy, or flexible sigmoidoscopy alone. Physicians therefore have the option of offering individuals a range of cost-effective screening strategies, including colonoscopy.

CitationsScopus - 14
1999Lam TCF, Kennedy ML, Chen FC, Lubowski DZ, Talley NJ, 'Prevalence of faecal incontinence: Obstetric and constipation-related risk factors; a population-based study', Colorectal Disease, 1 197-203 (1999)

Objective Patients suffering from faecal incontinence may be reluctant to seek medical advice and the true prevalence is uncertain. The aim of the study was to determine the preva... [more]

Objective Patients suffering from faecal incontinence may be reluctant to seek medical advice and the true prevalence is uncertain. The aim of the study was to determine the prevalence of faecal incontinence and to correlate this with possible risk factors. Subjects and methods A standardized questionnaire was posted to 955 subjects randomly selected from a local Sydney electoral role of 68 821 voters. Results The response rate was 71% (M:F = 259:359). The overall prevalence of faecal incontinence, defined as answering in the affirmative to at least two of three questions which incorporated stool leakage, wearing a pad because of bowel incontinence and frequent incontinence of flatus, was 15% and was more prevalent in men (20%) than women (11%) (P < 0.015). The prevalence of urinary stress incontinence in women was 31%, and similarly 31% for urge incontinence. In men the prevalence of stress and urge urinary incontinence was 4% and 12%, respectively. Overall, there was a significant association between faecal incontinence and a sensation of incomplete rectal evacuation (P < 0.001), obstructed defaecation (P < 0.001), and subjective patient assessment of being constipated (P < 0.001). In women there was a significant association between faecal incontinence and episiotomy (P < 0.01), forceps delivery (P < 0.01), perineal tears (P < 0.01) and hysterectomy (P < 0.049). There was also a strong association between stress urinary incontinence and parity (P < 0.001), episiotomy (P < 0.001), forceps (P < 0.01), perineal tears (P < 0.01) and hysterectomy (P < 0.003). Using logistic regression models, independent risk factors for faecal incontinence were gender (male, odds ratio (OR) = 3.9, 95% confidence interval (CI) = 2.0-7.5), constipation (OR = 27.1, 95% CI = 12.3-59.5), straining (OR = 0.24, 95% CI = 0.1-0.6) and episiotomy (OR = 2.9, 95% CI = 1.4-6.0). Conclusion A higher prevalence of faecal incontinence than previously reported was observed, particularly in males. The prevalence of urinary incontinence was consistent with other studies. Faecal and urinary incontinence are important community health problems in both sexes.

CitationsScopus - 52
1999Talley NJ, 'Irritable bowel syndrome: definition, diagnosis and epidemiology', BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY, 13 371-384 (1999)
DOI10.1053/bega.1999.0033Author URL
CitationsScopus - 86Web of Science - 69
1998Evans JM, Fleming KC, Talley NJ, Schleck CD, Zinsmeister AR, Melton LJ, 'Relation of colonic transit to functional bowel disease in older people: A population-based study', JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 46 83-87 (1998)
Author URL
CitationsScopus - 43Web of Science - 39
1998Roberts RO, Jacobsen SJ, Rhodes T, Reilly WT, Girman CJ, Talley NJ, Lieber MM, 'Urinary incontinence in a community-based cohort: Prevalence and healthcare-seeking', JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 46 467-472 (1998)
Author URL
CitationsScopus - 92Web of Science - 86
1998Xia HHX, Talley NJ, 'Helicobacter pylori infection, reflux esophagitis, and atrophic gastritis: An unexplored triangle', AMERICAN JOURNAL OF GASTROENTEROLOGY, 93 394-400 (1998)
DOI10.1111/j.1572-0241.1998.00394.xAuthor URL
CitationsScopus - 57Web of Science - 53
1998Holtmann G, Talley NJ, Mitchell H, Hazell S, 'Antibody response to specific H-pylori antigens in functional dyspepsia, duodenal ulcer disease, and health', AMERICAN JOURNAL OF GASTROENTEROLOGY, 93 1222-1227 (1998)
Author URL
CitationsScopus - 41Web of Science - 39
1998Komoto K, Haruma K, Kamada T, Tanaka S, Yoshihara M, Sumii K, et al., 'Helicobacter pylori infection and gastric neoplasia: Correlations with histological gastritis and tumor histology', AMERICAN JOURNAL OF GASTROENTEROLOGY, 93 1271-1276 (1998)
Author URL
CitationsScopus - 123Web of Science - 100
1998Talley NJ, Jones M, 'Self-reported rectal bleeding in a United States community: Prevalence, risk factors, and health care seeking', AMERICAN JOURNAL OF GASTROENTEROLOGY, 93 2179-2183 (1998)
Author URL
CitationsScopus - 73Web of Science - 52
1998Niec AM, Frankum B, Talley NJ, 'Are adverse food reactions linked to irritable bowel syndrome?', AMERICAN JOURNAL OF GASTROENTEROLOGY, 93 2184-2190 (1998)
Author URL
CitationsScopus - 109Web of Science - 88
1998Talley NJ, 'Healing of nonsteroidal anti-inflammatory drug-associated ulcers and erosions, and relief of dyspeptic symptoms: A commentary on the new data', American Journal of Medicine, 104 (1998)
DOI10.1016/S0002-9343(97)00214-3
CitationsScopus - 4
1998Kato M, Kephart GM, Talley NJ, Wagner JM, Sarr MG, Bonno M, et al., 'Eosinophil infiltration and degranulation in normal human tissue', ANATOMICAL RECORD, 252 418-425 (1998)
DOI10.1002/(SICI)1097-0185(199811)252:3<418::AID-AR10>3.0.CO;2-1Author URL
CitationsScopus - 121Web of Science - 108
1998Talley NJ, Xia HHX, 'Helicobacter pylori infection and non-ulcer dyspepsia', BRITISH MEDICAL BULLETIN, 54 63-69 (1998)
Author URL
CitationsScopus - 13Web of Science - 11
1998Talley NJ, Silverstein MD, Agreus L, Nyren O, Sonnenberg A, Holtmann G, 'AGA technical review: Evaluation of dyspepsia', GASTROENTEROLOGY, 114 582-595 (1998)
DOI10.1016/S0016-5085(98)70542-6Author URL
CitationsScopus - 363Web of Science - 298
1998Agreus L, Talley NJ, Svardsudd K, Nyren O, Tibblin G, Jones MP, 'Is it possible to simplify the definition of the irritable bowel syndrome in population-based studies and clinical practice?', GASTROENTEROLOGY, 114 A2-A2 (1998)
Author URL
CitationsWeb of Science - 4
1998Agreus L, Talley NJ, Svardsudd K, Nyren O, Tibblin G, Jones MP, 'Natural history of reflux, dyspepsia and irritable bowel over 7 years in the general population.', GASTROENTEROLOGY, 114 A2-A2 (1998)
Author URL
CitationsWeb of Science - 4
1998Shaw MJ, Beebe TJ, Adlis SA, Tomshine PA, Talley NJ, 'The clinical utility of the Park Nicollet Digestive Health Status Instrument for patients with gastroesophageal reflux disease.', GASTROENTEROLOGY, 114 A41-A41 (1998)
DOI10.1016/S0016-5085(98)81156-6Author URL
CitationsWeb of Science - 5
1998Shaw MJ, Kane RL, Fendrick AM, Adlis SA, Talley NJ, 'The impact of over-the-counter histamine-2-antagonists: Great expectations unfulfilled.', GASTROENTEROLOGY, 114 A41-A41 (1998)
DOI10.1016/S0016-5085(98)81156-6Author URL
CitationsWeb of Science - 5
1998Westbrook JI, Talley NJ, McIntosh JH, 'Dyspepsia - Prevalence, subgroups and health care seeking: A random survey of 2300 households.', GASTROENTEROLOGY, 114 A49-A49 (1998)
Author URL
CitationsWeb of Science - 4
1998Wiklund I, Junghard O, Grace E, Talley NJ, Kamm MA, van Zanten SV, et al., 'Quality of life in reflux and dyspepsia. Development and psychometric documentation of a disease-specific questionnaire (QOLRAD).', GASTROENTEROLOGY, 114 A49-A49 (1998)
DOI10.1016/S0016-5085(98)80199-6Author URL
1998Holtmann G, Neufang-Huber J, Goebell H, Talley NJ, 'Influence of repeated phasic distension on gastric mechanosensory function in subjects (non-patients) with and without functional dyspepsia.', GASTROENTEROLOGY, 114 A151-A151 (1998)
Author URL
CitationsWeb of Science - 16
1998Holtmann G, Neufang-Huber J, Kaune A, Goebell H, Talley NJ, 'Mechanisms involved in the development of dyspeptic symptoms during treatment with aspirin.', GASTROENTEROLOGY, 114 A151-A151 (1998)
Author URL
CitationsWeb of Science - 16
1998Howell S, Talley NJ, Cairns D, 'Do dyspepsia subgroups predict response to treatment in functional dyspepsia?', GASTROENTEROLOGY, 114 A154-A154 (1998)
DOI10.1016/S0016-5085(98)80625-2Author URL
1998Meineche-Schmidt V, Talley NJ, Pap A, Kordecki H, Schmid V, Ohlsson L, et al., 'Healthcare consumption and quality of life in patients with functional dyspepsia after omeprazole treatment.', GASTROENTEROLOGY, 114 A223-A223 (1998)
Author URL
1998Mitchell H, Xia HHX, Cullen DJE, Christiansen KJ, Epis J, Collins BJ, et al., 'The enigma of Busselton: A high seroprevalence of CagA in families living in a rural community of Australia.', GASTROENTEROLOGY, 114 A229-A229 (1998)
DOI10.1016/S0016-5085(98)80929-3Author URL
1998Shaw MJ, Adlis SA, Beebe TJ, Talley NJ, 'When does simple heartburn become a disease?', GASTROENTEROLOGY, 114 A284-A284 (1998)
DOI10.1016/S0016-5085(98)81156-6Author URL
CitationsWeb of Science - 5
1998Talley NJ, Meineche-Schmidt V, Pare P, Duckworth M, Raisanen P, Pap A, et al., 'Is acid suppression efficacious in non-ulcer dyspepsia? A double-blind, randomised, controlled trial with omeprazole.', GASTROENTEROLOGY, 114 A305-A305 (1998)
Author URL
CitationsWeb of Science - 20
1998Talley NJ, Janssens J, Lauritsen K, Racz I, Bolling-Stemevald E, Havu N, et al., 'Long-term follow-up of patients with non-ulcer dyspepsia after Helicobacter pylori eradication. A randomized double-blind placebo-controlled trial.', GASTROENTEROLOGY, 114 A305-A305 (1998)
Author URL
CitationsWeb of Science - 20
1998Talley NJ, Janssens I, Lauritsen K, Racz I, Bolling-Sternevald E, Havu N, et al., 'No increase of reflux symptoms or esophagitis in patients with non-ulcer dyspepsia 12 months after Helicobacter pylori eradication. A randomized double-blind placebo-controlled trial.', GASTROENTEROLOGY, 114 A306-A306 (1998)
DOI10.1016/S0016-5085(98)81240-7Author URL
CitationsWeb of Science - 26
1998van Zanten SV, Jones M, Talley NJ, 'Cisapride for treatment of non-ulcer dyspepsia (NUD): A meta-analysis of randomized controlled trials.', GASTROENTEROLOGY, 114 A323-A323 (1998)
Author URL
CitationsWeb of Science - 7
1998Xia HHX, Kalantar J, Wyatt JM, Adams S, Cheung K, Talley NJ, 'Helicobacter pylori-associated antralization of proximal gastric mucosa is linked to an increased risk of development of intestinal metaplasia.', GASTROENTEROLOGY, 114 A335-A335 (1998)
Author URL
CitationsWeb of Science - 2
1998Xia HHX, Kalantar J, Eslick GD, Wyatt JM, Adams S, Cheung K, Talley NJ, 'Anti-secretory drugs increase corpus gastritis but only in the presence of Helicobacter pylori infection.', GASTROENTEROLOGY, 114 A335-A335 (1998)
Author URL
CitationsWeb of Science - 2
1998Xia HHX, Kalantar J, Wyatt JM, Adams S, Cheung K, Mitchell HM, Talley NJ, 'Does Helicobacter pylori serology predict the intragastric bacterial density of H-pylori and the histological severity of gastritis?', GASTROENTEROLOGY, 114 A336-A336 (1998)
Author URL
CitationsWeb of Science - 2
1998Xia HHX, Kalantar J, Wyatt JM, Adams S, Cheung K, Mitchell HM, Talley NJ, 'Failure of Helicobacter pylori serology to identify most peptic ulcer disease in patients with dyspepsia.', GASTROENTEROLOGY, 114 A336-A336 (1998)
Author URL
CitationsWeb of Science - 2
1998Eslick GD, Talley NJ, 'Helicobacter pylori infection and gastric carcinoma: A meta-analysis.', GASTROENTEROLOGY, 114 A592-A592 (1998)
DOI10.1016/S0016-5085(98)82411-6Author URL
1998Holtmann G, Neufang-Huber J, Goebell H, Talley NJ, 'What is the optimal method for the assessment of visceral mechano-sensory thresholds in humans: Sensory tracking, phasic ramp or random ramp distension?', GASTROENTEROLOGY, 114 A767-A767 (1998)
DOI10.1016/S0016-5085(98)83136-3Author URL
1998Howell S, Talley NJ, 'Do symptoms or psychological factors sustain health-care seeking among patients with functional dyspepsia?', GASTROENTEROLOGY, 114 A768-A768 (1998)
DOI10.1016/S0016-5085(98)83140-5Author URL
1998Kutscher SU, Holtmann G, Heuft G, Neufang-Huber J, Senf W, Goebell H, Talley NJ, 'Prevalence of dyspepsia and other GI complaints in patients treated for psychosomatic disorders.', GASTROENTEROLOGY, 114 A782-A782 (1998)
DOI10.1016/S0016-5085(98)83197-1Author URL
CitationsWeb of Science - 1
1998Newcomer MK, Shaw MJ, Beebe TJ, Adlis SA, Talley NJ, 'Factors associated with health care seeking in irritable bowel syndrome', GASTROENTEROLOGY, 114 A810-A810 (1998)
DOI10.1016/S0016-5085(98)83306-4Author URL
1998Saito YA, Locke GR, Talley NJ, Zinsmeister AR, Melton LJ, 'A comparison of the Rome and Manning criteria in identifying individuals with the irritable bowel syndrome.', GASTROENTEROLOGY, 114 A830-A830 (1998)
DOI10.1016/S0016-5085(98)83380-5Author URL
1998Wiklund I, Glise H, Jerndal P, Carlsson J, Talley NJ, 'Does endoscopy have a positive impact on quality of life in dyspepsia?', GASTROINTESTINAL ENDOSCOPY, 47 449-454 (1998)
DOI10.1016/S0016-5107(98)70243-3Author URL
CitationsScopus - 86Web of Science - 76
1998Talley NJ, Boyce PM, Jones M, 'Is the association between irritable bowel syndrome and abuse explained by neuroticism? A population based study', GUT, 42 47-53 (1998)
Author URL
CitationsScopus - 107Web of Science - 100
1998Talley NJ, Boyce P, Jones M, 'Identification of distinct upper and lower gastrointestinal symptom groupings in an urban population', GUT, 42 690-695 (1998)
Author URL
CitationsScopus - 174Web of Science - 145
1998Talley NJ, Janssens J, Lauritsen K, Racz I, Bolling-Sternevald E, Havu N, et al., 'H-pylori eradication therapy for non-ulcer dyspepsia. A randomized double-blind placebo-controlled long-term trial', GUT, 43 A3-A3 (1998)
Author URL
1998Xia HHX, Kalantar J, Mitchell HM, Talley NJ, 'Helicobacter pylori serology cannot identify most peptic ulcer disease in patients with dyspepsia', GUT, 43 A51-A52 (1998)
Author URL
CitationsWeb of Science - 2
1998Talley NJ, Janssens J, Lauritsen K, Racz I, Bolling-Sternevald E, Havu N, et al., 'H-pylori eradication therapy for non-ulcer dyspepsia. A randomized double-blind placebo-controlled long-term trial', GUT, 43 A79-A79 (1998)
Author URL
CitationsWeb of Science - 2
1998Talley NJ, Meineche-Schmidt V, Pare P, Duckworth M, Raisanen P, Pap A, et al., 'Is acid suppression efficacious in non-ulcer dyspepsia? A double-blind, randomised, controlled trial with omeprazole', GUT, 43 A111-A111 (1998)
Author URL
CitationsWeb of Science - 2
1998Hu WHC, Talley NJ, 'Functional (non-ulcer) dyspepsia: unexplained but not unmanageable', MEDICAL JOURNAL OF AUSTRALIA, 168 507-512 (1998)
Author URL
CitationsScopus - 8Web of Science - 6
1998Blum AL, Talley NJ, O'Morain C, van Zanten SV, Labenz J, Stolte M, et al., 'Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia', NEW ENGLAND JOURNAL OF MEDICINE, 339 1875-1881 (1998)
DOI10.1056/NEJM199812243392602Author URL
CitationsScopus - 420Web of Science - 378
1998Agreus L, Talley NJ, 'Dyspepsia: Current understanding and management', ANNUAL REVIEW OF MEDICINE, 49 475-493 (1998)
Author URL
CitationsScopus - 45Web of Science - 37
1998Roberts RO, Jacobsen SJ, Jacobson DJ, Reilly WT, Talley NJ, Lieber MM, 'Natural history of prostatism: High American urological association symptom scores among community-dwelling men and women with urinary incontinence', UROLOGY, 51 213-219 (1998)
DOI10.1016/S0090-4295(97)00505-0Author URL
CitationsScopus - 31Web of Science - 28
1998Bensoussan A, Talley NJ, Hing M, Menzies R, Guo A, Ngu M, 'Treatment of irritable bowel syndrome with Chinese herbal medicine - A randomized controlled trial', JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 280 1585-1589 (1998)
DOI10.1001/jama.280.18.1585Author URL
CitationsScopus - 257Web of Science - 196
1998Talley NJ, Boyce P, Jones M, 'Dyspepsia and health care seeking in a community - How important are psychological factors?', DIGESTIVE DISEASES AND SCIENCES, 43 1016-1022 (1998)
DOI10.1023/A:1018878717715Author URL
CitationsScopus - 68Web of Science - 58
1998Hammer J, Talley NJ, 'Nonulcer dyspepsia', CURRENT OPINION IN GASTROENTEROLOGY, 14 447-451 (1998)
DOI10.1097/00001574-199811010-00005Author URL
CitationsScopus - 1Web of Science - 1
1998Talley NJ, Full-Young C, Wyatt JMA, Adams S, Lau A, Borody T, et al., 'Nizatidine in combination with amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 12 527-532 (1998)
Author URL
CitationsScopus - 4Web of Science - 6
1998Talley NJ, Lambert JR, Howell S, Xia HHX, Lin SK, Agreus L, 'An evaluation of whole blood testing for Helicobacter pylori in general practice', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 12 641-645 (1998)
Author URL
CitationsScopus - 31Web of Science - 26
1998Talley NJ, Meineche-Schmidt V, Pare P, Duckworth M, Raisanen P, Pap A, et al., 'Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies).', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 12 1055-1065 (1998)
Author URL
CitationsScopus - 292Web of Science - 257
1998Shaw M, Talley NJ, Adlis S, Beebe T, Tomshine P, Healey M, 'Development of a digestive health status instrument: tests of scaling assumptions, structure and reliability in a primary care population', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 12 1067-1078 (1998)
Author URL
CitationsScopus - 57Web of Science - 57
1998Agreus L, Talley NJ, 'Untitled', SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 16 64-64 (1998)
Author URL
CitationsWeb of Science - 1
1998Agréus L, Talley NJ, 'Working conditions and family situation in relation to functional gastrointestinal disorders.', Scandinavian journal of primary health care, 16 64-64 (1998)
CitationsScopus - 1
1998Weltman MD, Talley NJ, 'Recurrent, non-identifiable GI bleeding', Current Therapeutics, 39 37-45 (1998)

Gastrointestinal tract bleeding is a common problem in clinical practice. Although the cause is usually identifiable, the source of bleeding still goes undetected in up to 30% of ... [more]

Gastrointestinal tract bleeding is a common problem in clinical practice. Although the cause is usually identifiable, the source of bleeding still goes undetected in up to 30% of patients in whom adequate and timely gastroscopy and colonoscopy have been performed. This article will concentrate on unexplained or occult gastrointestinal bleeding from the upper gastrointestinal tract and small bowel.

1998Lam SJ, Talley NJ, 'Report of the 1997 Asia Pacific Consensus Conference on the Management of Helicobacter pylori Infection', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 13 1-12 (1998)
DOI10.1111/j.1440-1746.1998.tb00537.xAuthor URL
CitationsScopus - 350Web of Science - 272
1998Talley NJ, Lam SK, Goh KL, Fock KM, 'Management guidelines for uninvestigated and functional dyspepsia in the Asia-Pacific region: First Asian Pacific working party on functional dyspepsia', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 13 335-353 (1998)
DOI10.1111/j.1440-1746.1998.tb00644.xAuthor URL
CitationsScopus - 42Web of Science - 41
1998Nandurkar S, Talley NJ, 'Surveillance in Barrett's oesophagus: A need for reassessment?', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 13 990-996 (1998)
DOI10.1111/j.1440-1746.1998.tb00559.xAuthor URL
CitationsScopus - 14Web of Science - 12
1998Xia HHX, Kalantar J, Talley NJ, 'Metronidazole- and clarithromycin-resistant Helicobacter pylori in dyspeptic patients in western Sydney as determined by testing multiple isolates from different gastric sites', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 13 1044-1049 (1998)
DOI10.1111/j.1440-1746.1998.tb00568.xAuthor URL
CitationsScopus - 20Web of Science - 14
1998Talley NJ, 'Dyspepsia - Preface', BAILLIERES CLINICAL GASTROENTEROLOGY, 12 IX-X (1998)
DOI10.1016/S0950-3528(98)90014-8Author URL
1998Holtmann G, Stanghellini V, Talley NJ, 'Nomenclature of dyspepsia, dyspepsia subgroups and functional dyspepsia: clarifying the concepts', BAILLIERES CLINICAL GASTROENTEROLOGY, 12 417-433 (1998)
DOI10.1016/S0950-3528(98)90015-XAuthor URL
CitationsScopus - 34Web of Science - 25
1998Talley NJ, 'Preface', Bailliere's Clinical Gastroenterology, 12 (1998)
DOI10.1016/S0950-3528(98)90014-8
1998van Zanten SJOV, Talley NJ, 'Should antibiotic treatment of Helicobacter-positive patients with non-ulcer dyspepsia now be recommended?', EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 10 367-370 (1998)
Author URL
CitationsScopus - 8Web of Science - 5
1998Phung N, Kalantar J, Talley NJ, 'Management of dyspepsia in general practice', Modern Medicine of Australia, 41 10-19 (1998)

Dyspepsia is a very common complaint. The prevalence of dyspepsia shows considerable geographic variability, but in Western countries it affects about 25% of people each year and ... [more]

Dyspepsia is a very common complaint. The prevalence of dyspepsia shows considerable geographic variability, but in Western countries it affects about 25% of people each year and accounts for 2 to 5% of all general practice consultations. Most people with dyspepsia have mild or short- lasting symptoms and therefore do not seek medical attention. However, anxiety, severe symptoms, increasing age and fear of serious disease are some of the factors that may make a patient seek help. This article provides a simple, cost-effective management plan for dyspeptic patients in general practice.

1998Talley NJ, 'Scope of the problem of functional digestive disorders', EUROPEAN JOURNAL OF SURGERY, 164 35-41 (1998)
DOI10.1080/11024159850191427Author URL
CitationsScopus - 45Web of Science - 3
1998Talley NJ, 'Irritable bowel syndrome: Disease definition and symptom description', EUROPEAN JOURNAL OF SURGERY, 164 24-28 (1998)
DOI10.1080/11024159850191193Author URL
CitationsScopus - 26Web of Science - 1
1998Wiklund IK, Junghard O, Grace E, Talley NJ, Kamm M, van Zanten SV, et al., 'Quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD)', EUROPEAN JOURNAL OF SURGERY, 164 41-49 (1998)
Author URL
CitationsScopus - 227Web of Science - 16
1998Junghard O, Lauritsen K, Talley NJ, Wiklund IK, 'Validation of seven graded diary cards for severity of dyspeptic symptoms in patients with non ulcer dyspepsia', EUROPEAN JOURNAL OF SURGERY, 164 106-111 (1998)
Author URL
CitationsScopus - 35Web of Science - 1
1998Nandurkar S, Martin CJ, Talley NJ, Ma Wyatt J, 'Curable cancer in a short segment Barrett's esophagus', Diseases of the Esophagus, 11 284-287 (1998)
CitationsScopus - 6
1997McManis PG, Talley NJ, 'Nausea and vomiting associated with selective serotonin reuptake inhibitors - Incidence, mechanisms and management', CNS DRUGS, 8 394-401 (1997)
DOI10.2165/00023210-199708050-00005Author URL
CitationsScopus - 13Web of Science - 12
1997Roberts RO, Jacobsen SJ, Reilly WT, Girman CJ, Talley NJ, Lieber MM, 'Urinary incontinence among community-dwelling elderly persons: Prevalence and health care utilization.', AMERICAN JOURNAL OF EPIDEMIOLOGY, 145 37-37 (1997)
Author URL
1997Holtmann G, Goebell H, Talley NJ, 'Functional dyspepsia and irritable bowel syndrome: Is there a common pathophysiological basis?', AMERICAN JOURNAL OF GASTROENTEROLOGY, 92 954-959 (1997)
Author URL
CitationsScopus - 106Web of Science - 90
1997Xia HHX, Talley NJ, 'Natural acquisition and spontaneous elimination of Helicobacter pylori infection: Clinical implications', AMERICAN JOURNAL OF GASTROENTEROLOGY, 92 1780-1787 (1997)
Author URL
CitationsScopus - 122Web of Science - 119
1997Talley NA, Chen F, King D, Jones M, Talley NJ, 'Short-chain fatty acids in the treatment of radiation proctitis - A randomized, double-blind, placebo-controlled, cross-over pilot trial', DISEASES OF THE COLON & RECTUM, 40 1046-1050 (1997)
DOI10.1007/BF02050927Author URL
CitationsScopus - 78Web of Science - 56
1997Bolin TD, Korman MG, Lapsley H, Ho T, Hall W, Donnelly N, et al., 'Positive cost benefit of early diagnosis of colorectal cancer', GASTROENTEROLOGY, 112 A5-A5 (1997)
Author URL
CitationsWeb of Science - 2
1997Holtmann G, Talley NJ, NeufangHuber J, Goebell H, 'Comparison of the factorial structure of abdominal symptoms in a population-based sample and in patients with functional abdominal symptoms.', GASTROENTEROLOGY, 112 A151-A151 (1997)
Author URL
1997Kalantar J, Xia HHX, Wyatt JM, Rose D, Talley NJ, 'Determination of optimal biopsy sites for detection of H-pylori in patients treated or not treated with antibiotics and anti-secretory drugs.', GASTROENTEROLOGY, 112 A165-A165 (1997)
Author URL
CitationsWeb of Science - 11
1997Locke GR, Talley NJ, Zinsmeister AR, 'Can symptoms predict endoscopic findings in gastroesophageal reflux disease?', GASTROENTEROLOGY, 112 A201-A201 (1997)
Author URL
CitationsWeb of Science - 17
1997Nandurkar S, Talley NJ, Xia HHX, Patiag D, Hazel S, Mitchell H, Jones M, 'Dyspepsia in the community is linked to smoking and aspirin use but not to Helicobacter pylori.', GASTROENTEROLOGY, 112 A232-A232 (1997)
Author URL
CitationsWeb of Science - 3
1997Shaw M, Adlis S, Beebe T, Talley NJ, Cudeck R, Tomshine P, 'Development of a dyspepsia-specific health status instrument', GASTROENTEROLOGY, 112 A287-A287 (1997)
Author URL
1997Xia HHX, Gallagher C, English L, Hyde DK, Talley NJ, Keane CT, OMorain CA, 'Are cytotoxic strains of H-pylori risk factors for the subsequent development of duodenal ulcer in dyspeptic patients?', GASTROENTEROLOGY, 112 A334-A334 (1997)
Author URL
1997Xia HHX, Kalantar J, Wyatt JM, Rose D, Talley NJ, 'A semi-quantitative study on the distribution of H-pylori in the stomach - Does it determine the clinical outcome?', GASTROENTEROLOGY, 112 A334-A334 (1997)
Author URL
1997Locke GR, Talley NJ, Kelly KA, Harmsen WS, Zinsmeister AR, Melton LJ, 'Survival in gastric adenocarcinoma over a 50-year period: A population-based study.', GASTROENTEROLOGY, 112 A605-A605 (1997)
Author URL
1997Holtmann G, Gschossmann J, Keller M, NeufangHuber J, Goebell H, Talley NJ, 'Changes of heart rate variability in response to a meal in patients with functional dyspepsia.', GASTROENTEROLOGY, 112 A749-A749 (1997)
Author URL
1997Holtmann G, NeufangHuber J, Goebell H, Talley NJ, 'Central cholinergic stimulation and mechanosensory function in humans.', GASTROENTEROLOGY, 112 A749-A749 (1997)
Author URL
1997Holtmann G, NeufangHuber J, Keller A, Goebell H, Talley NJ, 'Influence of hyperventilation on gastric sensory thresholds and compliance in healthy subjects.', GASTROENTEROLOGY, 112 A749-A749 (1997)
Author URL
1997Talley NJ, Holtmann G, Zinsmeister AR, Jones M, 'Gastrointestinal symptoms cluster into distinct upper and lower groupings consistent with the Rome classification: A three country population-based study.', GASTROENTEROLOGY, 112 A835-A835 (1997)
Author URL
CitationsWeb of Science - 5
1997Talley NJ, Boyce P, Jones M, 'Symptoms but not psychological factors predict health care seeking in subjects with irritable bowel syndrome (IBS) and dyspepsia: A population-based study.', GASTROENTEROLOGY, 112 A835-A835 (1997)
Author URL
CitationsWeb of Science - 5
1997Xia HHX, Kalantar J, Rose D, Talley NJ, 'Susceptibility testing of H-pylori to metronidazole and clarithromycin: Is one isolate from a single site adequate?', GASTROENTEROLOGY, 112 A1122-A1122 (1997)
Author URL
CitationsWeb of Science - 2
1997Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ, 'Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmsted County, Minnesota', GASTROENTEROLOGY, 112 1448-1456 (1997)
DOI10.1016/S0016-5085(97)70025-8Author URL
CitationsScopus - 1511Web of Science - 1246
1997Talley NJ, Hunt RH, 'What role does Helicobacter pylori play in dyspepsia and nonulcer dyspepsia? Arguments for and against H-pylori being associated with dyspeptic symptoms', GASTROENTEROLOGY, 113 S67-S77 (1997)
Author URL
CitationsScopus - 91Web of Science - 56
1997Nandurkar S, Talley NJ, Martin CJ, Ng THK, Adams S, 'Short segment Barrett's oesophagus: Prevalence, diagnosis and associations', GUT, 40 710-715 (1997)
Author URL
CitationsScopus - 159Web of Science - 132
1997Xia HX, Kalantar J, Wyatt JM, Talley NJ, 'Histological characterisation of Helicobacter pylori - Infected and non-infected stomachs - A semi-quantitative mapping study', GUT, 41 A26-A27 (1997)
Author URL
1997Xia HX, Gallagher C, English L, Hyde D, Talley NJ, Keane CT, OMorain CA, 'Evaluation of McCoy cell line for detection of cytotoxicity of Helicobacter pylori', GUT, 41 A131-A131 (1997)
Author URL
1997Talley NJ, Boyce PM, Jones M, 'Predictors of health care seeking for irritable bowel syndrome: a population based study', GUT, 41 394-398 (1997)
Author URL
CitationsScopus - 190Web of Science - 156
1997Talley NJ, 'Visceral analgesics and functional dyspepsia: have we found the Holy Grail?', GUT, 41 717-718 (1997)
Author URL
CitationsScopus - 9Web of Science - 9
1997Xia HX, Talley NJ, Keane CT, OMorain CA, 'Recurrence of Helicobacter pylori infection after successful eradication - Nature and possible causes', DIGESTIVE DISEASES AND SCIENCES, 42 1821-1834 (1997)
DOI10.1023/A:1018827322470Author URL
CitationsScopus - 77Web of Science - 73
1997Kalantar SJ, Marks R, Lambert JR, Badov D, Talley NJ, 'Dyspepsia due to eosinophilic gastroenteritis', DIGESTIVE DISEASES AND SCIENCES, 42 2327-2332 (1997)
DOI10.1023/A:1018883121388Author URL
CitationsScopus - 29Web of Science - 19
1997Talley NJ, 'Chronic unexplained dyspepsia: What's new and what to do?', DIGESTIVE DISEASES, 15 313-315 (1997)
DOI10.1159/000171607Author URL
1997Agreus L, Xia HHX, Talley NJ, 'GP testing for Helicobacter pylori', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 11 1143-1143 (1997)
DOI10.1046/j.1365-2036.1997.00255.xAuthor URL
1997Talley NJ, 'Dyspepsia and heartburn: a clinical challenge', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 11 1-8 (1997)
Author URL
CitationsScopus - 14Web of Science - 13
1997Frankum B, Talley NJ, 'The Tired Listless Patient', Current Therapeutics, 38 41-45 (1997)

Fatigue may be the most common presenting symptom seen in general practice. Its potential causes are many and varied. As in all of medicine, the key to diagnosis is a thorough his... [more]

Fatigue may be the most common presenting symptom seen in general practice. Its potential causes are many and varied. As in all of medicine, the key to diagnosis is a thorough history and examination supplemented by a small number of targeted investigations. While it is tempting for the doctor to trivialise this nonspecific complaint, fatigue can be an early symptom of serious medical or psychiatric illness. The benefits of prompt diagnosis and institution of treatment in patients with this complaint should therefore not be underestimated.

1997Talley NJ, Agreus L, vanZanten SV, 'Is the Glasgow Dyspepsia Severity Score a useful tool for the measurement of dyspepsia?', EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 9 413-413 (1997)
Author URL
CitationsWeb of Science - 2
1997Talley NJ, Agreus L, Van Zanten SV, McColl KEL, El-Omar EM, Banerjee S, Wirz A, 'The Glasgow Dyspepsia Severity Score - A tool for the global measurement of dyspepsia (multiple letters) [1]', European Journal of Gastroenterology and Hepatology, 9 413-414 (1997)
CitationsScopus - 3
1997Agreus L, Talley N, 'Challenges in managing dyspepsia in general practice', BRITISH MEDICAL JOURNAL, 315 1284-1288 (1997)
Author URL
CitationsScopus - 62Web of Science - 65
1996Evans JM, Fleming KC, Talley NJ, Romero Y, Zinsmeister AR, Melton LJ, 'Risk factors for functional bowel disease (FBD) in the elderly: A population-based study.', JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 44 P123-P123 (1996)
Author URL
1996Talley NJ, Fleming KC, Evans JM, OKeefe EA, Weaver AL, Zinsmeister AR, Melton LJ, 'Constipation in an elderly community: A study of prevalence and potential risk factors', AMERICAN JOURNAL OF GASTROENTEROLOGY, 91 19-25 (1996)
Author URL
CitationsScopus - 152Web of Science - 110
1996Talley NJ, Owen BK, Boyce P, Paterson K, 'Psychological treatments for irritable bowel syndrome: A critique of controlled treatment trials', AMERICAN JOURNAL OF GASTROENTEROLOGY, 91 277-286 (1996)
Author URL
CitationsScopus - 131Web of Science - 107
1996Hu WHC, Talley NJ, 'Gastrointestinal sensory testing: Avoiding the limitations', AMERICAN JOURNAL OF GASTROENTEROLOGY, 91 404-404 (1996)
Author URL
1996Holtmann G, Goebell H, Talley NJ, 'Impaired small intestinal peristaltic reflexes and sensory thresholds are independent functional disturbances in patients with chronic unexplained dyspepsia', AMERICAN JOURNAL OF GASTROENTEROLOGY, 91 485-491 (1996)
Author URL
CitationsScopus - 56Web of Science - 58
1996vanZanten SJOV, Cleary C, Talley NJ, Peterson TC, Nyren O, Bradley LA, et al., 'Drug treatment of functional dyspepsia: A systematic analysis of trial methodology with recommendations for design of future trials', AMERICAN JOURNAL OF GASTROENTEROLOGY, 91 660-673 (1996)
Author URL
CitationsScopus - 179Web of Science - 155
1996Loy CT, Irwig LM, Katelaris PH, Talley NJ, 'Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis', AMERICAN JOURNAL OF GASTROENTEROLOGY, 91 1138-1144 (1996)
Author URL
CitationsScopus - 137Web of Science - 121
1996Talley NJ, Melton LJ, 'Constipation in the elderly: Do distinct symptom subgroups exist?', AMERICAN JOURNAL OF GASTROENTEROLOGY, 91 1666-1667 (1996)
Author URL
CitationsWeb of Science - 3
1996Talley NJ, Butterfield JH, 'Mast cell infiltration and degranulation in colonic mucosa in the irritable bowel syndrome', AMERICAN JOURNAL OF GASTROENTEROLOGY, 91 1675-1676 (1996)
Author URL
CitationsScopus - 20Web of Science - 21
1996Talley NJ, Xia HHX, 'Ethnicity as a risk factor for Helicobacter pylori infection and gastric cancer: Environment, genetics, or both?', AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 26 628-631 (1996)
DOI10.1111/j.1445-5994.1996.tb02930.xAuthor URL
CitationsScopus - 5Web of Science - 5
1996Silverstein MD, Petterson T, Talley NJ, 'Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: A decision analysis', GASTROENTEROLOGY, 110 72-83 (1996)
DOI10.1053/gast.1996.v110.pm8536890Author URL
CitationsScopus - 161Web of Science - 176
1996Talley NJ, Boyce P, 'Abuse and functional gastrointestinal disorders: What is the link and should we care?', GASTROENTEROLOGY, 110 1301-1304 (1996)
DOI10.1053/gast.1996.v110.agast961301Author URL
CitationsScopus - 8Web of Science - 9
1996Locke GR, Talley NJ, Zinsmeister AR, Melton LJ, 'The irritable bowel syndrome and functional dyspepsia: Familial disorders?', GASTROENTEROLOGY, 110 A26-A26 (1996)
Author URL
1996Locke GR, Talley NJ, Zinsmeister AR, Melton LJ, 'Evidence that the irritable bowel syndrome and functional dyspepsia are a single disorder: A longitudinal, population-based study.', GASTROENTEROLOGY, 110 A26-A26 (1996)
Author URL
1996Shaw MJ, Talley NJ, Ireland M, Tomshine P, 'The impact on health status of treatment for dyspepsia by primary care physicians.', GASTROENTEROLOGY, 110 A38-A38 (1996)
Author URL
CitationsWeb of Science - 1
1996Burgart LJ, Batts KP, Talley NJ, 'Chemical-type gastric injury: An assessment of histopathology and risk factors.', GASTROENTEROLOGY, 110 A72-A72 (1996)
Author URL
CitationsWeb of Science - 4
1996Nandurkar S, Ng T, Adams S, Brooks L, Keegan A, Cox M, et al., 'Short segment Barrett's esophagus: Prevalence, diagnosis and associations', GASTROENTEROLOGY, 110 A207-A207 (1996)
Author URL
CitationsWeb of Science - 7
1996Holtmann G, Goebell H, NeufangHuber J, Talley NJ, 'Comparison of duodenal sensory thresholds of patients with functional dyspepsia and irritable bowel syndrome.', GASTROENTEROLOGY, 110 A679-A679 (1996)
Author URL
1996Holtmann G, Talley NJ, NeufangHuber J, Goebell H, 'Comparison of gastric mechanosensory thresholds and maximal tolerance of a liquid meal.', GASTROENTEROLOGY, 110 A680-A680 (1996)
Author URL
1996Holtmann G, NeufangHuber J, Talley NJ, Goebell H, 'Pattern of symptoms in functional dyspepsia: Predictors of a response to treatment?', GASTROENTEROLOGY, 110 A680-A680 (1996)
Author URL
1996Holtmann G, NeufangHuber J, Fischer H, Goebell H, Talley NJ, 'Influence of the vagal nerve on intestinal mechano-sensory function and intestino-intestinal reflexes in humans.', GASTROENTEROLOGY, 110 A680-A680 (1996)
Author URL
1996Hu WHC, Newman P, Martin CJ, Talley NJ, 'The effects of intraesophageal acid on perception thresholds to balloon distention using a barostat', GASTROENTEROLOGY, 110 A682-A682 (1996)
Author URL
1996Reilly WT, Talley NJ, Pemberton JH, Schleck CD, Zinsmeister AR, 'Fecal incontinence: Association with frequency and severity of urinary and other somatic symptoms.', GASTROENTEROLOGY, 110 A743-A743 (1996)
Author URL
CitationsWeb of Science - 1
1996Talley NJ, Owen B, Bai J, Boyce P, 'Does psychological distress account for the apparent association between abuse and irritable bowel syndrome? A population based study.', GASTROENTEROLOGY, 110 A767-A767 (1996)
Author URL
1996Talley NJ, Boyce P, 'Gastrointestinal diagnosis, abuse history, and effects on health status - Reply', GASTROENTEROLOGY, 111 1160-1161 (1996)
Author URL
CitationsScopus - 5
1996Tey HK, Talley NJ, 'Use of cricoid pressure to facilitate gastric insufflation and stop hiccoughs during gastroscopy', GASTROINTESTINAL ENDOSCOPY, 44 760-761 (1996)
DOI10.1016/S0016-5107(96)70076-7Author URL
1996Talley NJ, 'Helicobacter pylori and non-ulcer dyspepsia', SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 31 19-22 (1996)
DOI10.3109/00365529609094745Author URL
CitationsScopus - 31Web of Science - 16
1996Talley NJ, 'Quality of life in functional dyspepsia', SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 31 21-22 (1996)
DOI10.3109/00365529609095547Author URL
CitationsScopus - 8Web of Science - 3
1996Holtmann G, Talley NJ, 'Is Helicobacter pylori a cause of nonulcer dyspepsia (vol 40, pg 11, 1996)', DIGESTIVE DISEASES AND SCIENCES, 41 232-232 (1996)
DOI10.1007/BF02208609Author URL
CitationsWeb of Science - 2
1996Talley NJ, Evans JM, Fleming KC, Zinsmeister AR, Melton LJ, 'Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly - Reply', DIGESTIVE DISEASES AND SCIENCES, 41 799-799 (1996)
Author URL
1996Holtmann G, Talley NJ, Goebell H, 'Association between H-pylori, duodenal mechanosensory thresholds, and small intestinal motility in chronic unexplained dyspepsia', DIGESTIVE DISEASES AND SCIENCES, 41 1285-1291 (1996)
DOI10.1007/BF02088548Author URL
CitationsScopus - 40Web of Science - 54
1996Tait C, Jones R, Talley NJ, Evans JM, Fleming KC, Zinsmeister AR, Melton III LJ, 'Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly [2]', Digestive Diseases and Sciences, 41 798-799 (1996)
CitationsScopus - 2
1996Holtmann G, Talley NJ, 'Is Helicobacter pylori a cause of nonulcer dyspepsia.', Digestive diseases and sciences, 41 232-232 (1996)
1996Hu WHC, Talley NJ, 'Visceral perception in functional gastro-intestinal disorders: Disease marker or epiphenomenon?', DIGESTIVE DISEASES, 14 276-288 (1996)
DOI10.1159/000171559Author URL
CitationsScopus - 15Web of Science - 14
1996Talley NJ, 'Modern management of dyspepsia.', Australian family physician, 25 47-52 (1996)

Dyspepsia affects one in four Australians; of those who present in general practice, the majority will have functional or non-ulcer dyspepsia, with no structural explanation for t... [more]

Dyspepsia affects one in four Australians; of those who present in general practice, the majority will have functional or non-ulcer dyspepsia, with no structural explanation for their symptoms. Older patients who present for the first time with dyspepsia, and those with 'alarm features' deserve immediate investigation (preferably by upper endoscopy), to exclude cancer, peptic ulcer or oesophagitis. Other patients may be given empiric therapy (for example, a prokinetic or H2 blocker) initially, but require investigation if this fails. The role of Helicobacter pylori infection in functional dyspepsia is uncertain.

CitationsScopus - 9
1996Talley NJ, Xia HH, 'Gastric Cancer: An infectious disease?', Current Therapeutics, 37 17-20 (1996)

In the last decade there has been a quiet revolution in our thinking about gastric cancer. The reformation began with the widespread recognition that Helicobacter pylori infection... [more]

In the last decade there has been a quiet revolution in our thinking about gastric cancer. The reformation began with the widespread recognition that Helicobacter pylori infection causes chronic gastritis. There is now convincing evidence that H. pylori gastritis is a major cause of gastric adenocarcinoma and gastric lymphoma, concepts that would have been considered unthinkable just 15 years ago. In this editorial, we summarise the evidence that gastric cancer is causally linked to H. pylori and consider the implications for Australian medical practitioners.

CitationsScopus - 1
1996Toma TP, Zighelboim J, Phillips SF, Talley NJ, 'Methods for studying intestinal sensitivity and compliance: In vitro studies of balloons and a barostat', NEUROGASTROENTEROLOGY AND MOTILITY, 8 19-28 (1996)
DOI10.1111/j.1365-2982.1996.tb00238.xAuthor URL
CitationsScopus - 35Web of Science - 29
1996Hua-Xiang Xia H, Talley NJ, 'Prospects for improved therapy for Helicobacter pylori infection', Expert Opinion on Investigational Drugs, 5 959-976 (1996)

Cure of Helicobacter pylori infection has been recommended for patients with peptic ulcer disease. However, an optimal treatment regimen has not been defined. Dual therapy regimen... [more]

Cure of Helicobacter pylori infection has been recommended for patients with peptic ulcer disease. However, an optimal treatment regimen has not been defined. Dual therapy regimens with omeprazole and amoxycillin or clarithromycin usually achieve eradication rates of 70-80%, while a combination of ranitidine bismuth citrate and clarithromycin produces eradication rates of over 80%. Triple therapy with a bismuth salt plus metronidazole and tetracycline or amoxycillin (the standard bismuth-based triple therapy), or a proton pump inhibitor (PPI-based therapy) plus two antimicrobial agents (metronidazole, amoxicillin or clarithromycin) is effective in eradicating H. pylori, with eradication rates of over 90% for metronidazole-sensitive strains. Drug resistance and compliance influence the clinical efficacy. Addition of a PPI to bismuth-based triple therapy (quadruple therapy) may overcome drug resistance, reduce side-effects, and shorten the treatment duration, but compliance may be reduced. Therefore, the search for a simple and effective therapy continues. Novel approaches include alternative types of drug administration (topical or parenteral), substitution with more powerful analogues or novel agents such as enzyme-inhibitors, Chinese herbs, honey, lactic acid and unsaturated fatty acids. Recently, vaccines against H. pylori infection have been developed and tested in animal models. The studies have demonstrated that oral immunisation with H. pylori whole cell sonicates or recombinant urease of the organism not only prevents the infection but can also eradicate it. Thus, therapeutic vaccines, which We believe are achievable, may finally eliminate H. pylori from the human stomach, and therefore cure most peptic ulcer disease.

CitationsScopus - 18
1995TALLEY NJ, 'HELICOBACTER-PYLORI - MORE THAN 10 YEARS ON AND STILL CATCHY', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 10 465-468 (1995)
DOI10.1111/j.1440-1746.1995.tb01601.xAuthor URL
CitationsScopus - 1Web of Science - 1
1995Talley NJ, 'Dyspepsia in the elderly: Diagnosis and management', Modern Medicine of Australia, 38 72-76 (1995)

Pain or discomfort centred in the upper abdomen (dyspepsia) in ambulatory elderly patients may be due to organic disease, especially peptic ulcer, gastro-oesophageal reflux or can... [more]

Pain or discomfort centred in the upper abdomen (dyspepsia) in ambulatory elderly patients may be due to organic disease, especially peptic ulcer, gastro-oesophageal reflux or cancer; however, in 40% of cases there is no structural explanation, that is, the patient has fuctional or nonulcer dyspepsia. Symptoms can help in the identificaticn of gastro-oesophageal reflux but they cannot accurately distinguish an ulcer from other causes of dyspepsia. The elderly patient with new onset dyspepsia therefore should usually be investigated; gastroscopy is the most useful test. Management depends on the underlying diagnosis, and current approaches are reviewed in this article.

1995Talley NJ, Hu W, Holtmann G, 'Symptoms, investigation and treatment of gastroparesis', Modern Medicine of Australia, 38 27-30+32 (1995)

In general practice, indigestion is a common presenting complaint. While patients may use this term to refer to all sorts of conditions (from halitosis to flatus), if a proper his... [more]

In general practice, indigestion is a common presenting complaint. While patients may use this term to refer to all sorts of conditions (from halitosis to flatus), if a proper history is taken it is clear that some of these patients have postprandial symptoms including nausea, bloating, fullness and early satiety (an inability to finish a normal meal). Such symptoms are often vaguely ascribed to a motor disturbance of the stomach causing delayed gastric emtpying (gastroparesis). How should the general practitioner approach a patient with suspected gastroparesis? Should a gastric emptying test be ordered? When is referral indicated? These are dealt with in this article.

1995OKEEFE EA, TALLEY NJ, ZINSMEISTER AR, JACOBSEN SJ, 'BOWEL DISORDERS IMPAIR FUNCTIONAL STATUS AND QUALITY-OF-LIFE IN THE ELDERLY - A POPULATION-BASED STUDY', JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 50 M184-M189 (1995)
Author URL
CitationsScopus - 156Web of Science - 94
1995TALLEY NJ, ZINSMEISTER AR, MELTON LJ, 'IRRITABLE-BOWEL-SYNDROME IN A COMMUNITY - SYMPTOM SUBGROUPS, RISK-FACTORS, AND HEALTH-CARE UTILIZATION', AMERICAN JOURNAL OF EPIDEMIOLOGY, 142 76-83 (1995)
Author URL
CitationsScopus - 261Web of Science - 216
1995TALLEY NJ, MELTON LJ, 'EPIDEMIOLOGY OF CELIAC-DISEASE - REPLY', AMERICAN JOURNAL OF GASTROENTEROLOGY, 90 164-164 (1995)
Author URL
1995TALLEY NJ, FETT SL, ZINSMEISTER AR, 'SELF-REPORTED ABUSE AND GASTROINTESTINAL-DISEASE IN OUTPATIENTS - ASSOCIATION WITH IRRITABLE BOWEL-TYPE SYMPTOMS', AMERICAN JOURNAL OF GASTROENTEROLOGY, 90 366-371 (1995)
Author URL
CitationsScopus - 112Web of Science - 96
1995TALLEY NJ, BOYCE P, OWEN BK, 'PSYCHOLOGICAL DISTRESS AND SEASONAL SYMPTOM CHANGES IN IRRITABLE-BOWEL-SYNDROME', AMERICAN JOURNAL OF GASTROENTEROLOGY, 90 2115-2119 (1995)
Author URL
CitationsScopus - 19Web of Science - 19
1995Hill ID, Horvath K, Fasano A, Talley NJ, Melton III LJ, 'Epidemiology of celiac disease [3]', American Journal of Gastroenterology, 90 163-164 (1995)
CitationsScopus - 11
1995OWENS DM, NELSON DK, TALLEY NJ, 'THE IRRITABLE-BOWEL-SYNDROME - LONG-TERM PROGNOSIS AND THE PHYSICIAN-PATIENT INTERACTION', ANNALS OF INTERNAL MEDICINE, 122 107-& (1995)
Author URL
CitationsScopus - 219Web of Science - 191
1995OWENS DM, NELSON DK, TALLEY NJ, 'IRRITABLE-BOWEL-SYNDROME - REPLY', ANNALS OF INTERNAL MEDICINE, 123 471-471 (1995)
Author URL
CitationsScopus - 1Web of Science - 1
1995DROSSMAN DA, TALLEY NJ, LESERMAN J, OLDEN KW, BARREIRO MA, 'SEXUAL AND PHYSICAL ABUSE AND GASTROINTESTINAL ILLNESS - REVIEW AND RECOMMENDATIONS', ANNALS OF INTERNAL MEDICINE, 123 782-794 (1995)
Author URL
CitationsScopus - 324Web of Science - 280
1995TALLEY NJ, BOYCE PM, OWEN BK, NEWMAN P, PATERSON KJ, 'INITIAL VALIDATION OF A BOWEL SYMPTOM QUESTIONNAIRE AND MEASUREMENT OF CHRONIC GASTROINTESTINAL SYMPTOMS IN AUSTRALIANS', AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 25 302-308 (1995)
DOI10.1111/j.1445-5994.1995.tb01894.xAuthor URL
CitationsScopus - 90Web of Science - 85
1995CARPENTER HA, TALLEY NJ, 'GASTROSCOPY IS INCOMPLETE WITHOUT BIOPSY - CLINICAL RELEVANCE OF DISTINGUISHING GASTROPATHY FROM GASTRITIS', GASTROENTEROLOGY, 108 917-924 (1995)
DOI10.1016/0016-5085(95)90468-9Author URL
CitationsScopus - 87Web of Science - 65
1995EVANS JM, FLEMING KC, ROMERO Y, TALLEY NJ, ZINSMEISTER AR, 'THE EFFECTS OF AGE, COLONIC TRANSIT, PHYSICAL-ACTIVITY, AND DIET ON FUNCTIONAL BOWEL-DISEASE (FBD) IN THE ELDERLY - A POPULATION-BASED STUDY', GASTROENTEROLOGY, 108 A13-A13 (1995)
Author URL
1995LOCKE GR, TALLEY NJ, FETT SL, ZINSMEISTER AR, MELTON LJ, 'THE IMPACT OF ATYPICAL SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE UPON HEALTH PERCEPTION AND HEALTH-CARE UTILIZATION', GASTROENTEROLOGY, 108 A24-A24 (1995)
Author URL
1995LOCKE GR, TALLEY NJ, FETT SL, ZINSMEISTER AR, MELTON LJ, 'RISK-FACTORS FOR GASTROESOPHAGEAL REFLUX DISEASE IN THE COMMUNITY', GASTROENTEROLOGY, 108 A25-A25 (1995)
Author URL
CitationsWeb of Science - 4
1995REILLY WT, TALLEY NJ, PEMBERTON JH, SCHLECK CD, ZINSMEISTER AR, 'FECAL INCONTINENCE - PREVALENCE AND RISK-FACTORS IN THE COMMUNITY', GASTROENTEROLOGY, 108 A32-A32 (1995)
Author URL
CitationsWeb of Science - 13
1995ROMERO Y, TALLEY NJ, EVANS JM, FLEMING KC, HARMSEN WS, ZINSMEISTER AR, PHILLIPS SF, 'PREVALENCE OF CONSTIPATION AND IRRITABLE-BOWEL-SYNDROME (IBS) AND THEIR IMPACT ON HEALTH-CARE SEEKING IN THE ELDERLY - A POPULATION-BASED STUDY', GASTROENTEROLOGY, 108 A33-A33 (1995)
Author URL
1995SHAW M, BEEBE T, ADLIS S, TALLEY NJ, TOMSHINE P, HEALEY M, 'DYSPEPSIA - COMPARISON OF COMMUNITY AND CLINIC POPULATIONS', GASTROENTEROLOGY, 108 A35-A35 (1995)
Author URL
CitationsWeb of Science - 2
1995ZINSMEISTER AR, TALLEY NJ, 'GASTROINTESTINAL (GI) SYMPTOMS MODIFY THE ASSOCIATION BETWEEN QUALITY-OF-LIFE (QOL) MEASURES AND COMMON SOMATIC SYMPTOM FREQUENCY AND SEVERITY IN THE ELDERLY', GASTROENTEROLOGY, 108 A42-A42 (1995)
Author URL
1995ZINSMEISTER AR, AN AB, TALLEY NJ, 'DO GASTROINTESTINAL (GI) SYMPTOM SUBGROUPS EXIST - A CLUSTER-ANALYSIS BASED ON SELF-REPORTED SYMPTOMS FROM A COMMUNITY-BASED RANDOM SAMPLE', GASTROENTEROLOGY, 108 A42-A42 (1995)
Author URL
1995HOLTMANN G, GOEBELL H, HOLTMANN M, GSCHOSSMANN J, HUBER J, TALLEY NJ, 'HELICOBACTER-PYLORI FUNCTIONAL DYSPEPSIA - INCREASED SERUM ANTIBODIES AN INDEPENDENT RISK FACTOR', GASTROENTEROLOGY, 108 A116-A116 (1995)
Author URL
CitationsWeb of Science - 7
1995HOLTMANN G, GOEBELL H, HUBER J, TALLEY NJ, 'HELICOBACTER-PYLORI AND SENSORY DYSFUNCTION IN PATIENTS WITH FUNCTIONAL DYSPEPSIA AND HEALTHY CONTROLS', GASTROENTEROLOGY, 108 A615-A615 (1995)
Author URL
CitationsWeb of Science - 3
1995HOLTMANN G, GUERRA G, GOEBELL H, GSCHOSSMANN J, HUBER J, TALLEY NJ, 'PERCEPTION OF GASTRIC DISTENSION - INFLUENCE OF THE MODE OF DISTENSION ON PERCEPTION THRESHOLDS AND GASTRIC COMPLIANCE', GASTROENTEROLOGY, 108 A615-A615 (1995)
Author URL
CitationsWeb of Science - 3
1995HOLTMANN G, KUTSCHER S, HEUFT G, HUBER J, SENF W, TALLEY NJ, GOEBELL H, 'PSYCHOLOGICAL DISTRESS AND SYMPTOM SUBGROUP - PREDICTORS OF TREATMENT RESPONSE IN PATIENTS WITH FUNCTIONAL DYSPEPSIA', GASTROENTEROLOGY, 108 A616-A616 (1995)
Author URL
1995MORRISYATES AD, TALLEY NJ, BOYCE P, ANDREWS G, 'EVIDENCE OF A GENETIC CONTRIBUTION TO SELF-REPORTED SYMPTOMS OF IRRITABLE-BOWEL-SYNDROME', GASTROENTEROLOGY, 108 A652-A652 (1995)
DOI10.1016/0016-5085(95)26921-5Author URL
CitationsWeb of Science - 1
1995REILLY WT, TALLEY NJ, PEMBERTON JH, SCHLECK CD, ZINSMEISTER AR, 'IMPACT OF FECAL INCONTINENCE ON HEALTH PERCEPTION AND DAILY ACTIVITIES IN A RANDOM SAMPLE OF COMMUNITY SUBJECTS', GASTROENTEROLOGY, 108 A676-A676 (1995)
Author URL
1995ROMERO Y, FLEMING KC, EVANS JM, TALLEY NJ, ZINSMEISTER AR, PHILLIPS SF, 'IMPACT OF PSYCHOSOCIAL FACTORS ON FUNCTIONAL BOWEL-DISEASE (FBD) IN THE ELDERLY', GASTROENTEROLOGY, 108 A679-A679 (1995)
Author URL
1995TALLEY NJ, BOYCE P, OWEN B, PATERSON K, 'PSYCHOLOGICAL DISTRESS AND SEASONAL SYMPTOM CHANGES IN COMMUNITY SUBJECTS WITH IRRITABLE-BOWEL-SYNDROME', GASTROENTEROLOGY, 108 A697-A697 (1995)
DOI10.1016/0016-5085(95)27100-7Author URL
CitationsWeb of Science - 1
1995TALLEY NJ, BUTTERFIELD JH, PETERSON E, 'MAST-CELL INFILTRATION AND DEGRANULATION IN COLONIC MUCOSA IN IRRITABLE-BOWEL-SYNDROME', GASTROENTEROLOGY, 108 A697-A697 (1995)
DOI10.1016/0016-5085(95)27100-7Author URL
CitationsWeb of Science - 1
1995HOLTMANN G, GOEBELL H, TALLEY NJ, 'GASTROINTESTINAL SENSORY FUNCTION IN FUNCTIONAL DYSPEPSIA', GASTROENTEROLOGY, 109 331-331 (1995)
DOI10.1016/0016-5085(95)90308-9Author URL
CitationsScopus - 8Web of Science - 8